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Neointimal hyperplasia, the proliferative growth of the innermost layer of the blood 
vessel wall, is a key process in the response to vascular injury, underlying conditions 
such as post-interventional restenosis and vein/arterial graft disease. One of the many 
mediators implicated in this process is endothelin-1 (ET-1), a potent vasoconstrictor 
with pro-inflammatory and pro-mitogenic actions, which acts through ETA and ETB 
receptor subtypes. It is well established that ET-1 increases, and ETA blockade 
reduces, neointima formation following vascular injury. The role of ETB is less clear 
because these receptors mediate potentially beneficial actions in endothelial cells 
(EC; such as nitric oxide production, and ET-1 clearance) but detrimental effects 
elsewhere (such as vascular smooth muscle) and it has been recently reported that 
non-cell-specific ETB deficiency is associated with increased neointimal lesion size 
following injury. The work described in this thesis addressed the hypothesis that 
endogenous ET-1 contributes to neointimal hyperplasia by activation of the ETA 
receptor, and that this action is moderated by concurrent activation of the ETB 
receptor expressed in EC. 
 
The role of ET receptors in neointimal lesion development was assessed using two 
models of femoral arterial injury in the mouse: (i) an established method of intra-
luminal wire-injury, and (ii) adaptation of a model of ligation injury that induces 
robust neointimal lesion formation without physical damage to the endothelium. 
Lesion development was assessed using standard histological techniques and this 
was augmented by development of quantitative optical projection tomography (OPT) 
to allow three-dimensional analysis of lesions. 
 
The role of ETA and ETB receptors in these models was addressed using suitable 
pharmacological ET receptor antagonists. Following wire-injury, selective ETB 
blockade (A192621; 30mg.kg-1.day-1; 35 days) increased lesion size and blood 
pressure without significant altering lesion composition. In contrast, selective ETA 
blockade (atrasentan; 10mg.kg-1.day-1; 35 days) reduced lesion size and blood 
pressure. Combined ETA+ETB antagonism had no effect on lesion size, despite 
 v
reducing blood pressure, and reducing collagen content of the lesions. In the ligation 
model, neither ETA selective, ETB selective nor ETA+ETB blockade altered lesion 
size as assessed by standard histology but analysis by OPT indicated that ETA 
blockade, with or without concurrent ETB blockade, reduced lesion volume. 
 
The influence of ETB receptors expressed by ECs on lesion formation was addressed 
using EC-specific ETB knockout mice. Small vessel myography indicated that 
endothelium-dependent relaxation was unaltered in femoral arteries from these mice. 
In addition, no effect on lesion size or rate of development was observed in either 
wire- or ligation-injury models of neointima formation (although subtle effects on 
lesion and medial composition were apparent after intra-luminal injury). 
 
These results indicate that ETB receptor activation can moderate the detrimental 
actions of the ETA receptor on neointimal lesion progression, and that this role is 
dependent on the mode of vascular injury. Furthermore, in this setting, this beneficial 
action is not primarily mediated by ETB expressed by EC, suggesting that ETB in 
other cell types can reduce lesion development through another, unidentified 
mechanism. Therefore, while both ETA selective and non-selective ETA/B 
antagonists are currently in clinical use, in conditions where similar arterial 
remodelling processes occur, selective ETA receptor antagonists might be preferred. 
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The impact of cardiovascular disease is difficult to over-state – it is the leading cause 
of death in Europe, North America and parts of Asia (Ross, 1999). Some remodelling 
of vascular structure is a common feature of these conditions and, whilst this may be 
beneficial in some cases, exuberant, dysfunctional or otherwise inappropriate 
remodelling is strongly implicated in disease progression. In particular, acute or 
chronic injury to the vascular wall initiates inflammatory and proliferative processes, 
which lead to the development of the intimal lesions that define atherosclerosis, post-
interventional restenosis and vascular graft disease. The discovery of endothelin-1 
(ET-1; Yanagisawa et al., 1988) was rapidly followed by the realisation that its 
release could contribute to the pathogenesis of a variety of cardiovascular diseases 
(reviewed by Haynes & Webb, 1992; Rubanyi & Polokoff, 1994). Considerable 
research effort has since revealed ET-1 to be a major mediator of vascular 
remodelling processes (section 1.3). Indeed, in addition to its potent vasomotor 
activity, ET-1 promotes many responses critical to intimal lesion development, 
including: inflammation, mitogenesis and extracellular matrix turnover. Further, an 
extensive literature describes the ability of blockade of the ET system to moderate 
lesion development in models of acute vascular injury. What is less clear, however, 
is the individual role of ET receptor subtypes (ETA and ETB) in this process. Whilst 
ETA mediates almost entirely detrimental actions in disease, ETB receptor 
stimulation may evoke actions that both diminish and enhance disease progression. 
This is of considerable importance because both ETA-selective and non-selective 
ETA/B antagonists are under investigation for a variety of clinical indications yet the 
relative merits of these treatment strategies is still the subject of debate. The work 
described in this thesis therefore addresses the role of ET receptor subtypes in 
regulation of neointimal lesion formation. Consequently, this introduction will 
consider the pathogenesis of neointimal proliferation, the biology of the ET system, 
and how their interaction may contribute to vascular remodelling. 
 
1.1 VASCULAR INJURY AND REMODELLING 
The vascular system comprises an integrated network of arterial and venous 
conduits, the primary function of which is the distribution of nutrients, heat, waste 
and endocrine messengers through the body. Whilst the heart ultimately drives this 
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process, the vascular wall crucially smoothes cardiac output by arterial compliance, 
regulates blood flow, blood pressure and organ perfusion by adjusting luminal 
diameter, and through changes in permeability controls nutrient flux. 
 
1.1.1 Structure of the vascular wall 
The structure of the vascular wall varies widely between arterial, capillary and 
venous vessels and can comprise up to three distinct layers – the tunica intima, 
tunica media and tunica adventitia.  
 
1.1.1.1 Tunica intima 
This innermost layer of the vascular wall is present in all vessels from large arteries 
to micro-vascular capillaries. It typically comprises a confluent monolayer of 
endothelial cells (EC) anchored to a basement membrane, although may contain 
interspersed vascular smooth muscle cells (VSMC) and additional layers of 
extracellular matrix. It is the only component of the capillary wall, and in larger 
vessels is delineated by the internal elastic lamina. The capillary endothelium allows 
passage of substances between the vascular and tissue compartments, under the 
regulation of various signals, including: cytokines (Bucana et al., 1988; Horvath et 
al., 1988), histamine and bradykinin (Majno et al., 1969). The endothelium also 
provides an anti-thrombotic coating to the vessel wall, reflecting expression of 
heparin-like anti-coagulant proteoglycans (Marcum et al., 1986) and enzymes that 
degrade pro-aggregants (Cooper et al., 1979) or activate plasminogen (Kester, 1969). 
The groundbreaking description of an endothelium-derived relaxing factor by 
Furchgott and Zawadzki (1980) demonstrated that endothelial cells play a pivotal 
role in control of vascular tone. It is now known that the endothelium generates a 
variety of vasodilator factors: nitric oxide (NO; Furchgott & Zawadzki, 1980; Palmer 
et al., 1987), prostacyclin (PGI2; Weksler et al., 1977), endothelium-derived 
hyperpolarising ‘factor’ (Chen et al., 1988; Nagao & Vanhoutte, 1992; Busse et al., 
2002) and vasoconstrictor factors: thromboxane A2 (TXA2; Moncada et al., 1976; 
Ingerman-Wojenski et al., 1981) and ET-1 (Yanagisawa et al., 1988). Endothelium-
derived vasoactive factors have several additional actions. NO, suppresses VSMC 
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mitogenesis (Garg & Hassid, 1989), reduces platelet aggregation (Radomski et al., 
1987b, 1987a), and inhibits leucocyte chemotaxis and adhesion (Bath et al., 1991; 
Hickey & Kubes, 1997). Similarly, PGI2 also inhibits both proliferation (Sinzinger et 
al., 1987) and platelet aggregation (Moncada et al., 1977; Whittle et al., 1978). In 
contrast, vasoconstrictors such as ET-1 may actively stimulate cell proliferation and 
inflammation (see 1.3.1). The synthesis and release of these EC-derived vasoactive 
substances is controlled by physicochemical stimuli (shear stress, wall stretch) and a 
variety of humoural substances (bradykinin, cytokines, catecholamines), and this 
allows acute regulation of luminal calibre in muscular vessels. 
 
1.1.1.2  Tunica media 
The tunica media contains circumferentially-organized layers of VSMCs 
interspersed with collagen and elastin fibrils and elastic laminae, the outermost of 
which (internal and external elastic laminae) define its borders. A principal function 
of the medial layer is the control of vessel diameter which is achieved by regulation 
of smooth muscle tone. The tunica media is absent in capillaries, and negligible in all 
but the largest veins. In arteries, however, it is substantial and its composition varies 
depending on the position of the artery within the vascular tree. In large elastic 
vessels such as the aorta, the media is rich in elastic fibres and relatively poor in 
smooth muscle, resulting in compliant vessels capable of accommodating and 
smoothing pulsed cardiac output. ‘Resistance’ vessels by comparison have a VSMC-
rich media affording greater regulation of blood flow and pressure (Berne & Levy, 
2000). 
 
1.1.1.3 Tunica adventitia 
Beyond the external elastic lamina, both in arteries and veins, lies the tunica 
adventitia. This is primarily composed of extracellular matrix components, 
especially collagen, but may also contain intermittent VSMCs, fibroblasts, resident 
macrophages and the sympathetic-innervation to the vascular wall. It provides 
mechanical strength and stability to the vessel and anchors it in the surrounding 
tissue. In large vessels, the adventitial layer contains microvasculature (vasa 
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vasorum) and lymphatic vessels and, therefore, serves to prevent hypoxia where the 
metabolic needs of the vascular wall are not served by blood in the vessel lumen 
(Berne & Levy, 2000).  
 
1.1.2 Vascular remodelling 
Rather than being determined solely at the time of development, vascular structure 
can dynamically respond to prevailing conditions. Chronically-elevated laminar 
shear stress (e.g. induced by an arterio-venous fistula or luminal stenosis) elicits 
dilation, wall stretch associated with hypertension promotes inward growth of the 
vessel wall (either by contraction or by medial thickening) and hypoxia initiates 
angiogenic processes leading to the formation of new capillary beds. The term 
vascular remodelling, therefore, refers to a variety of structural changes that occur as 
a result of alterations to the growth, death and migration of vascular cells and the 
balance between extracellular matrix synthesis and degradation (Gibbons & Dzau, 
1994). Some manner of vascular remodelling is associated with most cardiovascular 
diseases. This can be beneficial (as in the case of outward dilation in atherosclerosis) 
or detrimental (for example, medial hypertrophy in pulmonary hypertension). The 
‘response to injury’ represents a special case of vascular remodelling in which 
lesions develop in the intimal layer of the vessel wall (Figure 1-1). This response 
can be further sub-divided according to the nature of injury – chronic (coronary heart 
disease, peripheral vascular disease, cerebrovascular disease) or acute (post-
interventional restenosis, vascular graft disease). Whilst the term ‘neointimal lesion 
formation’ and derivatives technically describe responses to both chronic and acute 
vascular injury, for clarity it is reserved solely for the latter in this thesis. 
 
1.1.2.1 Chronic injury 
Chronic injury to the vascular wall, over decades, results in formation of 
atherosclerotic plaques – complex intimal lesions of heterogeneous composition 
which may include macrophage-foam cells, VSMCs, free cholesterol esters, 
thrombus and calcium deposits. The development of atherosclerosis is typically 




Figure 1-1 Structure of the arterial wall.  
Histological sections of healthy mouse brachiocephalic (a) and femoral arteries (c), the brachiocephalic 
arteries of apoE-/- deficient atherosclerotic mice (b), and the mouse femoral artery following intra-lumenal 
wire injury (d) stained by the United States Trichrome method. The arterial wall is composed of three layers. 
The intima lies within the internal elastic lamina (blue arrowheads), the media likes between the internal (blue 
arrowheads) and external elastic laminae (red arrowheads) and the adventitia lies beyond the external elastic 
lamina (red arrowheads). Chronic (atherosclerosis) and acute (mechanical) vascular injury elicits formation of 
lesions in the intimal layer of the vessel wall. The lesions induced by both injuries contain smooth muscle cells 




are eroded or otherwise rupture, revealing their thrombogenic contents. The resulting 
intravascular thrombosis (or its embolisation) may cause infarction, most 
catastrophically in the coronary or cerebral circulations, and this is the cause of 
substantial morbidity and mortality. Indeed, coronary heart disease and stroke 
accounted for 27% of all deaths in the UK in 2006 (www.heartstats.org). A perhaps 
more benign consequence of atherosclerosis is development of luminal stenoses (or 
vasospasm) that limit blood flow through the affected vessel sufficiently that the 
metabolic needs of the tissue distal to it are not met. This results in tissue hypoxia 
and pain, typically on exertion, and again, commonly affects the coronary 
vasculature (angina pectoris). Since the work described in this thesis is concerned 
with the processes involved in the response to acute injury, the pathogenesis of 
atherosclerosis will not be described in detail. Further information can be found in 
many excellent reviews (Ross, 1999; Lusis, 2000; Weissberg, 2000).  
 
1.1.2.2 Acute injury 
Although life-style modification and pharmacotherapy may retard atherogenesis, 
mechanical re-vascularisation procedures have proven invaluable for the treatment of 
advanced disease. Interventions such as percutaneous transluminal coronary 
angioplasty (PTCA) or coronary artery bypass grafting (CABG) restore patency to 
stenosed or thrombosed arteries but, in doing so, inevitably cause a degree of damage 
to the target vessel. This acute injury results in a rapid and resolving process of 
intimal lesion formation (~1 month in animal models, 3-7 months in man). The 
‘neointimal lesions’ resulting from acute injury differ substantially from those in 
atherosclerosis - they are rich in VSMC and extracellular matrix and are inherently 
stable. Neointima formation can be considered an appropriate response to acute 
injury, in which the vessel heals, gains mechanical strength and recovers its 
endothelial coating. An over-exuberant response to this acute injury, however, results 
in a neointimal lesion that can itself compromise vessel patency and this represents a 
major limitation in the ultimate success of these procedures. 
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1.1.2.2.1 Percutaneous coronary interventions 
First achieved in man by Andreas Gruntzig (Gruntzig et al., 1978), PTCA and its 
derivatives have become the most common interventions for the treatment of 
coronary artery stenosis, with over 70,000 performed in the UK in 2006 (BHF; 
www.heartstats.org). The procedure entails the dilation of the stenosed artery by 
intra-luminal inflation of a balloon, introduced via guide wire through the arterial 
circulation from a femoral arteriotomy. Whilst balloon inflation is traumatic to the 
vascular wall, this action serves to increase luminal cross-section by several possible 
means, including: outward distension of the arterial wall, axial re-distribution of 
plaque contents and plaque embolisation (Wolf et al., 1984). Simple PTCA is 
associated with a relatively high incidence of failure (~30%) which primarily reflects 
subsequent re-occlusion of the dilated vessel and the need for further re-
vascularisation interventions. Re-occlusion of dilated vessels (‘restenosis’) occurs 
via several mechanisms, including: acute elastic recoil (Rensing et al., 1990), 
structural contraction of the vessel wall and formation of neointimal lesions 
(Schneider & Gruntzig, 1985). To address these problems, several refinements to the 
technique have been developed. Most important among these has been the 
introduction of vascular stents; support structures expanded by the angioplasty 
balloon which remain in the stenosed artery (Sigwart et al., 1987) and substantially 
reduce the need for re-vascularisation (from 24.5% to 15% at 7 months in the 
Benestent trial; Serruys et al., 1994). While stent implantation reduces elastic recoil 
and structural contraction (Haude et al., 1993), the problem of neointima formation 
(‘in-stent restenosis’) is intensified due to the severity of injury and persistence of a 
foreign body within the arterial wall (Schwartz et al., 1992b). A more recent concept 
is of the drug-eluting stent, wherein the implanted device is coated with a 
pharmacological agent to inhibit neointima formation, which is slowly released into 
the vessel wall. Pivotal trials of the CYPHER® sirolimus-eluting stent indicate a 
reduction in the need for re-vascularisation of the stented lesion from 16.6% to 4.1% 
at 270 days (Moses et al., 2003). Although drug-eluting stents have been 
enthusiastically adopted, concerns have been raised regarding late (>1 year) 
thrombotic complications, probably reflecting powerful inhibition of this healing 
response. This necessitates extended anti-platelet therapy and possibly results in 
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increases in mortality, especially when used for off-label indications (Liistro & 
Colombo, 2001; McFadden et al., 2004; Camenzind et al., 2007). 
 
1.1.3 Mechanisms of neointima formation 
The formation of a neointimal lesion is the result of elaborate interactions between 
cells of the vascular wall, leucocytes and circulating progenitor cells. The commonly 
accepted ‘cascade model’ by which this occurs was proposed by Libby et al (1992). 
In this model, following vascular injury and EC damage/denudation, platelets adhere 
to the sub-endothelial surface and release a cocktail of mediators: notably including 
many VSMC mitogens. Medial and adventitial trauma and presentation of adhesion 
molecules by platelets also results in recruitment of leucocytes to the region of 
injury, which in turn, release further chemoattractants and mitogens initiating a self-
amplifying inflammatory response. Under mitogenic and chemotactic pressure from 
these events at the luminal surface, medial VSMCs proliferate and migrate towards 
the intima, where they adopt a synthetic phenotype. These intimal VSMCs also 
replicate in situ and deposit extracellular matrix, under the control of mitogens 
released from leucocytes and VSMCs themselves. Eventually, as replicating cells 
become quiescent, and the inhibitory properties of the luminal endothelium recover, 
lesion growth is slowed and a mature, VSMC-rich neointima remains. The individual 
processes contributing to neointima formation are further considered below: 
 
1.1.3.1 Role of thrombosis 
Thrombosis is an obvious candidate for an initiating event in neointima formation. 
The endothelium, which actively prevents thrombosis by release of inhibitors of 
platelet aggregation and catabolism of pro-aggregants, is damaged or destroyed by 
acute mechanical injury, and the thrombogenic sub-endothelial layer is revealed. 
Platelets secrete a variety of mitogens/chemoattractants such as platelet-derived 
growth factor (PDGF), transforming growth factor-β (TGFβ) and thrombin and 
present leucocyte adhesion molecules. Further, it has been suggested that mural 
thrombus formation provides a framework into which VSMCs and leucocytes can 
migrate and proliferate to form a neointima (Schwartz et al., 1992a). Whether 
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platelet activation and thrombosis are obligatory steps in neointima formation is open 
to question. Certainly, anti-thrombotic treatments reduce lesion formation in some 
models of neointima formation (Clowes & Karnowsky, 1977; Clopath, 1980; 
Buchwald et al., 1996). The role of thrombosis, however, varies between species and 
models, for example, being important in pigs but minimal in most rodent models 
(Schwartz et al., 2004). As such, the most damning evidence comes from the clinic. 
Numerous treatments that interfere with platelet activation/coagulation appear unable 
to inhibit restenosis in man including ADP receptor antagonists (Kastrati et al., 
1997), direct thrombin inhibitors (Bittl et al., 1995; Serruys et al., 1995), heparins 
(Karrillon et al., 1996), heparin-eluting stents (Serruys et al., 1996), 
aspirin/dipyridamole (Schwartz et al., 1988), epoprostanol (Gershlick et al., 1994) 
and possibly glycoprotein IIb/IIIa antagonists (Lefkovits et al., 1996; Gibson et al., 
1998; Kastrati et al., 2004). Indeed, the only anti-platelet agent that has been 
consistently shown to reduce the incidence of post-interventional restenosis is 
cilostazol (Douglas et al., 2005), and this response is easily attributable to the anti-
proliferative action of the molecule (Takahashi et al., 1992). Thrombosis, therefore, 
does not appear to be critical to neointima formation, at least in man. Regardless, 
post-interventional anti-platelet therapy has been widely adopted for the prevention 
of acute peri- and post-interventional thromboembolic events (Schwartz et al., 1988). 
 
1.1.3.2 Role of inflammation 
A role for inflammatory processes in neointima formation is more certain. Animal 
models suggest that neutrophil accumulation occurs within 24 hours of acute 
vascular injury with macrophage infiltration apparent within 14 days (Cole et al., 
1987; Tanaka et al., 1993). These cells release a variety of molecules that could 
contribute to the formation of a neointima including PDGF (Shimokado et al., 1985), 
tumor necrosis factor-α (TNFα; Matthews, 1981), interleukin-1 (IL-1), interleukin-6 
(IL-6), ET-1 and matrix metalloproteinase (MMPs). The release of these growth 
factors, cytokines and matrix remodelling enzymes enables the proliferation and 
migration of medial VSMCs and amplifies the inflammatory signal (Libby et al., 
1992). The importance of inflammatory processes in neointima formation is 
demonstrated by the dramatic reductions in lesion size associated with depletion of 
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leucocytes by any of several methods (Miller et al., 2001; Wolff et al., 2004). 
Indeed, in a rat carotid artery balloon-injury model, liposomal bisphosphonate 
administration reduced lesion size by >70% (Danenberg et al., 2003). Moreover, 
numerous specific disruptions of inflammatory pathways also result in reduced lesion 
size following acute vascular injury. These include the adhesion molecules P-selectin 
(Kumar et al., 1997; Hayashi et al., 2000), vascular cell adhesion molecule-1 
(VCAM-1; Oguchi et al., 2000) and intercellular adhesion molecule-1 (ICAM-1; Zou 
et al., 2000), subunits of the pro-inflammatory transcription factor nuclear factor-κB 
(NFκB; Squadrito et al., 2003; Ruusalepp et al., 2006), macrophage chemoattractant 
protein-1 (MCP-1; Furukawa et al., 1999; Schepers et al., 2006), and its receptor 
CCR2 (Roque et al., 2002). Further, deletion or blockade of the IL-1 receptor 
(Chamberlain et al., 2006), TNFα (Zimmerman et al., 2002) or infusion of the anti-
inflammatory cytokine, interleukin-10 (IL-10; Feldman et al., 2000) also reduces 
neointima formation. 
 
Data from clinical studies suggest this insight from animal models is applicable to 
man. Macrophages are abundant in atherectomy (Kornowski et al., 1998) and post-
mortem specimens (Komatsu et al., 1998) of post-interventional re-stenotic lesions. 
Plasma concentrations of inflammatory markers including MCP-1, IL-6, IL-1β, 
macrophage-colony stimulating factor (M-CSF) and C-reactive protein (CRP) are 
also increased following PCI, and those of M-CSF and CRP predict the incidence of 
restenosis (Pietersma et al., 1995; Buffon et al., 1999; Hojo et al., 2001; Kochiadakis 
et al., 2007). Similarly, there is evidence of rapid neutrophil activation following 
PTCA including increased circulating levels of elastase (De Servi et al., 1990) and 
lactoferrin (Steg et al., 1993). Isolated neutrophils from these patients also show 
increased expression of Mac-1, the level of which predicts the incidence of 
subsequent restenosis (Neumann et al., 1996; Serrano et al., 1997; Inoue et al., 
2003). Stents that elute sirolimus and its analogues are known to inhibit post-
interventional restenosis (Moses et al., 2003) and this may be, in part, a reflection of 
their immunosuppressive properties (Calne et al., 1989). Indeed, sirolimus eluting 
stents reduce the acute post-procedural increase in inflammatory markers that 
follows bare metal stent implantation (Kochiadakis et al., 2007).  
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1.1.3.3 Role of VSMCs and matrix deposition 
The role of VSMCs in neointima formation is also difficult to doubt. These cells are 
the major constituent of mature neointimal lesions in animal models (Clowes et al., 
1983; Zwolak et al., 1987; Groves et al., 1995) and post-interventional restenotic 
lesions (Essed et al., 1983; Ueda et al., 1991; Komatsu et al., 1998). In addition to 
providing neointimal mass, VSMCs actively contribute to lesion development by the 
expression of adhesion molecules, and secretion of cytokines and mitogens that 
amplify the inflammatory and proliferative response (Libby et al., 1992; Lindner & 
Reidy, 1993; Lindner, 1995; Tanaka et al., 1996; Crook et al., 2000). They are 
defined as ‘smooth muscle’ by their spindle-like morphology and immunoreactivity 
for α-smooth muscle actin but, in the neointima they commonly also express 
abnormal myosin chain subtypes (Leclerc et al., 1992) and demonstrate reduced 
expression of contractile proteins (Ueda et al., 1991). This switch from a 
‘contractile’ to a ‘synthetic’ phenotype is similar to that seen in cultured VSMCs 
(Chamley-Campbell et al., 1979) and is probably a response to various stimuli, 
including: stretch of the vessel wall (Birukov et al., 1995), endothelial denudation 
(Chamley-Campbell & Campbell, 1981), exposure to platelet and leucocyte products, 
and remodelling of the medial extracellular matrix (Thyberg, 1998). This synthetic 
phenotype is also characterised by hypersensitivity to mitogens and increased 
secretion of extracellular matrix (Chamley-Campbell et al., 1979; Chamley-
Campbell et al., 1981), and thus, is considered to be important in the pathogenesis of 
neointima formation. 
 
The kinetics of cell proliferation in neointimal lesion growth has been the subject of 
detailed study in animals. In the media, proliferation, presumably primarily of 
VSMC-like cells, peaks 2-3 days after injury, but in models featuring more severe 
medial damage, this may be as late as 14 days. In the intima, proliferation peaks 
between 7 and 14 days, and may remain high for long periods. The VSMC content of 
lesions appears to reach a stable maximum between 21 and 28 days and this is 
consistent between models of PCI and vein graft hyperplasia (Clowes et al., 1983; 
Zwolak et al., 1987; London & Mayberg, 1994; Groves et al., 1995; Reis et al., 
2000).  These values support the idea that medial VSMC proliferation precedes 
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migration to, and proliferation in, the intima (Spaet et al., 1975; Lee et al., 1993). 
Both proliferation and migration of VSMCs are likely to be driven by mitogens 
released from leucocytes and from platelets adhering to the injured luminal surface. 
It has also recently been suggested that neointimal VSMCs can be derived from 
circulating progenitor cells (Han et al., 2001; Sata et al., 2002) - a possibility 
considered in section 1.1.3.5. Nonetheless, reduced lesion size is observed following 
blockade of proliferative pathways either at the level of cell proliferation, by 
sirolimus (Burke et al., 1999), paclitaxel (Axel et al., 1997), anti-sense 
oligonucleotides against proliferating cell nuclear antigen (PCNA) or cyclin-
dependent kinase-2 (Morishita et al., 1993; Morishita et al., 1994), or by modifying 
activity of individual mitogens including PDGF (Banai et al., 1998; Matsuno et al., 
2002) and IL-1 (Chamberlain et al., 2006). Migration of medial VSMCs to the intima 
is also likely to depend on remodelling of the basement membrane and medial ECM. 
Several relevant enzymes, including MMP-9, are activated in the growing neointima 
(Godin et al., 2000) and MMP-9 deficiency both impairs VSMC migration in vitro 
and reduces neointima formation in vivo (Cho & Reidy, 2002). 
 
Neointimal lesion growth is not directly coupled to VSMC accumulation. Zwolak et 
al (1987), for example, describe lesion growth by continued extracellular matrix 
deposition in a model of vein graft hyperplasia. Rate of VSMC death may also be 
important because Clowes et al (1983) report high levels of VSMC proliferation in 
balloon-injured rat carotid arteries, without lesion growth. Indeed, continual VSMC 
apoptosis occurs in the neointima in several models (Han et al., 1995; Reis et al., 
2000) and treatments have been described that appear to modify lesion size by 
regulation of apoptosis (Blanc-Brude et al., 2002; Sata et al., 2003; Tanja Rauma-
Pinola, 2006). Perhaps the greatest discrepancy of kinetics is between animal studies 
of neointima formation and man. In almost all animal models, neointimal lesion size 
peaks approximately 1 month after the initiating injury. In man, whilst it is difficult 
to precisely determine the time course of lesion formation, the incidence of post-
PTCA restenosis peaks between 3 and 7 months (Holmes et al., 1984; Nobuyoshi et 
al., 1988; Serruys et al., 1988; Fitzgibbon et al., 1996). This inconsistency is 
probably attributable to the state of the vessels in which neointima formation is 
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elicited since most animal models involve injury of a young, healthy artery whereas, 
in man, re-vascularisation procedures are performed in aged, atherosclerosis-ridden 
vessels. Regardless, inhibition of cell proliferation using sirolimus (Moses et al., 
2003) or paclitaxel eluting stents (Stone et al., 2004) or local delivery of ionizing 
radiation (Teirstein et al., 1997; Leon et al., 2001) has proven a successful strategy 
for the reduction of post-interventional restenosis in human patients. 
 
1.1.3.4 Role of the endothelium and oxidative stress 
The endothelium releases factors, such as NO and PGI2, that suppress the 
inflammatory, proliferative and thrombotic processes implicated in neointima 
formation. Indeed, a role for these factors is supported by the ability of prostacyclin 
synthase (Todaka et al., 1999), eNOS gene transfer (Cooney et al., 2007), NO donor 
drugs (Chaux et al., 1998; Hou et al., 2005) or L-arginine (Schwarzacher et al., 
1997; Le Tourneau et al., 1999) to reduce lesion size in several models of 
endothelium-denuding acute vascular injury. Whether endogenous EC-derived 
factors modulate neointima formation is more difficult to predict because all 
common PCIs (Gravanis & Roubin, 1989; Ueda et al., 1991; Komatsu et al., 1998) 
denude the target vessel of EC. This removal may enhance inflammatory and 
mitogenic processes and, as such, stimulate lesion growth, but is not sufficient to 
induce neointima formation (Reidy & Silver, 1985; Miller et al., 2003). After such 
injury, the endothelium is able to recover by in-growth of cells from the borders of 
the denuded region and, probably, by recruitment of circulating cells (see section 
1.1.3.5). Whether this neo-endothelium is functionally normal is not clear and 
alterations to morphology and endothelium-dependent responses of varying degrees 
have been reported (Schatz et al., 1987; Shimokawa et al., 1987; Shimokawa et al., 
1989; Miller et al., 2003; Liao et al., 2007). Animal studies indicate that EC re-
growth can occur remarkably quickly, with complete recovery of a monolayer of 
cells expressing endothelial markers (von Willebrand factor+, CD31+) and mediating 
at least some ‘endothelium’-dependent vasodilator response within 7-14 days in most 
models (Fishman et al., 1975; Clowes et al., 1976; Reidy & Silver, 1985; Pellegreffi 
& Branzoli, 1987; Schatz et al., 1987; Lindner et al., 1989; Miller et al., 2003; Liao 
et al., 2007). In others, recovery can take up to 6 weeks (Shimokawa et al., 1987), 
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but only in rare cases is complete recovery not achieved (Haudenschild & Schwartz, 
1979; Reidy et al., 1983). In most models, therefore, the speed of endothelial 
recovery appears to be greater than that of lesion growth, indicating that a substantial 
window exists in which the endothelium might modulate neointima formation. 
Further, administration of the EC mitogen, vascular endothelial growth factor 
(VEGF), accelerates re-endothelialisation of denuded regions and inhibits lesion 
growth (Asahara et al., 1995; Hiltunen et al., 2000; Hutter et al., 2004).  
 
The effects of endothelium-targeted interventions in animal models of acute vascular 
injury further suggest this potential. eNOS deficiency, for example, increases lesion 
size (Moroi et al., 1998; Zhang et al., 2006), but has only so far been investigated in 
models of neointima formation that do not involve endothelial denudation. Chronic 
administration of the NOS inhibitor, L-NAME, however, has been shown to 
exacerbate lesion formation, even in EC-denuding models of injury (Le Tourneau et 
al., 1999). Treatments that might be expected to improve endothelial function have 
also been investigated. A variety of anti-oxidants including probucol (Ferns et al., 
1992; Ishizaka et al., 1995; Miyauchi et al., 1998; Yokoyama et al., 2004), N-acetyl 
cysteine (Hayashi et al., 2001) and even red wine (Feng et al., 1999) reduce 
neointima formation in EC-denuding models of vascular injury. This indicates that 
production of oxidative species may contribute to neointima formation, probably, in 
part, by reducing the bioavailability of NO. Dysfunctional ECs, as perhaps may be 
present early after re-endothelialisation, and other neointimal cell types (VSMCs, 
macrophages) are certainly capable of producing oxidative species. Indeed, in hph-1 
mice (a model of NOS uncoupling and EC dysfunction secondary to 
tetrahydrobiopterin (BH4) deficiency), neointima size after EC-denuding injury is 
increased (Wang et al., 2005a). Complementary data from Liao et al (2007) indicate 
that lesion size can be reduced, and basal NO release increased, by improving NOS 
function selectively in EC, by EC-specific over-expression of GTP cyclohydrolase I. 
These studies further suggest that EC can regulate lesion development, despite its 
removal by vascular injury and subsequent re-growth, and implicate the balance 
between production and oxidative deactivation of endothelium-derived NO in the 
pathogenesis of this process. It is also important to note that expression of NOS 
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isoforms has been described in VSMCs of the developing neointima and, thus, that 
beneficial mediators (such as NO) normally produced by the endothelium may be 
released from other cells in the lesion (Arthur et al., 1997; Wang et al., 2005a). 
 
Without longitudinal studies, the time-course of post-interventional re-
endothelialisation is difficult to determine in man. Necropsy samples of balloon-
injured coronary arteries have been reported to possess a complete EC-like 
monolayer as soon as 1 month after intervention (Gravanis & Roubin, 1989). 
Samples obtained 5 and 12 months after injury also possess an intact endothelium 
(Ueda et al., 1991), and at 6 months endothelium-dependent vasomotion of these 
injured vessels is present (Sabate et al., 1999). After stent implantation, Schatz et al  
(1991) report endothelial recovery at 2 months, whilst Komatsu et al (1998) describe 
partial EC coverage in a vessel 9 weeks after intervention. As in animal studies, 
therefore, recovery of the endothelium typically occurs prior to the peak incidence of 
restenosis (3-7 months), with the exact kinetics probably dependent on the nature of 
injury and underlying pathology. The presence of existing endothelial dysfunction, 
implicit in the atherogenic process, may also modulate the ability of EC to regulate 
neointima formation. Indeed, several studies indicate that peripheral flow-mediated 
dilatation is an independent predictor of the incidence of restenosis in coronary 
arteries (Kitta et al., 2005; Patti et al., 2005). This may, however, simply reflect the 
presence of other influences that contribute to both restenosis and EC dysfunction. 
Evidence from endothelium-targeted interventions in man is also limited. VEGF 
gene transfer has been suggested to be ineffective at reducing in-stent restenosis, but 
only in a small trial of low-risk patients of whom just 6 developed restenosis 
(Hedman et al., 2003). More encouragingly, probucol and its derivative AGI-1067 
are effective at reducing the incidence of restenosis (Setsuda et al., 1993; Tardif et 
al., 1997; Yokoi et al., 1997), an effect animal studies attribute to its potent anti-
oxidant potential rather than lipid lowering action (Ferns et al., 1992).  
 
1.1.3.5 Role of circulating progenitors 
The traditional model of neointima formation proposes that VSMC accumulation and 
EC re-growth are the result of proliferation of local vascular cells (Spaet et al., 1975; 
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Stemerman et al., 1977; Haudenschild & Schwartz, 1979; Lee et al., 1993). More 
recent evidence indicates that bone marrow-derived circulating progenitor cells can 
adopt VSMC or EC-like phenotypes to participate in the formation of a neointima 
after vascular injury. Numerous studies in which the bone marrow of myelo-ablated 
mice is reconstituted with that of transgenic reporter animals demonstrate that 20-
70% of the neointimal cells that express VSMC markers (αSMA, calponin), possess 
the donor genotype (Han et al., 2001; Saiura et al., 2001; Sata et al., 2002; Tanaka et 
al., 2003; Wang et al., 2006; Tanaka et al., 2008). Similarly, between 10-50% of the 
ECs regenerated after denudation, appear to be donor-derived (Sata et al., 2002; 
Werner et al., 2002; Tanaka et al., 2003). Moreover, specific populations of 
progenitor cells are implicated with mesenchymal stem cells contributing most 
(Wang et al., 2008). The importance of progenitor cell recruitment in neointima 
formation is not uniform between models, however, and may be related to the degree 
of medial damage inflicted by the initial injury (Tanaka et al., 2003).  
 
1.1.4 Modelling the response to vascular injury 
Direct study of human disease is the obvious means from which to gather 
information regarding pathogenesis and potential therapies must, of course, 
ultimately be tested in man. The practical and ethical limitations of working with 
human tissue, however, have necessitated the development of many animal models 
of neointima formation, from which much of our understanding of the mechanisms 
of this process have been gained. Vascular damage is typically induced by 
mechanical injury but a diverse range of other insults to the vasculature have also 
been devised that result in rapid development of a fibro-proliferative neointima.  
 
1.1.4.1 Intra-luminal injury models 
Models of mechanical damage, inflicted from within the vascular lumen, directly 
mimic the nature of injury induced by PCIs. Much of the early work on the 
pathogenesis of neointima formation was performed using intra-luminal balloon 
injured rat internal carotid arteries. The degree of injury is adjustable by altering 
inflation pressure and balloon compliance but typically induces rapid and 
 18
reproducible formation of a moderate neointima (intima/media ratio ~1-1.5; Clowes 
& Karnowsky, 1977; Fingerle et al., 1990; Morishita et al., 1993; Morishita et al., 
1994; Mnjoyan et al., 2008). Balloon-injury and stent implantation are also used to 
elicit neointima formation in larger animals, particularly swine (Steele et al., 1985; 
Heras et al., 1989). These species carry the considerable advantage that clinical 
interventional devices can be directly employed, but to ensure severe and 
reproducible injury, balloons and stents that would be considered over-sized for a 
human artery of the same calibre are commonly used (Schwartz et al., 1992b; Burke 
et al., 1997; Touchard & Schwartz, 2006). Nonetheless, the neointimal lesions-
induced by porcine coronary artery injury are characterised by their similarity to 
those in man and, these models have the highest accuracy in predicting the clinical 
efficacy of anti-re-stenotic treatments (Schwartz et al., 1992b; Schwartz et al., 1994; 
Touchard & Schwartz, 2006).  
 
Intra-luminal injury to the murine vasculature presents a particular challenge due to 
its scale. Lindner et al (1993) first reported a wire-injury model, which entails 
insertion of an angioplasty guide wire, of comparable diameter to the vessel lumen, 
into the mouse carotid artery. The neointimal response, however, is modest 
(intima/media ratios less than 0.1 have been reported), strongly dependent on mouse 
strain, and is of variable reproducibility (Lindner et al., 1993; Sullivan et al., 1995; 
Iafrati et al., 1997; Xu, 2004; Liao et al., 2007). This model was adapted by two 
separate groups for application to the femoral artery and these derivatives have been 
widely adopted. Both elicit a similar neointimal response, and differ only in that Sata 
et al (2000) describe insertion of the wire via the popliteal branch rather than the 
femoral artery itself (Roque et al., 2000); thereby allowing blood flow to be 
preserved over the injured region. Femoral artery wire-injury addresses each of the 
short-comings of the carotid wire-injury model - eliciting reproducible formation of a 
large VSMC-rich neointimal lesion (intima/media ratios ~2) in a variety of mouse 
strains (Roque et al., 2000; Sata et al., 2000): a greater responsiveness presumably 
attributable to the use of a wire of the same diameter in a substantially smaller vessel 
(Roque et al., 2000; Kawasaki et al., 2001). Wire-insertion is associated with severe 
medial stretch damage and endothelial denudation (Roque et al., 2000; Sata et al., 
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2000). Within hours of injury, apoptosis in the media and adhesion of platelets and 
neutrophils to the luminal surface occurs, and within 7 days macrophage infiltration 
is present (Reis et al., 2000; Roque et al., 2000; Sata et al., 2000; Osaka et al., 2007). 
Neointima formation is apparent from 7 days and reaches a maximum size between 
21 and 28 days where it is stable for at least 56 days (Roque et al., 2000; Sata et al., 
2000). Re-growth of the endothelium is also complete by 28 days (Sata et al., 2000), 
and unpublished data from this laboratory indicates this occurs between 7 and 14 
days (Macdonald et al., Unpublished data). Indeed, data from the carotid wire-injury 
model suggests restoration of endothelium-dependent vasodilatation occurs by 10 
days (Liao et al., 2007). Proliferation in both the media and neointima peak at 14 
days (Reis et al., 2000) and a substantial role for bone marrow-derived VSMCs and 
ECs is indicated (Saiura et al., 2001; Tanaka et al., 2003; Shoji et al., 2004). 
 
1.1.4.2 Peri-vascular injury models 
The relative complexities of these mechanical modes of injury, particularly in the 
mouse, have led to the adoption of numerous neointima-inducing insults that can be 
applied from the adventitial surface of the vascular wall. Robert Buck (1961) 
originally described ligation-induced neointima formation in the rat carotid artery but 
this mode of injury only found common use after its adaption to the mouse (Kumar 
& Lindner, 1997). Permanent ligation of the common carotid artery abolishes blood 
flow and elicits formation of a moderate, muscular neointima (intima/media ratio ~1-
1.5) within 28 days without overt EC damage (Kumar et al., 1997; Kumar & 
Lindner, 1997; Godin et al., 2000). Between 7 and 14 days, intimal and medial 
proliferation rates peak and formation of platelet-rich thrombus in the vessel lumen is 
apparent (Kumar & Lindner, 1997; Godin et al., 2000). Leucocytes adhering to the 
endothelium are detectable from 1 day after ligation, and at later time-points are 
associated with platelet aggregates and the adventitia (Godin et al., 2000). Little role 
for VSMC-like cells derived from circulating progenitors is apparent in this model, 
presumably due to the absence of direct injury to media, from where these cells may 
also be derived (Tanaka et al., 2003). Numerous potential stimuli exist for 
inflammation and neointima formation following arterial ligation. Loss of blood flow 
and, therefore, low shear stress may promote EC dysfunction and adhesion molecule 
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expression (Kumar & Lindner, 1997; Godin et al., 2000). Indeed, endothelial ICAM-
1 and VCAM-1 immunoreactivity can be detected from 3 days in this model 
(Kawashima et al., 2001). The absence of blood flow may also result in hypoxic 
damage to vascular wall cells and formation of stasis thrombus in the lumen, 
containing activated platelets that present leucocyte adhesion molecules and release 
mitogens (Kumar & Lindner, 1997; Godin et al., 2000).  
 
An alternative ‘endothelium-intact’ model of neointima formation comprises 
installation of a loose-fitting sheath of polyethylene or silicone tubing around an 
isolated artery. This peri-vascular cuff model was first applied to the rabbit carotid 
artery (Booth et al., 1989), and later adapted to the mouse femoral artery (Moroi et 
al., 1998). Over 14 days, a small neointima (intima/media ratios 0.5-1) reliably 
develops in the cuffed portion of vessel without thrombus formation or disruption of 
the endothelium (Kockx et al., 1992; Kockx et al., 1993; Moroi et al., 1998). 
Although various explanations for this response have been suggested (cuff toxicity 
and inflammatory activation, vessel distortion, damage to the adventitial vaso 
vasorum, lymphatic vessels or innervation) the exact stimuli for neointima formation 
remain unclear (Kockx et al., 1992). Electrical injury to the arterial wall is a more 
overt stimulus for neointima formation. Injury to the mouse femoral artery by a 
single application of electrical current across the adventitial surface results in 
necrosis of medial VSMCs, destruction of the endothelium and transient mural 
thrombus formation. Intimal proliferation peaks between 7 and 14 days, and results 
in formation of a moderate neointima (intima/media ratios ~1.5; Carmeliet et al., 
1997; Carmeliet et al., 1998).  
 
1.2 ENDOTHELIN & ENDOTHELIN RECEPTORS 
ET-1 is one of many mediators implicated in pathogenesis of neointima formation, 
and indeed, a variety of other cardiovascular diseases. This potent vasoconstrictor 
peptide was first isolated from cultured porcine ECs by Hickey et al  in 1985. The 
structure, generation and cardiovascular effects of ET-1 were subsequently described 
in a single remarkable paper (Yanagisawa et al., 1988). It is now established that ET-
1 is the principal cardiovascular isoform of a family of 21 amino acid peptides 
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comprising ET-1, ET-2 and ET-3 (Inoue et al., 1989; Bloch et al., 1991). ETs 
possess striking sequence homology with 4 further peptides, sarafotoxins, extracted 
from the venom of Atractaspis engaddensis (Kloog et al., 1988), which also contain 
the two disulphide bridges (Figure 1-2) that give these peptides their characteristic 
‘open loop’ tertiary structure (Janes et al., 1994). 
 
1.2.1 Synthesis and release of endothelins 
ET-1 is generated from precursor peptides via a two-step proteolytic pathway 
(Figure 1-2). Transcription of a gene on chromosome 6 generates mRNA encoding 
the 212 amino acid peptide, preproET-1 (ppET-1), which, once translated, is stripped 
of its signal sequence and secreted into the cytoplasm as proET-1 (Inoue et al., 
1989). ProET-1 is further cleaved by a furin-like endopeptidase to the 38 amino acid 
precursor big ET-1 which circulates in plasma at low concentration but is not thought 
to possess significant bioactivity (Yanagisawa et al., 1988; Kimura et al., 1989; 
Denault et al., 1995). Removal of a further 17 C-terminal residues classically (but 
not exclusively) by ET-converting enzymes (ECE) produces the mature 21 amino 
acid ET-1 (Yanagisawa et al., 1988; Ohnaka et al., 1990; Opgenorth et al., 1992). 
 
In humans and rodents two distinct isozymes of ECE, ECE1 (Xu et al., 1994) and 
ECE2 (Emoto & Yanagisawa, 1995), catalyse the second (rate-limiting) step in ET-1 
synthesis (Opgenorth et al., 1992). These type II integral membrane proteins have 
catalytic domains characteristic of zinc metalloproteinases and are closely related to 
other enzymes of this class, (Xu et al., 1994). ECE1 has four functionally-similar 
isoforms (ECE1a-d), defined by slight variations in NH2-terminal sequence, which 
determine their discrete sub-cellular localisation to plasma and intracellular 
membranes (Russell & Davenport, 1999). ECE2 has at least four distinct isoforms 
but is less well characterised than ECE1 and may have a role in the processing of big 







Figure 1-2 Generation and action of ET-1 within the vascular wall.  
The 21 amino acid peptide, ET-1, is the eventual product of a gene on chromosome 6 which encodes preproET-1 
protein. This is converted to proET-1 on secretion into the cytoplasm which itself undergoes enzymatic cleavage 
by a furin-like endopeptidase to form bigET-1. ET-1 is generated from bigET-1 by ECEs and is excreted 
predominantly abluminally into the vessel wall. Other enzymes may also process big ET-1 to yield bioactive 31- 
and 32-amino acid isoforms. ET-1 stimulates contraction, proliferation and migration of vascular cells by a direct 
action on VSMC ETA, and to a lesser extent, VSMC ETB receptors. ET-1 promotes ET-1 clearance and indirect 
relaxation and anti-proliferation by stimulation of the EC ETB receptor. The identity of the vasodilators released 
from the endothelium following ETB receptor stimulation varies between vascular beds. The principal 
pharmacological approaches to modulating the action of ET-1 are (1) inhibition of synthesis with ECE inhibitors 
and (2) blockade of receptors using ETA selective or non-selective ETA/B antagonists. EDRF, endothelium-
derived relaxing factors; ECE, endothelin-converting enzyme; VSMC, vascular smooth muscle cell; EC, 
endothelial cell. Reproduced from Kirkby et al (2008). 
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Surprisingly, ECE1/ECE2 double knockout mice continue to produce significant 
amounts of ET-1 (Yanagisawa et al., 2000), albeit alongside developmental defects 
characteristic of inhibition of the ET axis, suggesting substantial redundancy of this 
pathway. Indeed, several other enzymes can cleave big ET-1 to form both ET-1 and 
isoforms bearing extended C-terminal sequences. These include chymase (Wypij et 
al., 1992) and gelatinolytic MMPs (Fernandez-Patron et al., 1999), which mediate 
the production of ET-1[1-31] and ET-1[1-32] respectively. 
 
In ECs, ET-1 is released through both constitutive and regulated (rapid release) 
pathways (Russell & Davenport, 1999). Vesicles originating in the trans-Golgi 
network and Weibel-Palade bodies display immunoreactivity for ET-1, ECE and big 
ET-1 suggesting that, in addition to their role in transport and storage, they serve as 
sites of ECE-regulated ET-1 synthesis (Barnes et al., 1998). ET-1 release via the 
constitutive pathway is regulated principally at the level of gene transcription. 
Synthesis is enhanced by protein kinase C (PKC)- and phospholipase C (PLC)-
dependent pathways in response to low or turbulent shear stress, hypoxia, cytokines, 
angiotensin II and catecholamines. In contrast, increased levels of cyclic nucleotide 
monophosphates associated with high shear stress, NO, PGI2 and natriuretic peptides 
suppress ET-1 production (Gray & Webb, 1996). Although EC are the main 
physiological source of vascular ET-1 in humans and animals (Properzi et al., 1995), 
it is now recognised that VSMCs, macrophages, leucocytes, cardiomyocytes and 
fibroblasts are all capable of ET-1 production (Nunez et al., 1990; Resink et al., 
1990; Firth & Ratcliffe, 1992). In the kidney, tubular epithelial cells, mesangial cells 
and podocytes also release ET-1 (Kohan, 1997). Indeed, the kidney contains amongst 
the highest ET-1 concentrations of any organ. (Morita et al., 1991). 
 
1.2.2 Clearance of endothelins 
Clearance of ETs from plasma occurs primarily in the lungs (Anggard et al., 1989) 
by endocytosis and degradation of a complex of the ETB receptor and ET ligand 
(Fukuroda et al., 1994a; Dupuis et al., 2000). The speed of this clearance, together 
with the polarised, abluminal nature of ET-1 secretion by ECs, emphasises the poor 
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predictive value of plasma ET-1 concentration as a measure of synthesis and has 
resulted in difficulty assessing alterations to ET-1 activity in disease. EC-specific, 
but not inner-medullary collecting duct (IMCD) cell-specific, deletion of ETB 
receptors results in a 4-fold increase in plasma [ET-1] and impaired clearance of 
exogenous ET-1, supporting the view that EC ETB receptors contribute much of the 
capacity for ET-1 clearance (Bagnall et al., 2006; Ge et al., 2006). Enzymatic 
degradation also contributes to the clearance of ET-1. Neutral endopeptidase, 
probably that located in the brush-border vesicles of the proximal tubule, catabolises 
ET-1 and inhibition of this enzyme increases plasma and urinary ET-1 
concentrations (Abassi et al., 1992). Indeed, a significant role for the kidney in the 
clearance of ET-1 is indicated by the demonstration that bilateral nephrectomy 
impairs removal of exogenous ET-1 in rats (Shi et al., 1994). Elegant micro-PET 
studies suggest that renal ET-1 clearance occurs through both receptor-mediated and 
enzymatic processes and also highlight the liver as a further important site of ET-1 
clearance (Johnstrom et al., 2005). 
 
1.2.3 Endothelin receptors 
The downstream effects of ET-1 are mediated by two distinct receptor subtypes, 
ETA and ETB, which belong to the rhodopsin-like G-protein-coupled receptor 
superfamily. cDNAs encoding both receptors were isolated and cloned within two 
years of the initial characterisation of ET-1 and exhibit 59% sequence homology 
(Arai et al., 1990; Sakurai et al., 1990; Frelin et al., 1991; Sakamoto et al., 1991). 
Human ETA and ETB bind ET-1 with equal affinity but ETA possess at least 100-
fold less affinity for ET-3 than do ETB receptors (Davenport, 2002). Two additional 
receptor subtypes identified in Xenopus laevis, have no mammalian equivalent 
(Karne et al., 1993; Kumar et al., 1994). Additional classification of the ETB 
subtype (particularly prompted by the differential sensitivity of specific ETB-
mediated functional responses to the antagonist PD142893) has not been supported 
by detailed kinetic studies or the effects of ETB gene deletion (Gray & Webb, 1996; 
Mizuguchi et al., 1997). Furthermore, splice variants reported for both subtypes have 
not been shown to have functional significance (Davenport, 2002). 
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ET receptors are expressed in a variety of human tissues. In the vasculature, VSMCs 
express both ETA and ETB. ECs typically express only ETB (Molenaar et al., 1993) 
although ETA-like receptors have been reported in the endothelium of the human 
and rat brain microvasculature (Kawai et al., 1997; Spatz et al., 1997). The relative 
expression of ETA and ETB by VSMCs is variable but the ETA:ETB ratio is often 
considered to increase with vessel size (Tschudi & Luscher, 1994; Davenport et al., 
1995a). In the human heart, cardiomyocytes and fibroblasts predominantly express 
ETA, although ETB expression is more abundant in cardiac conducting tissue 
(Molenaar et al., 1993). ETB receptors are highly expressed in the renal medulla 
(Karet & Davenport, 1996; Kuc & Davenport, 2004) on both epithelial and 
endothelial (vasa recta) cells, in humans and animals. Renal ETA receptors are less 
abundant and are predominantly found on the larger renal vessels. 
 
Stimulation of ETA and ETB elicits diverse physiological responses, including: 
vasoconstriction, mitogenesis, inflammation, hypertrophy and differentiation. The 
precise response elicited in a particular tissue is dependent on the identity of the 
receptor expressed and the second messenger pathways activated - which are still the 
subject of much discussion (Motte et al., 2006). Further complication may result 
from the formation of ETA/ETB heterodimers giving rise to ligand-dependent 
differences in functional response and internalisation kinetics (Gregan et al., 2004). 
Acute stimulation of either ETA or ETB is associated with an increase in 
intracellular Ca2+. This is composed of an initial rapid, transient phase associated 
with release from intra-cellular stores mediated by the inositol-1,4,5-
trisphosphate/diacylglycerol pathway, followed by a sustained influx of extracellular 
Ca2+ across the sarcolemma. Although free intercellular Ca2+ is a key mediator of 
altered VSMC tone, ET receptors also directly activate phospholipase A2, modulate 
activity of adenylate cyclase and, by multiple pathways, promote membrane 
depolarisation (Motte et al., 2006). Effects of ET-1 on gene transcription are 
mediated both by PKC-dependent stimulation of the mitogen activated protein kinase 
(MAPK) pathways and PKC-independent activation of the signal transducers and 
activators of transcription pathways (Motte et al., 2006).  
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1.2.4 Cardiovascular consequences of ET receptor activation 
ETs are commonly defined by their impressive vasomotor effects (Yanagisawa et al., 
1988). Indeed, ET-1 remains one of the most potent and characteristically sustained 
vasoconstrictors yet described. Vascular tone is maintained, in part, by the action of 
endogenous ET-1, and, consequently, systemic ET receptor blockade in human 
subjects lowers blood pressure (Haynes et al., 1996). Bolus administration of an ET 
receptor agonist (especially a selective ETB agonist such as ET-3 or S6c) in whole 
animals or the human forearm causes transient hypotension/vasodilatation before the 
onset of vasoconstriction. Blockade of NO or prostacyclin synthesis at least partially 
prevents this depressor response, and potentiates the pressor phase (de Nucci et al., 
1988; Yanagisawa et al., 1988; Whittle et al., 1989; Gardiner et al., 1990; Clozel et 
al., 1992; Rogerson et al., 1993; Haynes et al., 1995). Moreover, in isolated vascular 
rings, ETB stimulation also elicits endothelium-dependent vasodilatation 
(Takayanagi et al., 1991; Clozel et al., 1993), even in the mouse aorta in some 
reports (Mizuguchi et al., 1997), despite the monophasic (vasoconstrictor) response 
of this species to an ET-1 bolus (Giller et al., 1997). Thus, the initial ET-1-evoked 
depressor action, is primarily mediated by the stimulated production of NO and other 
endothelium-derived relaxing factors by ETB receptors in the endothelium. The 
vasoconstrictor phase of the response to ET-1 is principally associated with VSMC 
ETA receptor activation (Ihara et al., 1992; Haynes & Webb, 1994).  VSMC ETB 
receptor-mediated contraction is also well-documented in many vascular beds though 
probably contributes little to vascular tone. Indeed, selective ETB receptor blockade 
increases peripheral vascular resistance in healthy humans (Strachan et al., 1999) 
suggesting the balance between vasodilator and vasoconstrictor ETB pathways 
favours vasodilatation. In pathological conditions, however, it is possible that this 
balance may be altered (Cardillo et al., 2000; Pernow et al., 2000). These effects of 
ET-1 on vascular resistance produce predictable reflex changes in heart rate and 
cardiac output. Direct effects on the heart including positive inotropy, are also 
reported (Meyer et al., 1996; Burrell et al., 2000). In many studies, however, 
concomitant effects on coronary blood flow may limit interpretation of such data.  
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The kidney is also an important target for ET-1. Exogenous ET-1 stimulates regional 
changes in renal blood flow, typically inducing vasoconstriction in the renal cortex 
and vasodilatation in the medulla (Rubinstein et al., 1995). Medullary vasodilatation 
appears to be solely mediated by ETB receptor stimulation whilst effects on the 
larger renal vessels and glomerular afferent and efferent arterioles are both ETA and 
ETB receptor-dependent (Dhaun et al., 2006). In mice, at least, IMCD cell-derived 
ET-1 exerts an autocrine natriuretic and diuretic effect that is at least partially 
mediated by ETB and inhibition of the epithelial sodium channel. Indeed, IMCD 
cell-specific deletion of ETB (but neither IMCD cell-specific ETA nor EC-specific 
ETB knockout) results in salt-sensitive hypertension (Bagnall et al., 2006; Ge et al., 
2006) suggesting that IMCD-derived ET-1 stimulates natriuresis by an autocrine 
action mediated by ETB.  
 
1.2.5 Lessons from genetic manipulation of the ET system 
The elegant dissection of the natriuretic response to ET-1 is one example of the 
power that studies of genetic manipulation of components of the ET system have 
provided. In particular, such use of conditional gene targeting technology has 
allowed the analysis of ET receptor function in a cell-specific manner, a goal that is 
not achievable by pharmacological means and is of great importance given the 
physiologically antagonistic effects of ET receptors expressed by different cell types. 
Gene over-expression and non-cell specific knockout studies have also been widely 
utilized to improve our understanding of the ET system.  
 
1.2.5.1 Gene over-expression 
Transgenic ET-1 mice, in which the human ppET-1 gene is introduced into the 
mouse germline under control of its natural promoter, exhibit modestly elevated 
plasma and renal ET-1 levels, but are not overtly hypertensive (Hocher et al., 1997; 
Shindo et al., 2002). Cross of ET-1 transgenic mice with eNOS-/- or iNOS-/- mice 
results in a relative increase in blood pressure, suggesting that vascular or renal NO 
production may suppress a hypertensive effect of ET-1 in this model (Hocher et al., 
2004; Quaschning et al., 2007; Quaschning et al., 2008). Transient viral transfection 
 28
of a cytomegalovirus promoter-controlled ppET-1 gene construct in rats, in contrast, 
results in large increases in both blood pressure and plasma ET-1 (Telemaque-Potts 
et al., 2000; Telemaque-Potts et al., 2002). The effect of ET-1 gene expression using 
cell-specific promoters has also been explored. EC-specific ET-1 over-expression 
using the Tie2 promoter is associated with EC dysfunction, small artery hypertrophy 
and macrophage infiltration into the vascular wall (Amiri et al., 2004; Amiri et al., 
2008). These mice too are normotensive; probably because the vasoconstrictor 
response to ET-1 is blunted (Amiri et al., 2004). Inflammatory activation is also 
apparent in cardiomyocyte-specific ET-1 over-expressing mice and this is associated 
with cardiac hypertrophy and premature death (Yang et al., 2004). 
 
1.2.5.2 Non-specific gene deletion 
Genetic deficiency of any major component of the ET system including ppET-1, 
ppET-3, ECE-1, ETA and ETB results in pre- or peri-natal mortality, thereby 
complicating the study of cardiovascular phenotype. Disruption of the ECE-1/ET-
1/ETA axis is associated with abnormal development of cardiac and cephalic neural 
crest-derived tissues leading to cardiac outflow tract and cranio-facial defects similar 
to those seen in velocardiofacial syndrome in man (Arinami et al., 1991; Hosoda et 
al., 1992; Scambler et al., 1992; Kurihara et al., 1994; Valdenaire et al., 1995; 
Clouthier et al., 1998; Yanagisawa et al., 1998). Disruption of the ECE-1/ET-3/ETB 
axis results in defects to trunk and enteric neural crest-derived tissues and this is 
associated with an absence of epidermal melanocytes and aganglionic megacolon. 
Mutations to the genes encoding these proteins have been described in patients with 
Hirschsprung’s disease and type IV Waardenburg’s syndrome; human conditions 
with similar presentation (Baynash et al., 1994; Hosoda et al., 1994; Yanagisawa et 
al., 1998). As a result, various ‘partial’ deletion strategies have been employed to 
investigate the roles of these gene products, generating some surprising data. For 
example, heterozygous deletion of the ppET-1 gene increases, rather than reduces, 
blood pressure (Kurihara et al., 1994), highlighting the role for ET-1 in the central 
regulation of sympathetic drive (Ling et al., 1998), whilst heterozygous ETA 
receptor knockout mice are normotensive (Berthiaume et al., 2000a; Berthiaume et 
al., 2000b). ETB receptor deficiency has been the subject of greater study; in part, 
 29
due to the description of a hypomorphic ETB allele which allows the responses to 
1/8th normal ETB expression to be investigated (Ohuchi et al., 1999), and the 
development of rescued ETB-deficient rodents in which neurocristopathies are 
prevented by introduction of a dopamine-β-hydroxylase promoter-driven ETB 
transgene (Gariepy et al., 1998). These models of ETB deficiency (summarised in 
Table 1-1) exhibit elevated blood pressure, which is sensitive to dietary salt intake 
and amiloride treatment. Kidney cross-transplantation studies in rats indicate the 
importance of both renal and extra-renal ETB genotype in this hypertensive effect, 
and in some reports it is abolished by concurrent ETA blockade (Ohuchi et al., 1999; 
Berthiaume et al., 2000a; Berthiaume et al., 2000b; Murakoshi et al., 2002; 
Elmarakby et al., 2004; Ohkita et al., 2005; Fryer et al., 2006). Loss of ETB 
expression is also associated with elevated plasma ET-1 levels (or impaired ET-1 
clearance), down-regulation of ETA receptor expression, and EC dysfunction 
secondary to oxidative stress (Berthiaume et al., 2000a; Berthiaume et al., 2000b; 
Gariepy et al., 2000; Quaschning et al., 2005).  
 
1.2.5.3 Cell-specific gene deletion 
Conditional gene targeting using the Cre-loxP recombination system offers 
considerable advantages to the study of the ET system because inducible or cell-
specific control of expression can avoid the developmental phenotype resulting from 
deficiency in the ET system. Moreover, cell-specific gene deletion studies can 
determine the contribution of ET and its receptors in specific cell types to the 
function of complex tissues such as the vascular wall and kidney, where the activity 
of the ET system is a composite response of diverse actions in many cell types. This 
is achieved by the introduction of two loxP sequences, flanking a critical portion of 
the gene of interest, by homologous recombination. These animals are subsequently 
crossed with mice bearing a transgenic insertion of a construct encoding the 
bacteriophage enzyme Cre recombinase. Deletion (or rather down-regulation) of the 
targeted gene occurs because Cre mediates the excision of loxP-flanked (‘floxed’) 
sequences by recombination, and this can be controlled in a spatial and/or temporal 





Model Species Blood Pressure Plasma ET-1 Endothelial function ETA expression Reference(s) 
       
ETB -/-, neonatal Mouse    Reduced lung and brain ETA ligand binding  
(Davenport & Kuc, 2004) 
(Kuc et al., 2006) 
ETB -/-, rescued Mouse Increased  (salt-sensitive)  
Impaired aortic EC-dependent 
vasodilatation 
Reduced ETA-mediated aortic 
constriction 
(Murakoshi et al., 2002) 
(Quaschning et al., 2005) 
ETB -/-, rescued Rat Increased  (salt-sensitive) Increased 
Increased aortic superoxide 
production Reduced renal ETA ligand binding 
(Gariepy et al., 2000) 
(Taylor et al., 2003) 
(Elmarakby et al., 2004) 
ETB -/s Mouse Increased Unchanged compared to +/s   (Ohuchi et al., 1999) 
ETB +/s Mouse Unchanged    (Ohuchi et al., 1999) 
ETB +/- Mouse Increased Impaired clearance of [
125I]-ET-
1  
Reduced hypotension to ETA 
blockade (Berthiaume et al., 2000b) 
EC-specific  
ETB -/- Mouse Unchanged 
Increased; Impaired clearance 
of [125I]-ET-1 
Impaired aortic EC-dependent 
vasodilatation Unchanged 
(Bagnall et al., 2006) 
(Kelland et al. Unpublished data) 
IMCD-specific  
ETB -/- Mouse 
Increased  
(salt-sensitive) Unchanged   (Ge et al., 2006) 
        
 
Table 1-1 Phenotypic changes in models of ETB receptor deficiency.  
Non-specific ETB deficiency is, in most reports, associated with increased blood pressure which is sensitive to dietary salt intake, and reductions in ETA receptor function or ligand binding. 
Elevated plasma ET-1 or reduced ET-1 clearance, and impaired aortic endothelial dysfunction also result from loss of ETB. Specific deletion of ETB from IMCD cells results in elevated blood 
pressure and salt-sensitivity without increasing plasma ET-1, whilst EC-specific ETB knockout impairs ET-1 clearance and aortic endothelium-dependent vasodilatation without altering 
blood pressure. ETB -/s and ETB +/s, refer to animals bearing a hypomorphic ETB allele, and respectively possess 1/8th and 5/8th normal ETB receptor expression levels. ETB -/-, rescued 
refers to animals possessing a dopamine-β-hydroxylase ETB transgene in addition to ETB deletion. EC, endothelial cell; IMCD, inner medullary collecting duct epithelial cell. 
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Mice bearing floxed portions of the genes encoding ET-1, ETA and ETB have so far 
been used for investigations into the roles of ET and its receptors in cardiomyocytes, 
ICMD cells, neurons and ECs. In the heart, cardiomyocyte-derived ET-1 appears to 
contribute to the pathogenesis of several cardiomyopathies (Huang et al., 2002; 
Shohet et al., 2004) whilst, in contrast, cardiomyocyte-specific ETA receptor 
deficiency does not alter cardiac function or hypertrophic responses (Kedzierski et 
al., 2003). In the kidney, as discussed above, IMCD-derived ET-1 regulates 
salt/water homeostasis and, consequently, IMCD ET-1 knockout mice exhibit salt-
sensitive hypertension (Ahn et al., 2004), which is partially recapitulated in IMCD 
ETB knockout mice (Ge et al., 2006). 
 
1.2.5.3.1 EC-specific ETB knockout mice 
EC-specific ETB knockout mice were produced, in part, to determine whether a 
paracrine action of IMCD-derived ET-1 on vasa recta ECs contributes to the 
natriuretic response. These animals were produced by the crossing floxed ETB mice 
with the Tie2-Cre transgenic mice produced by Kisanuki et al (2001). Tie2-Cre mice, 
when crossed with reporter strains, exhibit strong pan-endothelial expression of Cre 
with additional recombination apparent in the mesenchymal cells of the 
atrioventricular canal and proximal cardiac outflow tract (Kisanuki et al., 2001). This 
Cre construct has been shown to mediate ~80% deletion of the targeted gene in lung 
ECs isolated from EC-specific connexin 43 knockout mice, whilst expression in 
brain grey matter is not altered (Liao et al., 2001).  
 
EC-specific ETB knockout mice have been validated using several techniques. 
Binding of [125I]-ET-1 to EC-enriched lung homogenates is substantially reduced by 
EC-specific ETB deficiency, and that which remains is almost abolished by pre-
incubation with an ETA antagonist. Similarly, densitometry measurement of whole 
body autoradiographs of binding of an ETB-selective radioligand ([125I]-BQ3020) 
indicates dramatic reductions in EC-rich tissue (>94% in lung parenchyma and >96% 
in the renal medulla). In contrast, in non-EC ETB rich areas such as the respiratory 
bronchi, no significant alteration is apparent (Kelland et al., Unpublished data). ETB 
deficiency also impairs ETB agonist-stimulated vasodilatation in aortic rings to a 
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similar extent as pre-incubation with an ETB antagonist (Bagnall et al., 2006). EC-
specific ETB-deficient mice are normotensive and do not exhibit an exaggerated 
blood pressure response to increasing dietary salt intake; suggesting that IMCD-
derived ET-1 does not regulate natriuresis by paracrine activation of vasa recta EC 
ETB receptors (Bagnall et al., 2006). This also indicates that systemic, ETB-
mediated, EC-dependent vasodilatation is not critical to the regulation of blood 
pressure in the mouse, despite modest impairment of acetylcholine-stimulated EC-
dependent vasodilatation. A 4-fold elevation in plasma ET-1 concentration is 
apparent in these mice (Bagnall et al., 2006) and this is accompanied by impaired 
clearance of [125I]-ET-1 of similar degree to that seen following ETB antagonist 
administration, indicating that ETB expressed by EC is the primary mechanism for 
the clearance of ET-1 from plasma (Kelland et al. Unpublished data). Finally, 
following exposure to hypoxic conditions, EC-specific ETB deficiency is associated 
with an exaggerated increase in right ventricular pressures and hypertrophic 
remodelling of pulmonary arteries, indicating that EC ETB may exert a protective 
role in pulmonary hypertension (Kelland et al. Unpublished data).  
 
1.2.6 Pharmacological tools for manipulating the ET system 
Excellent pharmacological tools have also been developed for manipulating the ET 
system, primarily in response to their therapeutic potential. Analogous to inhibition 
of the RAAS with ACE inhibitors and AT1 receptor antagonists, pharmacological 
blockade of endogenous ET system has centered on two main strategies: (1) 
inhibition of ET biosynthesis by ECE and (2) direct antagonism of ET receptors. 
 
1.2.6.1 ECE Inhibition 
Blockade of ET synthesis, by inhibition of ECE1 (Figure 1-2), is an intuitive 
approach to reducing the activity of ET-1. The effectiveness of this strategy is 
illustrated by the ability of phosphoramidon to cause vasodilatation and attenuate big 
ET-1-induced vasoconstriction in healthy volunteers (Haynes & Webb, 1994). Many 
studies have also shown potentially beneficial effects of ECE inhibition in disease 
models (reviewed by Jeng et al., 2002). ECE inhibitors, however, have been eclipsed 
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by ET receptor antagonists both in experimental and in clinical use. This limited 
enthusiasm for ECE inhibition may be due to theoretical concerns regarding the 
approach; namely, the redundancy in ET-1-generating pathways and the presence of 
non-ECE big ET-1-processing enzymes. In addition, should ECE inhibitors 
successfully reduce ET-1, they would (as with mixed ETA/B receptor antagonists) 
reduce the beneficial ETB-receptor-mediated actions (vasodilatation and natriuresis) 
of endogenous ET-1, with the sole advantage that they would preserve receptor-
mediated ET-1 clearance.  
 
1.2.6.2 ET receptor antagonists 
Non-peptidic and peptidic ET receptor antagonists, developed from diverse sources 
in the wake of the initial characterisation of ET-1, have been pivotal in defining the 
role of ETs in cardiovascular physiology and pathophysiology (Battistini et al., 
2006). Animal and human studies using these compounds demonstrated the ability of 
ET receptor antagonists to oppose the biological effects of endogenous and 
exogenous ETs and identified distinct roles for ETA and ETB receptors (Ihara et al., 
1992; Haynes & Webb, 1994). Indeed, the defining pharmacodynamic variable of ET 
receptor antagonists is that of selectivity. To be considered ETA selective, 
antagonists must display at least 100-fold greater affinity for ETA than for ETB 
(Davenport, 2002), a selectivity ratio superior to that possessed by many so-called 
β1-selective adrenoceptor antagonists. Thus, at optimal concentration, an ETA-
selective compound should occupy >90% of ETA receptors while blocking <10% of 
ETB receptors. At first glance, the argument in favour of selective ETA antagonists 
seems compelling since ETB receptors mediate beneficial cardiovascular effects 
(natriuresis, NO release, ET-1 clearance). What remains unclear is whether changes 
in ETB-mediated response in disease may compromise any net beneficial effect of 
ETB receptor activation (Cardillo et al., 2000; Pernow et al., 2000). Further, it is 
suggested that cross-talk between ET receptors may allow the ETB receptor to adopt 
functions of the ETA receptor under conditions of selective ETA blockade 




1.2.7 Clinical progress  
Early clinical trials of the “-sentan” class of drugs have included both selective ETA 
and mixed ETA/ETB receptor antagonists. The following indications have been 
studied in large trials: pulmonary arterial hypertension (PAH), scleroderma, heart 
failure (chronic and acute), essential hypertension, erectile dysfunction and sub-
arachnoid haemorrhage (reviewed by Battistini et al., 2006). The results of these 
studies have been mixed. On one hand, numerous trials of ET blockade in chronic 
and acute decompensated heart failure have demonstrated, at best, no improvement 
in survival. In these and other conditions ET antagonists have also been associated 
with several tolerability issues, most concerningly dose-dependent abnormalities of 
liver function, in addition to their well-known teratogenicity. On the other hand, the 
most encouraging outcome of clinical trials has been the approval of bosentan (and, 
more recently, sitaxsentan and ambrisentan) for treating the symptoms of PAH. 
Clinical experience gained in this condition has also demonstrated that, with careful 
monitoring and dose titration, adverse effects of ET blockade are manageable rather 
than treatment limiting. Further, ongoing phase II and III trials of ET antagonists in a 
number of other conditions are yielding positive results. These include systemic 
hypertension (particularly that resistant to existing therapies, or with concurrent 
kidney disease), prostate cancer, scleroderma and sub-arachnoid haemorrhage. Thus, 
in the near future, ET antagonists may find use in the treatment of much larger 
patient populations. 
 
1.3 ENDOTHELINS AS MEDIATORS OF THE VASCULAR RESPONSE 
TO INJURY 
The ability of ET receptor antagonists to moderate processes of neointima formation 
in man (post-interventional restenosis, vascular graft disease) has yet to be 
determined by rigorous clinical investigation. This would be of interest not only 
because ET antagonists may be useful in the primary prevention of these conditions, 
but also because inhibition of intimal lesion formation may provide a secondary 
benefit where ET receptor blockade is otherwise indicated, for example, in 
hypertensive patients. Animal studies strongly suggest a role for ETs in the response 
to acute vascular injury. ETs stimulate a number of cellular processes crucial to 
35 
 
neointimal lesion formation and consequently, ETA receptor blockade reduces lesion 
size in many models of acute vascular injury. As in many cardiovascular diseases, 
however, the role of ETB receptors is less clear because they mediate actions that 
might either enhance (inflammation, proliferation) or reduce lesion formation (NO 
release, ET-1 clearance). As such, it is difficult to predict whether selective ETA or 
non-selective ETA/B antagonist treatment strategies would be more suitable for the 
prevention of similar vascular remodelling processes in man. This section discusses 
the current evidence implicating ETs and their receptors in processes of neointima 
formation. 
 
1.3.1 Relevant cellular actions of ETs 
1.3.1.1 VSMC turnover 
The ability of ETs to regulate growth of VSMCs was first reported by Komuro et al 
(1988) in the same year as the isolation and characterization of ET-1 by Yanagisawa 
et al (1988). ET agonists have since been shown to increase DNA synthesis and 
proliferation in a variety of VSMC lines including human (Yang et al., 1999), bovine 
(Di Luozzo et al., 2000), rat (Komuro et al., 1988; Hirata et al., 1989; Weissberg et 
al., 1990; Eguchi et al., 1992; Ohlstein et al., 1992; Mihara & Fujimoto, 1993; 
Sogabe et al., 1993; Kubo et al., 1998; Daou & Srivastava, 2004) and rabbit aortic 
VSMCs (Serradeil-Le Gal et al., 1991). Some reports indicate the ETs can induce 
modest proliferation of quiescent (G0) cells but, in most, the action of ETs might be 
better described as co-mitogenic. As such, ETs can elicit more dramatic increases in 
VSMC proliferation by potentiating the action of other mitogens including PDGF 
and serum (Hirata et al., 1989; Weissberg et al., 1990; Battistini et al., 1993; Irons et 
al., 1996). Indeed, ET-mediated mitogenesis in the absence of exogenous growth 
factors may be a co-mitogenic effect in association with endogenously-produced 
mitogens (Battistini et al., 1993). In vivo, chronic administration of ET-1 produces 
medial thickening in small mesenteric arteries (Dao et al., 2006), which is 
attributable to VSMC proliferation (or hypertrophy at lower doses). Given the crucial 
contribution of VSMC proliferation to neointima formation, the potential for ET-1 to 
influence lesion formation by stimulation of this response is obvious.  
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Where investigated, the (co-)mitogenic action of ETs is most commonly sensitive to 
ETA blockade (Eguchi et al., 1992; Ohlstein et al., 1992; Mihara & Fujimoto, 1993; 
Sogabe et al., 1993; Kanse et al., 1995; Yoshizumi et al., 1998; Yang et al., 1999) 
but some studies suggest a role for ETB (Yang et al., 1999; Di Luozzo et al., 2000). 
This variability probably reflects the origin of the cells investigated: in large arteries 
such as the aorta (the primary source of VSMC lines for most investigations) the 
ETA:ETB ratio is typically high (Davenport et al., 1995a; Davenport et al., 1995b). 
The phenotype of the cells investigated is also likely to be important as VSMCs 
switch from a contractile to a synthetic phenotype with extended culture. Indeed, 
Eguchi et al (1994) report that in early ‘contractile’ cultures of rat aortic VSMCs, 
ET-1 is only weakly mitogenic, and acts via the ETA receptor, whilst in late 
‘synthetic’ cultures, the mitogenic action of ET-1 is dramatically increased, and this 
becomes sensitive to ETB but not ETA blockade. This issue of phenotype is 
particularly relevant because proliferating intimal VSMCs in neointima formation 
are typically of a synthetic phenotype.  
 
ETs may also regulate the content of VSMCs in neointimal lesions by altering cell 
survival. ET-1 can protect cultured VSMCs from apoptosis induced by various 
insults, including: NO donors (Shichiri et al., 2000), serum deprivation (Shichiri et 
al., 2000; Wu-Wong et al., 2000),  ϖ-3 fatty acids (Diep et al., 2000) and paclitaxel 
(Wu-Wong et al., 2000). This effect appears to be mediated by ETA receptor 
activation (Shichiri et al., 2000), the p42/44 MAPK pathway (Shichiri et al., 2000; 
Wu-Wong et al., 2000) and inhibition of caspase 3 (Diep et al., 2000). This anti-
apoptotic action can also be demonstrated in vivo as treatment of 
deoxycorticosterone acetate (DOCA)/salt hypertensive rats with an ETA antagonist 
is associated with increased apoptosis of medial VSMCs (Sharifi & Schiffrin, 1997). 
Thus, endogenous ET-1, acting on the ETA receptor, may prevent apoptosis of 
intimal VSMCs (a continuous process in the developing neointima) with clear 
implications for lesion growth. The issue is complicated, however, by a pro-apoptotic 
action mediated by the ETB receptor. In cultured rat VSMCs exposed to cyclic 
strain, ET-1 stimulates apoptosis, which is sensitive to ETB blockade or deletion 
(Cattaruzza et al., 2000). Similarly, in rabbit carotid artery rings subject to excessive 
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pressure for short periods (160mmHg for 6 hours), ET-1 and ETB expression is 
increased, and apoptosis of medial VSMC can be prevented by ETB, but not ETA, 
blockade (Lauth et al., 2000). This pathway may be particularly important in post-
interventional restenosis because both PTCA and stent implantation cause stretch-
injury to the vascular wall and, in animal models, this is associated with rapid medial 
apoptosis (Sata et al., 2000). Consequently, ETB receptor stimulation may 
potentially limit lesion development by reducing the medial VSMC content and/or 
by increasing death of intimal VSMCs. 
 
1.3.1.2 Matrix remodelling 
The actions of ETs on fibroblasts are similar to those on VSMCs, stimulating 
proliferation and migration of Swiss 3T3 cells (Brown & Littlewood, 1989; Takuwa 
et al., 1989) and of primary fibroblasts derived from several human (Kahaleh, 1991; 
Cambrey et al., 1994; Shahar et al., 1999; Gallelli et al., 2005) and rat tissues (Yeh et 
al., 1991; Peacock et al., 1992). The proliferative effect of ETs on fibroblasts is 
greater in the presence of other mitogens suggesting that, as for VSMCs, they act 
primarily as co-mitogens (Brown & Littlewood, 1989; Takuwa et al., 1989; Kahaleh, 
1991; Yeh et al., 1991). Moreover, ET-1 stimulates the transition of fibroblasts to a 
myofibroblast phenotype, and increases their production of collagen type I and III as 
well as connective tissue growth factor release both from fibroblasts and VSMCs 
(Guarda et al., 1993; Rizvi et al., 1996; Shi-Wen et al., 2001; Shi-Wen et al., 2004; 
Xu et al., 2004; Rodriguez-Vita et al., 2005; Shi-Wen et al., 2007). These actions 
may be important in promoting the deposition of matrix in the growing lesion and, 
thus, contribute to lesion growth. Although in some studies ETA blockade has 
proven sufficient to inhibit these pro-fibrotic actions of ETs (Shi-Wen et al., 2004; 
Gallelli et al., 2005), in most they can only be prevented by the combination of ETA 
and ETB antagonists (Guarda et al., 1993; Cambrey et al., 1994; Xu et al., 1998; 
Shi-Wen et al., 2001; Clozel & Salloukh, 2005).  
 
The role of ETs in matrix degradation is more complex. On the one hand, ETA 
activation induces MMP-9 release from neutrophils (which may aid migration of 
VSMCs from the media by degradation of the elastin-rich elastic laminae) and 
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amplify local ET levels by generation of ET-1[1-32] (Fernandez-Patron et al., 2001). 
On the other hand MMP-1 expression in fibroblasts is reduced by ETA activation: an 
action that may be permissive to ET-induced matrix deposition, as MMP-1 degrades 
subtypes of collagen that are produced in response to the action of ETs (Shi-Wen et 
al., 2001).  
 
1.3.1.3 Inflammation 
ETs have also been implicated as pro-inflammatory mediators, acting directly on 
polymorphonuclear phagocytes and cells of monocyte lineage. In several studies, 
ET-1 administration is reported to increase rolling and adhesion/accumulation of 
neutrophils in vivo, an important early process in the response to acute injury 
(Espinosa et al., 1996; Helset et al., 1996; Boros et al., 1998; Sanz et al., 1999; Sato 
et al., 2000). Moreover, this has been shown to occur when labelled neutrophils are 
administered after pre-treatment with ET-1, indicating a direct effect on these cells 
rather than actions secondary to altered haemodynamics or other indirect actions 
(Sato et al., 2000). In vitro studies suggest that ET-1 increases neutrophil expression 
of the leucocyte integrin CD11b/CD18 by the p42/44 MAPK pathway and activation 
of the ETA receptor (Espinosa et al., 1996; Sato et al., 2000; Fernandez-Patron et al., 
2001; Jozsef et al., 2002). This is consistent with the demonstration that blockade of 
ETA or CD18 in vivo prevents neutrophil accumulation in response to ET-1 
(Espinosa et al., 1996; Boros et al., 1998). ETA receptor activation also increases 
neutrophil migration in vitro, although whether this reflects chemotaxis or 
chemokinesis is debated (Elferink & de Koster, 1994; Cui et al., 2001). Finally, in 
addition to recruitment, ET-1 elicits MMP-9 release from neutrophils (Fernandez-
Patron et al., 2001) and potentiates stimulated production of O2
- (Ishida et al., 1990). 
Thus, ETs, acting primarily on the ETA receptor, might contribute to the recruitment 
of neutrophils to sites of acute vascular injury and their subsequent activity. 
 
ET receptors are also expressed by monocytes and derived cells. Rat peritoneal 
macrophages express exclusively ETB whereas human peripheral blood monocytes 
and THP-1 monocyte-like cells express exclusively ETA. Human peripheral blood 
monocyte-derived macrophages, express both ETA and ETB (Sakurai-Yamashita et 
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al., 1997; Haug et al., 2001; Grimshaw et al., 2002). ETs appear to promote 
chemotaxis of both monocytes and macrophages, which, in the latter, is mediated by 
ETB receptor activation (Achmad & Rao, 1992; Cui et al., 2001; Grimshaw et al., 
2002). Monocytes have also been shown to release mediators that are chemotactic 
and mitogenic both for neutrophils and for macrophages (such as interleukin-8, 
MCP-1 and M-CSF) in response to ET receptor activation (Helset et al., 1994; 
Huribal et al., 1994; Cunningham et al., 1997). As with neutrophils, therefore, ETs 
may be important in the recruitment of macrophages (crucial mediators of neointimal 
lesion formation) to sites of vascular injury. Further, ETs promote macrophage 
‘activation’ – stimulating Ca2+ mobilization and activity of NFκB (Haller et al., 
1991; McMillen et al., 1995; Wilson et al., 2001). Accordingly, macrophage ET 
receptor stimulation increases release of a variety of mediators, including: TNFα, IL-
1β, IL-6, IL-8, TXA2 and O2
- (Haller et al., 1991; Millul et al., 1991; Helset et al., 
1993; McMillen et al., 1995; Chanez et al., 1996; Cunningham et al., 1997; Ruetten 
& Thiemermann, 1997; Shimada et al., 1998; Speciale et al., 1998; Juergens et al., 
2008). Both ETA and ETB have been implicated in mediating such responses, 
although in most cases, the subtype involved has not been determined (Ruetten & 
Thiemermann, 1997; Shimada et al., 1998; Speciale et al., 1998; Juergens et al., 
2008). ET receptor stimulated release of these mitogenic and pro-inflammatory 
factors may be important in the developing lesion, sustaining the inflammatory 
response and contributing to the migration and proliferation of VSMCs.  
 
ETs may further contribute to inflammatory processes by an indirect action on cells 
of the vascular wall. ET agonists stimulate expression of adhesion molecules 
(ICAM-1, VCAM-1, E-selectin) and cytokines (IL-8) in human 
cerebromicrovascular and coronary artery ECs (McCarron et al., 1993; Hofman et 
al., 1998; Fernandez-Patron et al., 2001), presumably by ETB activation. In addition, 
CRP-induced expression of ICAM-1, VCAM-1 and MCP-1 in human saphenous 
vein ECs can be prevented by ET receptor blockade (Verma et al., 2002). EC-
specific ppET-1 over-expression is associated with MCP-1 expression and 
macrophage accumulation in the wall of small arteries (Amiri et al., 2008). ETs also 
regulate inflammatory activation by VSMCs. In vitro, in cultured VSMC and in vivo, 
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in DOCA/salt hypertensive rats, ET-1 induces VCAM-1 expression, which can be 
prevented by anti-oxidants, NADPH oxidase inhibitors or ETA antagonists (Li et al., 
2003; Daou & Srivastava, 2004). 
 
1.3.1.4 Endothelial function 
The vasodilator effects of ETs are well known (see section 1.2.4). This action is 
mediated by stimulated production of NO and other endothelium-dependent relaxing 
factors by ETB receptors in endothelial cells and as such, cultured EC from several 
species demonstrate NO release upon ETB receptor stimulation (Hirata et al., 1993; 
Tsukahara et al., 1994). Endogenous ETs may, therefore, exert a moderating effect 
on lesion formation by stimulation of the EC ETB receptor to elicit release of 
vasodilator factors such as NO and prostacyclin, which are known to inhibit 
neointimal lesion formation (Moroi et al., 1998; Le Tourneau et al., 1999).  
 
The influence of ET-mediated regulation of endothelial function on neointimal 
proliferation is more complex, however, because ET receptor activation also 
stimulates the production of oxidative species. Indeed, in epicardial arteries (Halcox 
et al., 2001) and the forearm vasculature of human atherosclerotic patients (Bohm et 
al., 2005), ETA and ETA/B receptor blockade, respectively, improve endothelial 
function (response to acetylcholine). Also in the human forearm, ET-1 administration 
impairs EC-dependent vasodilatation and this action can be prevented with ascorbic 
acid (Bohm et al., 2007). Similarly, ETB-deficient rats (Elmarakby et al., 2004; 
Quaschning et al., 2005), EC-specific ETB-deficient mice (Bagnall et al., 2006), and 
EC-specific ET-1 over-expressing mice (Amiri et al., 2004), exhibit impaired EC-
dependent vasodilatation, probably owing to the elevated levels of ET-1 in these 
models. In EC-specific ET-1 over-expressing mice, endothelial dysfunction is 
inhibited by ascorbic acid and is associated with increased activity of NADPH 
oxidase and up-regulation of its gp91phox subunit (Amiri et al., 2004). This action has 
been further investigated in vitro: both in cultured VSMC (Wedgwood et al., 2001; 
Rodriguez-Vita et al., 2005) and ECs (Duerrschmidt et al., 2000; Dong et al., 2005), 
incubation with ET-1 stimulates O2
- production and up-regulation of NADPH 
oxidase subunits (gp91phox, gp47phox) and this is sensitive to the NADPH oxidase 
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inhibitor, apocyanin. In VSMCs, this is mediated primarily by the ETA receptor 
(Wedgwood et al., 2001), whilst in ECs it is (predictably) mediated by ETB 
(Duerrschmidt et al., 2000; Dong et al., 2005). Apocyanin-sensitive ET-1-induced 
O2
- production has also been reported in endothelium-denuded and endothelium-
intact rat aortic rings but, in the latter, an additional pathway for O2
- production 
appears to be present (Loomis et al., 2005). Here, ET-1 stimulated O2
- production 
appears to be mediated by NOS uncoupling, which follows oxidative de-activation of 
BH4 by NADPH oxidase-derived O2
-. Regardless of mechanism, increased ET-1-
induced O2
- production both in ECs and VSMCs may to contribute to lesion 
formation, because it impairs the bioactivity of NO, induces detrimental signaling 
pathways in VSMCs leading to mitogenesis and adhesion molecule expression and, 
at high concentrations, is cytotoxic, potentially amplifying the initial injury.  
 
Another aspect of ET-1-regulated EC function of possible relevance to the 
pathogenesis of lesion formation is the control of cell turnover. ET-1 and other ET 
agonists enhance proliferation and migration of isolated ECs from several species 
and vascular beds, and this is mediated by ETB-stimulated NO release (Goligorsky 
et al., 1999; Salani et al., 2000; Kuhlmann et al., 2005). In the presence of VSMCs, 
an additional pathway involving ETA-mediated induction of VEGF expression may 
also be important (Pedram et al., 1997; Matsuura et al., 1998; Herrmann et al., 
2002). Similarly, EC survival is also regulated by ET-1 and apoptosis, induced by 
either serum deprivation (Shichiri et al., 1997) or homocysteine (Dong et al., 2005), 
is inhibited by ETB receptor activation. These actions may contribute to re-
endothelialisation following mechanical injury and may protect ECs from apoptosis 
in vascular graft disease where they are subject to damage without denudation.  
 
Finally, ETB receptors expressed by ECs are an important mediator of the clearance 
of ET-1 from the circulation (see section 1.2.2). Certainly, ETB blockade (Fukuroda 
et al., 1994a) or EC-specific ETB knockout increases plasma ET-1 concentration 
(Bagnall et al., 2006), and this may regulate stimulation of non-EC ETB receptors. 
The extent that ETB receptors on ECs can regulate the levels of ETs in tissue is less 
clear. Indeed, because ET-1 circulates at such low (picomolar) concentrations, it is 
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likely that ‘tissue’ rather than plasma ETs are of greater contribution to intimal lesion 
formation. Regardless, it is interesting to note that balloon injury results in rapid 
accumulation of plasma [125I]-ET-1 in the denuded region (Kurata et al., 1995), 
indicating that ECs do protect sub-endothelial ET receptors from circulating ETs. 
 
1.3.2 Alterations to expression/function of the ET system 
It is clear that ETs have the potential to regulate many actions that might contribute 
to neointimal lesion formation. The importance of these effects in vivo, however, is 
dependent on activation of the ET system at sites of lesion formation. As such, many  
studies have detailed how the ET system is altered in response to vascular injury 
(Table 1-2). PTCA, but not angiography, in man is associated with a rapid increase 
in plasma [ET-1] (Ameli et al., 1993; Hojo et al., 2000; Takase et al., 2003). Patients 
with >50% restenosis continue to have elevated circulating [ET-1] at 3 months, but 
in those without, it returns to pre-interventional levels. Descriptions of the ETs in 
tissue from human neointimal lesions are limited. Shirai et al (2006) report both ET-
1 and ECE immunoreactivity in neointimal VSMCs and macrophages in atherectomy 
and post-mortem samples of re-stenotic lesions and this is diminished in specimens 
obtained >3 months after re-vascularisation. Several studies also indicate the 
presence of ET-1 protein and mRNA in failed saphenous vein and internal thoracic 
artery bypass grafts (Brody et al., 1996; Masood et al., 1996). These data are 
supported by results obtained from relevant animal models. Early work in the rabbit 
carotid balloon injury model indicates ET-1 immunoreactivity is increased within 24 
hours of vascular damage (Azuma et al., 1994; Azuma et al., 1995a). Studies of gene 
expression following balloon injury to the rat carotid artery also indicate rapid 
induction of the ET system, with ~2-3-fold increases in levels of ppET-1, ppET-3 
and ECE-1 mRNA apparent in whole vessels within days, and remaining elevated for 
several weeks (Wang et al., 1996). In the same model, ECE activity was also 
increased (~2-fold at 2 weeks) and, in contrast to uninjured vessels, was localised to 
non-endothelial cell types (Minamino et al., 1997). Similarly, immunohistochemical 
studies in balloon injury models show ET-1 predominantly localised to the neointima 
(Azuma et al., 1994; Dashwood et al., 1999), particularly in VSMCs (Wang et al., 




Species (Vessel) Injury  Method of detection Intimal VSMCs Medial VSMCs ECs Macrophages Reference 
        
Human (Coronary) PCIs IHC ET-1, ECE, ETA, ETB   ET-1, ECE, ETA, ETB (Shirai et al., 2006) 
Human (Saphenous) Vein Graft Autorad  ETA   (Maguire & Davenport, 1999) 
Pig (Coronary) Balloon Autorad ET-1, ETA, ETB ETA, ETB   (Dashwood et al., 1999) 
Pig (Femoral) Cuff Autorad  ETA/B ETA/B  (Dashwood et al., 1993) 
Pig (Saphenous) Graft Autorad   ETA/B  (Dashwood et al., 1993) 
Pig (Saphenous) Graft Autorad & IHC  ETA ET-1  (Dashwood et al., 1998) 
Rabbit (Carotid) Balloon Autorad ETB *   ETB (Azuma et al., 1994) 
Rabbit (Carotid) Balloon Autorad ETB * ETA   (Azuma et al., 1995a) 
Rat (Carotid) Balloon IHC ET-1    (Wang et al., 1996) 
Rat (Carotid) Balloon Autorad ETA * ETA   (Viswanathan et al., 1997) 
Rat (Carotid) Balloon ISH ETA *    (Ferrer et al., 1995) 
Rat (Carotid) Balloon + Diet ISH ET-1  ET-1  (Yoshida et al., 2000) 
        
 
Table 1-2 Distribution of the endothelin system within neointimal lesions.  
Studies investigating the localisation of components of the ET system within neointimal lesions have variously indicated the presence of ETs and ET receptors in most major lesion cell 
types, although the exact distribution is not consistent between reports (except perhaps the predomination of ETA in the media). * ET components are described as localising to the 
neointima, but not specifically to intimal VSMCs. VSMC, vascular smooth muscle cells; PCI, percutaneous coronary intervention; IHC, immunohistochemistry; Autorad, autoradiography; 
ISH, in situ hybridization; VSMC, vascular smooth muscle cell; EC, endothelial cell. 
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ET-1 release in the rat carotid artery balloon-injury model after endothelial re-
generation (Yoshida et al., 2000), and in a saphenous vein graft culture model where 
endothelial damage is likely to be less severe (Dashwood et al., 1998). 
 
The changes to ET receptor expression that occur after acute vascular injury are even 
more dramatic than those to ETs and ECE. In the rat carotid artery, ETA mRNA 
levels are reported to increase up to 153-fold (peaking at ~3 days) following balloon 
injury and remain elevated for ~2 weeks (Ferrer et al., 1995; Wang et al., 1996; 
Viswanathan et al., 1997; Picard et al., 1998). ETA appears principally associated 
with medial VSMCs (Azuma et al., 1995a; Dashwood et al., 1999), although 
Dashwood et al (1999) also describe strong ETA radioligand binding in the 
neointima and associated with neutrophils (Dashwood et al., 1998). Changes in ETB 
expression follow a similar pattern. Large increases (up to 63-fold) in ETB mRNA 
levels follow rat carotid artery balloon injury, peaking ~2 days post-injury, and 
declining to a stable, elevated level within 1 week (Wang et al., 1996; Picard et al., 
1998). Studies of ETB radioligand binding in the injured rabbit carotid artery also 
demonstrate increased ETB protein levels post-injury (Azuma et al., 1994; Azuma et 
al., 1995a). ETB receptors are typically described to predominate in the neointima, 
associated with intimal VSMCs and macrophages (Azuma et al., 1994; Azuma et al., 
1995a; Dashwood et al., 1999). ETB is also reported in the medial VSMC of 
balloon-injured porcine coronary arteries (Dashwood et al., 1999) and in sites of neo-
vascularisation in porcine saphenous vein/carotid artery interposition grafts 
(Dashwood et al., 1998). Further, binding sites for ET-1, (probably ETB) are present 
on ECs in the porcine femoral artery cuff model (Dashwood et al., 1993). In man, re-
stenotic lesions display strong immunoreactivity for ETA and ETB which is 
associated with intimal VSMCs and macrophages and declines from 3 months post-
injury (Shirai et al., 2006). In contrast, stable saphenous vein grafts harvested from 
the hearts of transplant recipients have ET receptor expression levels similar to un-
injured vessels (Maguire & Davenport, 1999), probably reflecting the graft age. 
Acute vascular injury, therefore, would appear to cause rapid activation of the ET 
system with increased ET-1 and ECE expression apparent within 24 hours despite, in 
most cases, removal of the endothelium. This activation is relatively transient, with 
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expression levels normalising with a time-course comparable to that of lesion 
stabilisation, consistent with the self-resolving nature of the response to acute injury. 
Changes in ET receptor expression following acute vascular injury are even more 
short-lived, possibly suggesting that the ET system is more important in early 
(inflammation and medial proliferation) than late (intimal proliferation and matrix 
deposition) stages of lesion formation. 
 
The activation of the ET system that occurs following acute vascular injury can be 
considered a response to increased gene expression by resident cells and influx of 
non-resident cell types that secrete ETs and/or express ET receptors. Both increased 
expression of ppET-1/ppET-3 and increased activity of ECE-1 are implicated in the 
response to vascular injury (Minamino et al., 1997; Bohm et al., 2002). Endothelial 
denudation, as occurs following mechanical injury, results in loss of the suppressive 
action of NO and PGI2 on vascular ppET-1 expression (Boulanger & Luscher, 1990) 
and promotes platelet aggregation and coagulation, stimulating further ET-1 release 
(Schini et al., 1989; Sethi et al., 2005). Numerous inflammatory cytokines (IL-1, 
TNFα, MCP-1) and growth factors (fibroblast growth factor-2, TGFβ) that are 
present in the developing neointima also induce ppET-1, ECE-1 and ET receptor 
expression (Yoshizumi et al., 1990; Maemura et al., 1992; Cristiani et al., 1994; 
Woods et al., 1999; Molet et al., 2000). Macrophages too have been shown to release 
ET-1, and express ET receptors (the subtype of which varies between analysed 
populations) and may, therefore, directly contribute to lesion ET and ET receptor 
content (Ehrenreich et al., 1990; Sakurai-Yamashita et al., 1997; Haug et al., 2001; 
Grimshaw et al., 2002). Similarly, neutrophils, which are recruited following acute 
mechanical injury express the ETA receptor subtype and secrete MMP-9, an enzyme 
capable of cleaving bigET-1 to form bioactive ETs (Fernandez-Patron et al., 2001). 
The proliferation and phenotypic changes of VSMCs are also likely to be central to 
explaining the increase in ETB:ETA ratio in intimal lesions, because those of the 
synthetic phenotype may have increased ETB expression (Eguchi et al., 1994). 
Finally, it is easy to envisage a system of feedback loops for ET-1 production where 
many of the cytokines and growth factors, which stimulate ET-1 release are 
themselves released in response to ET-1 (see section 1.3.1.3).  
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1.3.3 Manipulating the ET system in vascular remodelling 
The strongest evidence for the role for the ET system in intimal lesion formation is 
provided by interventional studies in which the effects of its stimulation or inhibition 
are investigated using in vivo models of disease. 
 
1.3.3.1 ET-1 administration 
Exogenous ET-1 reliably increases neointima formation in response to balloon injury 
to the rat carotid artery. Chronic ET-1 administration increases maximum lesion size, 
collagen content and cell proliferation (Trachtenberg et al., 1993; Barolet et al., 
2001) whilst acute administration causes dose-dependent increases in lesion size 
which are evident 7 days after injury (Douglas & Ohlstein, 1993; Douglas et al., 
1994). The target of these treatments has not been determined but, given that a single 
dose of ET-1 at the time of vascular injury can increase lesion formation, an action 
on the acute inflammatory response is plausible. A haemodynamic effect must also 
be considered, but it is difficult to envisage how a transient elevation in blood 
pressure could have such profound effects on lesion formation. 
 
1.3.3.2 ECE inhibition 
Combined inhibition of ECE and NEP by chronic administration of phosphoramidon 
or CGS 26303 reduced lesion size in the rat carotid artery after balloon injury 
(Minamino et al., 1997; Pham et al., 2002). Selective NEP inhibition, by contrast, 
did not alter lesion size, suggesting that the effects of these treatments are 
attributable to their action on ECE (Pham et al., 2002). This is, perhaps, unsurprising 
given the number of studies demonstrating increased ECE expression in neointimal 
lesions, but confirms the role of endogenous ET-1 in the response to vascular injury 
and of ECE in mediating intra-lesion ET-1 synthesis. 
 
1.3.3.3 Mixed ETA/B blockade 
The number of studies exploring the effects of ET receptor blockade on neointimal 
lesion formation is far greater than for ECE inhibition (Table 1-3). Chronic 
administration of non-selective ETA/B receptor antagonists (such as bosentan, 
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enrasentan and TAK 044) reduce neointima size after carotid balloon injury in rats 
(Douglas et al., 1994; Ohlstein et al., 1994; Douglas et al., 1995a; Tsujino et al., 
1995; Chandra et al., 1998) and rabbits (Marano et al., 1998; Azuma et al., 1999). 
Similarly, ETA/B blockade is reported to reduce lesion size in rabbit carotid artery 
cuff placement (Marano et al., 1998; Reel et al., 2005) and porcine coronary artery 
atherectomy models (Sanmartin et al., 2003). Inhibition of neointimal lesion 
formation by ETA/B blockade has been associated with reduced DNA synthesis 
(Azuma et al., 1999) but, given that VSMC proliferation can be considered a final 
common pathway for all processes leading to neointima formation, this does not 
necessarily indicate a direct effect on these cells.  
 
Not all studies of ETA/B blockade on neointima formation have been positive. In 
contrast to the acute effects of ET-1 administration, Douglas et al (1995a) report no 
detectable changes in lesion formation following acute treatment with an ETA/B 
antagonist. This may suggest that, whilst exogenous ET-1 can promote very early, 
detrimental responses in lesion formation (for example, enhanced neutrophil 
accumulation), endogenous ET-1 contributes to lesion progression at later stages (for 
example, increasing macrophage accumulation or VSMC proliferation). Huckle et al 
(2001) also report that even chronic administration of an ETA/B antagonist does not 
alter lesion size following porcine coronary artery balloon injury, even at a dose 5-
fold higher than is necessary to abolish the pressor response to exogenous bigET-1. 
Whilst this may simply reflect experimental variability or the severity of injury 
caused, this study is particularly notable for using a model that has been shown to 
have great predictive value of the clinical efficacy of anti-re-stenotic treatments. 
 
1.3.3.4 Selective ETA blockade 
ETA antagonist treatment is reported to reduce lesion size in the following models of 
neointima formation (Table 1-3): rat carotid artery after balloon injury (Ferrer et al., 
1995), rabbit aorta following diet/balloon injury (Tepe et al., 2002), rat femoral 
artery after photochemical injury (Takiguchi & Sogabe, 1996), mouse carotid artery 
following ligation (Murakoshi et al., 2002) and porcine saphenous vein/carotid artery 
interposition grafting (Wan et al., 2004). Importantly, in contrast to non-selective 
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Species (Vessel) Injury Treatment (Drug) Lesion Size Reference 
     
Pig (Carotid) Balloon ETA blockade (Atrasentan) Reduced (Burke et al., 1997) 
Pig (Coronary) Stent ETA blockade (Atrasentan) Reduced (McKenna et al., 1998)  
Pig (Illiac) Balloon ETA blockade (Atrasentan) Reduced (Burke et al., 1997) 
Rat (Carotid) Balloon ETA blockade (BMS182874) Reduced (Ferrer et al., 1995) 
Human (Saphenous) Vein Culture ETA blockade (BQ123) Unchanged (Porter et al., 1998) 
Rabbit (Carotid) Balloon ETA blockade (BQ123) Unchanged (Azuma et al., 1994) 
Rat (Carotid) Balloon ETA blockade (BQ123) Unchanged (Douglas et al., 1995a) 
Pig (Saphenous) Vein Graft ETA blockade (BSF302146) Reduced (Wan et al., 2004) 
Pig (Coronary) Balloon ETA blockade (Daruentan) Reduced (Dashwood et al., 1999) 
Rabbit (Aorta) Balloon ETA blockade (Daruentan) Unchanged (Tepe et al., 2002) 
Rabbit (Aorta) Balloon/Diet ETA blockade (Daruentan) Reduced (Tepe et al., 2002) 
Rat (Femoral) Chemical ETA blockade (FR139317) Reduced (Takiguchi & Sogabe, 1996) 
Mouse (Carotid) Ligation ETA blockade (TA0201) Reduced (Murakoshi et al., 2002) 
      
     
Rabbit (Carotid) Balloon ETA/B blockade (ATZ1993) Reduced (Azuma et al., 1999) 
Human (Saphenous) Vein Culture ETA/B blockade (Bosentan) Reduced (Porter et al., 1998) 
Pig (Coronary) Atherectomy ETA/B blockade (Bosentan) Reduced (Sanmartin et al., 2003) 
Rabbit (Carotid) Balloon ETA/B blockade (Bosentan) Reduced (Marano et al., 1998) 
Rabbit (Carotid) Cuff ETA/B blockade (Bosentan) Reduced (Marano et al., 1998) 
Rat (Carotid) Balloon ETA/B blockade (Enrasentan) Reduced (Chandra et al., 1998) 
Pig (Coronary) Stent ETA/B blockade (L749329) Unchanged (Huckle et al., 2001) 
Rat (Carotid) Balloon ETA/B blockade (SB209670) Reduced (Douglas et al., 1994) 
Rat (Carotid) Balloon ETA/B blockade (SB209670) Reduced (Douglas et al., 1995a) 
Rat (Carotid) Balloon ETA/B blockade (SB209670) Reduced (Ohlstein et al., 1994) 
Rabbit (Carotid) Cuff ETA/B blockade (TAK044) Reduced (Reel et al., 2005) 
Rat (Carotid) Balloon ETA/B blockade (TAK044) Reduced (Tsujino et al., 1995) 
     
     
Mouse (Carotid) Ligation ETB blockade (A192621) Increased (Murakoshi et al., 2002) 
Human (Saphenous) Vein Culture ETB blockade (BQ788) Reduced (Porter et al., 1998) 
Mouse (Carotid) Ligation ETB deletion Increased (Murakoshi et al., 2002) 
     
 
Table 1-3 The effect of chronic endothelin receptor blockade on neointima formation.  
Previous studies investigating the ability of chronic ET receptor blockade/deletion to alter neointima formation have 
demonstrated that both ETA selective and non-selective ETA/B antagonist treatment consistently reduce lesion size in 




ETA/B blockade, ETA selective blockade is reported to suppress neointima 
formation in the clinically-predictive porcine balloon- (McKenna et al., 1998; 
Dashwood et al., 1999) and stent-induced injury models (Burke et al., 1997). These 
results indicate that selective blockade of ETA is sufficient to moderate stimulation 
of lesion development mediated by endogenous ET-1. 
 
The effect of acute ETA blockade on neointima formation has also been investigated. 
Administration of a single dose of BQ123, a highly selective peptidic ETA receptor 
antagonist, at the time of balloon injury to the rat carotid artery did not alter lesion 
development (Douglas et al., 1995a; Douglas et al., 1995b). This is perhaps 
predictable given that acute ETA/B blockade is similarly ineffective at moderating 
lesion formation. What is more surprising is that chronic BQ123 administration by 
several means is also reported to be unable to reduce lesion size in the rat and rabbit 
carotid balloon injury models (Azuma et al., 1994; Douglas et al., 1995a; Douglas et 
al., 1995b), in which non-peptidic ETA and ETA/B antagonists are effective. As 
such, BQ123 may have specific qualities that render it unsuitable for the prevention 
of lesion formation following vascular injury such as poor penetration or accelerated 
degradation in neointimal lesions. This question is particularly important because 
Kyriakides et al (2003) describe the effect of BQ123 administration on post-PTCA 
neointima formation in man. No significant reductions in neointimal lesion size were 
reported with BQ123 treatment as determined by intravascular ultrasound, possibly 
reflecting the lack of power provided by the small number of patients treated. It is 
also important to note, however, that BQ123 was administered only acutely, at the 
time of PTCA and that no animal study of acute ETA/B or ETA selective blockade 
has ever demonstrated a beneficial effect on neointima formation.  
 
1.3.3.5 Selective ETB blockade/deletion 
The sheer number of studies demonstrating that both ETA/B and selective ETA 
antagonist treatment is effective in reducing lesion size following acute vascular 
injury suggests that any role for ETB is small. This is surprising given the 
widespread expression of ETB in neointimal lesions, but it is difficult to be sure of 
this interpretation because no studies (with the following exception) have directly 
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compared the effects of these treatment modalities. Douglas et al (1995a) reported 
reductions in rat carotid balloon injury-induced lesion formation following treatment 
with a non-peptidic ETA/B antagonist but not the peptidic ETA antagonist BQ123. 
This may simply be a reflection of the nature of BQ123, or a differing level of ETA 
blockade between treatment arms, but may also suggest some role for ETB in 
exacerbating lesion development in this model. Similarly, intimal hyperplasia in 
cultured human saphenous veins also involves a detrimental role for ETB because 
both ETA/B and ETB selective, but not ETA selective antagonists, reduced lesion 
size in this model (Porter et al., 1998).  
 
Some evidence also points to a protective role for ETB, an action that may be related 
to several theoretical beneficial effects of ETB receptor stimulation, such as: 
induction of NO release from ECs and ET-1 clearance. McKenna et al (1998), for 
example, demonstrated substantial reductions in lesion size following coronary artery 
balloon-injury in pigs treated with a selective ETA antagonist, yet the same group 
later reported that this model is insensitive to non-selective ETA/B blockade (Huckle 
et al., 2001). This may imply that ETB blockade can moderate the beneficial effects 
of ETA blockade on lesion formation. More compelling evidence comes from studies 
in rescued ETB-deficient mice by Murakoshi et al (2002). These animals, made 
normotensive by restricting dietary salt intake, demonstrated increased lesion size 
following carotid artery ligation. Additional studies conducted in parallel indicated a 
similar effect of selective ETB blockade. This was associated with reduced tissue 
levels of NO oxidation products, suggesting that loss of the EC ETB/ NO pathway 
may be the mediator of this effect, which may reflect the use of an injury model that 
does not feature EC denudation. It is difficult to be certain of the role of EC ETB in 
this setting, however, as neither pharmacological nor conventional knockout tools 
can distinguish between effects of ETB in EC from those on other cells important to 
neointima formation. Thus, ETB, possibly that expressed by EC, may act to moderate 
lesion formation following vascular injury and this may depend on the mode of 
injury, with particular emphasis on the state of EC. The scarcity and inconsistent 
findings of publications addressing this issue, however, prevent firmer conclusions. 
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1.4 HYPOTHESIS AND AIMS 
1.4.1 Hypothesis 
Acute injury initiates a cascade of thrombotic, inflammatory and mitogenic 
responses in the vascular wall, leading to intimal thickening by fibro-proliferative 
lesion formation. Activation of the endogenous ET system by vascular damage 
contributes to intimal lesion growth by exacerbating inflammatory and proliferative 
processes. ET-1-mediated stimulation of lesion development appears to be mediated 
primarily by the ETA receptor subtype but the role of the ETB receptor is less clear. 
Activation of ETB receptors in vascular smooth muscle and perhaps other cells may 
stimulate lesion formation whereas stimulation of those expressed by ECs can also 
mediate effects that might be expected to reduce lesion growth (including stimulation 
of NO release, endothelial re-growth and ET-1 clearance). Therefore, the work 
described in this thesis addressed the hypothesis that endogenous ET-1, acting in the 
ETA receptor, enhances neointima formation following acute vascular injury and 
that this action is moderated by concurrent stimulation of ETB receptors expressed 
by the vascular endothelium. 
 
1.4.2 Aims 
To determine the roles of ET receptor subtypes in the response to vascular injury, the 
primary aims of this project were:  
i) To establish two in vivo models of neointimal lesion formation (with and 
without removal of the endothelium) in the mouse which are amenable to 
pharmacological and genetic manipulation and to improve existing 
methodology for the measurement of neointimal lesion morphology. 
ii) To determine how selective blockade of ETA or ETB receptors alters 
neointimal lesion formation and whether concurrent blockade of ETB 
modulates the response to ETA antagonist treatment.  
iii) To determine whether EC-specific deficiency of the ETB receptor gene 














All animal experiments carried out in the course of this work were performed in 
accordance with the Animals (Scientific Procedures) Act (UK), 1986. Mice were 
bred and housed at the University of Edinburgh Biomedical Research Facility, Little 
France at 21-22°C and 50% humidity with a 12 hour diurnal light/dark cycle and free 
access to water and either standard mouse chow (RM1, Special Diets Services, UK) 
or a drug-containing derivative (section 2.3.2). Unless otherwise stated, experiments 
were performed on male mice aged 2-4 months. All non-genetically modified mice 
used were of the inbred C57Bl/6J strain and purchased from Harlan Laboratories, 
UK.  
 
2.1.1 Breeding and maintenance of EC-specific ETB knockout mice 
Dr Yuri Kotelevtsev and colleagues have previously bred mice bearing endothelial 
cell (EC) specific deletion of the ETB receptor in this laboratory (Bagnall et al., 
2006).  These animals were generated by the cross of floxed ETB mice (FF/--; 
background: 129/Ola x BKW) with Tie2-Cre transgenic mice (WW/tie2; 
background: C57Bl/6 x SJLF1), which express Cre recombinase under the control of 
a promoter region from the angiopoietin-1 receptor, Tie2 (Kisanuki et al., 2001).  
 
Experimental mice were the product of the cross of male FF/tie2 mice with female 
Cre-naïve FF/-- mice (maintained as an isolated line) to result in progeny of the 
genotypes FF/-- (Cre-negative control animals) and FF/tie2 (EC ETB-deficient 
animals). A small minority of the offspring was expected to possess the genotypes 
F0/-- or F0/tie2, indicating heterozygous deletion of the ETB gene in all cells. This is 
consistent with observations from several groups that sex-dependent non-specific 
Cre-mediated recombination of the floxed allele can occur within the gametes even 
with otherwise specific promoters including Tie2 (Constien et al., 2001; Koni et al., 
2001) and AQP2 (Nelson et al., 1998), resulting in deletion of the targeted locus in a 
non-cell specific manner. To avoid this problem, Tie2-Cre was transmitted 
exclusively through the male germline which previous experience (Kelland et al., 
Unpublished data) has shown to dramatically reduce the incidence of non-specific 
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recombination. Further, because F0/-- mice were detected by routine genotyping, 
breeding pairs producing animals of this genotype and their offspring were culled 
without further use. A further consequence of this breeding strategy over many 
generations is that experimental animals can be considered to possess only the 
genetic background of the floxed ETB line rather than that of the original Tie2-Cre 
line. 
 
2.1.2 Extraction of DNA from tail tips/ ear clips 
Genomic DNA was prepared from tissue samples to allow the genotyping of 
genetically-modified experimental animals. As mice required ear notching at the 
time of weaning for identification purposes, the resulting ear clips were collected for 
DNA extraction to minimize the number of procedures performed on each mouse in 
accordance with Home Office guidelines. Ear clips, stored at -20°C until needed, 
were digested in 300µl tail buffer (composition: 200mM Tris HCl pH 8.0, 400mM 
EDTA, 4.0M NaCl, 10% v/v SDS) containing 10mg.ml-1 proteinase K (Roche 
Applied Biosciences, UK) overnight while continuously rotated at 55°C (Techne 
HB-1D hybridiser oven). The following day, 10 µl DNAse-free RNAse (40ng.ml-1; 
Sigma, UK) was added to each sample and incubated (1 hour, 37°C) before cooling 
on ice until precipitation of SDS was observed. The aqueous phase was carefully 
removed and the DNA precipitated from this by addition of 300 µl isopropanol and 
gentle agitation (5 mins), before centrifugation (12000 x g, 2 mins) and removal of 
the supernatant. Precipitated DNA pellets were washed in 70% v/v ethanol, 
centrifuged (12000 x g, 2 mins) and the supernatant again discarded. To the resulting 
washed pellet, 200 µl Tris-EDTA buffer (composition: 100 µM Tris.HCl pH 8, 2 µM 
EDTA) was added and the samples incubated (30 mins, 37°C) to dissolve DNA 
before storage at -20°C until needed. Ear clip samples extracted in this way typically 





2.1.3 Polymerase chain reaction 
All genetically modified animal strains were genotyped by polymerase chain reaction 
(PCR) of genomic DNA and separation of products by agarose gel electrophoresis. 
PCRs for the ETB allele and Tie2-Cre were performed in a total volume of 25 µl 
containing 0.31 µl each of 200 mM dATP, dCTP, dGTP and dTTP, 0.75 µl of each 
of the appropriate forward and reverse primer (10 µM), 1 µl of approximately 
1 µg.ml-1 DNA, 2.5 µl of 10X PCR buffer (Bioline, UK), 1.125 µl of 50 mM MgCl2 
and 0.2 units of Taq polymerase (Bioline, UK). All reactions were performed in a 
Peltier Thermal Cycler PT-200 (MJ Research, USA), with heated lid, according to 
the cycle conditions detailed in Table 2-1. 
 
PCR for the ETB allele was performed routinely using the forward primer 5’-TCA 
GTT GTA ATG AGA CAC AGA C-3’ and reverse primer 5’-AGC CAT AAA GTC 
ACA GCC ATT C-3’. These oligonucleotides flanked a region of up to 2.2kb in 
length containing both loxP sites, exons 3 and 4 of the ETB allele and an 1166bp 
deletion in the intron 1 resulting in three possible PCR products: a 2.2kb amplicon 
‘W’ indicating the presence of the wild-type ETB allele, a 1.1kb amplicon ‘F’ 
indicating the presence of a loxP-flanked but otherwise intact (non-recombined) ETB 
allele, and a 186bp amplicon ‘0’ indicating the presence of a recombined loxP-
flanked ETB allele (Figure 2-1). PCR for the Tie2-Cre transgene was performed 
using the forward primer 5'-CGC ATA ACC AGT GAA ACA GCA TTG C-3' and 
reverse primer 5'-CCC TGT GCT CAG ACA GAA ATG AGA-3' as described by 
(Kisanuki et al., 2001). The presence of Tie2-Cre was indicated by the appearance of 
a single ~550bp band.  
 
2.1.4 Agarose gel electrophoresis 
PCR amplification products were separated according to size by agarose gel 
electrophoresis. Gels were prepared by dissolving agarose (Bioline, UK) to 1% w/v 
in Tris-Acetic acid-EDTA (TAE) buffer (composition: 40mM Tris base, 20mM 
acetic acid, 1mM pH 8 EDTA) at 95°C. After cooling to 60°C, ethidium bromide 
(0.5µg.ml-1; Sigma, UK) or SYBRsafe (1X; Invitrogen, UK) nucleic acid stains were 




Step ETB allele PCR Tie2-Cre PCR 
   
1 92°C, 2 mins 92°C, 3 mins 
2 92°C, 30 secs 92°C, 30 secs 
3 60°C, 30 secs 55°C, 30 secs 
4 68°C, 2 mins 68°C, 2 mins 
5 Return to step 2, 30 times Return to step 2, 29 times 
6 68°C, 10 mins 68°C, 10 mins 
   
 
Table 2-1 PCR cycle conditions for genotyping of EC ETB-deficient mice. 
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Figure 2-1 Floxed ETB allele and primer schematic.  
The ETB allele of floxed ETB mice contains loxP sites flanking exons 2 and 3. The insertion of these required deletion 
of a 1166bp span of intron 1. The forward primer for ETB allele genotyping lies before this deletion, in intron 1, and 
the reverse primer in intron 3. Wild-type ETB can be distinguished from floxed ETB by a shortened amplicon which 
lacks the deleted region of intron 1. The recombined ETB allele can be distinguished by a further abbreviated 
amplicon which also lacks exons 2 and 3. 
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PCR product, 2 µl 6x loading dye solution (Promega, UK) was added before loading 
of samples and separation at 100V for ~1 hour or as needed. To provide reference to 
molecular mass, standard 100bp DNA ladders (Promega, UK; band sizes: 1500, 
1000, 900, 800, 700, 600, 500, 400, 300, 200, 100bp) were loaded in parallel to PCR 
product. DNA was visualized by UV transillumination. 
 
2.2 MYOGRAPHY 
2.2.1 Tissue preparation for myography 
For myography studies, mice were killed by CO2 asphyxiation (Chapter 3) or cardiac 
puncture/ exsanguination following sodium pentobarbital anaesthesia (Chapter 5; 
~120mg/kg i.p.; Ceva Animal Health Ltd, UK). Femoral arteries, from the level of 
the abdominal wall to the bifurcation of the common femoral artery, were isolated 
using fine spring scissors and watchmaker forceps (Fine Science Tools, UK) under 
10X magnification. Aortas were separated from the thoracic wall and removed with 
the heart to the point of passage through the diaphragm. Once collected, arteries were 
immediately immersed in a physiological salt solution (PSS; composition: 119.0mM 
NaCl, 3.7mM KCl, 2.5mM CaCl2, 1.2mM MgSO4, 25.0mM NaHCO3, 1.2mM 
KH2PO4, 27.0µM EDTA, 5.5mM D-glucose) at 4˚C for transport to the myography 
laboratory.  
 
Here, vessels were secured on plates coated with Sylgard 184 elastomer (Dow 
Corning, UK) with minutien pins (Fine Science Tools, UK), further cleaned of peri-
adventitial fat and connective tissue under 10X magnification and divided into rings 
~2mm in length rings under 10X magnification. Femoral artery rings were cut 
immediately proximal to the common femoral artery bifurcation. Thoracic aortas 
were separated from the heart and rings taken immediately distal to the aortic arch. 
Arterial rings were mounted in the organ baths of a Mulvany-Halpern myograph 
(Multi-myograph 610M, Danish Myotech, Denmark) containing PSS for recording  
isometric tension. Briefly, rings were threaded over a 40µm diameter tungsten wire 
(Danish Myotech, Denmark) attached to a micrometer-driven support and secured. A 
second wire was passed parallel to the first, through the lumen of the vascular ring, 
59 
 
and attached to an opposing support connected to an isometric force transducer 
(Mulvany & Halpern, 1977). Transducer output was passed to a data acquisition 
computer (Apple Inc, USA) running Chart 3.4.3 software (AD Instruments, UK) via 
an analogue/digital converter (Maclab/8, AD Instruments, UK). Exact ring lengths 
were determined using a calibrated graticule eyepiece (Carl Zeiss Inc, UK). Baths 
were gradually warmed to 37oC by an integrated heating block and bubbled with 
95% O2 / 5% CO2 to provide buffering. Over ~30 mins, tensions of 7.5 mN and 
8.0mN was gradually applied to aortic and femoral artery rings, respectively, by 
adjustment of the micrometer. This optimal resting force for each vessel type has 
been previously determined in our laboratory by normalisation and is in accordance 
with published literature (Widmer et al., 2006; Bhattacharya et al., 2008).  
 
2.2.2 Common standard wire myography protocol elements 
To determine the receptor-independent contractility of tissues and to rejuvenate 
responsiveness following dissection and mounting, bathing media were replaced with 
iso-osmolar, high K+ PSS (KPSS; composition: 124.6mM KCl, 2.5mM CaCl2, 
1.2mM MgSO4, 25.0mM NaHCO3, 1.2mM KH2PO4, 27.0µM EDTA, 5.5mM D-
glucose). Once the resulting constriction stabilised, tissues were washed with PSS 
until tension had returned to baseline and the process was repeated twice more. On 
the third instance, the tension developed in KPSS was recorded as a reference for 
inherent contractility of that tissue.  
 
For all vascular rings, cumulative concentration-response curves to the α1-
adrenoceptor agonist, phenylephrine (Sigma, UK), were recorded over the range 10-9 
to 10-4M, using half-log unit steps. At the end of this procedure, rings were washed 
as necessary with PSS to return tension to baseline, before pre-contraction with a 
sufficient concentration of phenylephrine to result in 80% of maximal contraction 
(EC80). Once tension had stabilized, acetylcholine (Sigma, UK) was added in half-
log unit concentration steps over the range 10-9 to 10-4M to assess endothelium-
dependent vasodilatation, before washing with PSS. Subsequent responses to iso-
osmolar PSS containing increased K+ concentration (5-125mM), sodium 
nitroprusside (10-9 to 10-5M; Sigma, UK; in pre-contracted rings), endothelin-1 (10-11 
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to 10-7M; Merck Biosciences, UK) and/or sarafoxin 6c (10-6 or 10-7M; Merck 
Biosciences, UK; single dose in pre-contracted or un-contracted rings) were obtained 
as required by the experimental protocol (see appropriate chapters). Where 
necessary, prior to the exposure to the compound under investigation, inhibitors of 
nitric oxide synthase (L-NAME; N-nitro-L-arginine methyl ester; 2x10-4M; Sigma, 
UK) or antagonists to ETA (BQ123; Cyclo(D-Asp-Pro-D-Val-Leu-D-Trp); 10-6M; 
Merck Biosciences, UK) or ETB receptors (A192621; (2R,3R,4S)-2-(4-
propoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N-[(2,6-
diethylphenyl]acetamido)pyrrolidine-3-carboxylate; 10-7M; Abbott Laboratories, 
USA) receptors were incubated with tissues for 30 mins.  
 
2.2.3 Myography data analysis 
Myography data were recorded as tension developed following administration of 
drugs. Functional responses produced in response to vasoconstrictor agents were 
expressed both as absolute force per length of muscle:  
 
 
and/or normalised to the tension elicited by the third exposure to KPSS. Responses to 
vasodilator agents were expressed as a percentage of the pre-existing tension existing 
immediately before addition of the substance under study. Summary data for 
concentration-response relationships (Emax, maximum response; -log(EC50), 
concentration eliciting 50% Emax) were calculated using Prism 4.0 software 
(Graphpad software, USA) by iterative least squares fit to the logistic equation: 
 
 
 [ . −1] = [ ]2 × ℎ [ ] 
10 50 − ∙  
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2.3 TECHNIQUES FOR IN VIVO STUDIES 
2.3.1 Surgical procedures - femoral artery injury 
Vascular injury was inflicted to the femoral artery to enable the study of subsequent 
neointimal lesion formation. This was achieved by application of the widely used 
intra-luminal wire-injury model, described by Sata et al (2000) and derivatives of the 
carotid artery ligation-injury model (Kumar & Lindner, 1997), applied to the femoral 
artery.  
 
2.3.1.1 Animal preparation, femoral artery cut-down and isolation 
Mice undergoing femoral artery injury surgery were first weighed and placed in an 
exposure chamber containing 4-5% isoflurane (Merial Animal Health Ltd, UK) to 
induce anaesthesia. Upon loss of consciousness, animals were transferred to a heated 
pad, to maintain body temperature, where administration of anaesthetic (~2% 
isoflurane in oxygen) was maintained via a nose cone. To provide post-operative 
analgesia mice were administered 0.1 mg.kg-1 buprenorphine (Alstoe Animal Health 
Ltd, UK) by subcutaneous injection. Once surgical anaesthesia was attained, as 
assessed by pedal withdrawal reflex, mice were rotated to a supine position. Both 
hind limbs were secured with adhesive tape and the medial surface shaved. On the 
limb of interest, the inguinal ligament and femoral artery were visualized through the 
skin and at their convergence, a 5mm transverse incision made. The subcutaneous 
space was opened and the femoral artery/vein/nerve bundle isolated from the 
surrounding tissue by blunt dissection with micro-surgery forceps. About the 
femoropopliteal bifurcation, the femoral nerve was carefully separated from the 
attached vasculature. 
 
2.3.1.2 Wire injury 
Approximately 3mm proximal and distal to the arterial branch point, the artery and 
vein together were looped with 6-0 silk (Fine Science Tools, UK) to which gentle 
tension was applied with hemostats to temporarily halt blood flow. The popliteal 
branch was further separated from the adjacent vein and ligated with 6-0 silk. 
Tension was applied to this ligature with a third hemostat to bring the popliteal artery 
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from its descending anatomical path into the plane of the femoral artery before peri-
adventitial connective tissue was carefully stripped from both arteries. To prevent 
desiccation, to dilate the femoral artery and to reduce vasospasm following injury, 
the surgical field was irrigated with 1% w/v lignocaine (Hamlen Pharmaceuticals, 
UK), as necessary. A transverse arteriotomy was made in the isolated popliteal 
branch, ~2mm distal to the femoropopliteal bifurcation, through which, a 0.014” 
diameter straight sprung angioplasty guide wire (Cook Inc, USA) was introduced. 
The wire was slowly advanced through the femoral artery towards the iliac artery 
until resistance was met (~1.5 cm) and allowed to distend it for 30 secs. On 
withdrawal, the proximal loop was rapidly re-tensioned and a further permanent 
ligature applied immediately proximal to the arteriotomy to prevent egress of blood. 
Temporary ligatures were removed and reperfusion of the entire femoral artery was 
observed.  
 
2.3.1.3 Complete ligation injury 
Proximal to the femoropopliteal bifurcation, the femoral artery and vein were 
together looped with 6-0 silk (Fine Science Tools, UK) and gentle tension applied 
with a hemostat to aid access to the branch point. At the point of bifurcation, the 
artery was carefully separated from the underlying vein and ligated with 6-0 silk. The 
proximal loop was removed and the reperfusion of the femoral artery and its 
proximal (but not distal) branches confirmed.  
 
2.3.1.4 Partial ligation injury 
Partial ligation was achieved as in 2.3.1.3, with the exception that, a permanent 
ligature was applied to the femoral artery immediately distal to its junction with the 
popliteal artery, rather than proximal to this bifurcation. 
 
2.3.1.5 Wound closure and recovery 
Following closure of the external wound with 5-0 silk (Mersilk, Ethicon, UK), in 
some studies, vascular injury was inflicted on the contra-lateral femoral artery, 
according to the required technique. Where necessary, animals were ear notched for 
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identification purposes, and briefly transferred to an empty cage to recover from 
anesthesia. 
 
2.3.2 Administration of drugs for in vivo studies 
Pharmacological antagonists were employed to achieve non-cell specific blockade of 
ETB and ETA receptors in adult animals, thereby avoiding the developmental 
defects resulting from non-specific genetic deficiency of either receptor. Many 
potent, selective and well-characterised ET receptor antagonists are available, 
including the ETA antagonist atrasentan (ABT-627; 2000-fold ETA/ETB selective) 
and the ETB antagonist A192621 (1300-fold ETB/ETA selective) used in these 
studies, kind gifts of Abbott Laboratories (Opgenorth et al., 1996; von Geldern et al., 
1999). Both drugs are orally-active and were administered in food to achieve 
respective doses of 10mg.kg-1.day-1 and 30mg.kg-1.day-1 assuming consumption of 
10g.day-1 of prepared diet, values suggested by previous studies in our laboratory and 
in accordance with published values (Opgenorth et al., 1996; Wessale et al., 2002). 
Drugged diet was bound in gelatin and presented in tubes to prevent dispersion of 
food around the cage and, therefore, both reduce waste and allow a more accurate 
monitoring of consumption.  
 
To prepare gelled drug diet, powered beef gelatin (Supercook, UK) was first 
dissolved in distilled water at 100oC and cooled to 40oC. Drug vehicle was prepared 
by dispersing methylcellulose (Sigma, UK) in distilled water at 80oC to 0.2% w/v 
before rapid cooling until solvated. Where appropriate, atrasentan and/or A192621 
were powdered in a pestle and mortar and dispersed in vehicle solution to 
concentrations of 83.3 µg.ml-1 and 250 µg.ml-1 respectively. Gelatin and drug/vehicle 
solutions were combined with RM1 powdered mouse chow (Special Diet Services, 
UK) in the weight ratio 17:15:18. Therefore, each 1kg of food contained 360g 
powdered diet, 38g beef gelatin dissolved in 302ml distilled water and 300ml 0.2% 
w/v methylcellulose solution containing, where appropriate, 25mg atrasentan and/or 
75mg A192621 in suspension. After vigorous mixing, prepared gel diet was packed 




2.3.3 Tail plethysmography 
During chronic in vivo pharmacological studies, blood pressure measurements were 
made to verify effective absorption and activity of administered vasoactive drugs. 
Systolic blood pressure was determined using the technique of tail cuff photo-
plethysmography, in which, blood flow through a rodent’s tail is monitored by light 
transmittance (inversely proportional to tail volume) at a point distal to a 
progressively inflating/ deflating pressurised cuff. The cuff inflation pressure at 
which cyclical changes in tail volume and, therefore, blood flow are quenched 
indicates systolic blood pressure.  
 
Rodents dissipate excess body heat, in part, by increasing tail blood flow. To ensure 
sufficient tail blood flow for photoplethysmography, mice were placed in a 40oC 
chamber for 10 mins immediately prior to the procedure. Subjects were transferred to 
a Perspex tubular restraint mounted above a heated pad and an integrated pressure 
cuff/photosensor sleeve (Harvard Apparatus, UK) was placed around the base of the 
tail. Animal restraint force was adjusted to maximize comfort and until a regular 
cyclical tail volume (i.e. pulse) trace was observed on the connected data acquisition 
computer (International Business Machines Corporation, UK). Pulse traces were 
recorded while, under computer control, cuff pressures were progressively increased 
to above, then decreased to below, the pressure at which distal pulse was no longer 
apparent. For each animal, seven inflate/deflate pressure cycles were performed and 
systolic blood pressure recorded as the mean measurement from the last four deflate 
cycles only. Once adequate pressure measurements were acquired, mice were 
weighed and returned to their cages. 
 
2.3.4 Perfusion fixation  
Tissue fixation serves to inactivate tissue-catabolising enzymes, prevent growth of 
microorganisms and provide mechanical strength to delicate structures to allow 
storage and analysis of biological samples. Aldehyde fixatives such as formalin and 
glutaraldehyde achieve this by the formation of methylene crosslinks between tissue 
amine groups. Perfusion of whole animals via the vasculature offers a way to rapidly 
and evenly deliver fixative to all organs simultaneously, thereby affording rapid 
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fixation, deep within tissues.  Of greater relevance here, perfusion fixation confers 
sufficient rigidity to blood vessels to maintain their luminal dimensions once excised 
from their supporting structure.  
Trans-cardiac perfusion fixation was performed in mice terminally anaesthetised 
with sodium pentobarbital (80mg.kg-1, Ceva Animal Health Ltd, UK) administered 
by intraperitoneal injection. 2 hours prior to the induction of anaesthesia, 2.5mg of 5-
bromo-2-deoxyuridine (Sigma, UK), dissolved in 0.5ml 0.9% w/v NaCl, was 
administered by the same route to label proliferating cells. Following the onset of 
deep surgical anesthesia, as determined by loss of pedal withdrawal reflex and 
reduced respiratory rate, a bilateral thoracotomy and transverse sternotomy were 
made. For the delivery of perfusate, a 23 gauge needle was advanced ~4mm through 
the free left ventricular wall and secured. A further incision was made in the right 
atrial wall to allow perfusate to escape. 24ml phosphate-buffered saline (PBS; 
Sigma, UK) containing 10U.ml-1 heparin (Leo Laboratories, UK), was delivered to 
left ventricle at a constant rate of 6ml.min-1 by peristaltic pump (Gilson, UK). After 
perfusion with heparinised PBS, 24ml 10% neutral buffered formalin (Sigma, UK) 
was delivered in the same manner to provide fixation and maximize the preservation 
of tissue morphology. Adequate perfusion was indicated by blanching of the liver 
and other organs, and proper fixation by characteristic muscular contractions and 
subsequent rigidity. Following perfusion, blood vessels and organs of interest were 
dissected and immersed in fixative for a further 48 hours, before transfer to 70% v/v 
ethanol (Fisher Scientific, UK) for storage until needed.  
 
2.4 HISTOLOGICAL TECHNIQUES 
2.4.1 Tissue processing, paraffin embedding and microtomy 
To enable the cutting of high definition tissue sections for subsequent analysis of 
morphology and composition, femoral arteries were infiltrated with paraffin wax 
before sectioning and analysis. Formalin fixed tissues were loaded into identifying 
cassettes and processed to wax using a Tissue-Tek Vacuum Infiltraton Processor 
(Sakura Finetek Europe, The Netherlands). Briefly, cassettes were dehydrated in 
graded concentrations of ethanol (50%, 70%, 95%, 100%, 100% v/v, each for 2 
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hours; Fisher Scientific, UK), cleared in xylene (two changes, each for 2 hours; 
Fisher Scientific) and immersed in molten paraffin wax at 60°C (three changes, each 
for 2 hours; Thermo-Shandon, UK). Each step was performed under vacuum and 
with agitation to accelerate infiltration of solvents/wax. After processing, femoral 
arteries were positioned in molten paraffin wax-filled embedding moulds and rapidly 
cooled on a Tissue-Tek Cryo-console (Sakura Finetek Europe, The Netherlands) to 
form solid blocks bound to an identifying plastic support. To reduce the quantity of 
sections to be cut, in some studies, up to 5 arteries were embedded in each paraffin 
block. This was achieved either by embedding the vessels in 2% w/v agarose 
(Bioline, UK) prior to processing, or by careful placement and embedding of 
individually processed vessels in a single embedding mold. In both cases, vessels 
were arranged in a pattern that allowed the identification of individual arteries within 
each block, regardless of orientation. 
 
Paraffin blocks were cut into sequential 3µm thick sections using a Leitz 1512 
microtome (Leica Microsystems, Germany) and MB35 disposable blades (Thermo-
Shandon, UK). Immediately after cutting, ribbons of sections were floated on the 
surface of a 45oC water bath (Sakura Finetek Europe, The Netherlands), to remove 
wrinkles, and mounted on Superfrost Plus electrostatically-coated microscope slides 
(VWR International, UK). Slides were dried overnight at 37oC before further use, to 
ensure adherence of the sections. Wire-injured femoral artery blocks were sectioned 
in a repeating pattern, wherein, 16 sections were retained and mounted on 8 slides (2 
per slide) followed by discard of the proceeding 100µm of block. Sectioning was 
continued in this manner until either no vessel was visible, or the remaining vessel 
was morphologically normal upon microscopic scrutiny, resulting in ~250-300 
sections per block. Due to the more focal nature of lesions resulting from femoral 
artery ligation, when cutting these vessels 10 sections were retained (5 slides, 2 per 
slide) before discard of only the proceeding 50µm of block, typically requiring only 




2.4.2 United States trichrome staining 
For routine examination and morphometric analysis, tissue sections were stained 
using the “United States trichrome” (UST) method (Hadoke et al., 1995) either 
manually or using an automated cytology stainer (Varistain Gemini, Thermo-
Shandon, UK). This technique is a simple combination of a selective elastin stain 
(Gomori’s aldehyde fuchsin) with Gomori’s one-step trichrome and thus allows 
differentiation of collagen (blue-green), elastin (deep purple) and cells (cytoplasm: 
red; nuclei: black) in a single section. 
 
Gomori’s aldehyde fuschin was prepared by dissolving pararosaniline (Sigma, UK) 
to 1% w/v in 60% v/v ethanol and, to this, addition of 1% v/v HCl (VWR 
International, UK) and 2% v/v paraldehyde (Sigma, UK). The solution was allowed 
to ‘ripen’ for at least two days in sunlight to allow reaction of pararosaniline and 
acetaldehyde, and vacuum filtered before use through Whatman #1 paper (GE 
Healthcare, UK). Gomori’s trichrome was prepared in distilled water by addition of 
0.6% w/v phosphotungstic acid (Sigma, UK), 0.6% w/v chromotrope 2R (Sigma, 
UK), 0.3% w/v fast green FCF (Sigma, UK) and, after vigorous mixing, 1% v/v 
acetic acid (Fisher Scientific, UK). Weigert’s hematoxylin was prepared from 
Weigert’s solution A and B (Bios Europe, UK) immediately before each use. 
Acidified potassium permangantate solution (0.3% v/v concentrated H2SO4, 0.3% 
w/v KMnO4) was also freshly prepared before each staining batch, from 3% v/v 
H2SO4 (Fisher Scientific, UK) and 1% w/v KMnO4 (Sigma, UK) stock solutions. 
 
After de-waxing in xylene (Fisher Scientific, UK) and rehydration through graded 
alcohols (Fisher Scientific, UK) tissue sections were bleached of any inherent 
pigment by immersion in acidified potassium permanganate and rinsing in oxalic 
acid (Sigma, UK). Bleached sections were placed in the elastin-stain, Gomori’s 
aldehyde fuschin and differentiated in 70% v/v alcohol. Nuclei were counter-stained 
with Weigert’s acid-fast iron hematoxylin. After rinsing in distilled water, slides 
were placed in 5% w/v phosphotungstic acid (Sigma, UK) to displace previously 
applied dyes from collagen fibres and again rinsed in distilled water. In the final 
staining step, slides were immersed in Gomori’s trichrome reagent to stain cytoplasm 
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and collagen and then rinsed in acetic acid, dehydrated through graded alcohols, and 
cleared in xylene. Coverslips were mounted with resinous medium (Di-n-butyl 
phthalate in xylene, Fisher Scientific, UK, or Consulmount, Thermo-Shandon, UK) 
either manually or with an automated coverslipping device (Consul, Thermo-
Shandon, UK). The complete staining protocol is detailed in Table 2-2. 
 
2.4.3 Picro-sirius red staining 
Staining with picro-sirius red, a sensitive and specific collagen fibre stain (Puchtler 
et al., 1973) was performed to evaluate lesion collagen content. After de-waxing in 
xylene (2 x 5 mins), re-hydration through graded alcohols (100%, 90%, 70%, each 
for 2 mins) and rinsing in running tap water (5 mins), slides were immersed in picro-
sirius red staining solution. Staining solution was prepared by dissolving the collagen 
stain Direct Red 80 (Sigma, UK) and plasma counter-stain Fast Green FCF (Sigma, 
UK) in saturated aqueous picric acid (Sigma, UK), each to 0.1% w/v. After 2 hours, 
slides were briefly rinsed in tap water, dehydrated in graded alcohols (70%, 90%, 
100%, 2 mins each) to xylene (2 x 2 mins) and cover-slipped using resinous media 
(Consolmount, Thermo-Shandon, UK). Photomicrographs (see section 2.4.4) of 
picro-sirius red stained sections were quantified by colour deconvolution as for 
immunohistochemistry (see section 2.4.6.2). 
 
2.4.4 Digital image acquisition 
To allow analysis of lesion size and composition, colour photomicrographs of 
histologically- or immunohistochemically-stained tissues were required. These were 
captured to a data acquisition computer (Dell Inc, UK) running MCID Basic 7.0 
software (Imaging Research, USA) under 10X objective magnification (Axioskop 
stage microscope, Carl Zeiss Inc, UK) by a monochromatic CCD camera 
(CoolSNAP Colour, Photometrics, USA) with liquid crystal RGB filter 
(MicroColour, CRI Inc, USA).  
2.4.5 Morphometry 
Morphometric analysis was performed from photomicrographs of femoral artery 




 Step Reagent Duration 
   
1 Xylene (VWR International, UK) 2 x 5 mins 
2 100% v/v ethanol (Fisher Scientific, UK) 2 x 5 mins 
3 95% v/v ethanol (Fisher Scientific, UK) 1 x 5 mins 
4 Running tap water 1 x 5 mins 
5 0.3% w/v KMnO4 (Sigma, UK) in 0.3% v/v H2SO4 (Fisher Scientific, UK) 1 x 1 min 
6 Running tap water 1 x 1 mins 
7 2% v/v oxalic acid (Sigma, UK) 1 x 5 secs 
8 70% v/v ethanol (Fisher Scientific, UK) 1 x 5 mins 
9 Gomori’s aldehyde fuchsin 1 x 5 mins 
10 70% v/v ethanol (Fisher Scientific, UK) 1 x 2 mins 
11 Running tap water 1 x 5 mins 
12 Weigert’s hematoxylin (Bios Europe, UK) 1 x 5 mins 
13 5% w/v phosphotungstic acid (Sigma, UK) 1 x 5 mins 
14 Running tap water 1 x 2 mins 
15 Gomori’s trichrome 1 x 20 mins 
16 0.2% v/v acetic acid (Fisher Scientific, UK) 1 x 1 min 
17 95% v/v ethanol (Fisher Scientific, UK) 1 x 1 min 
18 100% v/v ethanol (Fisher Scientific, UK) 2 x 2 mins 
19 Xylene (VWR International, UK) 2 x 2 mins 
   
 
Table 2-2 United States Trichrome staining protocol. 
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these, measurements of medial area, intimal area and luminal area were made. Media 
was defined as the region delineated by the internal (IEL) and external (EEL) elastic 
laminae; intima by the region within the IEL composed of cellular or stable 
thrombotic material; and lumen by any remaining “empty” area within the IEL. 
Borders of the relevant areas were traced using Photoshop CS3 Extended software 
(Adobe Systems Inc, USA) and each area calculated according the scale: 1 pixel = 
0.5126 µm2, as determined by imaging of a graticule slide. From these values, 
additional morphometric parameters of intima/media ratio and stenotic ratio were 





2.4.6    Immunohistochemistry 
Immunohistochemistry is a powerful technique for conferring molecular-specificity 
to histological preparations first described by Albert Coons in 1941. Common 
implementations of the original process involve visualization of the binding of a 
specific antibody/anti-serum to its target, by fluorescence or the enzymatic 
development of a chromogenic substrate, and necessitate several interleaved 
amplification steps depending on the abundance of antigen and quality of antibody. 
In this work, immunohistochemistry was performed according to the indirect labeled 
streptavidin-biotin (LSAB) method and reported by the peroxidase-catalysed 
oxidation of 3,3’-diaminobenzidine to an insoluble phenazine polymer, as detailed in 
Figure 2-2. Because chemical fixation, especially by aldehydes, can disturb the 
structure and accessibility of antigens of interest, protease-induced epitope retrieval 
(PIER) was used, where necessary, to facilitate specific binding of the primary 
antibody. To increase throughput, immunohistochemistry reactions were carried out 
using the ‘semi-automated’ Sequenza system (Thermo-Shandon, UK). This 
comprises an electrostatically-charged coverplate, which is affixed to each slide to  
/ =  





Figure 2-2 Schema for immunohistochemistry by the indirect labelled streptavidin biotin method.  
Primary antibodies are allowed to bind to epitopes of interest on tissue sections. To these bind secondary 
antibodies which are reactive to immunoglobulins of the species and isotype of the primary antibody. 
Secondary antibodies employed are pre-labelled with biotin. After formation of the epitope-primary-secondary 
antibody complex, sections are treated with a conjugate of streptavidin and horseradish peroxidase. Peroxidase 
catalyses conversion of the 3,3-diaminobenzidine to an insoluble brown product. Thus, after incubation with 
this substrate, the location of the original epitope of interest can be visualised. The use of these successive 
steps provides simple amplification as the stoichiometry of each reaction is greater than 1:1. αSMA, α-smooth 
muscle actin; IgG, immunoglobulin G. 
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form a narrow gap over the slide surface and is fed by a small reservoir to which 
reagents can be added. The charged surface of the coverplate ensures free and rapid 
passage of solutions, facilitating washing of slides, while capillary action dictates 
that the final ~80µl of added liquid is retained, allowing incubation of reagents with 
tissue sections and protecting slide contents from desiccation. 
 
To provide routine validation of immuno-staining procedures, at least four control 
slides were included in each experimental batch. Three negative control slides were 
included to ensure positive staining was not explicable by non-specific binding of a 
reagents: two reagent negatives in which both the target tissue and a tissue highly 
expressing the antigen of interest were treated with a control reagent in place of 
primary antibody (such as a non-reactive antibody of the same immunoglobulin 
isotype at a matched concentration) and a tissue negative in which the relevant 
antigen is not expected to occur. To confirm the effectiveness of each immuno-
staining batch and provide a references for colour deconvolution (see section 
2.4.6.2), a positive control slide bearing a section of tissue expected to strongly 
express the antigen of interest was also stained in parallel to experimental sections. 
Details of control tissues/reagents for each immunohistochemistry protocol used are 
given in Table 2-3 and examples of staining in Figure 2-3. 
 
2.4.6.1 Immunohistochemical staining protocol 
All immunohistochemistries in this work were carried out according to the following 
general protocol. Antibody-specific variations are given in Table 2-4. Paraffin 
sections were first baked at 55°C to ensure adherence of tissues to slides. After 30 
mins, slides were removed from the oven, de-waxed in xylene (2 changes, each for 5 
mins), rehydrated through graded ethanols (100%, 90%, 70%, each for 2 mins) and 
rinsed under running tap water (5 mins).  
 
For anti-BrdU staining, slides were pre-treated by enzymatic digestion to restore the 
confirmation of antigens lost to fixation. To achieve this, slides were immersed in 








Tissue Positive Control 
 
Reagent Negative Control 
(reagent; dilution; supplier) 
Tissue Negative Control 
 
    
αSMA Uninjured femoral artery (media) Kidney (muscular arteries) 
NS-1 myeloma ascites fluid, 1/400 
Sigma, UK Kidney (tubules) 
Mac2 Spleen 14-day injured femoral artery 
IgG2a κ, 1/3000 
BD Pharmingen, UK 
Uninjured femoral artery 
BrdU Ileum from BrdU treated mouse NS-1 myeloma ascites fluid, 1/800 Sigma, UK Ileum from BrdU untreated mouse 
    
 
Table 2-3 Control tissues and reagents for immunohistochemistry reactions.  






Figure 2-3 Example immunohistochemistry staining in control tissues.  
αSMA immunohistochemistry in kidney sections reveals strong staining of vascular smooth muscle in renal 
blood vessels (a) and no staining in tubular epithelial cells (c). When primary antibody is substituted for ascites 
fluid from NS-1 myeloma cells, no immunoreactivity is observed in any renal cell type (b). Mac2 staining is 
abundant throughout the red pulp of the spleen (d) and this is abolished upon substitution of primary anti-
Mac2 antibody with an irrelevant antibody of the same species and isotype (e). In uninjured femoral arteries, no 
Mac2 immunoreactivity is apparent (f). Intense BrdU immunoreactivity is present in the crypts of intestinal villi 
from mice treated with BrdU (g) but is completely absent in untreated animals (i). BrdU staining is also 












(antibody; dilution; incubation; supplier) 
E-P 
(dilution) 
    
Mouse anti-mouse αSMA Clone 1A4 
1/600, 30 mins @ 20oC 
Sigma, UK 
None 
1: 2.5% MP, 2.5% BSA 60 mins  
2: 20% GS, 30 mins 
Goat anti-mouse, 1/400, 30 mins @ 20oC 
Vector Laboratories, UK 
1/400 
Rat anti-mouse Mac2 (galectin-3) Clone M3/38 
1/6000, overnight @ 4oC 
Cedarlane Laboratories, USA 
None 1: 20% GS, 1% BSA, 30 mins 
Goat anti-rat, 1/200, 30 mins @ 20oC  
Vector Laboratories, UK 
1/200 
Mouse anti-BrdU Clone BU-33 
1/800, 1 hr @ 20oC 
Sigma, UK 
1: Trypsin  
2: HCl 
None 
Goat anti-mouse, 1/200, 30 mins @ 20oC 
Vector Laboratories, UK 
1/200 
     
 
Table 2-4 Details for specific immunohistochemistry reaction protocols.  
E-P, extravidin-peroxidase; PECAM-1, platelet-endothelial cell adhesion molecule-1; GS, normal goat serum; BSA, bovine serum albumin; αSMA, α-smooth muscle actin; MP: milk 
powder (J Sainsburys Ltd, UK); BrdU, 5-bromo-2-deoxyuridine. 
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(Sigma, UK) at pH 7.8. Sections were incubated for 30 mins at 37°C before rinsing 
in PBS (5 mins). Sections were subsequently subject to denaturation (acid 
hydrolysis) of DNA by incubation of sections with 2N HCl (30 mins at 37°C, Sigma, 
UK) to allow access of antibody to incorporated BrdU before further rinsing.  
 
For all protocols, slides were installed in Sequenza coverplates trapping 80µl of PBS 
between slide and coverplate and ensuring the capillary gap was free of air bubbles. 
Sequenzas were twice flushed with PBS before the addition of 3% v/v H2O2 solution 
(Sigma, UK) to block endogenous peroxidase activity. After 5 mins, Sequenzas were 
again twice flushed with PBS. To reduce non-specific binding of primary antibodies, 
sections were incubated with various blocking solutions, most commonly PBS 
containing 1% w/v bovine serum albumin (BSA, Sigma, UK) and 20% normal serum 
from the species in which the appropriate secondary antibody was raised. Blocking 
solutions were allowed to equilibrate with tissues, as required, at room temperature. 
Without washing, primary antibody diluted in 1% w/v BSA in PBS was added to the 
Sequenzas and incubated for the required time and at the appropriate temperature 
(Table 2-4). Primary antibody solution was removed from slides with three 5 min 
washes in PBS and replaced by secondary antibody solution, also diluted in 1% w/v 
BSA in PBS. After the required incubation at room temperature, slides were again 
washed with PBS (3 x 5 mins). Extravidin-Peroxidase (Sigma, UK), a conjugate of 
streptavidin and horseradish peroxidase, was diluted as necessary in PBS containing 
1% w/v BSA and incubated with slides for 30 mins before final washing in PBS (3 x 
5 mins). To visualise the distribution of HRP, and, therefore, antibody binding to 
tissues, a proprietary solution of H2O2 and 3,3’-diaminobenzidine (DAB+, prepared 
according to manufacturer’s instructions, Dako Cytomation Ltd, UK) was applied to 
tissue sections. To determine the appropriate incubation time, positive control slides 
were removed from Sequenzas, tissue sections circled using a hydrophobic barrier 
pen (Calbiochem, UK) and incubated with DAB+ solution while the development of 
brown precipitate was observed under 40X magnification. DAB+ was applied to 
remaining slides within Sequenzas for the determined time (typically 1-2 mins). The 
reaction was quenched by flushing Sequenzas with tap water, removal of slides, and 
immersion in running tap water for a further 5 mins. Sections were counterstained by 
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5 brief dips in Harris’s aluminum hematoxylin solution (Fisher Scientific, UK) 
before bluing in 0.1% v/v NH3OH solution (Sigma, UK) for 5 mins, dehydration 
through graded alcohols (70%, 90%, 100%, 2 mins each) to xylene (2 changes, 2 
mins each) and coverslip mounting using resinous medium (Shandon Consulmount, 
Thermo-Shandon). In some studies, immuno-stained slides were dehydrated and 
coverslipped without counterstain to improve clarity and aid quantification. 
 
2.4.6.2 Quantification 
Quantification of immunoreactivity was performed from photomicrographs of 
immuno-stained tissues, acquired as described in section 2.4.4. To increase accuracy 
and reduce the potential for bias, positive staining was indentified using a semi-
automated colour de-convolution process (Figure 2-4) with Photoshop CS3 
Extended software (Adobe Systems Inc, USA). Briefly, colour values corresponding 
to DAB+ precipitate were recorded from positive control slides stained in parallel to 
sections of interest. Colour definitions were applied to images of experimental 
sections for the calculation of the appropriate quantity. αSMA and Mac2 
immunoreactivity were expressed as the percentage of area occupied by DAB+ 
precipitate within specific areas (neointima, media), delineated as defined in section 
2.4.5. For the measurement of BrdU immunoreactivity, the number of distinct BrdU 
positive (i.e. visibly DAB stained) within these defined regions were counted 
manually. To avoid problems of inter-batch variability in immunohistochemistry 
reactions, quantitative comparisons were only made between slides stained in 
parallel. 
 
2.5 OPTICAL PROJECTION TOMOGRAPHY 
Optical projection tomography (OPT) is a recently described 3D imaging technique 
(Sharpe et al., 2002) with similarities to optical computed tomography (CT) and 
single photon emission CT (SPECT). Compared with rival methods, OPT is able to 
image samples too large for (single photon) confocal microscopy and optical 
coherence tomography systems while providing images of greater resolution than 








Figure 2-4 Example colour deconvolution of immunohistochemistry staining.  
Colour deconvolution allows the area of antigen expression to be calculated from immunohistochemically 
stained sections. To do this, photomicrographs of immunoperoxidase-stained vessels are recorded (a), and in 
these colour values corresponding to DAB precipitate are determined from positive control slides (b, highlighted 
in green). Images are then segmented according to this definition (c) and the area expressed as a fraction of the 
region of interest (e.g. neointima, media).  
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sections offer superior resolution and flexibility but, unlike OPT, 3D reconstructions 
of 2D sections are desctructive, slow and labour-intensive to produce, do not retain 
the true confirmation of the sections in 3D space and do not possess the accurate z-
axis position information necessary for volumetric measurements. 
 
The optical projection tomograph (Bioptonics 3001, Bioptonics, UK) comprises a 
diffuse light source, illuminating a rotating, biological sample, suspended in a 
refractive index matching solution. Adjustable optics focus light from a plane of 
interest in the sample onto a charged coupled device (CCD), which captures intensity 
data to a connected computer (Dell Inc, UK) for acquisition and reconstruction. The 
device operates in two modes – transmission OPT (tOPT) and emission OPT 
(eOPT). In tOPT, a polychromatic visible and/or infrared source is employed and 
light transmitted through, rather than absorbed or reflected by, the sample, is focused 
to the CCD, which, as in x-ray or optical CT, captures shadow images. In eOPT, a 
metal-halide ultraviolet source illuminates the sample through a chromatic filter 
selective for an excitation wavelength of interest. Photons emitted by excited 
flourophores within the specimen are focused through an emission filter to the CCD, 
a process analogous to SPECT. In both modes, a 3D image is reconstructed using a 
modified computed tomography back-projection algorithm from multiple single 
projections covering 360º of sample rotation. In these studies only eOPT was 
employed as the small size and great transparency of refractive index matched 
femoral arteries precluded the capture of useful opacity data. 
 
2.5.1 Tissue preparation, sample embedding and mounting 
Femoral arteries intended for OPT imaging were excised from mice following trans-
cardiac perfusion fixation under terminal pentobarbital anesthesia (see section 2.3.4). 
Samples were cleaned of peri-adventitial fat and post-fixed by immersion in 10% 
neutral buffered formalin (Sigma, UK) for 48 hours. Low melting point agarose 
(Invitrogen, UK) was dissolved in distilled water to 1.5% w/v at 90°C. Agarose 
solution was allowed to cool (40-50°C) before filtering through Whatman 113V 
paper (GE Healthcare, UK) to eliminate particulate contaminants. Each fixed femoral 
artery was suspended in 40ml of filtered agarose solution and rapidly cooled (<20°C) 
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to accelerate gelling of the agarose. Gelled agarose blocks were bonded to magnetic 
OPT mounts with cyanoacrylate adhesive (Henkel, UK) so each contained artery was 
suspended in the axis of the mount. The mounted blocks were trimmed to a conical 
shape to minimize back-reflection of light within the plane of scanning. Mounted 
samples were dehydrated in methanol (Fisher Scientific, UK) for 24 hours and 
transferred to a refractive index-matching solution (BABB) of 34% v/v benzyl 
alcohol (Acros Organics, UK), 66% v/v benzyl benzoate (Acros Organics, UK) and 
allowed to clear for >24 hours. 
 
2.5.2 Scanning and tomographic reconstruction 
Before each session, the optical projection tomograph was registered to the axis of 
sample rotation by scanning a calibration pin during its rotation over 360º and 
calculating an appropriate correction factor. Tissue sample mounts prepared as 
described (section 2.5.1) were installed in the scanning chamber by magnetic 
attachment to an internal support. Under bright-field conditions (i.e. illuminated by 
white light), the placement of each mount was adjusted by the control of integrated 
pusher devices and variable vertical positioning, until the sample was seen to revolve 
about its own axis in the centre of the field of view. Optical magnification was set to 
1 pixel = 4µm and 1 pixel = 6µm respectively for ligation- and wire-injured femoral 
arteries, in each case, the maximum magnification possible when imaging the entire 
lesion-afflicted length of vessel. For scanning, samples were illuminated by a metal-
halide UV source with 425/40nm band-pass excitation filter and emission 475nm 
low-pass emission filter (‘GFP filter’, a filter set seen to strongly detect auto-
fluorescence). CCD exposure time was adjusted to maximise the dynamic range of 
the resulting image, typically 300-600ms. The scanner was finely focused to a point 
¼ of the sample thickness from its front as described by Walls et al (2007). Raw data 
were acquired by automated capture of projection images (1024x1024 pixels) at 
rotation increments of 0.9º to give 400 images covering 360º of rotation. After 
scanning, mounted femoral arteries were cleared of BABB by immersion in 
methanol for >24 hours. Tissues were removed from mounts and trimmed of excess 




Projection images were manually evaluated for focus and rotation misalignment 
using supplied software (Data Viewer; Skyscan, Belgium) before computed 
tomography reconstructions were calculated. Hamming filtered back-projection of 
the axial plane was performed by standard methods using NRecon software 
(Skyscan, Belgium). For each dataset, misalignment correction was applied to 
compensate for minor and unavoidable defects in the apparent axis of rotation. The 
correction required was estimated by manual scrutiny of test reconstructions of 2D 
planes within each data set, calculated about a value determined in software by the 
comparison of the 0° and mirror inverted 180° projections. 
 
2.5.3 Quantification 
CT data analysis software (CTan; Skyscan, Belgium) was used for the quantification 
of reconstructed OPT data. For each vessel scan, a vertical region of interest was 
defined containing the 2.5mm (ligation-injury) or 5mm (wire-injury) immediately 
proximal to the bifurcation of the common femoral artery. These lengths were 
sufficient to encompass the entire neointimal lesion in each respective model. Within 
this, for every 50th scan-line, the border between media and neointima (i.e. the 
position of the internal elastic lamina) was estimated and traced. This was possible 
due to the greater fluorescent signal emitted by the media and by observation of the 
luminal conformation. Intima/media borders for the interleaved scan lines were 
interpolated in software, and the fit verified and corrected where required. This 
defined three dimensional volume was further segmented according to a manually-
defined intensity threshold to a produce a binary image set in which white pixels 
represented neointima and black pixels represented patent lumen. Volumes (µm3) of 
each segment were calculated to give measures of neointimal and luminal volume, 
and the fraction of the total defined volume occupied by neointima, a volumetric 
‘stenotic ratio’, was calculated. 
 
2.6 STATISTICS AND DATA ANALYSIS 
Statistical testing and data analysis was performed using Prism 4.0 software 
(Graphpad software, USA). Data sets comprising two groups were compared using 
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Student’s un-paired t-test (Chapters 3 and 5). Where comparison between three or 
more groups was required, data were tested by one-way ANOVA with Dunnett’s 
post-hoc test (Chapter 4). Myography data were analysed by unpaired t-test of 
summary stats, and two-way ANOVA of complete concentration-response data sets. 
In all studies, n refers to the number of individual animals from which data were 
acquired. Where the same data were obtained from multiple samples from a single 
animal (e.g. myography responses in multiple artery rings), the mean of these 

















An obvious pre-requisite to studies of the role of endothelin (ET) receptors in the 
response to vascular injury is the ability to induce injury and quantify the response. 
For previous studies in this laboratory investigating the role of glucocorticoids in 
neointimal proliferation (Dover et al., 2007), two models of acute vascular injury 
have been utilised. The first is the well-characterised and widely published model of 
intra-luminal wire-injury to the mouse femoral artery, originally described by Sata et 
al (2000). The second involves ligation of the popliteal artery, just distal to the 
femoropopliteal bifurcation – a modified wire-injury sham procedure. Lesions 
resulting from popliteal artery ligation, however, are extremely focal and far smaller 
than those induced by carotid artery ligation (Kumar & Lindner, 1997) complicating 
analysis of lesion size. Studies of ligations applied about the carotid artery 
bifurcation indicate that the position of the ligation has a dramatic effect on the 
degree of lesion formation (Kumar & Lindner, 1997; Sullivan & Hoying, 2002; 
Korshunov & Berk, 2003). The effect of alternative ligations to the femoropopliteal 
bifurcation on neointima formation in this location is unknown and, as such, it may 
follow that optimising the site of the ligation may provide a greater stimulus for 
neointima formation and result in larger, more easily analysed lesions.  
 
The issue of analysing sporadic, focal lesion formation might also be addressed by a 
utilising a method of visualising complete lesions in three-dimensions. This would 
provide further advantage in the ability to consider volumetric parameters of lesion 
formation resulting from any injury: a more robust and sensitive measure than the 
traditionally used maximum lesion cross-sectional area (McAteer et al., 2004). Few 
techniques have been successfully applied to 3D analysis of vascular morphology in 
mouse arteries, and those that have, such as magnetic resonance imaging (MRI), 
have many practical limitations (cost, imaging time and resolution; McAteer et al., 
2004). Optical projection tomography (OPT) is a recently-described 3D imaging 
technique originally applied to the study of mouse embryos (Sharpe et al., 2002). In 
principal, OPT has many features that make it attractive for imaging isolated mouse 
arteries – it offers high, isotropic resolution for specimens of this size, short 
acquisition times, and is non-destructive to the specimen (Sharpe et al., 2002; 
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Alanentalo et al., 2007). Whether this technique is suitable for determining the extent 
of lesion formation in injured mouse arteries in practice has yet to be determined. 
 
These caveats aside, by utilizing ligation and wire-injury models in parallel 
(potentially in the same animals) additional insight can be drawn. These models are 
complementary because they differ in several ways including the nature of injury and 
the origin of neointimal cells (Kumar & Lindner, 1997; Sata et al., 2000; Tanaka et 
al., 2003). Perhaps the most critical difference between models in the context of 
these studies is the relative status of endothelial cells (EC) as wire- but not ligation-
induced injury effectively denudes the endothelium (Sata et al., 2000). Previous 
studies in this laboratory have demonstrated the regeneration of EC-like cells by 14 
days post-injury in this model (MacDonald et al, Unpublished data) but the degree 
and time-course of functional recovery is not known. Further, in models of both 
‘endothelium-denuding’ intra-luminal injuries (Azuma et al., 1990; Heijenbrok et al., 
1998; Miller et al., 2003; Liao et al., 2007), and ‘endothelium-intact’ peri-vascular 
injuries (De Meyer et al., 1991; De Meyer et al., 1992), some degree of endothelial 
dysfunction is commonly reported. Any impairment of endothelial function 
following femoral artery wire- and ligation-injury is of great importance as a deficit 
here may complicate interpretation of the hypothesized protective role for ETB 
receptors in EC in the response to acute vascular injury. 
 
The experiments conducted in this chapter were therefore intended to determine the 
effects of femoral artery wire- and ligation-injuries on vascular structure and 
function, using histology, myography and 3D tomographic imaging. As such, the 
specific aims are: 
a) To determine whether alternative ligations of the femoral artery (proximal or 
distal to the femoropopliteal bifurcation) elicit robust neointimal thickening. 
b) To visualise lesion distribution resulting from wire and ligation-injury using 
OPT and evaluate the potential of this technique for the quantitative analysis 
of lesion size. 
c) To determine how endothelium-dependent vasodilatation and other aspects of 





All studies presented in this chapter were performed using 20-30g C57Bl/6J mice 
purchased from Harlan, UK. Animals were allowed to acclimate to their environment 
for at least 1 week prior to their further use. For vascular injury studies, identifying 
ear notches were cut at the time of surgery. 
 
3.2.2 Femoral artery injury 
To inflict femoral artery wire-injury, in order to determine any effect on vascular 
function (Figure 3-1), a straight sprung angioplasty guide wire (0.014” diameter) 
was advanced in a retrograde manner through an arteriotomy in the popliteal artery 
into the femoral artery, before withdrawal of the wire and ligation of the popliteal 
artery proximal to the arteriotomy (Sata et al., 2000). The procedure was performed 
on the left femoral artery only. Animals were killed by asphyxiation in CO2 14 days 
post-injury, a time point at which an EC-like monolayer of von Willebrand Factor 
immunoreactive cells has returned (MacDonald et al. Unpublished data) but at which 
lesion formation is sufficiently moderate to permit mounting of vessels in a 
myograph (Sata et al., 2000). Left (injured) and right (uninjured) femoral arteries 
were harvested for parallel functional evaluation. 
 
For investigations into the morphological and functional consequences of femoral 
artery ligation, two groups of animals were employed (Figure 3-1). In the first 
group, following isolation of the left femoral artery from the surrounding tissue and 
the adjacent vein and nerve, a 5-0 silk ligature was applied to the femoral artery, just 
distal to the femoropopliteal bifurcation. This study group is referred to as partial 
ligation. In the second group, the procedure was identical except that the ligature was 
applied to the femoral artery across the bifurcation. This study group is referred to as 
complete ligation. To the right femoral artery, in both groups, a sham operation was 
performed, in which, after isolation of the artery, a ligature was passed under the 
appropriate point, but removed rather than tied. Animals were killed 28 days post-





Figure 3-1 Study protocol for investigation of the structural and functional consequences of femoral artery 
injury.  
Wire-injury entails wire insertion into the proximal femoral artery through an arteriotomy in the popliteal artery 
(a). Vessels were collected after 14 days and subject only to functional investigation in the region just proximal to 
the femoropopliteal bifurcation. ‘Partial’ ligation entails ligation of the femoral artery just distal to the bifurcation 
(b). Vessels were collected after 28 days and subjected to functional and morphometric evaluation. Analysis was 
performed on sections from the femoral artery proximal to the ligation, and the popliteal artery just distal to it. 
‘Complete’ ligation entails ligation of the femoral artery over its junction with the popliteal artery (c). Vessels 
were collected after 28 days and subject to functional and morphometric evaluation. Analysis was performed 
only on the section of femoral artery immediately proximal to the ligation. 
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maximum stable lesion size in the similar mouse carotid artery ligation model 
(Kumar & Lindner, 1997; Godin et al., 2000). Vessels were collected after 28 days 
and subject to functional and morphometric evaluation.  
 
3.2.3 Myography 
Vascular function was investigated by isometric wire myography (section 2.2) 
utilising ~2mm long arterial rings cleaned of extraneous peri-adventitial material. 
For wire-injured vessels, the investigated portion of the femoral artery was that 
immediately proximal to the femoropopliteal bifurcation. For partial ligation-injured 
vessels, two vascular rings were isolated from each artery – the femoral artery 
immediately proximal to the ligated branch, and the popliteal artery immediately 
distal to the ligated branch. For complete ligation-injured arteries, only the section of 
femoral artery immediately proximal to the ligature was examined as both popliteal 
and femoral arteries distal to this point were no longer identifiable. Details of the 
location of the investigated portions of each vessel are given in Figure 3-1. In each 
case, the equivalent position in the contra-lateral, sham-operated femoral/popliteal 
artery was examined in parallel as a control. For comparison, additional studies of 
femoral artery function were performed using mice that were not subject to any prior 
surgical intervention. In these, femoral artery rings were collected just proximal to 
femoropopliteal bifurcation from the left and right hind-limb, one of which 
(randomly selected) was subsequently denuded of endothelium by gentle rubbing of 
the luminal surface with a human hair. All vessels were mounted across parallel 
intra-luminal wires (40µm diameter), bathed in physiological salt solution (PSS) at 
37°C and a baseline tension of 8mN gradually applied – a value determined by 
pervious normalisation studies in this laboratory and consistent with those in the 
literature (Widmer et al., 2006; Bhattacharya et al., 2008). 
 
In every vessel the response to 125mM KCl, iso-osmolar PSS (KPSS) was assessed 
in triplicate to rejuvenate tissue responsiveness and to provide reference basal 
contractility of each vascular ring. Cumulative concentration-response curves were 
then recorded, in sequence, to phenylephrine (PE; 10-9-10-4M; 2 min addition cycle), 
acetylcholine (ACh; 10-9-3x10-5M; 1 min addition cycle), KPSS (5x10-3-1.25x10-1M; 
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2 min addition cycle), sodium nitroprusside (SNP; 10-9-10-5M; 1 min addition cycle) 
and endothelin-1 (ET-1; 10-11-3x10-7M; 3 min addition cycle). Tissues were 
thoroughly washed with PSS between agonists. Responses to vasodilators (ACh, 
SNP) were measured in vessels pre-contracted with PE to 80% of the maximal 
response to this agent. The only exception to this protocol was that, in endothelium-
intact and -denuded femoral arteries from un-operated mice, the concentration-
response relationship to KPSS and SNP was not determined. At the conclusion of 
each functional experiment, vessels subject to partial or complete ligation were 
carefully removed from the myograph and immersed in formalin for 24 hours to 
allow subsequent histological analysis of lesion formation. 
 
3.2.4 Histology 
Fixed, ligation-injured arteries were dehydrated and infiltrated with wax, using an 
automated vacuum infiltration processer, before embedding in a paraffin wax block 
for microtomy to produce transverse sections. From each vascular ring, 3µm thick 
sequential sections were cut in a repeating pattern, wherein 15 sections were retained 
and mounted on 5 electrostatically-charged microscope slides (3 on each), and the 
subsequent 100µm of tissue discarded, until the entire artery had been traversed. One 
slide from each level was stained according the United States trichrome method 
(section 2.4.2) to highlight the elastic laminae and allow delineation of media and 
neointima. The slide containing the largest neointimal lesion from each vessel was 
identified and the cross-sectional area of neointima (area of tissue within the internal 
elastic lamina) and media (area of tissue lying between internal and external elastic 
laminae) measured from photomicrographs using Photoshop CS3 Extended software 
(Adobe Systems Inc, USA). Luminal measurements were not recorded as the prior 
functional investigations in these arteries prevented in vivo perfusion fixation. 
 
3.2.5 Immunohistochemistry 
In sections adjacent to those bearing the largest neointimal lesion for each vessel, 
medial composition was assessed using immunohistochemistry for  α-smooth muscle 
actin (αSMA) according to the indirect labelled streptavidin biotin method (section 
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2.4.6). Antibody binding was revealed by the peroxidase-catalysed development of 
3,3’-diaminobenzidine (DAB) to an insoluble brown product. Immunoreactive area 
was measured from photomicrographs using a semi-automated colour de-convolution 
process and the absolute area in which DAB product was present was expressed as a 
percentage of the total medial area. 
 
3.2.6 OPT 
OPT was used to acquire 3D images of uninjured femoral arteries, and those subject 
to wire-injury, partial ligation-injury and complete ligation-injury procedures. 
Arteries in which functional investigations were performed were not subject to OPT 
scanning. Instead, un-injured, 28 day wire-injured and 28 day partial ligation-injured 
femoral arteries were produced specifically for this purpose (n=2 per injury) by the 
same methods outlined above (see sections 3.2.2 and 2.3.1), and combined with data 
from wire- and complete ligation-injured arteries primarily produced for the 
experiments described in chapters 4 and 5. For the sake of simplicity, these data 
relating to the description and validation of the OPT technique are presented as one, 
in this chapter. Regardless of the source of the artery, imaging and analysis was 
conducted according to the following method. Perfusion fixed femoral arteries were 
embedded in low melting point agarose, bonded to a magnetic OPT mount, de-
hydrated in methanol (>24 hours) and made translucent by immersion in a refractive 
index matching solution (benzyl alcohol:benzyl benzoate; >24 hours). Vessels were 
individually scanned for emission (475nm low pass filter) after excitation at 425nm 
(with 40nm band pass filter) using a Bioptonics 3001 optical projection tomograph. 
1.048Mpixel projection images were captured at 0.9° rotation increments and 
reconstructed by Hamming-filtered back-projection in NRecon software. From these, 
the position of the intima/media border was manually traced for every 50th scan line, 
and the position interpolated (and corrected, where necessary) for the interleaved 
regions. The neointima/lumen border was delineated by grey-level segmentation. 
Absolute neointimal and luminal sizes were expressed as total volume or 2D area for 
each scan line. Cross-sectional profiles were produced by plotting 2D lesion and 
luminal areas (mean of 20 scan lines) against distance of scan line from site of 
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ligation (ligation-injured vessels) or the femoropopliteal bifurcation (uninjured and 
wire-injured vessels). 
 
For the comparison of OPT and histological measures, femoral arteries were 
removed from OPT mounts, washed in methanol (>24 hours) and processed for 
histology as described in section 3.2.4. 3µm thick serial sections were stained using 
the United States trichrome method and the regions depicted in a subset of these 
were located in the reconstructed OPT tomograms of the same vessels. At these 
points, measurements of 2D neointimal and luminal areas were recorded both from 
OPT scans and from histological sections. It was not possible to truly blind this 
comparison, as the poor accuracy of z-axis position information in serial sections 
required their location within the length of artery, in part, by use of visual cues, such 
as vessel conformation or the position of arterial branches and ligatures. 
 
3.2.7 Statistics and data analysis 
For myography data, force developed to vasoconstrictor agents was expressed as 
absolute value per unit length of vessel (mN.mm-1) and as a percentage of the 
maximal contraction elicited in that vessel by the 3rd initial application of KPSS. 
Responses to vasodilator agents were expressed as a percentage of the tension 
existing immediately prior to the addition of the tested agent. Myograpy-generated 
concentration-response curves were analysed by two-way ANOVA between injured 
and sham, or endothelium-intact and -denuded pairs. Summary data were generated 
by least-squares fit of raw data to a logistic equation (chapter 2). Myography 
summary data, vascular morphometry and composition were tested by Student’s un-
paired t-test. Comparisons between OPT and histological methods were performed 
by linear regression, and subsequent F-testing to determine if the slope deviates from 
a hypothetical value of 1.0. Statistical analysis of all data was performed using Prism 




3.3.1 Physiological parameters 
Neither femoral artery wire-injury, nor partial/complete ligation procedures was 
obviously detrimental to animal health. No post-operative deaths or infections 
occurred, and no harm was apparent to the limb supplied by the ligated femoral 
artery. In agreement, no abnormalities of post-operative body weight change were 
observed (Table 3-1, page 108). 
 
3.3.2 Vasomotor function in uninjured femoral arteries 
In un-injured femoral arteries, the α1-adrenoceptor agonist phenylephrine stimulated 
concentration-dependent vasoconstriction. Maximum responses to this agent, 
expressed as % of contraction to KPSS to normalise for the medial damage implicit 
in mechanical endothelial denudation, was significantly enhanced by removal of the 
endothelium (Table 3-2, page 109). Endothelial denudation also abolished the 
otherwise robust vasodilator response to acetylcholine in phenylephrine pre-
contracted femoral artery rings (Figure 3-2). ET-1 potently elicited vasoconstriction 
in intact and denuded vessels (Figure 3-2). Two-way ANOVA indicated that this 
response was enhanced by endothelial removal, but changes in pD2 and Emax (% 
KPSS) did not reach significance. 
 
3.3.3 Vasomotor function in wire-injured femoral arteries 
Wire-injured (14 days) femoral arteries failed completely to contract to either 
membrane depolarisation (KPSS) or α1-adrenoceptor stimulation (phenylephrine). In 
contrast, un-injured contra-lateral femoral arteries from the same mice, tested in 
parallel to their injured counterparts, robustly responded to both agents in the 
expected manner (Figure 3-3). After this striking pattern had been observed in 
injured/un-injured femoral artery pairs from 2 animals, further attempts were 






Figure 3-2 Impact of endothelial denudation on the vasomotor response to acetylcholine and ET-1.  
Femoral artery rings were examined by wire myography. Acetylcholine elicited relaxation of pre-contracted rings, 
and this was abolished by removal of the endothelium (a). Endothelial denudation also modestly sensitised 
vessels to the contractile effect of ET-1 (b). n=7-9. Data are mean ± SEM. **, p<0.01; ***, p<0.001 by two-way 
ANOVA. 








































































Figure 3-3 Impact of femoral artery wire-injury on vasomotor response.  
Vascular function of wire-injury femoral arteries was investigated by wire myography, 14 days post-injury. 
Representative tension traces of the response of thus injured vessels (a) and contra-lateral uninjured control 
vessels (b) to membrane depolarization (KPSS, K+ 125mM Na+ 0mM) and the α1-adrenoreceptor agonist, 
phenylephrine (PE; 10-5M) are shown. 14 day wire-injured vessels completely failed to response to either stimuli, 
in contrast to robust responses to both in uninjured control vessels. Traces are representative of 2 experiments. 
(a)



































3.3.4 Partial ligation injury 
3.3.4.1 Vasomotor function 
Although not the basis of statistical testing, several differences in character were 
apparent between femoral and popliteal artery rings. Absolute (mN.mm-1) Emax 
values to tested vasoconstrictors, were, in general, substantially lower in the popliteal 
than the femoral artery (Table 3-3, page 110).  The response to endothelin-1 also 
appeared to by bi-phasic in popliteal arteries and monophasic in femoral arteries. 
Insufficient data points were acquired to allow fitting of these to a bi-phasic logistic 
equation, however, and thus summary data were produced by best-fit of a 
monophasic relationship. 
 
In contrast to wire-injured femoral arteries, all vessels subject to partial ligation-
injury demonstrated contractile responses to tested substances. Indeed, partial 
ligation was associated with little to no defects in vasomotor responsiveness in the 
popliteal artery. In adjacent femoral artery rings however, clear defects in vascular 
function were evident. Absolute (mN.mm-1) responses to both KPSS (Figure 3-4) 
and ET-1 were significantly impaired by injury in femoral (both p<0.0001 by two-
way ANOVA) but not popliteal artery rings (KPSS p=0.38; ET-1 p=0.99). In both 
cases, however, neither changes in pD2 nor Emax reached statistical significance 
(Table 3-3, page 110). The absolute (mN.mm-1) vasoconstrictor response to 
phenylephrine was also not different in either the femoral or popliteal artery between 
injured and sham groups (Table 3-3, page 110).  
 
Endothelium-dependent vasodilator responses were also altered. Acetylcholine-
stimulated relaxation of phenylephrine pre-contracted femoral (but not popliteal) 
artery rings (Figure 3-5), was significantly impaired in partial ligation injured, 
manifesting as reduced sensitivity to this agent (lower –log(EC50); p=0.013; Table 
3-3, page 110). No concurrent changes in endothelium-independent vasodilatation to 
sodium nitroprusside were apparent in either injured femoral or popliteal rings 






Figure 3-4 Impact of partial femoral artery ligation on vasoconstrictor response to potassium in femoral and 
popliteal artery rings.  
Femoral arteries were ligated just distal to the femoropopliteal bifurcation. 28 days later, vascular function was 
studied in the proximal femoral artery (a) and popliteal artery (b) by wire myography. Injured and uninjured 
vessels from both locations contracted strongly to potassium. In the femoral (a) but not popliteal artery (b), this 
response was significantly impaired with partial ligation injury, as compared to sham operated contralateral 
controls. n=5-6. Data are mean ± SEM. ns, p>0.05; ***, p<0.001 by two-way ANOVA. 
















































3.3.4.2   
 
Figure 3-5 Impact of partial femoral artery ligation on vasodilator response to acetylcholine in femoral and 
popliteal artery rings.  
Femoral arteries were ligated just distal to the femoropopliteal bifurcation. 28 days later, vascular function was 
studied in the proximal femoral artery (a) and popliteal artery (b) by wire myography. Phenylephrine pre-
contracted vessels from both locations dose-dependently relaxed in response to acetylcholine. In the femoral (a) 
but not popliteal artery (b), this response was significantly impaired (parallel rightward shift) by partial ligation 
injury, as compared to sham operated contra-lateral controls. n=5-6. Data are mean ± SEM.  ns, p>0.05; **, 
p<0.01 by two-way ANOVA. 




































































3.3.4.3 Morphology and composition 
Following functional investigations, injured and sham femoral artery rings from mice 
subject to the partial ligation procedure were examined for morphological alterations 
(Figure 3-6). Popliteal artery rings, in which no functional disturbances were 
observed, were not analysed further. Most partially-ligated femoral artery rings 
contained some neointimal lesion although this was typically extremely small and 
focal. Indeed, neointimal lesion size was not significantly different to that in sham 
operated rings, which also contained occasional, small neointimal lesions as a result 
of peri-vascular manipulations (Figure 3-7). Medial area was also not altered by 
partial ligation-injury and consequently, neither was intima/media ratio (Table 3-4, 
page 111). αSMA immunoreactivity was observed throughout the media in both 
groups (Figure 3-6), although the fractional area of this was not different between 
injured and sham-operated control vessels (Figure 3-7). 
 
3.3.5 Complete ligation injury 
3.3.5.1 Vasomotor function 
Functional disturbances in complete ligation-injured femoral arteries were broadly 
similar to those seen in the proximal femoral artery following partial ligation. 
Absolute (mN.mm-1) contractions induced by phenylephrine (Table 3-4, page 111) 
and KPSS (Figure 3-8) were significantly impaired in injured vessels as compared to 
sham (PE p=0.006; KPSS p<0.0001). A trend (p=0.06) towards similarly reduced 
responsiveness to ET-1 was also apparent (Figure 3-8). For KPSS only, this was 
associated with a reduction in Emax (p=0.029; Table 3-4, page 111). Although the 
response to ET-1 was not significantly different between sham-operated and 
complete ligation-injured arteries, it was apparent that the responses elicited in both 
were dramatically lower than those that would be expected. Indeed, these values 
(sham Emax=0.53 ± 0.13mN.mm
-1, complete ligation Emax=0.46 ± 0.09 mN.mm
-1) 
were lower than those determined for the response to ET-1 any other studies in this 
thesis, including femoral arteries from un-operated mice of the same age and strain 







Figure 3-6 Impact of partial and complete femoral artery ligation on vascular structure.  
Femoral arteries were ligated just distal (partial ligation) or across (complete ligation) the femoropopliteal 
bifurcation and allowed to respond for 28 days. After functional investigation, vessels were histologically 
examined. Representative photomicrographs for these vessels stained by United States Trichrome (a-d) or 
immunohistochemistry for α-smooth muscle actin are shown. In all, probable sites of damage by myography 
mounting are indicated with arrowheads. Partial ligation-injured vessels were similar in appearance to their sham 
operated controls with only minor evidence of neointima formation (a-b). αSMA immunoreactivty was present 
throughout the media and was similar between injured and sham vessels (e-f).  Complete ligation-injured vessels 
contained large neointimal lesions, in contrast to sham-operated vessels (c-d). αSMA immunoreactivity was again 




     
Figure 3-7 Impact of partial and complete femoral artery ligation on neointimal lesion size and medial 
composition.  
Femoral arteries were ligated just distal (partial ligation) or across (complete ligation) the femoropopliteal 
bifurcation and allowed to respond for 28 days before functional and histological examination. United States 
Trichrome stained sections indicated some evidence of neointima formation in some vessels from all groups. 
Maximum lesion size in partial ligation-injured vessels was not different from sham-operated controls. In 
contrast, complete ligation-injury stimulated formation of much larger lesions (a). αSMA immunoreactivity was 
present throughout the media in all groups. The areas of this did not differ between partial ligation and sham-
operated vessels but were significantly greater in complete ligation-injured vessels than their controls (b). n=3-6. 
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Figure 3-8 Impact of complete femoral artery ligation on vasoconstrictor responses to potassium and ET-1.  
Femoral arteries were ligated across the femoropopliteal bifurcation. 28 days later, vascular function was studied 
in the proximal femoral artery by wire myography. Injured and uninjured vessels contracted strongly to 
potassium (a) and ET-1 (b). Complete ligation was associated with a significant impairment of the vasoconstrictor 
response to potassium as compared to sham-operated controls (a). A trend towards reduced responsiveness to 
ET-1 in injured vessels was not significant (b; p=0.06). n=6. Data are mean ± SEM. ET-1, endothelin-1; ns, p>0.05;  
***, p<0.001 by two-way ANOVA. 














































Endothelium-dependent vasodilatation stimulated by acetylcholine (Figure 3-9) was 
impaired in injured vessels (p=0.001 by two-way ANOVA). This appeared to be a 
reduction in maxium response, but neither changes in Emax nor –log(EC50) reached 
significance (Table 3-5, page 112). The endothelium-independent relaxation elicited 
by sodium nitroprusside (Figure 3-9) was also reduced by complete ligation injury 
(p<0.0001) and this was associated with a decrease in Emax (p=0.046; Table 3-5, 
page 112). 
 
3.3.5.2 Morphology and composition 
Unlike partial ligation-injured and sham-operated control vessels, those subject to 
complete ligation had the gross appearance of lesion formation and indeed, were 
substantially more difficult to mount in the myograph owing to luminal stenosis. 
Analysis of vessel morphology revealed the presence of large extracellular matrix- 
and smooth muscle-rich neointimal lesions in complete ligation-injured femoral 
artery rings (Figure 3-6). These were significantly larger than the small, occasional 
neointimal lesions formed in sham-operated control vessels (p=0.001; Figure 3-7). 
Medial cross-sectional area was not different between injured and sham vessels 
(p=0.72; Table 3-4, page 111) and therefore, intima/media ratio was increased 
relative to sham vessels (p=0.004; Table 3-4, page 111). Whilst these lesions were 
apparent in every vascular ring from injured arteries they did not typically extend the 
full length of segment of artery isolated for functional analysis. αSMA 
immunoreactivity was present throughout the media both in injured and in sham 
vessels and was also abundant in the neointima of injured vessels (Figure 3-6). The 
fractional area of this immunoreactivity was significantly greater in the media of 
complete ligation-injured vessels than in those subject to the sham procedure 







Figure 3-9 Impact of complete femoral artery ligation on vasodilator responses to acetylcholine and sodium 
nitroprusside.  
Femoral arteries were ligated across the femoropopliteal bifurcation. 28 days later, vascular function was studied 
in the proximal femoral artery by wire myography. Phenylephrine pre-contracted, injured and uninjured vessels 
dose-dependently relaxed in response to both acetylcholine (a) and sodium nitroprusside (b). Complete ligation 
was associated with a significant impairment of the vasodilator response to both agents as compared to sham-
operated controls. n=6. Data are mean ± SEM. **, p<0.01;  ***, p<0.001 by two-way ANOVA. 





































































Figure 3-10 Comparison of OPT and histological methods for 2D analysis of lesion size.  
Wire and ligation injured femoral arteries were subject to perfusion fixation and optical projection tomographic 
scanning, 28 days post-injury, before histological analysis of the same vessels. Neointimal lesions were clearly 
visible in both projection images (a) and in re-constructed virtual sections (b). In the latter, media, neointima and 
lesion could be clearly distinguished by the difference in auto-fluorescence from these layers. These possessed 
striking similarity to histological, United States Trichrome stained sections of the same regions of the same 
vessels (c). Comparison of 2D measures of neointimal area derived from OPT scans and histological sections of 
the same area by linear regression showed a strong correlation and that the slope of relationship did not differ 







Slope ≠ 1.0  p=0.66


























3.3.6 Optical projection tomography (OPT) 
3.3.6.1 Comparison with histology 
OPT imaging of femoral arteries proved very successful. Arterial structure was 
clearly visible both in raw projection images, and back-projected reconstructions 
(Figure 3-10). In injured vessels, neointimal lesion-like structures were identifiable 
within the lumen, and could be delineated from the media and lumen by the stronger 
auto-fluorescent signal emitted by the former, and the absence of signal from the 
latter. Furthermore, tomographically reconstructed cross-sections possessed a 
striking resemblance to equivalent United States trichrome stained histological 
sections cut from the same vessels. 
  
As such, it was possible to develop methods for quantitative measurement of 
neointimal and luminal dimensions from OPT re-constructions. To validate these, 
cross-sectional areas of neointima and lumen were determined from serial 
histological sections and corresponding 2D planes within OPT reconstructions of the 
same vessels. For both neointimal and luminal areas, strong and significant 
correlations (R2 = 0.92, R2 = 0.74 respectively) were present by linear regression 
between the two measurement modalities (Figure 3-10). Importantly, in each case, 
the slope of the relationship between histological and OPT measurements did not 
significantly deviate from 1.0, and intercepted the y-axis close to 0. 
 
3.3.6.2 Application to comparison of injury models 
OPT reconstructions of separate vessels were used to visualise the extent of lesion 
formation in partial and complete ligation models along the length of vessels. Lesion 
profiles were produced by plotting neointimal lesion size against distance proximal 
to femoropopliteal bifurcation (Figure 3-11). These confirmed that, in the partial 
ligation model, any neointimal thickening that occurs is restricted to the immediate 
vicinity of the ligature with little impact on luminal dimensions. Indeed, lesion 
profiles from partial ligation-injured vessels were similar to those of uninjured 







Figure 3-11 Impact of femoral artery wire and ligation injury on the axial distribution of neointima formation.  
Uninjured (a), partially (b) or completely ligated (c) and wire-injured femoral arteries (d) were subject to optical 
projection tomographic scanning, 28 days post-injury. Volumes corresponding to neointima and lumen were 
defined in reconstructed tomograms. From these, neointimal (grey) and lumenal area (orange) were plotted 
against distance from the femoropopliteal bifurcation or ligation. Almost no neointima was detected in uninjured 
vessels (a). In partial ligation vessels, lesion formation was minimal and restricted to the immediate vicinity of 
ligature (b). Complete ligation elicited formation of lesions of moderate size and length (c). Wire-injury induced 
formation of large lesions that extend proximally much further than those induced by ligation (d). Profiles are 
representative of at least 2 vessels. 
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seen proximal to the site of ligation and this gradually transitioned to morphological 
normal vessel over a moderate distance. For comparison, profiles of wire-injured 
vessels indicated lesions of the largest size and which extended the furthest down the 
vessel length and were associated with outward remodelling (i.e. increased 















































Study Group Wire Injury Partial Ligation Complete Ligation 
    
N 2 6 6 
Body weight at study start (g) 25.10 ± 0.10 26.27 ± 0.72 22.43 ± 0.82 
Body weight at study end (g) 26.15 ± 0.75 29.97 ± 1.37 25.60 ± 1.04 
Body weight change (g) 1.05 ± 0.85 3.42 ± 0.73 3.17 ± 0.35 
    
 
Table 3-1 The impact of femoral artery injury models on post-operative weight gain.  
All studied animals gain weight normally following femoral artery wire- and ligation-injury procedures. The lesser 
increase in body weight observed following wire- than ligation- injury reflects the shorter period of post-











n 9 7 
pD2 5.64 ± 0.11 5.83 ± 0.10 
Emax (%) 66.3 ± 7.1 84.8 ± 4.6 * 
Emax (mN.mm
-1) 1.72 ± 0.27 1.26 ± 0.26 
   
ACh 
n 9 7 
-log(EC50) 7.25 ± 0.19 - 
Emax (%) 87.3 ± 3.5 - 
ET-1 
n 7 7 
pD2 8.48 ± 0.10 8.59 ± 0.22 
Emax (%) 83.9 ± 3.9 101.3 ± 9.2 
Emax (mN.mm
-1) 2.43 ± 0.23 1.36 ± 0.38 * 
   
 
Table 3-2 Impact of endothelial denudation on femoral artery vasomotor function.  
Femoral artery vascular function was investigated by wire myography. Removal of the endothelium almost 
abolished the vasodilator response to ACh and potentiated constrictor responses to PE and ET-1 when expressed 
as % of response to KPSS, but reduced absolute contractility. n=7-9. Data are mean ± SEM. PE, phenylephrine; 
ACh, acetylcholine; ET-1, endothelin-1; KPSS, high potassium physiological salt solution; *, p<0.05 by Student’s 


























n 6 5 6 5 
pD2 6.21 ± 0.10 5.96 ± 0.05 6.01 ± 0.07 6.22 ± 0.13 
Emax (mN.mm
-1) 1.11 ± 0.15 1.43 ± 0.17 0.82 ± 0.18 0.87 ± 0.18 




n 6 5 6 5 
pD2 1.67 ± 0.02 1.67 ± 0.02 1.59 ± 0.03 1.63 ± 0.02 
Emax (mN.mm
-1) 1.48 ± 0.21 1.99 ± 0.22 1.24 ± 0.21 1.32 ± 0.18 
ACh 
n 6 5 6 5 
-log(EC50) 7.20 ± 0.10 7.70 ± 0.13 * 7.78 ± 0.10 7.40 ± 0.14 
Emax (%) 91.7 ± 3.1 86.3 ± 4.9 84.9 ± 5.9 89.5 ± 2.2 
SNP 
n 6 5 6 5 
-log(EC50) 7.91 ± 0.07 7.96 ± 0.16 7.85 ± 0.10 7.85 ± 0.03 
Emax (%) 97.6 ± 0.8 98.0 ± 1.9 96.1 ± 1.9 97.6 ± 0.8
ET-1 
n 6 5 6 5 
pD2 8.53 ± 0.09 8.79 ± 0.30 8.50 ± 0.10 8.43 ± 0.17 
Emax (mN.mm
-1) 1.53 ± 0.18 1.98 ± 0.19 1.15 ± 0.18 1.23 ± 0.14 




Table 3-3 Impact of partial femoral artery ligation on vasomotor responses.  
Femoral arteries were ligated just distal to the femoropopliteal bifurcation. 28 days later, vascular function was 
studied in the proximal femoral artery and popliteal artery by wire myography. Partial ligation was associated 
with numerous changes to vasomotor function in the proximal femoral artery including impaired absolute 
(mN.mm-1) responses to vasoconstrictors, and to the endothelium-dependent vasodilator, acetylcholine. In the 
adjacent popliteal artery, few changes in responsiveness to these agents were noted. n=5-6. Data are mean ± 
SEM. PE, phenylephrine; KPSS, high potassium physiological salt solution; ACh, acetylcholine; SNP, sodium 
















(a) Morphometry (Histology) 
n 6 6 3 4 
Neointimal area (x103μm2) 19.10 ± 4.12 0.70 ± 0.24 * 3.46 ± 2.16 0.22 ± 0.22 
Medial area (x103μm2) 13.68 ± 1.70 14.48 ± 1.38 19.07 ± 1.84 17.97 ± 1.10 
Intima/Media ratio 1.54 ± 0.40 0.05 ± 0.02 * 0.21 ± 0.15 0.01 ± 0.01 
(b) Composition (IHC) 
n 6 6 3 4 
Intimal αSMA IR (%) 78.9 ± 4.2 - - - 
Medial αSMA IR (%) 78.3 ± 3.8 57.9 ± 4.6 ** 46.24 ± 11.62 32.36 ± 9.28 
       
 
Table 3-4 Impact of partial and complete femoral artery ligation of vascular morphology and composition.  
Femoral arteries were ligated just distal (partial ligation) or across (complete ligation) the femoropopliteal 
bifurcation and allowed to respond for 28 days. After functional investigation, vessels were histologically 
examined by sectioning and staining with United States Trichrome (a-d) or immunohistochemistry for α-smooth 
muscle actin. Although some neointima formation was present in all groups, only complete ligation was 
associated with significantly greater lesion size and intima/media ratio than sham operated control vessels. The 
fraction of medial area immunoreactive for αSMA was also increased in complete ligation-injured vessels relative 
to sham. No such change to medial composition was apparent following partial ligation-injury. n=3-6. Data are 
mean ± SEM. αSMA, α-smooth muscle actin; IR, immunoreactivity. *, p<0.05; **, p<0.01 by Student’s unpaired t-











    
PE 
n 6 6 
pD2 5.91 ± 0.08 6.00 ± 0.08 
Emax (mN.mm
-1) 0.57 ± 0.07 0.83 ± 0.21 
   
KPSS 
n 6 6 
pD2 1.63 ± 0.01 1.61 ± 0.02 
Emax (mN.mm
-1) 0.99 ± 0.11 1.56 ± 0.22 * 
ACh 
n 6 6 
-log(EC50) 7.3 ± 0.27 7.35 ± 0.13 
Emax (%) 79.4 ± 4.9 90.6 ± 2.7 
SNP 
n 6 6 
-log(EC50) 7.91 ± 0.10 8.02 ± 0.07 
Emax (%) 86.3 ± 2.3 92.2 ± 1.2 * 
ET-1 
n 6 6 
pD2 8.16 ± 0.11 8.31 ± 0.24 
Emax (mN.mm
-1) 0.46 ± 0.09 0.53 ± 0.13 
   
 
Table 3-5 Impact of complete femoral artery ligation of vasomotor function.  
Femoral arteries were ligated just across (complete ligation) the femoropopliteal bifurcation. 28 days later, 
vascular function was studied in the proximal femoral artery by wire myography. As with partial ligation, 
complete ligation resulted in several functional impairments in the femoral artery. Absolute contractility to K+ 
was significantly reduced, and both endothelium-dependent (acetylcholine) and –independent (SNP) vasodilator 
responses were attenuated. n=6. Data are mean ± SEM. PE, phenylephrine; KPSS, high potassium physiological 
salt solution; ACh, acetylcholine; SNP, sodium nitroprusside; ET-1, endothelin-1; *, p<0.05 by Student’s unpaired 




The experiments described in this chapter address the functional and morphological 
consequences of acute injury to the mouse femoral artery by intra-luminal wire-
insertion or ligation of arteries that divide from the femoropopliteal bifurcation. 
Following wire-injury, all contractile function of femoral rings was lost, reflecting 
the severity of this insult and preventing any determination of endothelial function. 
In ligation-injury models functional changes were present but less severe. Both 
partial and complete ligation of the femoral artery resulted in moderate impairment 
to contractility and endothelium-dependent vasodilatation. Interestingly, however, 
partial ligation was associated with only minimal neointimal lesion formation whilst 
in complete ligation-injured vessels substantial neointimal thickening was present. 
Analysis of lesion morphology resulting from each injury in three dimensions using 
the technique of optical projection tomography (OPT) confirmed these observations 
and demonstrated the potential of this imaging modality in studies of this kind. 
Lesion profiles generated in this way indicated that partial ligation-injured vessels 
were barely distinguishable from those without injury, whereas complete ligation 
resulted in lesions of considerable size. These in turn, however, were smaller in 
length and cross-sectional area than those resulting from wire-injury. Thus, 
functional, histological and tomographic analysis of injured femoral arteries has 
revealed complete but not partial ligation of this vessel to be a robust model of 
neointima formation associated with more modest lesion growth and deficits to 
function, and in which, the retention of some endothelial function is certain. 
  
3.4.1 Femoral artery wire-injury abolishes vascular reactivity  
At 14 days, wire-injured femoral arteries were completely unresponsive to 
vasoconstrictor substances, preventing subsequent determination of endothelial cell 
function by these means. This is perhaps unsurprising due to the severity of the 
medial stretch injury inflicted in this model. Sata et al (2000) report the onset of 
medial apoptosis within 2 hours of wire-insertion, and in this laboratory it has been 
previously demonstrated (also described in chapter 5) that this is followed by loss of 
medial cellularity and  α-smooth muscle actin immunoreactivity for an extended 
period (at least 28 days; MacDonald et al., Unpublished data). It is, therefore, likely 
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that the complete absence of vascular reactivity is a response to loss of those cells 
that normally mediate contractility. A second possibility is that wire-induced stretch 
has stripped any cells that survive from their connections to the surrounding 
cells/matrix, and as such, that contraction of individual cells is no longer coupled to 
contraction of the vessel. This suggestion is consistent with additional previous work 
in this lab in which contractility of wire-injured femoral arteries was also found to be 
abolished immediately after injury (MacDonald et al., Unpublished data), possibly 
before substantial loss of medial cells could occur (Reis et al., 2000; Sata et al., 
2000). Consideration must also be given to the neointima. Whilst it was not 
specifically shown in these vascular rings, it is assumed that as 14-day wire-injured 
vessels, they contain neointimal lesions of moderate extent (Sata et al., 2000; Dover 
et al., 2007).  A large cellular mass residing within the vessel might physically 
prevent vascular reactivity, but this seems unlikely to be the sole explanation given 
the severity of the functional deficit. Also with regard to the neointima, it is 
interesting that these lesions, rich in smooth muscle-like cells are themselves 
incapable of mediating vasoconstriction. This probably reflects the synthetic 
phenotype typically adopted by initmal smooth muscle cells, in which, synthesis of 
contractile proteins is reduced (Ueda et al., 1991; Leclerc et al., 1992). Orientation of 
cells may also be important, as vasoconstriction probably requires a structured 
circumferential arrangement of contractile cells, whereas cells of the neointima are 
disordered, and even if capable of contraction, likely do so in opposition to one 
another. 
 
Impaired contractility is also described in other intra-luminal models of acute 
vascular injury, although this is typically far less severe. Balloon-injured rat carotid 
arteries display reduced contractile response to phenylephrine (Heijenbrok et al., 
1998). Similarly, the same injury applied the rabbit carotid artery is said to result in 
reduced responsiveness to both phenylephrine and K+ but not 5-HT or the 
thromboxane mimetic U46619 by Manderson et al (1989), suggesting modulation of 
specific agonist stimulation pathways by neointima formation. Azuma et al (1990), 
however, describe no such changes in contractility in the same model. Thus, some 
reduction in contractility may be common to models of intra-luminal vascular injury 
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with the severity probably determined by the severity of medial injury, which in the 
femoral artery wire-injury model is particularly great.  
 
In models of this type, endothelium-dependent vasodilatation is also often reported to 
be impaired, even after EC regeneration. Reduced responsiveness to endothelium-
dependent vasodilator agonists including acetylcholine, isoprenaline, 5-HT, the Ca2+ 
ionophore A23187 and ADP is variously reported in balloon-injured rabbit (Azuma 
et al., 1990) and rat carotid (Heijenbrok et al., 1998), rabbit iliac (Weidinger et al., 
1990) and porcine coronary arteries (Shimokawa et al., 1987). This impairment is 
often, but not always agonist-dependent. Heijenbrok et al (1998), for example, report 
that vasodilator responsiveness to muscarinic receptor stimulation takes ~6 weeks to 
recover following balloon-injury to the rat carotid artery whilst α2-adrenoceptor-
mediated vasodilatation recovers within 2 weeks (Heijenbrok et al., 2000). Further, 
similar dysfunction of responses mediated by re-generated EC are reported following 
in vivo denudation of the mouse carotid artery, an injury that does not induce 
neointima formation (Miller et al., 2003). Thus, the endothelial dysfunction seen in 
these models may be a result of EC denudation and re-growth rather than a response 
to neointima formation. As it has not been possible to determine the extent of 
changes to endothelial function in the femoral artery wire-injury model, perhaps the 
most useful reports are those of EC function in the closely related mouse carotid 
wire-injury model. In this, EC-dependent vasodilatation to acetylcholine returns by 
day 10 and is only modestly impaired (~15%) indicating rapid recovery of EC which 
may, therefore, act to moderate lesion development (Liao et al., 2007). 
 
3.4.2 Femoral artery ligation-injury impairs vascular function 
Although much less severe, altered vascular function was also detected in femoral 
arteries subject to either partial and complete ligation procedures; manifesting as 
impaired responsiveness both to acetylcholine and to vasoconstrictor substances. 
These defects may actually be an under-estimation of the functional consequences of 
ligation-injury because any changes are likely to be restricted to the vicinity of the 
ligature. Therefore, functionally normal portions of investigated vascular rings may 
have disguised more severe functional abnormalities present in injured sections. 
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These changes cannot be directly attributable to the presence of a neointima as, 
despite relatively similar functional impairments in partial and complete ligation 
models, partial ligation-injured vessels contained no more neointima than their sham-
operated controls. For the same reason, the greater difficulty in mounting lesion-
containing complete-ligation injured vessels and possible associated physical damage 
to EC or smooth muscle cells can be discounted.  
 
In both partial and complete femoral artery ligation models, vasodilator 
responsiveness to acetylcholine, which in this artery probably reflects stimulation of 
NO production by EC (see chapter 5 and Crauwels et al., 2000), was impaired 
(although the pattern of this defect was not identical). These changes are consistent 
with impaired acetylcholine-stimulated vasodilatation in rabbit carotid arteries 
injured by peri-vascular cuff placement, another non-denuding model of neointima 
formation (De Meyer et al., 1991; De Meyer et al., 1992). Many possible 
explanations have been proposed to mediate similar endothelial dysfunction in other 
situations of vascular injury, particularly in atherosclerosis, and may be applicable 
(reviewed by Harrison, 1997). Release of oxidative species from EC, smooth muscle 
cells or macrophages infiltrating the vascular wall or reduced production of anti-
oxidant molecules, may result in increased oxidative deactivation of NO and thus 
impair its activity (Minor et al., 1990). eNOS activity may also be reduced, either by 
reduced expression/phosphorylation (Wilcox et al., 1997) or increased production of 
endogenous inhibitors. Balloon-injury to the rat carotid artery, for example, is 
associated with increased levels of the endogenous NOS inhibitor asymmetric-N,N-
dimethylarginine, although this may simply be a response to the endothelial 
denudation and re-growth that occurs in the model (Azuma et al., 1995b). 
Alternatively, the observed impairment of response to acetylcholine may reflect 
specific defects to muscarinic receptor signaling. Certainly, in the rabbit carotid 
artery peri-vascular cuff model, whilst the response to acetylcholine is impaired, 
vessels respond normally to other endothelium-dependent vasodilators including 
substance P, β-adrenoceptor agonists and Ca2+ ionophores (De Meyer et al., 1991; 
De Meyer et al., 1992). Further study would therefore be required to determine the 
exact nature of the mechanism for this defect. An attractive proposition for an 
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initiating stimulus for such changes to endothelial function in ligation-injured 
femoral arteries is alterations to arterial blood flow patterns that likely occur in both 
partial and complete ligation models (Sullivan & Hoying, 2002; Korshunov & Berk, 
2003). Low or turbulent shear stress, detected through deformations of the EC 
cytoskeleton, is certainly known to modify the activity of many gene products 
critical to endothelial function. For example, low or oscillatory shear stress reduces 
expression and phosphorylation of eNOS (Corson et al., 1996; Ziegler et al., 1998; 
Jin et al., 2003), its obligate co-factor tetrahydrobiopterin (Widder et al., 2007) and 
the anti-oxidant enzyme Cu/Zn superoxide dismutase (Inoue et al., 1996) whilst 
increasing expression of the superoxide generator NAD(P)H oxidase (De Keulenaer 
et al., 1998).  
 
Some further insight may be gleaned from the effect of sodium nitroprusside (SNP), 
a drug typically considered to induce vasodilatation by enzyme-catalysed release of 
NO from its structure. A small but significant impairment of the relaxant response to 
this agent was observed in complete but not in partial ligation-injured vessels. This 
reduced responsiveness implies that reduced bioactivity of NO, rather than altered 
production, may underlie the impaired response to acetylcholine. This may be 
because production of oxidative species is increased in complete ligation-injured 
vessels and thus, NO derived from both SNP and the endothelium is oxidatively 
deactivated before exerting a vasodilator effect. Further, NO release from SNP 
occurs intracellularly in smooth muscle cells, perhaps rendering it less sensitive to 
deactivation than endogenously produced NO which must diffuse further to exert its 
effect (Gruetter et al., 1979). Therefore, the lesser effect of complete ligation on 
SNP-stimulated as compared to acetylcholine-stimulated vasodilatation may reflect 
the relative sites of NO release. An alternative possibility is that because responses to 
both exogenous and endogenous NO are impaired (although not to the same degree) 
that this defect reflects reduced sensitivity of the effector mechanisms of NO such as 
soluble guanylate cyclase activation.  
 
Impaired absolute contractile responses to a variety of vasoconstrictor substances 
was also present in partial and complete ligation injured vessels. The apparent 
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agonist-independence of this defect suggests a reduction in inherent contractility 
rather than altered expression of particular receptor systems. No overt medial 
damage occurs in ligation models, making this contractile deficit more difficult to 
explain than that observed following wire-injury. Indeed, the presence of endothelial 
dysfunction might predict increased contractile responsiveness due to the loss of 
basal release of endothelium-derived relaxing factors (Waldron et al., 1999; 
Crauwels et al., 2000) as was observed in endothelium-denuded, un-injured femoral 
arteries. These data are, however, consistent with those from the rabbit carotid artery 
peri-vascular cuff placement model, in which (despite a similar absence of medial 
trauma) impaired contractile response to K+, noradrenaline and U46619 were 
described (De Meyer et al., 1990; De Meyer et al., 1994). In contrast, 5-HT-
stimulated contraction is enhanced by this injury (De Meyer et al., 1990; De Meyer 
et al., 1994), probably reflecting the increased expression of 5HT1B receptors in this 
model (Geerts et al., 2000). The mechanism behind this impairment of contraction is 
unclear. De Meyer et al (1994) suggest that this reflects an adoption of a synthetic 
phenotype by smooth muscle cells, which, therefore, exhibit reduced expression of 
contractile proteins. This is certainly plausible here given that flow-induced changes 
in endothelial function, tissue hypoxia, and/or macrophage infiltration into the 
medial layer may be present in both partial and complete ligation models and 
regulate smooth muscle phenotype (Thyberg, 1998). This suggestion is not 
consistent, however, with the maintained level of  α-smooth muscle actin, a key 
contractile protein, in the media of ligation-injured vessels. Immunoreactivity for this 
antigen was even increased following complete ligation, which although suggestive 
of some change to smooth muscle phenotype might, again, be expected to result in 
increased rather than reduced responsiveness to vasoconstricting stimuli.  
 
An alternative explanation is that impaired contractility in these ligation-injured 
vessels is a methodological artefact. It was not possible to determine optimal resting 
tension for injured vessels by normalisation as insufficient tissue was available for 
this procedure. As such, resting tension values determined previously for uninjured 
femoral arteries were utilised for both and sham and ligation-injured vessels. It may 
be, however, that application of excess passive tension caused smooth muscle cell 
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damage at the time of study. Similarly, as active contractility increases with the 
extent of stretch, reduced contractile responses of injured vessels could also result 
from application of sub-optimal resting tension (Mulvany & Halpern, 1977).  
 
No change was noted in the responsiveness of vessels subject to partial or complete 
ligation to ET-1 as compared to their sham operated controls, beyond that which 
might be expected to result from altered basal contractility. It therefore appears that 
in this model neointima formation does not directly alter ET receptor function in 
cells mediating vasoconstriction: probably medial smooth muscle cells. It is curious, 
however, that in both complete ligation injured arteries and their sham operated 
controls, contractions induced by ET-1 were extremely weak, as compared to that 
seen in femoral arteries from un-operated mice. This may indicate a systemic 
alteration in ET receptor expression in this model, perhaps in response to the 
systemic inflammatory response (Pietersma et al., 1995; Buffon et al., 1999; Hojo et 
al., 2001; Kochiadakis et al., 2007) or elevation in circulating [ET-1] (Takase et al., 
2003) that is known to proceed acute vascular injury in man. More practical 
considerations, for example, contamination or low activity of the particular batch of 
ET-1 used in these tests cannot be excluded as no vessels from un-operated mice 
were studied in parallel. 
 
In the case of both impaired endothelium-dependent vasodilatation and contractility a 
final question is why, in the partial ligation model, changes to vascular function were 
only present in the femoral artery proximal to the ligation and not the popliteal artery 
beyond it. This may simply be because ligation-induced changes to blood flow 
patterns do not extend distally and thus, that there is no stimulus for altered vascular 
function here. It may also reflect fundamental differences between these vessels. 
Certainly, vasomotor responses in popliteal arteries had several differences in 
characteristics compared to femoral arteries such as lesser contractile responsiveness, 




3.4.3 Complete femoral artery ligation as a model of neointimal hyperplasia 
Complete ligation of the femoral artery resulted in formation of neointimal lesions in 
all vessels analysed. These lesions were broadly similar in composition to wire 
injury-induced lesions (see chapter 4 and 5) – rich in elastin, as indicated by United 
States trichrome staining, and smooth muscle-like cells, as indicated by  α-smooth 
muscle actin immunohistochemistry. At the time point investigated, however, these 
lesions were ~50% smaller in absolute cross-sectional area than those in wire-injured 
arteries (chapter 4 and 5). Complete ligation-induced neointimal lesions were also a 
smaller than those reported to result from ligation of the carotid artery, by a similar 
degree (Kumar & Lindner, 1997). The former is easily attributable to the severity of 
the injury induced by wire-insertion. The latter may be a consequence of the larger 
calibre of the carotid than the femoral artery (Roque et al., 2000; Kawasaki et al., 
2001). Indeed, the intima/media ratios observed here following complete femoral 
artery ligation are greater than those reported by Kumar et al (1997) in the carotid 
ligation model. Qualitative assessment of individual lesion cross-sections generated 
by OPT agree with histological analysis, and unsurprisingly indicate that wire-
induced lesions afflict a greater length of vessel than do those induced by complete-
ligation. Further, they confirm that in the partial ligation model, any morphological 
disturbances are restricted to the immediate vicinity of the ligature and, therefore, 
that the absence of lesions in myography rings from this model is not due to poor 
isolation and division of the injured artery.  
 
The mechanism of lesion development in this model has not been investigated but 
several possible stimuli are present, including an inflammatory response to the 
ligature, local blood stasis, hypoxia and altered EC function (either reduced NO 
bioactivity or increased adhesion molecule expression). Some insight may be 
gleaned from the absence of neointima formation following partial femoral artery 
ligation. Thus, features that are common to both models may be eliminated from 
consideration as candidates for the primary stimulus of neointimal proliferation 
(although more subtle modulatory effects may still apply). In both models a ligature 
is present from the time of surgery, suggesting that either an inflammatory response 
to this, or its occlusion of the adventitial vasa vasorum, does not directly stimulate 
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neointimal hyperplasia. Lesion formation in response to severe hypoxic damage to 
vascular cells also seems unlikely as following ligation, the region is sufficiently 
nourished to support development of a large, richly cellular neointima.  
 
Impaired endothelium-dependent vasodilatation is common to both models of arterial 
ligation. Endothelial dysfunction can certainly modulate neointima formation, as 
seen, for example, in eNOS-/- mice (Moroi et al., 1998; Zhang et al., 2006). Neither 
these animals, nor those in which the carotid artery endothelium is carefully denuded 
in vivo, spontaneously develop neointimal lesions however, indicating this too is not 
a primary cause of neointima formation (Miller et al., 2003). Despite this, it cannot 
be excluded that impairment of stimulated NO release does not represent other 
changes in endothelial function. For example, adhesion molecule expression may be 
differentially regulated by complete and partial ligation. It would certainly be 
reasonable to expect that disturbances to blood flow are more substantial in the 
complete ligation model. If a modulatory role for the observed impairment of 
stimulated NO release at 28 days post-ligation is present, it may also be that changes 
in vascular function at this time point, do not reflect changes which are prevalent at 
earlier time points of active lesion growth.  
 
This leaves blood stasis as a possible candidate for an initiating influence for 
neointimal proliferation. In the complete ligation model, some blood flow through 
arterial branches near to the femoropopliteal bifurcation may be preserved. Blood 
stasis, however, is likely to be much greater than following partial ligation, where 
any no-flow is probably restricted to a very small area immediately proximal to the 
ligature. Similarly, a lesser degree of blood stasis in a popliteal artery ligation model 
previously utilised in this laboratory (MacDonald et al, Unpublished data), may 
explain the comparatively small lesions resulting from this procedure. Moreover, 
studies of broadly analogous ‘partial’ ligations to the mouse carotid arteries are 
supportive of this dependence of lesion formation on the absence of flow. Ligation of 
the internal carotid just distal to the bifurcation of the superior thyroid artery results 
in 80% reduction in blood flow without appreciable neointima formation (Sullivan & 
Hoying, 2002). Similarly, ligation just distal to the occipital branch results in 90% 
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reduction of flow, with only minimal lesion formation (Korshunov & Berk, 2003). 
By comparison, the model of neointima formation described by Kumar & Lindner 
(1997) results from ligation just proximal to the occipital branch i.e. across the 
bifurcation of the common carotid artery, and therefore presumably results in 
complete cessation of flow. 
 
Any regions of no-flow may allow the development of stasis thrombi, which secrete 
platelet-derived growth factor and other mitogens and provide a framework into 
which smooth muscle cells can migrate to form a neointima - a mechanism of lesion 
formation more reminiscent of that suggested by Schwartz et al (1992a) than the 
conventional model (Libby et al., 1992). Certainly, in the mouse carotid artery 
ligation model, thrombi are described to occur in the region of injury (Kumar et al., 
1997; Kumar & Lindner, 1997; Kawasaki et al., 2001). Whilst none have been 
observed in these studies of femoral artery ligation, any thrombotic response is likely 
to have resolved by the 28 day post-injury time-point investigated. Further, the 
carotid artery ligation model is sensitive to manipulations to processes of 
coagulation, fibrinolysis and platelet aggregation (Kawasaki et al., 2001; Wang et 
al., 2005b; Martin-McNulty et al., 2007)- supporting the view that thrombus 
formation is important in ligation-induced lesion formation. Therefore, whilst 
somewhat speculative, it is tempting to suggest that the degree of neointimal lesion 
formation resulting from ligations about the femoropopliteal bifurcation (as for the 
carotid) is a response to the degree of blood stasis and thrombus formation resulting 
from each procedure. 
 
3.4.4 Optical projection tomography for the analysis of neointima formation 
Data from the three-dimensional OPT imaging of injured femoral arteries indicate 
that this technique offers potential advantages in the measurement of vascular lesion 
formation in small arteries. The qualitative similarities between images produced by 
this method, and by subsequent histological analysis of the same vessels, are striking 
and this is confirmed by strong correlations between planimetric measurements of 
neointimal and luminal cross-sectional areas made between these techniques. Any 
deviations in these correlations are likely to be a consequence of the difficulties in 
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identifying the exact same regions in histological sections and OPT scans and, as 
such, may reflect a limitation of the comparison method rather than the imaging 
technique. Alternatively, because the delineation of the neointima/media border is, in 
some cases, subjective, inclusion of portions of media in neointimal measurements 
may provide an additional source of variability. If this were common, however, a 
positive bias in the correlation between OPT and histology measures of neointima 
might be expected, and none was apparent. Regardless, the greater power of this 
technique is in the assessment of volumetric parameters and these are likely to be 
relatively insensitive to small, unbiased errors in individual 2D measurements. 
 
OPT offers a number of potential benefits over traditional histological methods of 
lesion analysis. Analysis of long lengths of vessels by microtomy of serial sections 
and histological staining is both extremely time-consuming and labour-intensive. 
OPT analysis in comparison is rapid, requires less user input and, after scanning, 
tissues remain undamaged for further use (including histological analysis). Also for 
reasons of practicallity, histological analysis is typically limited to description of 
injured vessels by one site in which the largest lesions are present. Full 3D analysis 
of lesion size and distribution, however, may offer greater power to detect an effect 
of intervention, and describe more subtle changes in lesion development (McAteer et 
al., 2004). Given the unproven nature of this technique, the workflow adopted for 
this thesis was of OPT scanning before full histological analysis. In future, a better 
compromise between these potentially complementary methods might be adopted - 
to determine lesion volume and distribution by OPT, and to selectively analyse only 
the regions containing the largest lesions in detail using histological means. 
 
Surprisingly few alternative methods for the 3D imaging of small vascular lesions 
have been described, perhaps reflecting a greater interest in in vivo imaging 
modalities. One relevant outcome of this focus is the possible use of MRI for the 
analysis of tissues ex vivo, which allows for greater resolution than is possible in 
vivo. McAteer et al (2004) have described the use of this technique for the analysis 
of atherosclerotic lesions in the brachiocephalic artery, but the work performed in 
this chapter indicates OPT may be equivalent or superior. Even though the resolution 
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of these ex vivo MRI images appears similar to those produced by OPT, it must be 
considered that this only because the brachiocephalic is substantially larger than the 
femoral artery. Of more practical concern, image acquisition time to produce such 
MRI images is 7 hours per vessel, despite use of an exceptionally powerful scanner 
(11.7 Tesla). For comparison, OPT images are acquired in <20 mins using a 
tomograph of only modest expense. OPT also possesses the potential to visualise the 
extent and distribution of particular antigens. Whole mount immunoflourescent 
staining of tissue samples can be imaged alongside basic morphology (i.e. tissue 
auto-fluorescence) using an alternative UV filter set. Whilst an exciting possibility, 
attempts to utilise this process here have been frustrated by difficulties associated 
with antibody penetration and removal from intact tissues. Other possible techniques 
for the 3D imaging of blood vessels such as optical coherence tomography and 
whole-mount confocal microscopy remain to be investigated. In the latter case, 
whilst this method might offer superior resolution to all others discussed, any use 
may be severely limited by depth of sample that can be studied.  
  
3.4.5 Conclusions 
The studies presented in this chapter describe the functional and morphological 
consequences of a novel model of femoral artery ligation-induced neointimal 
hyperplasia, and a new technique for rapidly analyzing vascular lesion formation in 
three dimensions. The complete femoral artery ligation model will provide a useful 
complement to the wire-injury model owing to the absence of physical damage to the 
endothelium. This is of particular importance given the hypothesis that ETB 
expressed by EC modulates the response to vascular injury, and that it has not been 
possible to determine how well endothelial function returns following wire-injury. 
Finally, OPT appears to be well suited to the 3D imaging of injured femoral arteries 
and should allow the assessment of volumetric parameters and lesion distribution 
following injury, and how these parameters respond to interventions. 
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There is little doubt that acute injury to the vascular wall provokes activation of the 
endothelin (ET) system, for example, resulting in both local (Kurata et al., 1995; 
Dashwood et al., 1999; Shirai et al., 2006) and systemic (Takase et al., 2003) 
increases in the tissue and circulating levels of the ET peptides in human patients. 
Interventional studies in animals have established that endogenous ETs are not 
simply a marker of disease progression but are themselves powerful stimulants for 
the development of neointimal hyperplasia. This literature consistently states that 
selective blockade of the ETA receptor is sufficient to moderate neointimal 
thickening following various insults to the vascular wall, in a variety of non-human 
species (Ferrer et al., 1995; Takiguchi & Sogabe, 1996; Burke et al., 1997; McKenna 
et al., 1998; Dashwood et al., 1999; Murakoshi et al., 2002; Tepe et al., 2002; Wan 
et al., 2004).  
 
The role of the ETB receptor in vascular lesion formation following injury is more 
difficult to deduce. Certainly, ETB receptors expressed by vascular smooth muscle 
cells (VSMC) and leucocytes may mediate many actions common to ETA; such as 
promotion of mitogenesis (Eguchi et al., 1994; Yang et al., 1999; Di Luozzo et al., 
2000), monocyte chemotaxis (Achmad & Rao, 1992; Cui et al., 2001; Grimshaw et 
al., 2002) and cytokine production (Ruetten & Thiemermann, 1997; Shimada et al., 
1998; Speciale et al., 1998; Juergens et al., 2008). On endothelial cells (EC) and 
collecting duct epithelial cells (IMCD), however, the ETB receptor may mediate 
actions that might plausibly limit the response to vascular injury such as induction of 
nitric oxide (NO) release by EC, clearance of circulating ET-1 and natriuresis 
(Bagnall et al., 2006; Ge et al., 2006). Therefore, whilst activation of ETA and ETB 
on VSMCs and leucocytes probably contributes to neointima formation, this may be 
moderated by local (NO release) and systemic actions (ET-1 clearance, natriuresis) 
mediated by the ETB receptor. 
 
The body of work that describes the effects of ETB blockade in neointimal 
hyperplasia is both small and inconsistent. On one hand, most (Douglas et al., 1994; 
Ohlstein et al., 1994; Douglas et al., 1995a; Tsujino et al., 1995; Chandra et al., 
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1998; Marano et al., 1998; Azuma et al., 1999; Sanmartin et al., 2003; Reel et al., 
2005) but not all (Huckle et al., 2001) studies that investigate the effects of non-
selective ETA/ETB blockade on neointima formation demonstrate a reduction in 
lesion size. This might suggest that any contribution of ETB is modest since ETA 
blockade alone has a similar effect but no direct comparisons of the magnitude of 
these changes have been reported. On the other hand, Murakoshi et al (2002) report 
that lesions resulting from carotid artery ligation are increased in size, both in 
“rescued” ETB knockout mice and in wild-type mice treated with a selective ETB 
antagonist. This is associated with reduced tissue levels of NO oxidation products 
suggesting that NO release from EC may be important, particularly because this 
model does not feature physical damage to endothelium. 
 
The work in this chapter addressed the hypothesis that endogenous ET-1 stimulates 
neointimal proliferation after arterial injury by activation of the ETA receptor 
subtype but that this action is opposed by concurrent ETB receptor stimulation. To 
examine this, the effects of selective pharmacological ETA and ETB receptor 
blockade, both alone and in combination, were observed. The possible requirement 
of a physically-intact endothelium on the role of both receptors was assessed by use 
of both wire-induced (endothelium-denuding) and ligation-induced (endothelium-





Experiments were carried out on male 25-30g C57Bl/6J mice purchased from Harlan 
Laboratories, UK. Animals were ear-clipped for identification purposes and allowed 
to acclimate to their environment for at least one week before further use.  
 
4.2.2 Drug administration  
The orally active endothelin receptor antagonists atrasentan (2000-fold ETA-
selective; 10mg.kg-1.day-1), A192621 (1300-fold ETB-selective; 30mg.kg-1.day-1) 
individually or in combination were administered in chow. These doses have been 
shown previously to achieve strong and selective blockade of their respective targets 
in rodents, as assessed by alterations to the ETB-mediated depressor and ETA-
mediated pressor phases of the response to acute ET-1 administration (Opgenorth et 
al., 1996; Wessale et al., 2002). Drug solutions, prepared by dispersion of the 
relevant agent(s) in 0.2% methylcellulose were bound with RM1 mouse chow with 
beef gelatin as described in section 2.3.2. Drugged diet was packed into 60ml 
centrifuge tubes for consumption, providing at least 1 tube for every 2 mice. Diet 
was checked daily for depletion or signs of spoilage and replaced as necessary. 
Tubes were regularly weighed to monitor consumption. Drug diet was administered 
from 1 week prior to femoral artery injury surgery until the completion of the study 
(Figure 4-1).  
 
4.2.3 Blood pressure 
To verify effective absorption and activity of ET receptor antagonists systolic blood 
pressure was measured over the study period using the technique of tail cuff  
plethysmography (section 2.3.3). To familiarise animals to handling, restraint and 
cuff inflation, blood pressure measurements were commenced 2 weeks prior to the 
period of drug administration, and were recorded twice-weekly until femoral artery 
injury surgery was performed. Following a 10 day post-operative recovery period, 






Figure 4-1 Study protocol to determine the effects of ET receptor blockade on neointima formation.  
Experiments were conducted in male, 11 week old C57Bl6J mice. Blood pressure was measured twice weekly by tail cuff plethysmography during a 21 day run-in period. On day 
14, animals were placed on diet containing 1: vehicle (n=10), 2: atrasentan (10mg/kg/day; n=8), 3: A192621 (30mg/kg/day; n=8) or 4: atrasentan + A192621 (10mg/kg/day and 
30mg/kg/day, respectively; n=8) and remained so for the study duration. At the end of this period (day 21), each mouse underwent left femoral artery wire-injury and right 
femoral artery complete ligation-injury. Animals were allowed to recover for a further 28 days, during which, after a 10 day rest period, blood pressure was measured weekly. At 
the end of this (day 49), mice were culled by perfusion fixation and injured femoral arteries isolated for examination by OPT, histology and immunohistochemistry. Food 
consumption and body weight were recorded at the same intervals as blood pressure measurement, throughout the study. LFA, left femoral artery; RFA, right femoral artery; 
OPT, optical projection tomography. 
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(Figure 4-1). Animals were weighed and body weights recorded according to the 
same schedule. 
 
4.2.4 Femoral artery injury 
To induce neointimal hyperplasia, two models of femoral artery injury were 
employed as detailed in section 2.3.1. Both procedures were performed in each 
mouse to minimise the number of animals and amount of drugged diet required 
(Figure 4-1). Previous studies in our laboratory have demonstrated that dramatic 
alterations in lesion size (produced by local drug delivery) have no effect on the 
neointimal thickening in the contra-lateral artery, suggesting that that there is little 
potential for interaction between wire- and ligation- injuries performed in the same 
animals (MacDonald et al., Unpublished data). Further, multiple models of 
neointimal proliferation in a single mouse have been used previously to assess the 
mechanisms of remodelling (Tanaka et al., 2003). 
 
Intra-luminal wire-injury was inflicted to the left femoral artery of each mouse, using 
the method of Sata et al (2000), wherein a 0.014” diameter straight sprung 
angioplasty guide wire is advanced ~1.5cm proximally into the isolated femoral 
artery through an arteriotomy in the popliteal branch. In the contra-lateral (right) 
femoral artery, injury was induced using an adaptation of the model of carotid artery 
ligation (Kumar & Lindner, 1997). The isolated femoral artery was ligated with 5-0 
silk at its junction with the popliteal artery. Mice were allowed to recover for 28 days 
to permit lesion development in both arteries after which mice were killed by 
exsanguination and trans-cardiac perfusion fixation under terminal pentobarbital 
anesthesia. Two hours prior to induction of terminal anaesthesia, 5-bromo-2-
deoxyuridine (100mg.kg-1, i.p.) was administered to allow assessment of cell 
proliferation. Vessels were isolated, cleaned of extraneous peri-adventitial material 




4.2.5 Optical projection tomography (OPT) 
For three-dimensional evaluation of injured femoral arteries, vessels were embedded 
in agarose for analysis by OPT (section 2.5). Briefly, after dehydration in methanol 
and refractive index matching in benzyl alcohol/benzyl benzoate, each for 24 hours, 
vessels were scanned for fluorescent emission (excitation filter: 425/40nM; emission 
filter: 475nm low pass) using a Bioptonics OPT tomograph with a scanning 
resolution of 1.048Mpixels. Computed tomography reconstruction was performed by 
filtered back-projection of raw data using NRecon software. Volumetric 
measurements were acquired by manual tracing of the estimated position of the 




Following acquisition of OPT scans, vessels were prepared for histological 
evaluation by washing in methanol (>24 hours) before processing to paraffin wax. 
To reduce the required amount of microtomy, several arteries were embedded in 
each paraffin block. 3µm serial sections were cut at intervals of 100µm and 50µm for 
wire- and ligation-injured femoral arteries, respectively. At each interval, 1 section 
was stained using the ‘United States trichrome’ method (Hadoke et al., 1995) to 
highlight the borders of each arterial layer, and to locate the region bearing the 
largest neointimal lesion. All further histological/compositional analysis was carried 
out on sections adjacent to this region. For ligation-injured arteries, only vessels 
containing patent lumen were considered for analysis to exclude areas crushed by the 
application of the ligature. Measurements of intimal area, medial area and luminal 
area were recorded using image analysis software (Photoshop CS3 Extended, Abode 
Systems, USA) and intima/media ratio and stenotic ratios calculated. For evaluation 
of lesion collagen content, adjacent sections were stained with picro-sirius red and 
the area of staining within the neointimal layer calculated by colour deconvolution 
and expressed as a percentage of total neointimal area using Photoshop CS3 





For analysis of lesion composition and cell proliferation, immunohistochemistry was 
performed on sections from each vessel adjacent to the region identified as having 
the largest neointimal lesion. Reactions were performed according to the 
immunoperoxidase, labelled streptavidin-biotin method using primary antibodies 
reactive to  α-smooth muscle actin (αSMA), Mac2 and bromodeoxyuridine (BrdU). 
αSMA and Mac2 immunoreactivity were quantified by semi-automated colour 
deconvolution (Photoshop CS3 Extended, Abode Systems, USA) and expressed as a 
fraction of the total area of the arterial layer (media, neointima) of interest. BrdU 
incorporation was recorded by blinded, manual count of immunoreactive nuclei. 
 
4.2.8 Statistics 
All statistical analysis was performed by one-way ANOVA with Dunnet’s post-hoc 
test for comparison of drug treatments with vehicle, using Prism 4.0 software 
(Graphpad software, USA). Systolic blood pressure for each animal was taken as the 
mean of the measurement taken immediately prior to induction of vascular injury, 




4.3.1 Physiological parameters 
Prior to administration of pharmacological agents, systolic blood pressure (SBP), as 
measured by tail cuff plethysmography, was of expected physiological value and not 
significantly different between intended treatment groups (vehicle: 101.4±1.2mmHg; 
atrasentan: 100.0±1.4mmHg; A192621: 98.6±0.9mmHg; atrasentan+A192621: 
100.7±1.3mmHg; p=0.434). Similarly, pre-study body weight was not different 
between groups (Table 4-1, page 146). During the period of drug dosing, SBP 
(Figure 4-2) was decreased by 6.5mmHg and 6.3mmHg, respectively, for atrasentan- 
and atrasentan+A192621-treated animals (both p<0.01), and increased by 8.3 mmHg 
in mice treated with A192621 alone (p<0.001). The rate of change of body weight 
was not significantly altered by treatments (Table 4-1, page 146). Consumption of 
drugged food was consistent with predicted intake of 10g.day-1.mouse-1 over the 
period of drug dosing (vehicle: 10.3g.day-1.mouse-1; atrasentan: 9.4g.day-1.mouse-1; 
A192621: 9.4g.day-1.mouse-1; atrasentan+A192621: 10.3g.day-1.mouse-1). A 
moderate drop (<50%) in consumption of diet was noted in the immediate post-
operative period but returned to normal levels within 3 days. At the study end, 
obvious evidence of infection was noted at the surgical site in several mice (1 
vehicle-treated, 1 atrasentan-treated, 1 A192621-treated). Vessels from these animals 
were excluded from further analysis.  
 
4.3.2 Wire injury 
4.3.2.1 3D morphometry – wire injury 
Optical projection tomography was used to evaluate the total lesion and luminal 
volumes of wire-injured femoral arteries. As in chapter 3, neointimal lesions were 
clearly visible in reconstructed OPT scans and were present in all treatment groups. 
Treatment of animals with A192621 (10mg.kg-1.day-1) was associated with a 
significant increase in the fraction of the total vessel volume occupied by wire-
induced lesion (‘volumetric stenotic ratio’; Figure 4-3). Trends towards reduced 







Figure 4-2 Impact of endothelin receptor blockade on systolic blood pressure.  
SBP was measured in mice subject to femoral artery injury and treated with vehicle or antagonists to ETA 
(atrasentan; 10mg/kg/day), ETB (A192621; 30mg/kg/day) or ETA+ETB (atrasentan+A192621) using tail cuff 
plethysmography. Pre-drug administration SBPs were similar between all groups (a). SBP was reduced by ETA and 
ETA+ETB blockade, and increased by ETB blockade and these effects were maintained over the treatment period 
(a). As such, mean SBPs over the study duration were significantly increased by A192621 and decreased by 
atrasentan ± A192621 (b). n=8-10. Data are mean ± SEM. SBP, systolic blood pressure; **, p<0.01; ***, p<0.001 
by two-way ANOVA with Dunnet’s post-test. 































































Figure 4-3 Impact of endothelin receptor blockade on wire injury-induced lesion volume, as assessed by optical 
projection tomography.  
Neointima formation was induced by femoral artery wire-injury in mice treated with vehicle or antagonists to ETA 
(atrasentan; 10mg/kg/day), ETB (A192621; 30mg/kg/day) or ETA+ETB (atrasentan+A192621) and lesions allowed 
to develop for 28 days before isolation and optical projection tomographic scanning. Lesions were clearly visible 
in raw projection images (a, arrowheads). Lesion volumes were recorded from reconstructed tomograms and 
expressed as a fraction of vessel occupied by lesion. This measure was significantly reduced by ETA blockade, 
increased by ETB blockade and not altered by ETA+ETB blockade. n=6-8. Data are mean ± SEM. ns, p>0.05; *, 
p<0.05; **, p<0.01 by two-way ANOVA with Dunnet’s post-test.






































apparent in this treatment group, but neither reached statistical significance (Table 
4-2, page 147). In animals treated with atrasentan (30mg.kg-1.day-1), the fraction of 
vessel volume occupied by lesion was significantly reduced by treatment (Figure 
4-3), but again, trends toward reduced absolute neointimal volume, and increased 
luminal volume did not attain statistical significance (Table 4-2, page 147). No 
changes in any measure of 3D lesion morphology were apparent in mice treated with 
the combination of atrasentan and A192621 – volumetric stenotic ratio (Figure 4-3) 
and neointimal volume were similar to those in arteries from vehicle treated mice, 
and a trend towards increased luminal volume was not significant (Table 4-2, page 
147).  
 
4.3.2.2 2D morphometry – wire injury 
Histological analysis of the largest wire-induced lesions in each vessel provided 
confirmatory data. Femoral artery wire injury resulted in formation of fibro-
proliferative neointimal lesions in all treatment groups (Figure 4-4). Selective ETB 
blockade with A192621 was associated with increased maximum lesion size (Figure 
4-5) and intima/media ratio (Table 4-2, page 147). No changes in luminal area, 
medial area or the stenotic ratio were apparent in arteries from this group. As such, 
A192621 was associated with an increase in the total area inside the external elastic 
lamina (Table 4-2, page 147).  
 
In animals treated with the selective ETA antagonist, atrasentan, an increase in 
luminal area at the point of maximum neointimal lesion size was observed in wire-
injured femoral arteries (Figure 4-5), and accordingly, stenotic ratio was 
significantly decreased (Table 4-2, page 147). A trend towards reduce neointimal 
lesion size and intima/media ratio was also apparent in this group, but did not reach 
significance (p>0.05; Figure 4-5). Medial area was also unaltered by atrasentan 
treatment. As such, outward structural dilation would appear to contribute to the 
increased luminal area, although the total area inside the external elastic lamina was 






Figure 4-4 Impact of endothelin receptor blockade on femoral artery wire injury-induced lesion size and 
composition.  
Neointima formation was induced by femoral artery wire-injury in mice treated with vehicle or antagonists to ETA 
(atrasentan; 10mg/kg/day), ETB (A192621; 30mg/kg/day) or ETA+ETB (atrasentan+A192621) and lesions allowed 
to develop for 28 days before histological examination. Representative photomicrographs of lesions from all 
treatment groups stained by United States Trichrome (a-d), Picro-sirius red (n-q) and immunohistochemistries for 
αSMA (e-h) and Mac2 (i-m), are shown. Trichrome staining reveals formation of large, elastin (purple) and 
collagen (blue)-rich lesions in all groups which are reduced and increased in size by ETA (b) and ETB blockade (d), 
respectively (a-d). From these, the lumen/intima (white arrowheads), intima/media (blue arrowheads) and 
media/adventitia border (black arrowheads) can be clearly seen. All lesions are rich in immunoreactivity for 
αSMA which is also present in the media, and often, adventitia (e-h). Mac2 immunoreactivity is also found 
throughout the vascular wall in injured vessels, although the extent is much less. Picro-sirius red staining further 
reveals the high collagen content (red) of these lesions (n-q) which is somewhat lower in those from mice treated 




Figure 4-5 Impact of endothelin receptor blockade on neointimal and lumenal area in wire-injured femoral 
arteries, as assessed by histology.  
Neointima formation was induced by femoral artery wire-injury in mice treated with vehicle or antagonists to ETA 
(atrasentan; 10mg/kg/day), ETB (A192621; 30mg/kg/day) or ETA+ETB (atrasentan+A192621) and lesions allowed 
to develop for 28 days before histological examination. Neointimal (a) and lumenal cross-sectional areas (b) were 
measured at the point of largest lesion size by morphometry. Neointimal area was increased in mice subject to 
ETB blockade (a). A trend towards reduced lesion size (p>0.05) was apparent with ETA blockade. ETA blockade did 
significantly increase lumenal area (b). Lumenal cross-sectional was not altered by ETB or ETA+ETB blockade. n=7-
9. Data are mean ± SEM. ns, p>0.05; *, p<0.05; **, p<0.01 by two-way ANOVA with Dunnet’s post-test. 
 













































Combined blockade of ETA and ETB receptors by treatment with both atrasentan 
and A192621 was not associated with any change in histological measures of 
luminal, medial or neointimal area (Figure 4-5). Consistently, the total area inside 
the external elastic lamina was similar to that in vessels from vehicle treated animals 
(Table 4-2, page 147). 
 
4.3.2.3 Lesion composition – wire injury 
Immunoreactivity for α-smooth muscle actin, indicating VSMC and myofibroblast 
content, was detected throughout the neointima and media in all treatment groups 
(Figure 4-4). The fractional area of immunoreactivity was not different between 
treatment groups in either layer of wire-injured femoral arteries (Table 4-2, page 
147).  
 
Mac2 immunoreactivity, a marker of macrophage content, was typically present only 
at a low level, but was variably associated with the adventitia, media and neointima 
(Figure 4-4). The fraction of neointimal and medial area immunoreactive for Mac2 
was also not significantly different between treatment groups. A non-significant 
trend towards increased fractional Mac2 immunoreactive area, however, was noted 
in the neointima of A192621 treated animals, with or without concurrent ETA 
receptor blockade (both p>0.05; Figure 4-6).  
 
Lesion collagen content was evaluated by histological staining with picro-sirius red, 
and was abundant in all layers of injured vascular wall (Figure 4-4). The fraction of 
the neointima staining for collagen was significantly lower in injured femoral arteries 
from ETA/ETB receptor antagonist-treated animals (Figure 4-6). A non-significant 
trend towards decreased collagen area was also apparent in lesions from mice treated 
only with an ETA antagonist. In wire injury-induced neointimal lesions from ETB 








Figure 4-6 Impact of endothelin receptor blockade on macrophage and collagen content of wire injury-induced 
neointimal lesions.  
Neointima formation was induced by femoral artery wire-injury in mice treated with vehicle or antagonists to ETA 
(atrasentan; 10mg/kg/day), ETB (A192621; 30mg/kg/day) or ETA+ETB (atrasentan+A192621) and lesions allowed 
to develop for 28 days before histological examination. Macrophage content was identified by Mac2 
immunoreactivity and collagen content picro-sirius red staining in the largest lesions from each vessel. Results 
were expressed as % of neointimal area stained. A trend (p>0.05) towards increased neointimal Mac2 content 
was present in mice treated with ETB or ETA+ETB antagonists (a). The combination of ETA+ETB blockade 
significantly reduced neointimal collagen content (b). A trend (p>0.05) towards reduced collagen content was 
also seen with ETA blockade. n=7-9. Data are mean ± SEM. ns, p>0.05; *, p<0.05; by two-way ANOVA with 
Dunnet’s post-test. 




































































Measurement of BrdU incorporation indicated few cells in S phase at this point of 
lesion development in either the media or neointima of wire-injured vessels from 
mice treated with vehicle, atrasentan or the combination of atrasentan and A192621 
(Table 4-2, page 147). In the intimal lesions of mice treated with A192621 alone, 
however, a significant increase in the number of proliferating cells was observed. 
 
4.3.3 Ligation injury 
4.3.3.1 3D morphometry – ligation injury 
The presence and distribution of neointimal lesions in femoral arteries subject to 
complete ligation was clearly indicated by OPT reconstructions, as described in 
chapter 3. In the typical ligation-injured vessel, immediately proximal to the ligation, 
an occluding, cellular neointima was present. Beyond this, the lesion was seen to 
gradually dwindle to a morphologically normal artery. In this area of transition, a 
variably-sized lesion was present surrounding patent lumen, typically connecting 
with an arterial branch. Although in most vessels, no further disturbances were 
observed proximal to this, in a small fraction, intermittent regions of intimal 
hyperplasia were seen (Figure 4-7). 
 
In mice treated with the ETB antagonist A192621, no changes in 3D morphological 
parameters were apparent – luminal volume, neointimal volume and volumetric 
stenotic ratio (Figure 4-7) were similar to those in arteries from vehicle treated mice 
(Table 4-3, page 148). Selective ETA blockade by atrasentan treatment, however, 
was associated with a reduction in the fraction of vessel volume occupied by 
neointimal lesion (Figure 4-7), and trends (both p>0.05) towards reduced neointimal 
volume and increased luminal volume (Table 4-3, page 148). Similar changes were 
present in mice treated with the combination of ETA and ETB antagonists, with a 
significant reduction of volumetric stenotic ratio (Figure 4-7) and non-significant 
trends towards increased luminal volume and decreased neointimal volume (Table 






Figure 4-7 Impact of endothelin receptor blockade on neointimal volume and axial distribution in complete 
ligation-injured femoral arteries, as assessed by optical projection tomography.  
Neointima formation was induced by complete femoral artery ligation-injury in mice treated with vehicle or 
antagonists to ETA (atrasentan; 10mg/kg/day), ETB (A192621; 30mg/kg/day) or ETA+ETB (atrasentan+A192621) 
and lesions allowed to develop for 28 days before optical projection tomographic evaluation. From reconstructed 
tomograms, neointima was delineated and expressed as a fraction of vessel occupied by lesion (a) and by plotting 
cross-sectional area against distance from the ligature (b). Neointimal volume fraction was significantly reduced 
by ETA and ETA+ETB blockade but not altered by ETB blockade (a). Axial profiles of lesion size indicated that this 
effect was mediated reduction of the axial lesion extent, rather than maximum lesion size (b). n=5-7. Data in (a) 
are mean ± SEM. Data in (b) are mean only, SEM is omitted here for clarity. ns, p>0.05 by two-way ANOVA with 
Dunnet’s post-test. 





























































Longitudinal profiles of lesion size along the length of ligation-injured vessels were 
produced from OPT scans to describe the distribution of lesion (Figure 4-7). These 
indicated that any reduction in lesion size associated with ETA blockade (with or 
without concurrent ETB blockade) was due to a decrease in the axial length of 
lesions rather than in maximum lesion cross-sectional area. 
 
4.3.3.2 2D morphometry – ligation injury 
Analysis of ligation-induced lesion formation in the femoral artery by histology also 
demonstrated the presence of fibro-proliferative neointima formation, although these 
were somewhat smaller than those found in their wire-injured counterparts (Figure 
4-8). In contrast to volumetric data by OPT, no significant changes in any 
histological measures including the areas of the largest neointimal lesions (Figure 
4-9), the lumen and the media, was associated with any treatment group (Table 4-3, 
page 148). This is consistent with the OPT generated lesion profiles, which indicate 
that lesion length rather than maximum lesion size is modulated by ETA blockade 
(Figure 4-7). 
 
4.3.3.3 Lesion composition – ligation injury 
As in wire-injured vessels, immunoreactivity for α-smooth muscle actin 
immunoreactivity was abundant throughout the media and neointima of ligation-
injured arteries (Figure 4-8). The fractional area of this, however, was not 
significantly altered by any applied treatment (Table 4-3, page 148). As in wire-
injured vessels, punctate Mac2 immunoreactivity was also present in all layers of the 
vessel wall (Figure 4-8) and similarly, was not modified by any combination of 
atrasentan and A192621 treatment (Table 4-3, page 148). Cell proliferation, as 
indicated by BrdU incorporation, was rarely detectable in either the media or the 
neointima of ligation-injured arteries (Figure 4-8) and again, levels were not 





Figure 4-8 Impact of endothelin receptor blockade on complete femoral artery ligation injury-induced lesion 
size and composition.  
Neointima formation was induced by complete femoral artery ligation-injury in mice treated with vehicle or 
antagonists to ETA (atrasentan; 10mg/kg/day), ETB (A192621; 30mg/kg/day) or ETA+ETB (atrasentan+A192621) 
and lesions allowed to develop for 28 days before isolation and histological examination. Representative 
photomicrographs of lesions from all treatment groups stained with United States Trichrome (a-d), Picro-sirius 
red (n-q) and immunohistochemistries for αSMA (e-h) and Mac2 (i-m), are shown. Trichrome staining reveals 
formation of large, elastin (purple) and collagen (blue)-rich lesions which are similar in size in all treatment 
groups (a-d). All lesions are rich in immunoreactivity for αSMA which is also present in the media, but rarely in 
the adventitia (e-h). Mac2 immunoreactivity is also found throughout the vascular wall in injured vessels, 
although the extent of this is much less. BrdU immunoreactivity (yellow arrowhead) is rarely present in any layer 







Figure 4-9 Impact of endothelin receptor blockade on neointimal and lumenal area in complete ligation-injured 
femoral arteries, as assessed by histology.  
Neointima formation was induced by complete femoral artery ligation-injury in mice treated with vehicle or 
antagonists to ETA (atrasentan; 10mg/kg/day), ETB (A192621; 30mg/kg/day) or ETA+ETB (atrasentan+A192621) 
and lesions allowed to develop for 28 days before histological examination. Neointimal (a) and lumenal cross-
sectional areas (b) were measured at the point of largest lesion size by morphometry. Neointimal area was not 
significantly altered by any treatment (a). Similarly, lumenal cross-sectional area was not different between 
lesions from any treatment group. n=6-8. Data are mean ± SEM. ns, p>0.05 by two-way ANOVA with Dunnet’s 
post-test. 
 









































Measurement Vehicle Atrasentan Atrasentan +A192621 A192621 
   
Body weight at study start (g) 24.5 ± 1.3 27.1 ± 0.8 27.3 ± 0.7 26.1 ± 0.7 
Body weight at study end (g) 29.2 ± 1.3 31.6 ± 0.9 30.9 ± 0.6 29.7 ± 0.9 
Change in body weight (g) 4.1 ± 0.4 4.5 ± 0.6 3.5 ± 0.4 3.9 ± 0.9 
Food consumption (g/day/mouse) 10.3 ± 0.6 9.4 ± 0.5 10.3 ± 0.4 9.4 ± 0.5 
     
 
Table 4-1 Impact of endothelin receptor blockade and femoral artery injury on body weight and food 
consumption.  
Body weight and food consumption were measured in mice subject to femoral artery injury and treated with 
vehicle or antagonists to ETA (atrasentan; 10mg/kg/day), ETB (A192621; 30mg/kg/day) or ETA+ETB 
(atrasentan+A192621). Pre-study body weights were similar between all treatment groups. At the study end, 
body weights and change in body weight over the study duration did not differ between groups. Similarly, food 
consumption over the period of drug dosing was in-line with expected intake of 10g/day/mouse and not different 
between treatment groups. n=8-10. Data are mean ± SEM.   
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(a) 3D Morphometry (OPT)     
n 6 7 8 6 
Intimal volume (x107μm3) 12.6 ± 0.9 3.6 ± 1.0 11.9 ± 3.4 23.5 ± 4.6 
Lumenal volume (x107μm3) 19.3 ± 2.2 25.3 ± 2.9 23.3 ± 2.5 11.5 ± 2.1 
Volumetric stenotic ratio 0.40 ± 0.04 0.12 ± 0.03** 0.30 ± 0.07 0.65 ± 0.08* 
  
(b) 2D Morphometry (Histology)     
n 9 7 8 7 
Lumenal area (x103μm2) 17.8 ± 5.5 50.2 ± 8.9** 23.6 ± 5.8 12.4 ± 5.5 
Intimal area (x103μm2) 42.9 ± 3.6 27.0 ± 3.4 49.7 ± 6.9 79.2 ± 11.5** 
Medial area (x103μm2) 14.4 ± 1.4 15.1 ± 1.1 12.3 ± 1.0 15.2± 2.1 
Intima/Media ratio 3.1 ± 0.3 1.9 ± 0.5 4.3± 0.7 5.4 ± 0.7* 
Stenotic ratio 0.7 ± 0.1 0.4± 0.1** 0.7± 0.1 0.9± 0.1 
Area inside EEL (x103μm2) 75.1 ± 6.9 93.1 ± 6.6 85.6 ± 4.7 106.7 ± 12.6* 
  
(c) Composition & Proliferation (Immunohistochemistry)   
n 9 7 8 7 
Intimal αSMA IR(%) 46.5 ± 11.0 41.7 ± 9.6 30.4 ± 8.8 42.0 ± 8.3 
Intimal Mac2 IR (%) 1.2 ± 0.3 1.4 ± 0.2 2.9 ± 1.2 2.9 ± 1.3 
Intimal PSR staining (%) 54.9 ± 7.4 38.4 ± 5.0 30.6 ± 8.7* 52.2 ± 5.7 
Intimal BrdU IR (count) 1.3 ± 0.4 1.1 ± 0.4 1.1 ± 0.5 5.1 ± 2.2 * 
Medial αSMA IR (%) 32.7 ± 7.5 32.9 ± 7.5 31.4 ± 8.1 32.6 ± 7.7 
Medial Mac2 IR (%) 6.8 ± 2.0 6.4 ± 2.4 9.7 ± 3.2 14.3 ± 6.4 
Medial BrdU IR (count) 0.5 ± 0.3 0.5 ± 0.3 0.8 ± 0.3 0.7 ± 0.4 
     
 
Table 4-2 Impact of endothelin receptor blockade on the size and composition of femoral artery wire injury-
induced neointimal lesions.  
Neointima formation was induced by femoral artery wire-injury in mice treated with vehicle or antagonists to ETA 
(atrasentan; 10mg/kg/day), ETB (A192621; 30mg/kg/day) or ETA+ETB (atrasentan+A192621) and lesions allowed 
to develop for 28 days before examination by optical projection tomography (a), histology (b) and 
immunohistochemistry (c). ETA blockade was associated with reduced lesion size and volume, and preserved 
lumenal cross-section without compositional changes. ETB blockade increased lesion size and volume, and the 
number of proliferating nuclei in lesions. The combination of ETA+ETB blockade did not alter lesion size or 
volume, but reduce lesion collagen content. Data are mean ± SEM. αSMA, α-smooth muscle actin; BrdU, 5-





Measurement Vehicle Atrasentan Atrasentan +A192621 A192621 
  
(a) 3D Morphometry (OPT)     
n 5 5 7 6 
Intimal volume (x107μm3) 4.0 ± 0.9 1.7 ± 0.1 1.9 ± 0.3  3.9 ± 0.8 
Luminal volume (x107μm3) 4.9 ± 1.0 8.0 ± 1.5 8.0 ± 1.3 5.7 ± 0.9 
Volumetric stenotic ratio 0.45 ± 0.09 0.20 ± 0.04 * 0.20 ± 0.02 * 0.41 ± 0.08 
  
(b) 2D Morphometry (Histology)     
n 8 7 8 6 
Luminal area (x103μm2) 7.6 ± 3.6 12.9 ± 4.4 18.6 ± 4.2 21.0 ± 7.3 
Intimal area (x103μm2) 25.6 ± 6.3 30.5 ± 4.2 31.0 ± 3.9 34.8 ± 7.5 
Medial area (x103μm2) 10.8 ± 1.3 14.0 ± 1.1 13.3 ± 1.0 11.9 ±1.1 
Intima/Media ratio 2.4 ± 0.4 2.5 ± 0.1 2.4 ± 0.3 2.9 ± 0.6 
Stenotic ratio 0.8 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 
Area inside EEL (x103μm2) 44.1 ± 10.7 62.3 ± 7.4 62.8 ± 8.1 67.7 ± 12.0 
  
(c) Composition & Proliferation (Immunohistochemistry)   
n 8 7 8 6 
Intimal SMA IR (%) 20.2 ± 7.0 16.4 ± 3.5 13.4 ± 2.3 26.2 ± 5.0 
Intima Mac2 IR (%) 1.7 ± 0.3 2.0 ± 0.3 1.7 ± 0.5 1.4 ± 0.3 
Intimal BrdU IR (count) 0.4 ± 0.2 0.4 ± 0.2 0.5 ± 0.2 0.3 ± 0.2 
MedialαSMA IR (%) 19.0 ± 3.7 13.2 ± 1.6 10.4 ± 1.1 21.2 ± 4.0 
Medial Mac2 IR (%) 2.8 ± 0.5 3.6 ± 1.0 2.2 ± 0.2 2.9 ± 1.1 
Medial BrdU IR (count) 0.3 ± 0.2 0.1 ± 0.1 0.3 ± 0.2 0.2 ± 0.2 
     
 
Table 4-3 Impact of endothelin receptor blockade on the size and composition of complete femoral artery 
ligation-induced neointimal lesions.  
Neointima formation was induced by femoral artery complete ligation-injury in mice treated with vehicle or 
antagonists to ETA (atrasentan; 10mg/kg/day), ETB (A192621; 30mg/kg/day) or ETA+ETB (atrasentan+A192621) 
and lesions allowed to develop for 28 days before examination by optical projection tomography (a), histology (b) 
and immunohistochemistry (c). Both ETA and ETA+ETB blockade reduced complete ligation-induced lesion 
volume fraction (a). This measure was not altered by ETB blockade. No treatment had any significant effect on 
histological measures of lesion size (b), or on lesion composition (c). Data are mean ± SEM. αSMA, α-smooth 
muscle actin; BrdU, 5-bromo-2-deoxyuridine; EC, endothelial cell. *, p<0.05 by two-way ANOVA with Dunnet’s 




The experiments in this chapter were designed to determine the effects of systemic 
blockade of ET receptors on neointimal lesion formation following injury to the 
mouse femoral artery. Following intra-luminal, wire-induced injury, treatment with a 
selective ETB receptor antagonist was associated with an increase in lesion size, an 
observation which is in support of that of Murakoshi et al (2004) and suggests that 
the ETB acts primarily to limit neointimal growth. ETA blockade in contrast, 
reduced the size of lesions resulting from both femoral artery wire- and ligation-
injury, further demonstrating the well-established role of ETA in exacerbating 
processes of neointima formation. Further, ETB blockade in ETA antagonist treated 
mice abolished the beneficial effects of the latter, clearly illustrating the ability of 
ETB activation to moderate the detrimental effects associated with stimulation of the 
ETA receptor by endogenous ETs. These studies also provide further validation to 
the use of the OPT imaging technique for measurement of vascular lesions.  
 
4.4.1 ETB blockade increases wire-injury induced lesion size 
Increases in several measures of wire injury-induced lesion size were apparent in 
mice treated with a selective ETB antagonist including maximal neointimal cross-
sectional area as measured by histology and the fraction of the total vessel volume 
occupied by lesion, as determined by OPT. Importantly, these increases were present 
at 28 days post-injury, a time point known to reflect the maximum stable lesion size 
in this model (Sata et al., 2000). As such, these data can be considered to represent 
an increase in stable lesion size rather than acceleration of lesion growth. Further, 
lesions from ETB antagonist treated mice exhibit a substantial increase in the number 
of actively proliferating cells (BrdU immuno-reactive nuclei following in vivo BrdU 
pulse). This increase in proliferation was of similar magnitude to that of lesion size 
(2.1-fold, 1.8-fold, respectively) and as such, may simply reflect the larger size of 
lesions in this group. Alternatively, an increase in cell proliferation may indicate that 
lesions continue to grow actively and therefore, it is the possible that in ETB 
antagonist treated animals, lesion size would continue to increase beyond 28 days. 
Whilst this proliferation is presumably of the smooth muscle-like cells that dominate 
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lesion content at this time point, without co-localisation studies, it cannot be ruled 
out that other cell types (such as macrophages) exhibit altered proliferation in situ.  
 
Contrasting with the substantial increase in neointimal lesion dimensions observed in 
ETB antagonist treated animals, luminal dimensions remained similar to those in 
lesions from vehicle treated mice. This probably reflects the well-established 
phenomenon of compensatory outward ‘Glagovian’ remodelling of the vessel wall to 
accommodate increased lesion burden without restricting blood flow to distal sites, 
rather than specific modulation by ETB blockade (Glagov et al., 1987). In 
agreement, the total area inside the external elastic lamina was increased, indicating 
that maintained luminal cross-section does not occur at the expense of atrophy of 
other layers of the arterial wall.  
 
Whilst the mechanism by which ETB receptor blockade might increase lesion size in 
the femoral artery wire-injury model was not explicitly investigated, (immuno)-
histochemical studies of lesion composition may offer some indications. The fraction 
of lesion occupied by smooth muscle-like cells and collagen, two major lesion 
constituents at this time point (Sata et al., 2000), was not altered by ETB blockade. 
This suggests that ETB blockade does not alter lesion size by specifically regulating 
collagen synthesis or metabolism and may also indicate that an action on smooth 
muscle cells can be discounted. The latter, however, is less certain because any 
increase in smooth muscle cell content is likely to be associated with increased 
extracellular matrix deposition thus blunting any effect on fractional composition. 
ETB blockade was also associated with a non-significant trend in the fraction of 
neointima (but not media) that exhibited Mac2 immunoreactivity. This may indicate 
that an enhanced inflammatory response, or defects to its resolution, underlies the 
increase in lesion size. This is certainly plausible given the central role of the 
macrophage in lesion formation, but further studies are required to confirm this 
observation. Indeed, the studies reported here investigate the 28 day time point so as 
to best address the primary end point, lesion size. However, by definition, this time 
of stable lesion size poorly represents the processes of lesion development including 
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cell proliferation and macrophage content. As such, detailed studies of these 
processes would require analysis of lesions at earlier time points of lesion 
development (7 and 14 days). 
 
Proposing the mechanism by which ETB can moderate neointima formation is 
difficult because numerous cell types from which it is composed, including smooth 
muscle cells, macrophages and endothelial cells, have been shown to express ETB, 
both in vitro and, in neointimal lesions, in vivo (see section 1.3.2). A primary 
hypothesis of this thesis is that such an effect is a product of stimulation of the EC 
ETB receptor by endogenous ET-1. Certainly, the vasodilator response to EC ETB 
activation is well known, and cultured endothelial cells from a variety of species 
(Hirata et al., 1993; Tsukahara et al., 1994), including mouse (Azfer et al., 
Unpublished observations), release nitric oxide and up-regulate expression of eNOS 
in response to ETB activation. The potent inhibitory effect of endogenous NO on 
smooth muscle proliferation and macrophage activation is also clear (Moroi et al., 
1998; Le Tourneau et al., 1999; Zhang et al., 2006). ET-1, abundantly produced 
within vascular lesions, may, therefore, act upon the EC ETB pathway to stimulate 
NO release and moderate development of the underlying lesion. Thus, blockade of 
this protective system might mediate the increase in lesion size observed in 
A192621-treated animals following femoral artery wire-injury. This explanation is 
certainly consistent with the conclusions of Murakoshi et al (2004) who reported 
decreased levels of NO oxidation products in the carotid artery ligation-induced 
lesions of ETB-deficient mice. Further, reduced NO production might explain both 
the trend towards increased intimal macrophage content and the increase in cell 
proliferation observed in wire-injured femoral arteries from ETB antagonist-treated 
mice.  
 
Any explanation of the effect of ETB blockade on lesion formation in the femoral 
artery wire-injury model depending on endothelial cells might be considered 
implausible because wire-insertion effectively removes the endothelium (Sata et al., 
2000). As such, there may be too few ECs remaining on which ET-1 can act to alter 
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lesion development. Some effect on those EC not directly overlying the site of lesion 
formation may still be plausible such as those at the fringes of the denuded length or 
those lining the adventitial vaso vasorum, which is abundant in injured vessels. A 
more compelling argument, however, is that the luminal endothelium can recover 
sufficiently quickly that modulation of its function can impact on underlying lesion 
formation. Previous work with this model in this laboratory indicates that complete 
luminal coverage, by a monolayer of cells with endothelial-like morphology and 
immuno-reactivity for von Willebrand factor, returns between 7 and 14 days 
following injury (MacDonald et al., Unpublished data). As discussed (chapter 3), 
assessment of the function of this neo-endothelium has been prevented by the severe 
medial damage caused by wire insertion, although data from similar models suggests 
that substantial endothelium-dependent responses may recover with a similar time 
course (Miller et al., 2003; Liao et al., 2007). Importantly, this time point precedes 
the majority of neointimal smooth muscle accumulation and lesion growth (Sata et 
al., 2000). Therefore, in murine models similar to femoral artery wire-injury, 
recovery of the function of the luminal endothelium may be rapid enough to allow 
for endothelium-mediated modulation of lesion development.  
 
The ability of ETB to regulate lesion size in the femoral artery wire-injury model, 
despite endothelial denudation, still raises the intriguing possibility of an 
endothelium-independent mechanism of action. The literature would suggest that the 
primary actions of ETB activation on non-endothelial cell types (vascular smooth 
muscle cells, fibroblasts, macrophages) are those that might enhance lesion 
formation. For example, in culture, ETB stimulates proliferation of various smooth 
muscle and fibroblast cell lines, chemotaxis of macrophages and their release of pro-
inflammatory and mitogenic mediators (see section 1.3.1). One possibility is that 
ETB blockade can increase lesion size by reducing smooth muscle cell apoptosis. 
Such a pro-apoptotic effect of ETB has been observed in cultured VSMCs exposed 
to cyclic stretch (Cattaruzza et al., 2000), and arterial rings subject to brief over-
pressurisation (Lauth et al., 2000). It might also be considered that the phenotype of 
cells participating in neointima formation does not reflect that seen in cell culture or 
other in vivo models. Intimal smooth muscle cells in femoral artery wire-induced 
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lesions, for example, have been shown to express eNOS and iNOS (Wang et al., 
2005a). It is plausible, therefore, that, in VSMC as in EC, ETB could stimulate 
release of NO, a powerful inhibitor of neointimal proliferation (Moroi et al., 1998; 
Le Tourneau et al., 1999). 
 
4.4.2  ETB blockade does not increase lesion size by a systemic action? 
An indirect mechanism of action, in which ETB receptors reduce lesion size by 
regulation of systemic cardiovascular parameters, is also plausible. A modest 
elevation in blood pressure was observed in ETB antagonist treated mice and this is 
consistent with previous studies showing chronic ETB blockade (Fryer et al., 2006) 
or ETB knockout is associated with hypertension (Gariepy et al., 2000). Whilst this 
provides useful confirmation of the effective administration of A192621, 
hypertension is associated with worsening of many vascular remodelling processes 
including medial hypertrophy, atherosclerosis and possibly restenosis following 
percutaneous coronary interventions (Gibbons & Dzau, 1994; Klugherz et al., 2000; 
Singh et al., 2005; Feihl et al., 2008). The increase in wire injury-induced lesion size 
observed in ETB antagonist treated mice might, therefore, simply be a response to 
the hypertensive action of this treatment. The strongest evidence against this 
supposition is that even in the presence of concurrent ETA blockade, ETB antagonist 
treatment was still associated with a relative increase in lesion size (as compared to 
ETA blockade alone) despite an absence of further blood pressure alteration. 
Moreover, data from  α1D-adrenoceptor knockout mice also indicate that, in the 
femoral artery wire-injury model, alterations in blood pressure of the order seen here 
(~10mmHg) do not inevitably result in reciprocally-altered lesion development 
(Hosoda et al., 2007). 
 
A second systemic role for ETB, blockade of which might explain an increase in 
lesion size in mice treated with A192621, is the clearance of circulating ETs. A 
wealth of studies indicate that blockade or deletion of ETB increases plasma ET-1 
concentration due to loss of this important receptor-mediated clearance pathway 
(Fukuroda et al., 1994a; Giller et al., 1997).  Given the obviously detrimental effect 
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of ET-1 on lesion formation, it may be that ETB blockade enhances lesion formation 
by increasing the activation of the ETA receptor by endogenous ET-1, as a direct 
consequence of this impaired clearance. The ability of ETB blockade to reduce 
lesion size even in the presence of concurrent ETA blockade, again suggests that this 
systemic action of ETB blockade does not underlie the observation. Indeed, the dose 
of atrasentan administered is reported sufficient to abolish the pressor response to 
pharmacological amounts of ET agonists: doses of far greater magnitude than those 
that might be predicted to result from impaired clearance of endogenous ETs 
(Opgenorth et al., 1996).  
 
4.4.3 ETB does not regulate femoral artery ligation-induced neointima formation 
The striking effects of ETB blockade on neointima formation in the femoral artery 
wire-injury model must be tempered by the observations that, following femoral 
artery ligation-injury, selective ETB blockade has little effect on any parameter of 
the neointima. Such a finding was surprising given that A192621-treatment and 
ETB-deletion substantially increase lesion size following ligation of the carotid 
artery (Murakoshi et al., 2002). This may reflect inherent differences between carotid 
and femoral arteries in either the ET system or the mechanism of neointima 
formation. ET-1-mediated vasoconstriction in the carotid artery is certainly less 
dramatic than that observed in the femoral artery (see chapters 3 and 5; Widmer et 
al., 2006; Bhattacharya et al., 2008). This discrepancy may also reflect the stage of 
lesion development analysed. Murakoshi et al (2002) examined ligated carotid 
arteries for lesions 14 days after surgery, a time of active growth and intermediate 
lesion size (Godin et al., 2000). In contrast, here arteries were examined 28 days 
post-ligation, a time at which lesion size appears to have peaked (see chapter 5). 
Thus, following both femoral and carotid arterial ligation, lesion growth may be 
accelerated - the endpoint investigated by Murakoshi et al (2002) rather than 
maximally increased - the endpoint investigated here. 
  
The divergent effects of ETB antagonism on wire- and ligation-induced injuries are 
also difficult to explain. As both injuries were performed in contra-lateral arteries of 
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the same animals, any doubts regarding effective drug administration (or ETA/ETB 
selectivity) can be dismissed. The numerous differences between the two models 
complicate interpolation of a differential mechanism of action, although several 
possibilities exist, including the absence of physical damage to the endothelium. It is 
plausible that, following vascular injury, ET stimulates EC to produce oxidative 
species (Duerrschmidt et al., 2000; Dong et al., 2005) or exert other potentially 
lesion enhancing actions. Removal of these influences by wire-injury might, 
therefore, reveal a beneficial effect of ETB on other cell types. Moreover, although 
the endothelium is intact throughout the period of lesion development in the ligation 
model, prior studies (Chapter 3) indicate it to be moderately dysfunctional at 28 
days. Further, more severe defects may be present at earlier time points at which 
lesions are actively developing. As such, despite physical integrity, it may be that the 
endothelial cell ETB/ NO production pathway is functionally impaired in this model. 
It is also pertinent that in conditions of endothelial dysfunction, as induced by 
tetrahydrobiopterin deficiency, stimulation of NOS activity by ETB results in 
generation of superoxide (Loomis et al., 2005), a smooth muscle mitogen and 
scavenger of NO that may contribute to lesion growth. 
 
The origin of the smooth muscle cells in wire- and ligation-induced injuries may also 
warrant consideration as a mechanism of differential sensitivity to ETB blockade. 
Studies of femoral artery wire-injury following bone-marrow transplant indicate that 
between 20% and 80% of αSMA immunoreactive cells in the neointima are derived 
from circulating progenitors. In contrast, in both carotid artery ligation and femoral 
artery cuff placement models circulation-derived smooth muscle-like cells do not 
contribute to lesion formation (Tanaka et al., 2003). In principle, at least, ETB 
blockade may either alter recruitment of these cells, or elicit unpredictable responses 
in them, explaining the divergent responses to this treatment in these two models. 
Whilst this is purely speculative, reductions in vascular NO, perhaps as induced by 
ETB blockade, are associated with increased circulating and adventitial levels of 
putative smooth muscle cell progenitors in eNOS-/- mice (Zhang et al., 2006). A final 
possibility for discussion is that ETB attenuates the response to wire-induced lesion 
formation purely by inhibition of stretch-induced VMSC apoptosis. If true, it follows 
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that the ligation model would be insensitive to ETB blockade because no comparable 
apoptosis-inducing stimulus is present here.  
 
4.4.4 ETA blockade inhibits wire- and ligation-induced lesion formation 
In both femoral artery wire-injury and ligation models, selective ETA blockade was 
seen to reduce lesion formation suggesting the role of ETA in the response to 
vascular injury is less dependent on the etiology of the initiating insult. This finding 
is supported by much literature and the principle that ETA activation enhances the 
processes of neointimal hyperplasia (see Table 1-3, page 48). Given the muscular 
nature of the mature neointimal lesion, a compelling explanation for this effect is the 
well described (co)-mitogenic action of ETA receptor activation on vascular smooth 
muscle cells. Immunohistochemical analyses of lesion composition do not directly 
support this as neither  αSMA immunoreactivity nor proliferating (BrdU 
incorporating) cell count was altered by atrasentan treatment in either model. As 
described above for ETB blockade, however, because VSMCs may drive deposition 
of other major lesion constituents (particularly extracellular matrix components), an 
inhibitory action on smooth muscle cells may not necessarily translate into a 
reduction into fractional VSMC content. In wire-injured vessels from ETA 
antagonist treated mice, a trend towards reduced fractional collagen content was 
seen. This may reflect reduced collagen deposition or increased activity of 
collagenolytic MMPs - both processes that have been observed to result from ETA 
activation in vitro (Shi-Wen et al., 2004; Gallelli et al., 2005). Although ETA is also 
implicated in fibroblast proliferation any inhibition of this process might be expected 
to alter proliferating cell count and immunoreactivity for αSMA, an antigen also 
expressed by myofibroblasts.     
 
4.4.5 ETA and ETB blockade have additive effects on lesion size  
The combination of ETA and ETB antagonist treatment did not alter any parameter 
of wire injury-induced lesion size at the time point investigated. This is in contrast to 
the effect of either treatment when administered alone. Differing levels of ETA 
blockade between ETA and ETA+ETB treatment arms cannot explain this 
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observation, as identical doses of atrasentan were administered in both groups. Given 
the magnitude of individual responses to ETA and ETB blockade, it is likely that this 
absence of effect of their combination reflects a simple composite of two 
functionally antagonistic responses i.e. ETA blockade-mediated inhibition and ETB 
blockade-mediated enhancement of lesion size. In support of this notion, in the 
ligation-injury model, combined ETA+ETB blockade was seen to reduce lesion 
volume to a similar extent as ETA blockade alone. This, therefore, also describes a 
composite of the response to selective ETA and ETB blockade as ETB blockade is 
without effect on lesion size in this model. As such, the alternative explanation of a 
direct interaction whereby ETB receptor activation is required for ETA blockade to 
reduce wire-injury (but not ligation injury-induced) lesions is less likely. Such an 
interaction is plausible, however, as complex interactions between ET receptor 
subtypes have been proposed such as formation of ETA:ETB heterodimers which 
may be important in determining receptor pharmacology (Gregan et al., 2004). 
Regardless, these conflicting responses between ligation- and wire-induced injuries 
also mirror the inconsistent responses to ETA/B blockade on neointimal lesion 
development reported in the literature (McKenna et al., 1998; Huckle et al., 2001). 
As both injury models have been performed in the same animals here, this suggests 
that such variability reflects a genuine dependence of the response to this treatment 
on the type of injury inflicted, rather than differences in experimental execution or 
design, such as the particular ET antagonist(s) used. Moreover, this comparison of 
ETA and ETA+ETB blockade is of relevance to man as both treatment modalities 
are in clinical use and being investigated for a variety of other cardiovascular 
indications (see chapter 6 for discussion). These data may, therefore, indicate that 
selective ETA antagonists have additional benefits to vascular health, which are lost 
in the presence of concurrent ETB blockade. 
 
Analysis of the composition of lesions from mice treated with both ETA and ETB 
antagonist are also broadly in line with the suggestion that lesion phenotype in this 
treatment group is a composite of that seen when either antagonist is administered 
alone. In ligation injury induced lesions, no compositional abnormalities were 
observed in any treatment group. In wire injury-induced lesions, as for selective ETA 
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and ETB blockade, lesion αSMA immunoreactivity was unaltered by ETA+ETB 
blockade, and as for selective ETB blockade, a trend towards increased Mac2 
immunoreactivity was apparent. Lesion collagen content, however, was significantly 
reduced by combined ETA+ETB blockade but neither treatment alone (a trend 
towards reduction was present with selective ETA blockade). This may be explained 
by the published literature that consistently indicates that whilst ET-1-stimulated 
fibroblast activation can be inhibited by the combination of ETA and ETB blockade, 
it is not sensitive to either treatment alone (Guarda et al., 1993; Cambrey et al., 
1994; Xu et al., 1998; Shi-Wen et al., 2001; Clozel & Salloukh, 2005).  
 
4.4.6 OPT for vascular imaging 
In addition to addressing hypotheses regarding the role of ET receptor subtypes in 
the response to acute vascular injury, these experiments further highlight the 
potential of the OPT imaging technique for quantification of vascular lesions.  In 
wire-injured femoral arteries, measures of neointima size produced from OPT scans 
faithfully represented the effect of treatment indicated by traditional histological 
means i.e. both histological and OPT-derived measures of the neointima were 
increased by ETB blockade and reduced by ETA blockade. Treatment-induced 
changes in luminal volumes appeared to be less representative of those to luminal 
cross-sectional area as determined by histology, however. This probably reflects an 
unavoidable consequence of the methodology of quantification: a constant length of 
vessel must be considered across all arteries studied, thus, in most cases, measures of 
luminal volume describe large regions of vessel which are not afflicted by neointima 
formation. As such, any impact of the response to vascular injury on luminal volume 
is likely to be strongly diluted, whereas, by contrast, the finite nature of the 
neointimal layer makes it relatively insensitive to such concerns.   
 
OPT measurements of neointimal volume in ligation-injured vessel highlight the 
potential importance of considering changes to vessel morphology in three 
dimensions. In this model, treatment regimens that included ETA blockade were 
seen to reduce neointimal volume without any apparent effect on the cross-sectional 
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area of neointima at its greatest point, the quantity conventionally recorded during 
histological examination. Analysis of the cross-sectional profile of lesion formation 
provided by OPT revealed that rather than a genuine discrepancy between 
measurement techniques, the effect of treatment was to reduce the length of vessel 
afflicted by neointima. This effect would not have been observed had vessels been 
analysed only by traditional means. Thus, the application of the OPT technique to the 
studies of vascular injury presented in this chapter has further highlighted its value 
for rapid, non-destructive imaging of neointimal lesion formation, and has provided 
additional insight into the effects of ET antagonists on lesion formation which might 
otherwise have been missed.  
 
4.4.7 Conclusions 
The data presented in this chapter provide critical proof of concept for the role of the 
ETB receptor in the response to vascular injury, strongly supporting the hypothesis 
that the ETB receptor represents an endogenous mechanism for limiting the 
otherwise exuberant proliferative response to acute vascular injury induced by ETs. 
The detrimental response to ETB blockade following wire-injury is unlikely to be a 
result of systemic actions such as elevated blood pressure and circulating ET-1 
concentration, but the mechanism is otherwise not yet clear. These straightforward 
conclusions are also complicated by the inability of ETB blockade to alter ligation-
induced lesion development in the femoral artery. Whether this indicates the 
unimportance of ETB in this model, or a dichotomous role for this receptor, 
mediating both lesion promoting and diminishing effects in competition, also 
remains to be addressed. Data from both models support the well-established view 
that blockade of ETA might be useful in the clinical prevention of vascular 
remodelling processes. Further, given the possibility that concurrent ETB blockade 
might abrogate this effect, this work supports the argument in favor of selective ETA 
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The previous chapter described the ability of pharmacological blockade of the 
endothelin-B receptor to exacerbate neointimal hyperplasia following acute vascular 
injury. This effect serves to confirm the observations of Murakoshi et al (2002) and 
highlights a role of the ETB receptor as a mechanism to moderate the detrimental 
actions of endogenous ET-1 on the ETA receptor following vascular injury. Any 
understanding of the mechanism of this action, however, is complicated by the 
expression of ETB by many of the cell types important to neointimal lesion 
development, including vascular smooth muscle cells (VSMC), leucocytes, 
fibroblasts and endothelial cells. Neither pharmacological nor classical gene 
knockout approaches are able to distinguish between the diverse actions mediated by 
ETB on these different cell types. To address this issue, a cell-specific ETB knockout 
system was previously developed in our laboratory using Cre-lox technology 
(Bagnall et al., 2006).  
 
ETB receptors expressed in the endothelium may be important regulators of vascular 
function and the response to vascular injury. Certainly, in most species, bolus 
administration of ET agonists stimulates transient hypotension before prolonged 
vasoconstriction (de Nucci et al., 1988; Yanagisawa et al., 1988; Whittle et al., 1989; 
Gardiner et al., 1990; Clozel et al., 1992; Rogerson et al., 1993; Haynes et al., 1995). 
Similarly, ETB activation stimulates endothelium-dependent vasodilatation in 
isolated arteries (Takayanagi et al., 1991; Clozel et al., 1993), and nitric oxide (NO) 
production in cultured endothelial cells (Hirata et al., 1993; Tsukahara et al., 1994). 
The mouse is unusual in that the response to an intravenous bolus of ET-1 comprises 
only vasoconstriction without prior vasodilatation (Giller et al., 1997). In isolated 
mouse aortas, however, ETB-stimulated vasodilatation has been reported in several 
(Mizuguchi et al., 1997; Bagnall et al., 2006) but not all studies (Zhou et al., 2004). 
Further, aortas from both transgenically-rescued, non-cell-specific ETB knockout 
mice (Quaschning et al., 2005) and EC-specific ETB-deficient mice, exhibit 
modestly impaired endothelium-dependent vasodilatation, even to non-ET agonists 
(Bagnall et al., 2006). These models also feature elevated plasma ET-1 
concentrations, highlighting the importance of ETB in endothelial cells in the 
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clearance of circulating ET-1 (Fukuroda et al., 1994a; Bagnall et al., 2006). As NO 
release is known to suppress (Moroi et al., 1998), and ET-1 release to enhance, 
neointima formation (Douglas et al., 1994), ETB expressed by endothelial cells may 
be important in limiting lesion growth following vascular injury. Specifically, 
reduced NO production and increased ET-1 levels may explain why in the previous 
chapter, pharmacological ETB blockade increased the size of femoral artery wire 
injury-induced neointimal lesions. Indeed, Murakoshi et al (2002) report that the 
increase in carotid artery ligation-induced neointima formation observed in ETB-
deficient mice is associated with reduced levels of NO oxidation products.  
 
This chapter addresses the hypothesis that disruption of the ETB receptor gene 
selectively in endothelial cells is sufficient to increase neointimal lesion size 
following acute vascular injury as a consequence of impaired endothelium-dependent 
vasomotor function. Therefore, the specific aims of this work were to determine: 
a) whether EC ETB deficiency increases neointimal lesion size following 
femoral artery wire- and ligation-injury 
b) the effects of EC ETB deficiency on femoral artery vasomotor function in 





5.2.1 Generation of EC-specific ETB knockout mice 
The studies presented in this chapter were performed using EC-specific ETB 
receptor knockout mice, generated by the cross of homozygous floxed ETB mice 
(FF/--) with transgenic Tie2-Cre mice (Kisanuki et al., 2001). The vast majority of 
the resulting progeny were of the genotypes FF/tie2 (EC-specific ETB knockout) and 
FF/-- (floxed, Cre-negative). In line with previous studies with these animals and 
other work utilising the Cre-loxP recombination system (Liao et al., 2001; Ge et al., 
2006), floxed Cre-negative littermates (FF/--) were used as experimental controls 
(Bagnall et al., 2006; Kelland et al., Unpublished data). 
 
5.2.2 Genotyping 
PCR of genomic DNA isolated from ear clip tissue samples and gel electrophoresis 
of the resulting products was used to identify the genotype of experimental animals. 
The presence of the Tie2-Cre transgene was indicated by a single ~550bp amplicon 
when PCR was performed using primer oligonucleotides 5'-CGC ATA ACC AGT 
GAA ACA GCA TTG C-3' and 5'-CCC TGT GCT CAG ACA GAA ATG AGA-3' 
(Kisanuki et al., 2001). The genotype of the ETB allele was determined to confirm 
the presence (FF/tie2) or absence (FF/--) of recombination of the floxed loci. 
Products of PCR using the primers 5’-TCA GTT GTA ATG AGA CAC AGA C-3’ 
and 5’-AGC CAT AAA GTC ACA GCC ATT C-3’ included a ~1kb amplicon ‘F’ 
representing the floxed, non-recombined ETB allele, and a ~200bp amplicon ‘0’ 
representing the recombined, non-functional allele (Bagnall et al., 2006). As DNA 
extracted from ear clips contained both endothelial and non-endothelial cell types, in 
FF/tie2 animals, both F and 0 products were expected. 
 
5.2.3 Vascular injury studies 
5.2.3.1 Femoral artery injury 
Femoral artery injury was performed as described (section 2.3.1) in 2-4 month old 
male FF/tie2 mice and FF/-- littermates. For study of lesions at 28 day after injury, 
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the time point investigated with ET antagonists (chapter 4), wire-injury was 
performed on the left femoral artery. To the right femoral artery of the same mice, 
partial ligation (ligation of the femoral artery immediately distal to the 
femoropopliteal bifurcation) was conducted. As discussed (chapter 3) neointimal 
lesions resulting from this treatment proved to be extremely variable and focal. Thus, 
data from this study arm were not analysed. For investigation into the effects of 
complete femoral artery ligation (ligation of the femoral and popliteal arteries across 
their junction) in EC ETB knockout mice at 28 days, ligation was performed on the 
left femoral artery only of a further group of mice, in which the right femoral artery 
remained uninjured to allow the study of baseline morphology and composition. 
 
To address the possibility that EC ETB knockout might alter the rate of lesion 
development, and to better analyse macrophage content and cell proliferation, 
additional studies of wire/ligation-injury at 14 days after surgery, a time-point of 
active lesion growth, were carried out. Here, wire-injury was inflicted to the left 
femoral artery and complete ligation to the right femoral artery of the same mice. 
 
Following the appropriate surgical recovery time (14 or 28 days), mice were killed 
by transcardiac perfusion fixation under terminal anesthesia. In 14 day wire/ligation 
injury mice and 28 day complete ligation injury mice, 100mg.kg-1 5-bromo-2-
deoxyuridine was administered by the intra-peritoneal route 2 hours prior to the 
induction of terminal anesthesia. Vessels were isolated, formalin fixed and their 
identity blinded for further analysis. 
 
5.2.3.2 Optical projection tomography (OPT) 
OPT scans and reconstructions of injured femoral arteries were produced according 
to the methods set out in section 2.5. Briefly, optically cleared tissues were scanned 
in a Bioptonics 3001 tomograph under metal-halide lamp illumination (excitation 
filter: 425/40nM; emission filter: LP475nM). 1.048Mpixel resolution projection 
images were captured at 0.9° rotation increments and reconstructed using NRecon 
software. From these, intima/media borders were manually traced and the area within 
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grey-level thresholded to delineate neointimal from luminal volume. OPT scans were 
not acquired from either uninjured or 28 day wire-injured femoral arteries. 
 
5.2.3.3 Histological evaluation 
Femoral arteries from all studies were subject to morphometric assessment. 
Following infiltration and embedding in paraffin wax, 3μm thick sections were cut 
perpendicular to the axial plane of each vessel. Sets of 16 (wire-injury) or 10 
(ligation-injury) serial sections were retained at intervals of 100µm (wire-injury) or 
50µm (ligation-injury) along the vessel until the lesion-afflicted portion had been 
traversed. From each set, 1 slide was stained according to the United States 
trichrome method (see section 2.4.2) and the largest lesions from each vessel 
identified. Photomicrographs were recorded under 10X objective magnification, and 
from these, measurements of neointimal area, luminal area, medial area, 
intima/media ratio and stenotic ratio were made. In uninjured vessels, media/lumen 
ratio was also calculated to assess the presence of medial hypertrophy. 
 
5.2.3.4 Immunohistochemistry 
Lesion composition and cell proliferation in neointimal lesions were assessed by 
immunohistochemistry for cell-specific antigens (α-smooth muscle action; αSMA 
and Mac2) and incorporated BrdU. Staining was performed on sections adjacent to 
those from which measurement of morphometric parameters was made and carried 
out according to the labelled streptavidin-biotin method. Antibody complex binding 
was visualised by the peroxidase-catalysed development of 3,3-diaminobenzidine. 
For αSMA and Mac2, immunoreactivity was quantified by colour segmentation of 
photomicrographs according to definitions defined from positive control slides. 
Immunoreactive area was expressed as a percentage of total area of the neointima or 




5.2.4 Vascular function studies 
5.2.4.1 Tissue and myography preparation 
Experiments to determine vascular function were undertaken in vessels taken from 
FF/tie2 and FF/-- mice (young: 2-4 month and aged: 7-10 month) killed by CO2 
asphyxiation. Left and right femoral arteries were excised, cleaned of peri-adventitial 
tissue and divided into ~2mm rings. Aortic rings were taken from the first ~2mm 
immediately distal to the curvature of the aortic arch and similarly cleaned of fat and 
connective tissue. Vessels were mounted on parallel intra-luminal wires in a small-
vessel myograph (Danish Myo Technology 610M) and bathed in physiological salt 
solution (PSS). Resting tension of 8mN was gradually applied to both vessel types, 
after which isometric tension developed by each vascular ring was recorded.  
 
5.2.4.2 Common myography protocol elements 
In all vessels, contractility was initially assessed by repeated (3) exposure to iso-
osmolar, 125mM KCl PSS (KPSS) before recording cumulative concentration 
response curves (CRCs) to phenylephrine (PE, 10-9–10-4M, 2 min addition cycle) and 
acetylcholine (10-9–3x10-5M, 1 min addition cycle). Responses to acetylcholine 
(ACh) and all other dilator agents were measured in vessels pre-contracted with a 
concentration of phenylephrine producing 80% of maximal constriction. Following 
these common elements, two main protocols were used to investigate vascular 
function, each culminating in the measurement of a response to an ET agonist. The 
prolonged nature of ET-stimulated vasoconstriction (Yanagisawa et al., 1988; 
Widmer et al., 2006) and the resistance of S6c-treated vessels to further ETB agonist 
stimulation (Lodge et al., 1995) necessitated the use of a separate femoral artery ring 
for every combination of ET agonist and antagonist. In aortic rings, experiments 
were carried out according to protocol 2, except that responses to S6c were not 
assessed. 
 
5.2.4.3 Myography protocol 1 – ET-1/S6c studies 
After washing ACh from the tissue, a CRC to KPSS (containing 5-125mM KCl with 
reciprocal molar reduction of [NaCl]; 2 min addition cycle) was recorded. Each 
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concentration was achieved by replacement of the bathing solution with of an 
appropriate mixture of PSS and KPSS. After further washing, a CRC to sodium 
nitroprusside (SNP; 10-9–3x10-5M; 2 min addition cycle) was measured in PE pre-
contracted rings and thoroughly washed out. In all vessels this protocol was 
completed by recording either (i) responses to ET-1 (10-11-3x10-7M, 3 min addition 
cycle) after a 30 minute incubation with, where appropriate, BQ123 (10-6M), 
A192621 (10-7M) or vehicle or (ii) by assessing the effect of a single dose of 
sarafotoxin S6c (10-7M) in PE pre-contracted rings.  
 
5.2.4.4 Myography protocol 2 – L-NAME/S6c studies 
After washing ACh from the tissue, vessels were incubated with the NOS inhibitor 
L-NAME (2x10-4M) for 30 mins before washing, re-addition of L-NAME and 
measurement of an additional CRC to ACh. After further washing, L-NAME was re-
added to the tissue bath, and the response to a single dose of S6c (10-7M) recorded.  
 
5.2.5 Statistics and data analysis 
All data describing vascular morphology and composition in mouse femoral arteries, 
and the response to S6c were statistically-analysed by Student’s un-paired t-test 
between FF/tie2 and FF/-- group. Where multiple time points were investigated, only 
the effect of genotype was the basis of statistical testing. Because absolute 
contractility to KPSS did not differ between genotypes (FF/--, 5.94±0.35 mN.mm-1; 
FF/tie2, 5.60±0.54 mN.mm-1; p=0.59), all other vasoconstrictor responses were 
expressed and analysed as percentage of the maximum response to KPSS for that 
vessel, to reduce variability associated with trauma to the vessel during preparation. 
Myography CRCs were analysed by two-way ANOVA between FF/tie2 and FF/-- 
groups within each treatment. These data were additionally fitted to a logistic 
equation to derive summary data of Emax (maximum response) and logEC50 
(concentration resulting in 50% maximal response). These too were subsequently 
analysed by Student’s unpaired t-test between genotypes. Where the same response 
was measured in multiple rings from one animal, the mean value was treated as n=1. 





Deletion of the endothelial cell ETB receptor was confirmed by genomic PCR of ear 
clip DNA (Figure 5-1). FF/tie2 animals tested positively for Tie2-Cre and exhibited 
floxed and recombined ETB alleles, reflecting genotype of endothelial and non-
endothelial cells in the test tissue, respectively. In FF/-- animals, neither Tie2-Cre, 
nor recombination of the ETB allele was observed. 
 
5.3.2 Physiological parameters 
No abnormalities of litter size, development or body weight (either pre- or post-
operative) were noted in endothelial cell specific ETB knockout mice (FF/tie2), as 
compared to floxed, Cre-negative littermates (FF/--). Wet weight of isolated organs 
(heart, liver, kidneys) was also not altered by EC-ETB deficiency in either age group 
(Table 5-1, page 186).  
 
5.3.3 Un-injured femoral artery morphometry and composition 
Un-injured femoral arteries from FF/tie2 and FF/-- animals were of similar 
appearance when examined by routine histology (Figure 5-2). Measurements of 
medial area (p=0.156), luminal area (p=0.948) and media/lumen ratio (p=0.507) 
were not different between these genotypes (Table 5-2, page 187). Immunoreactivity 
for  α-smooth muscle actin in the medial layer was also similar between uninjured 
femoral arteries from FF/-- and FF/tie2 mice (Figure 5-2; p=0.121). 
 
5.3.4 Wire injury 
5.3.4.1 3D Morphometry 
OPT imaging of wire-injured femoral arteries, as previously described (chapters 3 
and 4), clearly indicated the presence of neointima formation at 14 days. Volumetric 
analysis, however, indicated no effect of genotype on either neointimal volume 





Figure 5-1 Electrophoresis-separated products of EC ETB-deficient mouse genotyping PCRs.  
Genotyping of EC ETB-deficient mice was routinely performed using PCR primers spanning exons 2 and 3 of the ETB 
allele (a) and those recognizing the Tie2-Cre transgenic construct (b). Products of the ETB allele PCR include the 
wild-type ETB allele amplicon ‘W’, the floxed ETB allele amplicon ‘F’ and recombined ETB allele ‘0’. The single 
product of the Tie2-Cre PCR indicates the presence of absence of the Tie2-Cre transgene. Lanes 1-2 therefore 
describe an EC ETB-deficient mouse (FF/tie2). In these, the Tie2-Cre product is present indicating animals are Tie2-
Cre positive. The ETB allele PCR demonstrates the presence of the ‘F’ floxed ETB amplicon, which is contributed by 
DNA from non-EC. The ‘0’ recombined ETB amplicon is contributed by DNA from EC and confirms the activity of Cre. 
Lanes 3-7 describe a floxed, Tie2-Cre negative control animal (FF/--). Here, no product is formed in the Tie2-Cre 
PCR, and the ETB allele PCR demonstrates only the presence of floxed, non-recombined ETB alleles. EC, endothelial 




Figure 5-2 Impact of EC ETB-deficiency on femoral artery structure and composition.  
Uninjured femoral arteries were perfusion fixed and isolated from FF/tie2 (EC ETB-deficient) and FF/-- (littermate 
control) mice and examined by United States trichrome staining (a) and αSMA immunohistochemistry (a,b). 
Immunoreactive area was expressed as a percentage of the total medial area. EC ETB-deficiency had little effect 
on the outward appearance of uninjured femoral arteries (a) and did not significantly alter the fractional area of 
αSMA immunoreactivity (b). n=5-8. Data are mean ± SEM. αSMA, α-smooth muscle actin; EC, endothelial cell. ns, 



































small, but significant increase in luminal volume (p=0.035) was observed in lesions 
from EC-ETB knockout animals at this time point (Table 5-3, page 188). OPT 
measurements were not made of 28 day wire-induced lesions in FF/tie2 or FF/-- 
mice. 
 
5.3.4.2  2D morphometry 
Femoral artery wire injury was associated with the development of large, cell- and 
extracellular matrix-rich neointimal lesions and loss of nuclei from the medial layer 
(Figure 5-3). Lesion size was, in general, considerably larger at 28 days after 
surgery, than at 14 days, in agreement with previous studies in this laboratory and the 
literature (Sata et al., 2000).  
 
In agreement with measures derived from OPT images, morphometric analysis, 
performed on the largest neointimal lesions from each wire-injured femoral artery, 
indicated no significant effect of genotype on luminal area (day 14: p=0.753; day 28: 
p=0.593; Figure 5-4), neointimal area (day 14: p=0.348; day 28: p=0.875; Figure 
5-4), medial area (day 14: p=0.755; day 28: p=0.788; Table 5-3, page 188), 
intima/media ratio (day 14: p=0.320; day 28: p=0.870) or stenotic ratio (day 14: 
p=0.553; day 28: p=0.348).  
 
5.3.4.3 Lesion composition & proliferation 
Mac2 immunoreactivity was seen in all layers of the vessel wall at both 14 and 28 
days post-injury with the greatest densities occurring in the adventitial layer (Figure 
5-3). Both medial and neointimal macrophage content (fractional Mac2 
immunoreactive area) appeared to be substantially greater at 14 days post-injury than 
28 days in both genotypes. At neither time point was a significant difference in Mac2 
immunoreactivity seen between injured arteries from FF/tie2 and FF/-- mice (Table 
5-3, page 188) in either the media (day 14: p=0.549; day 28: p=0.710) or neointima 








Figure 5-3 Impact of EC ETB-deficiency on femoral artery wire injury-induced lesion size and composition. 
Neointima formation was induced by femoral artery wire-injury in FF/tie2 (EC ETB-deficient) and FF/-- (littermate 
control) mice and lesions allowed to develop for 14 or 28 days before histological examination. Representative 
photomicrographs of lesions from both genotypes and time points, stained by United States Trichrome (a-d) and 
αSMA (e-h), Mac2 (i-m) and BrdU immunohistochemistry (n-o), are shown. Trichrome staining reveals large, 
elastin (purple) and collagen (blue)-rich lesions that appear smaller at 14 days than 28 days in both genotypes, 
but similar between genotypes (a-d). αSMA immunoreactivity is strong in the neointima and weaker in the media 
(e-h). At 14 but not 28 days, neointimal αSMA staining is stronger in FF/tie2 than FF/-- (e-f). At both time points, 
medial αSMA staining is stronger in FF/tie2 than FF/-- mice (e-h). Punctate Mac2 immunoreactivity present 
throughout the vascular wall at 14 days in both genotypes (i-j), but is barely present in either at 28 days (l-m). 
BrdU immunoreactive nuclei (yellow arrowheads) are present in the media and neointima of both genotypes at 
14 days (n-o). BrdU staining was not performed on 28 day lesions. αSMA, α-smooth muscle actin; BrdU, 5-bromo-




Figure 5-4 Impact of EC ETB-deficiency on neointimal and lumenal area in wire-injured femoral arteries. 
 Neointima formation was induced by femoral artery wire-injury in FF/tie2 (EC ETB-deficient) and FF/-- (littermate 
control) mice and lesions allowed to develop for 14 or 28 days before histological examination. Neointimal (a) 
and lumenal cross-sectional areas (b) were measured at the point of largest lesion size by morphometry. 
Neointimal area was not significantly different between genotypes at either time point (a). Similarly, EC ETB-
deficiency did not alter lumenal cross-sectional area at 14 or 28 days (b). Although not the basis of statistical 
testing, in both neointimal areas appeared larger (a), and lumenal areas smaller, at 14 than 28 days (b). n=7-10. 




















































Immunoreactivity for αSMA was also detectable throughout the vessel wall (Figure 
5-3). At both 14 and 28 days levels of this antigen in the media were low (as 
compared to un-injured vessels) and, in the adventitia, staining was variable and 
most commonly associated with the media-adventitia border and microvasculature. 
At both 14 (p=0.003) and 28 days (p=0.014), significantly greater αSMA 
immunoreactivity was detected in the media of wire-injured femoral arteries from 
FF/tie2 mice compared to those from FF/-- mice (Figure 5-5).  
 
αSMA immunoreactivity was also present in the neointima (Figure 5-3). Neointimal 
lesions from FF/tie2 mice contained fractionally more αSMA immunoreactivity than 
those from FF/-- mice at 14 (p=0.012), but not 28 days (p=0.295), post-surgery 
(Figure 5-5). As such, fractional neointimal αSMA immunoreactive area in FF/-- 
mice appeared to be considerably greater at 28 days than at 14 days post-surgery, 
whereas in FF/tie2 mice levels were similar at both time-points.  
 
Proliferating nuclei (BrdU immunoreactive) were present in all layers of vessel wall, 
14 days post-injury (Figure 5-3). The absolute number, however, was not 
significantly different between genotypes (Table 5-3, page 188) in either the media 
(p=0.754) or neointima (p=0.689).  
 
5.3.5 Ligation injury 
5.3.5.1 3D morphometry 
OPT images, again, revealed clear neointima formation in ligation-injured arteries at 
14 and 28 days post-injury which appeared of similar size between time points 
(Figure 5-6), and to those observed in previous studies (chapter 4). Quantification of 
reconstructed tomograms indicated no effect of EC ETB knockout on neointimal 
volume (day 14: p=0.172; day 28: p=0.349), luminal volume (day 14: p=0.299; day 
28: p=0.557) or volumetric stenotic ratio (day 14: p=0.473; day 28: p=0.969) at 








Figure 5-5 Impact of EC ETB-deficiency on neointimal and medial αSMA immunoreactivity in wire-injured 
femoral arteries.  
Neointima formation was induced by femoral artery wire-injury in FF/tie2 (EC ETB-deficient) and FF/-- (littermate 
control) mice and lesions allowed to develop for 14 or 28 days before examination by αSMA 
immunohistochemistry. Immunoreactive area was expressed as % of the total area of the appropriate layer of the 
vascular wall. At 14 but not 28 days, EC ETB-deficiency was associated with a significant increase in fractional 
αSMA immunoreactive area. At both 14 and 28 days, medial αSMA stained area was greater in lesions from 
FF/tie2 mice than in those from control FF/-- animals. n=6-10. Data are mean ± SEM. αSMA, α-smooth muscle 












































































Figure 5-6 Impact of EC ETB-deficiency on complete femoral artery ligation-induced neointimal lesion volume, 
as assessed by optical projection tomography.  
Neointima formation was induced by complete femoral artery ligation-injury in FF/tie2 (EC ETB-deficient) and 
FF/-- (littermate control) mice and lesions allowed to develop for 14 or 28 days before examination by optical 
projection tomography. Lesion formation and adventitial inflammation were clearly visible in raw projection 
images (a, arrowheads). Lesion volumes were recorded from reconstructed tomograms and expressed as a 
fraction of vessel occupied by lesion. Fractional lesion volume was not altered by EC ETB-deficiency. Lesion 
volumes also appeared similar between 14 and 28 days points in both genotypes. n=5-8. Data are mean ± SEM. 










































5.3.5.2 2D morphometry 
As previously discussed (chapters 3 and 4), complete ligation of the femoral artery 
across the femoropopliteal bifurcation resulted in the formation of localised 
neointimal lesions (Figure 5-7). These appeared somewhat smaller than those 
elicited by wire-injury. 
 
Neointimal cross-sectional area was similar at 14 (p=0.228) and 28 (p=0.429) days 
post-ligation in both genotypes (Figure 5-8). EC ETB genotype was also not 
associated with significant changes in luminal area (day 14: p=0.286; day 28: 
p=0.883; Figure 5-8), medial area (day 14: p=0.947; day 28: p=0.487), intima/media 
ratio (day 14: p=0.233; day 28: p=0.829) or stenotic ratio (day 14: p=0.209; day 28: 
p=0.651) at 14 or 28 days post-ligation (Table 5-4, page 189).  
 
5.3.5.3 Lesion composition & proliferation 
In ligation-injured vessels, distribution of Mac2 immunoreactivity was broadly 
similar to that seen in wire-injured vessels at 28 days with staining present in the 
adventitia, media and, more weakly, in the neointima (Figure 5-7). Lesions induced 
by this method had obvious differences in the pattern of αSMA immunoreactivity to 
those induced by wire-injury. Here, staining was intense throughout both the media 
and neointima and was present at similar levels between 14 and 28 days (Figure 
5-7). Adventitial αSMA immunoreactivity was variably present at 14 days but rarely 
at 28 days. BrdU immunoreactivity was common at 14 days, and in all layers of the 
vascular wall but again, appeared less frequent at 28 days. (Figure 5-7).  
 
Neointimal macrophage content (Mac2 immunoreactivity; day 14: p=0.306; day 28: 
p=0.527), smooth muscle-like cell content (αSMA immunoreactivity; day 14: 
p=0.524; day 28: p=0.255) and proliferating cell count (BrdU immunoreactivity; day 
14: p=0.703; day 28: p=0.833) were not significantly different between ligation-
induced lesions in FF/-- and FF/tie2 mice at 14 or 28 days post-injury (Table 5-4, 






Figure 5-7 Impact of EC ETB-deficiency on complete femoral artery ligation injury-induced lesion size and 
composition. 
Neointima formation was induced by complete femoral artery ligation-injury in FF/tie2 (EC ETB-deficient) and 
FF/-- (littermate control) mice and lesions allowed to develop for 14 or 28 days before histological examination. 
Representative photomicrographs of lesions from both genotypes and time points, stained by United States 
Trichrome (a-d) and αSMA (e-h), Mac2 (i-m) and BrdU immunohistochemistry (n-q), are shown. Trichrome 
staining reveals large, elastin (purple) and collagen (blue)-rich lesions that are similar in size in all genotypes and 
time points (a-d). αSMA immunoreactivity is strong in the neointima and media (e-h). In some vessels, αSMA 
staining is also associated with the adventitia at 14 but not 28 days. Mac2 immunoreactivity present throughout 
the vascular wall at 14 and 28 days in both genotypes (i-m). BrdU immunoreactive nuclei (yellow arrowheads) 
were common in lesions from both FF/tie2 and FF/-- mice at 14 days in the neointima, media and adventitia (n-o), 





Figure 5-8 Impact of EC ETB-deficiency on neointimal and lumenal area in complete ligation-injured femoral 
arteries.  
Neointima formation was induced by complete femoral artery ligation0-injury in FF/tie2 (EC ETB-deficient) and 
FF/-- (littermate control) mice and lesions allowed to develop for 14 or 28 days before histological examination. 
Neointimal (a) and lumenal cross-sectional areas (b) were measured at the point of largest lesion size by 
morphometry. Neointimal area was not significantly different between genotypes at either time point (a). 
Similarly, EC ETB-deficiency did not alter lumenal cross-sectional area at 14 or 28 days (b). Neointimal areas 
appeared similar in size in lesions from both genotypes at 14 and 28 days. n=7-10. Data are mean ± SEM. EC, 

















































(day 14: p=0.594; day 28: p=0.549) and BrdU immunoreactivity (day 14: p=0.191; 
day28: p=0.725) did not differ between genotypes (Table 5-4, page 189). 
 
5.3.6 Vasomotor function  
5.3.6.1 Vasoconstrictor responses to phenylephrine and KPSS 
In femoral arteries isolated from mice of all ages and genotypes tested, the α1-
adrenoceptor agonist phenylephrine stimulated concentration-dependent contraction. 
The response to this agent was significantly increased in vessels from young 
(p=0.014) but not aged EC-ETB knockout animals (Table 5-5, page 190). In the 
aorta of FF/tie2 mice, a small but significant decrease in the response to 
phenylephrine was observed (Table 5-6, page 191).  
 
Increasing K+ concentrations in the solution bathing femoral arteries also resulted in 
constriction of all tested vessels. The magnitude and sensitivity of this response was 
not altered by EC ETB genotype in young or aged mice (Table 5-5, page 190). 
 
5.3.6.2 Vasodilator responses to acetylcholine and sodium nitroprusside 
Acetylcholine stimulated concentration-dependent relaxation of phenylephrine pre-
contracted femoral artery rings and this action was almost abolished by pre-
incubation with an inhibitor of NO synthases, L-NAME (Figure 5-9). The maximum 
relaxation elicited appeared to be reduced by ageing, but in neither young nor aged 
animals was a difference in any parameter of this response seen between FF/tie2 and 
FF/-- mouse vessels. In isolated aortas, a significant difference between genotypes in 
the response to acetylcholine was present (Figure 5-10). This was only apparent at 
high concentrations where, in FF/tie2 mouse vessels, a contractile phase of the 
response occurred at lower acetylcholine concentrations than in aortas from FF/-- 
mice. As a consequence of this bi-phasic response, it was not possible to derive 
summary data from this response. In the presence of L-NAME, the relaxant effect of 
acetylcholine in aortic rings was abolished, and the contractile phase occurring at 







Figure 5-9 Impact of EC ETB-deficiency on the vasodilator response to acetylcholine in isolated femoral arteries 
from young and aged mice.  
Femoral artery rings from young (2-4 month old) and aged (7-10 month old), EC ETB-deficient (FF/tie2) and 
littermate control (FF/--) mice were examined by wire myography. Acetylcholine elicited relaxation of pre-
contracted vessels that was not different between genotypes in either young (a) or aged groups (b). Pre-
incubation with the nitric oxide synthase inhibitor, L-NAME (2x10-4M) abolished the response to acetylcholine in 
vessels from young mice of both genotypes (a). n=6-19. Data are mean ± SEM. EC, endothelial cell. ns, p>0.05 by 
two-way ANOVA between genotypes, within each age/treatment group. 



































(a) Young (2-4 month old)
(b) Aged (7-10 month old)



































Figure 5-10 Impact of EC ETB-deficiency on the vasomotor response to acetylcholine in isolated aortas.   
Aortic rings from young (2-4 month old) EC ETB-deficient (FF/tie2) and littermate control (FF/--) mice were 
examined by wire myography. The response to acetylcholine appeared bi-phasic comprising relaxation at low 
concentration, and re-contraction at high concentration. In FF/tie2 mouse aortas the contractile phase of the 
response occurred at lower concentration than in aortas from FF/-- mice. Pre-incubation with the nitric oxide 
synthase inhibitor L-NAME (2x10-4M) abolished the relaxant but not contractile phase in both genotypes. The 
response to acetylcholine in the presence of L-NAME was not different in between FF/tie2 and FF/-- mouse 
aortas. n = 5-6. Data are mean ± SEM. EC, endothelial cell. ns, p>0.05; *, p<0.05 by two-way ANOVA between 
genotypes, within each treatment group.  








































Pre-constricted vessels from FF/tie2 and FF/-- mice relaxed in response to increasing 
concentrations of the NO donor drug sodium nitroprusside. Neither age nor genotype 
altered any parameters of this response (Table 5-5, page 190). 
 
5.3.6.3 Vasomotor responses to ET agonists 
Endothelin-1 elicited vasoconstriction of femoral artery rings from mice of all ages 
and genotypes (Figure 5-11). This response was not different between vessels taken 
from FF/tie2 mice and FF/-- mice, in either young or aged groups. In the presence of 
BQ123, a selective ETA receptor antagonist, a parallel rightward shift in the 
concentration-response curve was observed, the magnitude of which was not 
different between any experimental groups. In femoral arteries from young FF/-- 
mice, pre-incubation with A192621, a selective ETB receptor antagonist, did not 
alter the sensitivity or maximum response to ET-1 (Figure 5-11). In contrast, pre-
treatment with this antagonist was able to completely abolish the contractile response 
of isolated rings of mouse trachea to sarafotoxin S6c (data not shown). 
 
Sarafotoxin 6c (10-7M) elicited a small but definite contraction in isolated femoral 
arteries pre-treated with L-NAME (Figure 5-12), the magnitude of which was not 
different (p=0.402) between FF/-- (5.72 ± 1.62 %) and FF/tie2 mice (3.67 ± 1.70 %). 
In phenylephrine pre-contracted femoral arteries, some response was also apparent 








Figure 5-11 Impact of EC ETB-deficiency and acute endothelin receptor blockade on the vasoconstrictor 
response to ET-1 in isolated femoral arteries.  
Femoral artery rings from young (2-4 month old) EC ETB-deficient (FF/tie2) and littermate control (FF/--) mice 
were examined by wire myography. In all vessels, ET-1 potently stimulated contraction. This response did not 
differ between vessels from EC ETB-deficient and control mice (a). Pre-incubation with the selective ETA 
antagonist, BQ123 (10-6M) resulted in a rightward shift in the concentration-response curve to ET-1 of similar 
extent in both genotypes (a). The response to ET-1 in FF/-- femoral arteries was not altered by pre-incubation 
with the selective ETB antagonist A192621 (b; 10-7M). KPSS, high potassium physiological salt solution, n = 3-9. 
Data are mean ± SEM. EC, endothelial cell. ns, p>0.05; *, p<0.05 by two-way ANOVA between genotypes (a) or 
treatments (b). 














































































Figure 5-12 Vasomotor responses of isolated femoral arteries to sarafotoxin S6c.  
Femoral artery rings from young (2-4 month old) control (FF/--) mice were examined by wire myography. 
Representative traces of tension changes in femoral artery rings exposed to acetylcholine (a) or to the ETB 
agonist sarafotoxin S6c are shown (b,c). Stepwise addition of acetylcholine (10-9-10-5M) elicits strong 
concentration-dependent relaxation of phenylephrine pre-constricted femoral arteries (a). Application of S6c (10-
7M) to phenylephrine pre-constricted femoral arteries elicited extremely variable responses possibly comprising 
dilator and constrictor components (b). In un-constricted vessels, pre-treated with the nitric oxide synthase 
inhibitor L-NAME (2x10-4M), application of S6c (10-7M) reliably elicited a small but definite contraction (c). Traces 
are representative of at least 3 experiments. S6c, sarafotoxin S6c.  
(a)
(c)





















































  Genotype 









     
(a) Wire Injury Studies 
Body weight at study start (g) 29.11 ± 1.38 30.60 ± 0.67 27.50 ± 1.30 29.10 ± 0.80 
Body weight at study end (g) 28.76 ± 1.29 29.73 ± 0.55 28.20 ± 1.10 29.20 ± 2.00 
Body weight change (g) -0.36 ± 0.28 -0.87 ± 0.53 0.70 ± 0.60 0.20 ± 2.40 
  
(b) Ligation Injury Studies 
Body weight at study start (g) as (a) as (a) 30.83 ± 1.77 30.11 ± 0.62 
Body weight at study end (g) as (a) as (a) Not recorded Not recorded 
Body weight change (g) as (a) as (a) Not recorded Not recorded 












     
(c) Vascular Function Studies 
Age Range (weeks) 11-20 13-19 41-47 43-47 
Mean Age (weeks) 15.7 ± 0.4 15.1 ± 0.6 44.6 ± 0.7 45.4 ± 0.4 
Body weight (g) 31.1 ± 1.3 31.2 ± 0.9 45.8 ± 2.6 49.0 ± 4.3 
Heart weight (mg) 202.0 ± 8.1 209.6 ± 10.2 222.7 ± 15.6 229.3 ± 14.7 
Liver weight (mg) 1906 ± 68.0 1782 ± 32.0 2287 ± 119.0 2204 ± 221.3 
Total kidney weight (mg) 614.1 ± 38.3 567.0 ± 25.0 675.5 ± 41.9 728.3 ± 41.5 
     
 
Table 5-1 Impact of EC-specific ETB deficiency on body and organ weights.  
EC ETB-deficient mice (FF/tie2) and their littermate controls (FF/--) were weighed at beginning and end of 
femoral artery injury and vascular function studies, and in the latter, organs were removed and weighed. Pre- and 
post-operative body weights were not different for mice undergoing any of the vascular injury studies presented 
in this chapter. Similarly, neither body weights nor the weight of major organs (liver, kidneys, heart) of mice used 
for vascular function studies differed between genotypes, in either young or aged groups. For organ weights, n = 




  Genotype FF/-- FF/tie2 
  
(a) 2D Morphometry (Histology) 
n 5 8 
Luminal area (x103μm2) 47.65 ± 5.25 47.95 ± 1.56 
Medial area (x103μm2) 14.06 ± 0.87 16.71 ± 1.25 
Lumen/Media ratio 3.39 ± 0.08 3.20 ± 0.20 
  
(b) Composition (Immunohistochemistry) 
n 5 8 
Medial αSMA IR (%) 50.0 ± 3.4 57.3 ± 2.7 
   
 
Table 5-2 Impact of EC ETB-deficiency on femoral artery structure and medial composition.  
Uninjured femoral arteries were perfusion fixed and isolated from FF/tie2 (EC ETB-deficient) and FF/-- (littermate 
control) mice and examined by United States trichrome staining (a) and αSMA immunohistochemistry (b). No 
differences in histological measures of morphology (a) or of medial αSMA immunoreactivity were apparent 
between genotypes. Data are mean ± SEM. αSMA, α-smooth muscle actin; EC, endothelial cell.  
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  Genotype 










 (a) 3D Morphometry (OPT) 
n 10 10   
Intimal volume (x107μm3) 6.34 ± 0.18 5.18 ± 0.72 - - 
Luminal volume (x107μm3) 20.34 ± 1.92 25.40 ± 1.10 * - - 
Volumetric stenotic ratio 0.23 ± 0.05 0.17 ± 0.02 - - 
  
(b) 2D Morphometry (Histology) 
n 10 9 7 8 
Luminal area (x103μm2) 32.28 ± 0.95 36.26 ± 0.76 15.42 ± 0.65 10.97 ± 0.50 
Neointimal area (x103μm2) 49.46 ± 15.74 31.66 ± 0.50 73.66 ± 14.65 70.49 ± 13.19 
Medial area (x103μm2) 21.86 ± 0.23 22.98 ± 0.27 25.23 ± 0.55 27.82 ± 0.74 
Intima/Media ratio 2.93 ± 1.14 1.58 ± 0.33 3.22 ± 0.73 3.09 ± 0.40 
Stenotic ratio 0.57 ± 0.12 0.48 ± 0.10 0.81 ± 0.06 0.88 ± 0.04 
  
(c) Composition & Proliferation (Immunohistochemistry) 
n 10 9 7 7 
Intimal αSMA IR (%) 19.0 ± 8.0 51.7 ± 6.9 * 46.3 ± 5.2 55.9 ± 6.6 
Intimal Mac2 IR (%) 3.8 ± 0.8 4.5 ± 0.9 1.2 ± 1.0 1.1 ± 0.8 
Intimal BrdU IR (count) 9.7 ± 1.8 8.4 ± 1.7 - - 
Medial αSMA IR (%) 8.8 ± 2.6 33.7 ± 5.4 ** 14.4 ± 3.2 29.9 ± 4.9 * 
Medial Mac2 IR (%) 4.6 ± 0.8 5.4 ± 1.1 0.7 ± 0.3 0.9 ± 0.3 
Medial BrdU IR (count) 7.6 ± 2.6 6.8 ± 1.6 - - 
     
 
 
Table 5-3 Impact of EC ETB-deficiency on the size and composition of femoral artery wire injury-induced 
neointimal lesions.  
Neointima formation was induced by femoral artery wire-injury in FF/tie2 (EC ETB-deficient) and FF/-- (littermate 
control) mice and lesions allowed to develop for 14 or 28 days before examination by optical projection 
tomography (a), histology (b) and immunohistochemistry (c). Optical projection tomography indicated no 
difference in lesion volume between genotypes at 14 days, but vessels from FF/tie2 mice showed a significant 
increase in luminal volume (a). No histological measures were altered by genotype at either 14 or 28 days post-
injury (b). Intimal αSMA immunoreactivity was significantly greater in lesions from FF/tie2 mice as compared to 
those from FF/-- mice at 14 but not 28 days post-injury. In the media, αSMA staining was increased by EC ETB-
deficiency at both 14 and 28 days post-injury. No other compositional changes were noted between genotypes. 
Data are mean ± SEM. αSMA, α-smooth muscle actin; BrdU, 5-bromo-2-deoxyuridine; EC, endothelial cell. *, 
p<0.05; **, p<0.01 by Student’s unpaired t-test between genotypes, at each time point.  
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  Genotype 









     
(a) 3D Morphometry (OPT) 
n 8 9 5 7 
Intimal volume (x107μm3) 5.41 ± 0.70 8.96 ± 2.25 4.48 ± 0.88 6.55 ± 1.65 
Luminal volume (x107μm3) 6.93 ± 0.59 8.05 ± 0.81 6.08 ± 1.59 7.16 ± 1.00 
Volumetric stenotic ratio 0.43 ± 0.05 0.50 ± 0.07 0.45 ± 0.09 0.45 ± 0.89 
  
 (b) 2D Morphometry (Histology) 
n 10 8 7 9 
Luminal area (x103μm2) 18.92 ± 0.34 13.49 ± 0.35 30.09 ± 0.43 31.14 ± 0.52 
Neointimal area (x103μm2) 33.46 ± 0.43 44.92 ± 0.87 24.08 ± 0.99 35.07 ± 0.86 
Medial area (x103μm2) 29.10 ± 0.29 29.40 ± 0.35 19.22 ± 0.21 21.10 ± 0.16 
Intima/Media ratio 1.16 ± 0.14 1.48 ± 0.23 1.57 ± 0.52 1.72 ± 0.46 
Stenotic ratio 0.62 ± 0.06 0.75 ± 0.08 0.41 ± 0.10 0.48 ± 0.09 
  
(c) Composition & Proliferation (Immunohistochemistry) 
n 10 8 7 9 
Intimal αSMA IR (%) 45.0 ± 6.6 37.9 ± 9.0 41.3 ± 7.6 51.2 ± 4.5 
Intimal Mac2 IR (%) 7.0 ± 2.7 3.6 ± 1.3 5.0 ± 2.0 3.5 ± 1.3 
Intimal BrdU IR (count) 7.1 ± 2.1 6.1 ± 1.0 3.6 ± 2.2 3.0 ± 1.7 
Medial αSMA IR (%) 43.5 ± 6.3 38.5 ± 6.7 48.6 ± 8.2 43.1 ± 4.7 
Medial Mac2 IR (%) 3.2 ± 0.8 3.7 ± 1.9 4.7 ± 2.2 5.8 ± 2.1 
Medial BrdU IR (count) 3.6 ± 1.3 1.5 ± 0.3 1.1 ± 0.6 1.6 ± 0.9 
     
 
Table 5-4 Impact of EC ETB-deficiency on the size and composition of complete femoral artery ligation-induced 
neointimal lesions.  
Neointima formation was induced by complete ligation of the femoral artery in FF/tie2 (EC ETB-deficient) and 
FF/-- (littermate control) mice and lesions allowed to develop for 14 or 28 days before examination by optical 
projection tomography (a), histology (b) and immunohistochemistry (c). Both optical projection tomographic (a) 
and histological analysis (b) indicated no effect of genotype on vascular morphology at either 14 or 28 days post-
injury. Similarly, no compositional differences were noted between lesions from FF/tie2 and FF/-- mice (c). Data 
are mean ± SEM. αSMA, α-smooth muscle actin; BrdU, 5-bromo-2-deoxyuridine; EC, endothelial cell.  
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PE 
n 19 12 8 8 
pD2 6.00 ± 0.08 5.86 ± 0.12 6.07 ± 0.06 5.96 ± 0.08 
Emax (%) 85.4 ±  2.5 94.2 ± 7.2 97.1 ± 5.2 97.4 ± 1.4 
Emax (mN.mm
-1) 2.31 ± 0.21 2.17 ± 0.27 2.44 ± 0.27 2.54 ± 0.43 
     
KPSS 
n 6 4 6 6 
pD2 1.63 ± 0.03 1.63 ± 0.03 1.59 ± 0.03 1.59 ± 0.01 
Emax (%) 103.2 ± 4.2 97.7 ± 3.3 111.3 ± 5.4 110.2 ± 2.7 
Emax (mN.mm
-1) 2.36 ± 0.39 3.13 ± 0.46 2.38 ± 0.30 2.28 ± 0.26 
ACh 
n 19 10 8 6 
-log(EC50) 7.03 ± 0.08 7.19 ± 0.10 6.92 ± 0.15 7.41 ± 0.44 
Emax (%) 77.4 ± 3.3 79.4 ± 3.3 54.4 ± 8.0 59.9 ± 9.5 
SNP 
n 6 4 6 6 
-log(EC50) 8.00 ± 0.10 7.88 ± 0.08 7.96 ± 0.08 7.95 ± 0.05 
Emax (%) 97.5 ± 0.8 97.5 ± 0.6 95.2 ± 2.8 97.2 ± 1.0 
ET-1 
n 9 6 6 6 
pD2 8.26 ± 0.10 8.32 ± 0.07 8.42 ± 0.07 8.34 ± 0.10 
Emax (%) 103.2 ± 4.2 101.9 ± 5.8 106.4 ± 5.6 105.8 ± 6.5 
Emax (mN.mm
-1) 2.42 ± 0.18 2.99 ± 0.50 3.17 ± 0.31 1.68 ± 0.21 ** 
ET-1 
+BQ123 
n 6 4 6 6 
pD2 7.20 ± 0.14 7.40 ± 0.12 7.16 ± 0.15 7.28 ± 0.12 
Emax (%) 110.1 ± 6.9 97.7 ± 13.6 126.8 ± 11.5 115.9 ± 5.6 
Emax (mN.mm




n 3 - - - 
pD2 8.73 ± 0.09 - - - 
Emax (%) 112.9 ± 10.4 - - - 
Emax (mN.mm
-1) 3.11 ± 0.28 - - - 
ET-1 
+A192621 
n 3 - - - 
pD2 8.29 ± 0.14 - - - 
Emax (%) 103.6 ± 3.4 - - - 
Emax (mN.mm
-1) 3.46 ± 0.28 - - - 
     
 
Table 5-5 Impact of EC ETB-deficiency on femoral artery vasomotor function.  
Femoral artery rings from young (2-4 month old) and aged (7-10 month old), EC ETB-deficient (FF/tie2) and 
littermate control (FF/--) mice were examined by wire myography. No parameters of any measured response 
differed between FF/tie2 and FF/-- mouse femoral arteries except the absolute Emax response to ET-1 in aged 
vessels, which was significantly reduced in vessels from FF/tie2 mice. Data are mean ± SEM PE, phenylephrine; 
KPSS, high potassium physiological salt solution; ACh, acetylcholine; SNP, sodium nitroprusside; ET-1, endothelin-
1; EC, endothelial cell. **, p<0.01 by Student’s unpaired t-test between genotypes, within age group. 
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  Genotype FF/-- FF/tie2 
     
PE 
n 6 6 
pD2 6.50 ± 0.11 6.46 ± 0.05 
Emax (%) 131.7 ± 7.7 105.5 ± 5.0 * 
Emax (mN.mm
-1) 1.68 ± 0.16 1.23 ± 0.19 
     
 
Table 5-6 Impact of EC ETB-deficiency on aortic vasomotor function.  
Aortic rings from young (2-4 month old) EC ETB-deficient (FF/tie2) and littermate control (FF/--) mice were 
examined by wire myography. The relative Emax response, but neither pD2 not absolute Emax response to 
phenylephrine was significantly impaired in aortas from FF/tie2 mice as compared to FF/-- controls. Data are 
mean ± SEM PE, phenylephrine; EC, endothelial cell. *, p<0.05 by Student’s unpaired t-test between genotypes, 




The experiments described in this chapter were conducted to determine the effects of 
selective deficiency of ETB from endothelial cells on neointimal lesion formation 
following acute femoral artery injury. The results suggest that ETB receptors 
expressed by EC contribute little to the response to vascular injury, and this is 
consistent with a similar lack of effect of EC ETB-deficiency on endothelium-
dependent vasodilatation and other vasomotor function in the femoral artery. These 
results could reflect the methodological approaches used. When compared with the 
impact of non-specific ETB blockade/deletion previously observed (Chapter 4 and 
Murakoshi et al 2002), however, they may suggest that ETB expressed in cells other 
than the vascular endothelium act to moderate neointimal proliferation.  
 
5.4.1 EC ETB deficiency does not alter endothelium-dependent vasodilatation 
Almost no alteration in vasomotor function was observed in isolated femoral arteries 
from EC-specific ETB deficient mice. Acetylcholine-stimulated vasodilatation, a 
commonly used measure of the ‘endothelial dysfunction’ seen in atherosclerotic and 
other diseased arteries (Freiman et al., 1986; Bonthu et al., 1997; Barton et al., 1998; 
Ross, 1999; Monnink et al., 2002) is perhaps the most relevant in the context of 
vascular injury. This process can be attributed to production of the vasodilator 
radical NO, as indicated by its near complete blockade by the NO synthase inhibitor, 
L-NAME, and was not altered by EC ETB knockout. As relaxations to the NO donor 
sodium nitroprusside were similarly unaffected, the absence of defects to this 
response cannot be explained by sensitisation of VSMCs to NO, as is reported in 
other situations of chemical or physical endothelial inhibition/damage (Moncada et 
al., 1991). Acetylcholine-stimulated relaxation did appear to be impaired by ageing, 
consistent with previously reported defects in the NO pathway in aged mouse arteries 
(Blackwell et al., 2004; Gendron et al., 2006). This age-dependent dysfunction was 
not, however, exacerbated by EC ETB knockout. EC ETB, therefore, does not appear 
to modulate the bioactivity of NO or stimulated release of NO in the femoral artery, 
even in the presence of pre-existing endothelial dysfunction. Indeed, the only 
possible indication of altered endothelial function in these studies was an increased 
responsiveness of FF/tie2 vessels to the α1-adrenoceptor agonist phenylephrine. 
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Given that inherent contractility, as measured by contraction to K+, was not altered 
by genotype, this might indicate a reduction in the physiological antagonism of this 
constrictor response provided by basal or α1-stimulated release of NO (Bullock et al., 
1986; Waldron et al., 1999; Hadoke et al., 2001). An alternative mechanism could be 
that EC ETB knockout has a more specific action on α1-mediated vasoconstriction. 
Indeed, low concentrations of ET-1 (as might be produced by impaired ET-1 
clearance in EC ETB deficient mice) are known to sensitise vascular rings to 
noradrenaline (Tabuchi et al., 1989; Yang et al., 1990). 
 
These data describing the absence of effect of EC ETB deficiency on acetylcholine-
induced vasodilatation contrast with those previously reported in aortic rings from 
both EC ETB knockout mice (Bagnall et al., 2006) and transgenically-rescued ETB 
knockout mice (Quaschning et al., 2005). Aortas from EC ETB-deficient mice were, 
therefore, examined in an attempt replicate these findings. No impairment to 
endothelium-dependent relaxation was seen with only the constrictor-phase of the 
response to acetylcholine being altered by EC ETB knockout. This enhanced 
contraction may, however, reflect an impaired ability of the endothelium to 
physiologically antagonise the constrictor component of the response to 
acetylcholine in FF/tie2 mouse aortas. This might be either due to loss of basal EC 
ETB-stimulated NO release or increased production of oxidative species by 
NAD(P)H oxidases (Duerrschmidt et al., 2000; Wedgwood et al., 2001; Dong et al., 
2005; Rodriguez-Vita et al., 2005). This interpretation is supported by the identical 
constrictor response to acetylcholine between genotypes in vessels where NO 
production was blocked by pre-treatment with L-NAME. As such, alternative 
explanations such as altered VSMC muscarinic receptor function or enhanced 
cholinesterase activity appear less likely. It is not clear, however, why the impaired 
acetylcholine-mediated relaxation reported previously in these mice (Bagnall et al., 
2006) was not fully replicated in this investigation.  
 
The remaining discrepancy of the complete absence of changes to endothelial 
function in the femoral artery, as compared to the modest alterations in the aorta has 
several possible explanations. This may indicate a different phenotype of endothelial 
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cells between vascular beds, either with regard to ETB expression, or pro-/anti-
oxidant systems. Differences in mediators of endothelium-dependent vasodilatation 
between aortas and femoral arteries may also provide explanation as Crauwels et al 
(2000) report that the response to acetylcholine in the femoral artery is partly 
meditated by endothelium-derived hyperpolarisation. This is not supported by the 
data presented here, however, as in both arteries, L-NAME was seen to almost 
completely abolish this dilator response indicating complete-dependence on NO 
synthase activity. 
 
5.4.2 ET receptor distribution in the mouse femoral artery 
An additional aim of studies of vascular function was to clarify the distribution of ET 
receptor subtypes in the mouse femoral artery. Deficiency of ETB from EC had little 
effect on the constrictor response to ET-1 suggesting that, in the mouse femoral 
artery, expression and/or function of the ETB receptor in endothelial cells is weak. 
This may also reflect the rather crude nature of this measure – a composite of a 
powerful ETA/B-mediated constrictor response and an ETB-mediated dilator 
response, which in mouse vascular rings, is typically small, short-lived and 
inconsistent (Mizuguchi et al., 1997; Zhou et al., 2004). To address this issue, the 
response of pre-contracted vessels to a single dose of the ETB agonist, sarafotoxin 
S6c, was recorded. The responses elicited however were impossible to interpret - 
being extremely variable in size and direction and not altered in a consistent way by 
EC ETB deficiency (or endothelial denudation). In contrast, a clear constrictor 
response to 10-7M sarafotoxin S6c was observed in mouse tracheal rings, which was 
sensitive to ETB blockade. The inability to observe this notoriously difficult to 
measure response, is not necessarily meaningful.  
 
The distribution of contractile ET receptors proved easier to determine. ET-1-
induced vasoconstriction was inhibited by a selective ETA antagonist in a manner 
consistent with the competitive nature of this agent (parallel rightward shift) but was 
not altered by a selective ETB antagonist. When applied to L-NAME treated, non-
contracted femoral arteries, stimulation with an ETB agonist did elicit a small but 
obvious constrictor response. These data are consistent with the idea ETA is the 
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dominant vasoconstrictor receptor for ETs in conduit arteries (Davenport et al., 
1995a; Davenport et al., 1995b), and confirms the expression of ETA and to a lesser 
extent ETB by femoral artery smooth muscle cells. It may also be that a population 
of ETB receptors is normally quiescent, and in this case, become active only in the 
presence of ETA blockade. Such a cross-talk phenomenon has been previously 
reported, for example, in rat mesenteric arteries (Mickley et al., 1997).  
 
Neither the response to ET-1 in the presence of ETA blockade nor that to an ETB 
agonist in non-contracted femoral artery rings was altered by EC ETB deficiency. 
This suggests that ETB-deficiency specifically in EC does not result in alterations to 
ETA and ETB receptor function in other cells. These observations are consistent 
with previous work demonstrating that, in all tissues, binding of an ETA-specific 
and, in non-EC rich tissues, of an ETB-specific radioligand to whole body 
autoradiographs is not altered in EC ETB-deficiency (Kelland et al., Unpublished 
observations.). This is somewhat surprising given that ETA-mediated 
vasoconstriction is substantially impaired (~50% of control) in aortic rings from 
transgenically-rescued, non-cell-specific ETB knockout mice, independent of blood 
pressure (Quaschning et al., 2005). Reduced ETA receptor expression is also 
reported in the kidneys of ETB knockout rats (Taylor et al., 2003) and the lung and 
brain of neonatal ETB-/- mice (Davenport & Kuc, 2004; Kuc et al., 2006). In each 
model this is suggested to be a consequence of chronic exposure to the elevated 
plasma ET-1 concentrations associated with ETB deficiency. EC-specific ETB 
knockout mice (Bagnall et al., 2006) and EC-specific ET-1 over-expressing mice 
(Amiri et al., 2004), however, have similarly elevated circulating ET-1 levels. In 
these models, no down-regulation of vascular ETA receptors is apparent. Smooth 
muscle cell ETA receptor expression may, therefore, be directly regulated by ETB by 
an intracellular mechanism rather than indirectly via exposure to excess ligand. This 
is consistent with work by Davenport & Kuc (2004) who report, in ETB-deficient 
rats, that ETA down-regulation is more pronounced in tissues which would normally 
strongly co-express both receptor subtypes. An alternative explanation lies in the 
distribution of ET-1 clearance receptors. EC ETB appears essential to the removal of 
ET-1 from plasma (Fukuroda et al., 1994a; Johnstrom et al., 2005; Bagnall et al., 
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2006; Kelland et al., Unpublished observations). Deeper within tissues, such as in the 
arterial media, however, ETB expressed by other cells types, such as VSMC may be 
more important in determining local concentration. As such, whilst plasma levels are 
similar between EC-specific and non-specific models of ETB deficiency, local tissue 
concentrations in the vascular wall may be much greater in non-specific ETB 
knockout animals and elicit compensatory down-regulation of ETA. 
 
5.4.3 EC ETB deficiency does not alter the neointimal lesion size 
The weak effects of EC ETB deficiency on femoral artery vascular function may go 
some way to explain data from vascular injury studies. No effect of EC-specific ETB 
receptor deletion on any histology- or OPT-derived measure of neointimal lesion size 
following wire-induced injury, the primary endpoints of these studies, was observed. 
This contrasts with the data in chapter 4, which demonstrates that non-cell-specific 
ETB blockade increases lesion size following femoral artery wire-injury. Any effect 
on the rate of lesion progression, perhaps a more sensitive measure, is also unlikely: 
lesion size was equally unaffected by EC ETB deficiency at 14 days post-surgery, a 
known time-point of intermediate lesion size (Sata et al., 2000), and no difference in 
proliferating cell count was noted. These data support the obvious conclusions that 
ETB in mouse femoral artery endothelial cells does not exert a moderating effect on 
neointimal thickening and, therefore, that the effects of ETB blockade described in 
chapter 4 are mediated by a receptor expressed by a non-endothelial cell type. They 
might also provide further evidence against a role for impaired ET-1 clearance and 
resulting ET-1 excess in the effects of pharmacological (chapter 4) and genetic 
(Murakoshi et al., 2002) inhibition of ETB on neointimal lesion formation. Plasma 
ET-1 concentrations are similarly elevated between EC-specific ETB deficient mice 
and rats treated with 30mg/kg/day A192621 or deficient in ETB (Gariepy et al., 
2000; Opgenorth et al., 2000; Bagnall et al., 2006). Only non-specific ETB 
blockade/deletion, however, is associated with increased neointimal thickening 
following vascular injury. As discussed in the context of ETA receptor expression 
above, one likely caveat to this interpretation is the possibility that these two 
manipulations might have a differential effect on local tissue concentrations of ET-1. 
Indeed, neointimal lesions are typically reported to possess high densities of both 
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ETB expressing and ET-1 secreting cells implying that intra- lesion ET-1 levels may 
be regulated by non-EC ETB pathways (Dashwood et al., 1999; Shirai et al., 2006). 
 
As in the wire injury model, neointimal lesions arising from ligation of the femoral 
artery were unaffected by EC ETB deficiency at 28 days. In this case, these data are 
in agreement with a similar absence of effect of pharmacological ETB blockade on 
neointima formation in this model (chapter 4).  This indicates that the inability of 
ETB blockade to increase neointimal lesion size following femoral artery ligation-
injury is not the result of competition between EC-mediated, lesion-moderating 
actions (such as NO release), and non-EC-mediated lesion-enhancing actions (such 
as mitogenesis/inflammation).  
 
To address any effect of EC ETB deficiency on the rate of lesion development in this 
model, ligation-injured vessels were also analysed at 14 days. This was predicted to 
represent a time point of active lesion growth, as it does both in femoral artery wire-
injury (Sata et al., 2000) and in carotid artery ligation-injury models (Godin et al., 
2000). No differences in lesion size or composition, however, were apparent between 
14 and 28 days post-ligation suggesting that complete femoral artery ligation-
induced lesions stabilise in size within 14 days. This may reflect the smaller size of 
lesions induced by this method (similar in cross-sectional area to wire-induced 
lesions at 14 days) or the severity of blood stasis/flow disturbance caused by 
complete ligation of this major artery.  
 
Injury-induced changes in endothelial cell phenotype might explain why EC ETB-
deficiency is unable to alter the response to vascular injury in these models. 
Certainly, the data presented in chapter 3 indicate that ligation-injury is associated 
with impairment of acetylcholine-stimulated vasodilatation. In the wire-injury model, 
whilst investigations of vascular function have been prevented by the unavoidable 
severe medial damage that is implicit to this injury, it seems likely that a rapidly re-
grown endothelium, possibly of progenitor cell origin, might have at least some 
altered properties. In support of this, whilst Miller et al (2003) showed the return of 
endothelium-dependent vasodilatation to Ca2+ mobilisation by cyclopiazonic acid 
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within 10 days of in vivo endothelial denudation in the mouse the carotid artery, 
complete muscarinic receptor stimulated vasodilator responses were slower to return. 
Any relevance of this issue, however, is restricted to the matter of mechanism as 
various models of endothelial dysfunction are associated with increased neointimal 
lesion size in femoral artery wire-injury and carotid artery ligation models (Wang et 
al., 2005a; Zhang et al., 2006). Further, any manifestation of neointimal hyperplasia 
in man, such as post-interventional restenosis or vein graft disease, is likely to be 
associated with endothelial damage or dysfunction.  
 
It must also be considered that in other experimental models or situations, EC ETB 
might play a greater role. Foremost, it has not been possible to prove the presence of 
ETB in the femoral artery endothelium or observe any effect of ETB deficiency on 
endothelial cell function in this vessel. In some cases, this may simply reflect 
experimental limitations but may also suggest that the role or expression of EC ETB 
in femoral arteries is not representative of all murine vessels. This would certainly 
offer an explanation for the differing effects of pharmacological ETB blockade on 
neointimal hyperplasia following carotid (increased; Murakoshi et al., 2002) and 
femoral artery ligation (no effect; chapter 4). Species differences might also warrant 
consideration as, whilst EC ETB receptors undoubtedly exist in the mouse, in this 
species administration of an ET-1 bolus elicits only vasoconstriction (Giller et al., 
1997). This may indicate that, in the mouse, either EC ETB function or distribution 
is not representative of that in larger animals and as such, that in these species, EC 
ETB might exert a more obvious effect of neointimal proliferation. 
 
5.4.4 EC ETB regulates femoral artery composition following wire-injury 
Despite the apparent inability of deletion of ETB from ECs to alter lesion size, 14 
days following injury, increased intimal α-smooth muscle actin immunoreactivity 
was observed. This was not accompanied by increases in the number of proliferating 
cells suggesting either changes in cell size or increased survival rather than 
proliferation. Alternatively, it may be that a transient increase in cell proliferation 
rate has normalised by 14 days. Whatever the mechanism, the result is a lesion with a 
more mature appearance, more similar to those in FF/-- mice at 28 days than 14 days 
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following injury. Thus, although lesion size was not altered, the rate of maturation 
may be reduced by influences of EC ETB. This may be because vascular NO, which 
suppresses smooth muscle migration and proliferation (Garg & Hassid, 1989), is 
reduced by EC ETB-deficiency. These compositional changes were apparent at 14 
days, however, suggesting that they are not mediated by an effect of deletion from 
the endothelial cells lining the femoral artery lumen as EC function probably only 
returns by day 10 (Liao et al., 2007). As such, these effects may reflect a response to 
a systemic phenotype such as elevated circulating ET-1 concentrations, which are 
inherent to EC ETB knockout mice (Bagnall et al., 2006). ET-1 is known to promote 
both smooth muscle proliferation (Komuro et al., 1988) and, when acting on the 
ETA receptor, to protect smooth muscle cells from a variety of pro-apoptotic 
influences (Diep et al., 2000; Shichiri et al., 2000; Wu-Wong et al., 2000). Excess of 
ET-1 may also stimulate hypertrophy of smooth muscle cells, and this process is 
stimulated by lower concentrations of ET-1 than is necessary to promote mitogenesis 
(Dao et al., 2006). This may be of particular relevance as levels of ET-1 in plasma, 
even in (EC) ETB deficient mice, are extremely low (Bagnall et al., 2006). This 
leaves the question of why an apparent increase in smooth muscle cells manifests as 
altered composition rather than lesion size. It may be that smooth muscle cells can 
migrate into a relatively acellular framework (fibrin, platelets, extracellular matrix) at 
this time point without requiring concurrent lesion expansion (Schwartz et al., 
1992a). EC ETB deficiency may also negatively regulate a non-smooth muscle 
lesion component that has not been analysed such as elastin or ground substance. 
Alternatively, any differences seen may reflect an effect on the level of αSMA 
expression in otherwise normal smooth muscle cells rather than an increase in their 
number or size.  
 
Even greater increases in αSMA immunoreactivity were noted in the media of wire-
injury femoral arteries from EC ETB-deficient mice. This increase was observed at 
both 14 and 28 days post-injury and may explain changes observed in neointimal 
composition as they result in a larger pool of smooth muscle cells that can migrate 
into the developing neointima. In this model, the severe stretch associated with wire 
insertion induces rapid apoptosis of medial smooth muscle cells, resulting in a 
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dramatic loss of these cells within 24 hours (Sata et al., 2000). It therefore seems 
likely that the mechanism for this effect of EC ETB deficiency is the inhibition of 
stretch-induced apoptosis. These changes were not associated with increased BrdU 
incorporation further implying an effect on cell survival rather than growth. The 
strength of this effect at 14 days, once again suggests that a systemic effect of EC 
ETB knockout, such as impaired plasma ET-1 clearance, rather than a local effect of 
femoral artery luminal ECs, is responsible. The same mechanisms which potentially 
contribute to increased neointimal smooth muscle-like cell content are all possible: 
an anti-apoptotic action of ETA activation, hypertrophy, proliferation prior to day 14 
and changes in αSMA expression levels. Both intimal and medial compositional 
changes in EC ETB knockout mouse wire-induced lesions may also be explicable by 
enhancement to the recruitment or differentiation of circulating progenitor cells to 
the injured vascular wall. At first glance this is consistent with the absence of such 
changes in the lesions of ligation-injured vessels, which are anticipated to develop 
without contribution of circulating progenitors (Tanaka et al., 2003). This 
discrepancy between models, however, equally implicates any altered response to the 
medial damage that occurs in wire but not ligation-injury including an anti-apoptotic 
action. Regardless, it is interesting that no such changes in medial composition at 28 
days post-wire-injury were present in ETB antagonist treated mice (chapter 4). It is 
not clear whether this indicates that the mechanism is mediated by non-EC ETB 
receptors and is, therefore, prevented by non-specific ETB blockade, or that the 
effect is masked by whatever process results in increased lesion size following this 
treatment. 
 
These alterations to medial composition may also offer explanation for the small, but 
significant, increase in total luminal volume observed at 14 days following wire-
injury in EC ETB knockout mice. At this time point, because neointimal formation is 
not extensive, luminal volume is determined in large part by medial structure. As 
wire-injured arteries from this point are extremely fragile, even following perfusion 
fixation, an increase smooth muscle-like cells in the media may protect 14 day 
arteries from FF/tie2 animals from compression of the lumen during tissue 
preparation and handling. The alternative, that this finding reflects arterial 
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dilation/outward remodelling, is unlikely. No changes in the area inside the internal 
elastic lamina (neointima + lumen) were present in histologically-evaluated sections. 
These measurements were made on the largest neointimal lesions from each artery, 
and therefore, describe the regions most resistant to handling artifacts. 
 
5.4.5 Non-EC ETB receptors moderate neointimal proliferation? 
If the increases in neointimal lesion size observed following pharmacological ETB 
blockade cannot be explained by actions of this receptor expressed by ECs, then ETB 
expressed by other cell types must be responsible. An effect on vascular smooth 
muscle cells is certainly a reasonable proposition given that these cells are not only 
the most numerous in the developing and mature neointima but are thought to 
strongly express ETB (Azuma et al., 1994; Azuma et al., 1995a; Dashwood et al., 
1999; Shirai et al., 2006). Indeed, myography studies in this chapter have shown that 
even in the uninjured femoral artery, smooth muscle cells express functional ETB 
receptors. ETB receptors, in these cells, may promote apoptosis, including that 
induced by stretch injury. This could explain why ETB blockade but not EC ETB-
deficiency increases lesion size following wire-injury. Certainly, continual apoptosis 
of neointimal cells has been noted in this model (Reis et al., 2000; Sata et al., 2003) 
and modification of apoptosis appears to regulate lesion growth  (Blanc-Brude et al., 
2002; Sata et al., 2003; Tanja Rauma-Pinola, 2006). Whilst convenient, this 
explanation is somewhat contradictory to the suggestion that an ETA-mediated, anti-
apoptotic effect regulates lesion composition in EC ETB knockout mice. Many other 
explanations can be speculated such as a negative regulation of 
macrophage/neutrophil function by ETB, an effect on recruitment of smooth muscle 
progenitor cells to the neointima or induction of NO production in smooth muscle 
cells. Further study is, therefore, required to determine the mechanism by which non-
EC ETB moderates the response to vascular injury. 
 
5.4.6 Experimental limitations 
It must be considered that the inability of EC ETB deficiency to alter neointima 
formation following femoral artery wire-injury could be a consequence of limitations 
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of the experimental approach, rather than truly reflecting physiological processes. In 
these mice, specific deletion of the ETB receptor gene is dependent on robust 
expression of the Tie2 promoter. Following the initial removal of endothelium in this 
model, it may be that the ECs that re-grow do not express Tie2 as might be expected. 
This seems unlikely considering the role of the angiopoietin-1/Tie2 system in 
angiogenesis and EC maturation (Suri et al., 1996; Wong et al., 1997), but the 
possibility exists that the absence of Tie2 expression in the neo-endothelium allows 
these cells to retain ETB expression. Similarly, the specificity of deletion to EC is 
dependent on the expression of Tie2. Reporter animals suggest that the vast majority 
of Tie2 expression occurs in EC; however, both expression of Tie2-Cre mRNA and 
Tie2-Cre mediated recombination have been suggested to occur in cells of 
hematopoietic lineage (Constien et al., 2001). In the context of wire-injury-induced 
neointimal lesions, this may result in ETB deletion from macrophages and 
neutrophils, both critical to lesion formation. Zhao et al (2006), however, report that 
Tie2-Cre mediated recombination is absent in bone marrow lymphocytes and in total 
white blood cells. Unlike the work of Constien et al (2001), this study utilised the 
same transgenic Tie2-Cre line used to create EC ETB-deficient mice. Further, recent 
work in this laboratory has demonstrated that macrophages isolated from EC ETB-
deficient mouse bone marrow, retain ETB expression (Azfer et al., Unpublished 
observations). Smooth muscle like-cells derived from circulating progenitors may 
also be affected, although the early work that suggested these are of hematopoietic 
origin (Sata et al., 2002) has since been called into doubt (Sahara et al., 2005). The 
possibility cannot be completely excluded, however, that a beneficial effect of EC 
ETB deficiency is masked by unintended ETB deficiency in other cell types 
important to lesion development.  
 
Finally, the comparison of the effects of pharmacological ETB blockade (chapter 4) 
and EC-specific ETB deficiency on neointimal lesion formation may be complicated 
by the effects of genetic background. EC ETB knockout mice used in this chapter are 
of a mixed strain comprising 129/Ola and BKW. Studies of the effects of ET 
antagonists on lesion formation (chapter 4), and of femoral artery injury on vascular 
function (chapter 3), however, were performed in mice of the strain C57Bl/6J (for 
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unavoidable practical reasons). It is possible, therefore, that the effects of ETB 
blockade observed in chapter 4 are indeed mediated by ETB receptors on EC, and 
that the negative results presented here are a consequence of differences in the role of 
ETB in the response to acute vascular injury between these two strains.  
 
5.4.7 Conclusions 
The data presented in this chapter indicate that, whilst femoral artery endothelial 
function is not overtly regulated by endothelial ETB activity, regional differences 
exist in the response of EC to ETB deletion. It is perhaps not surprising, therefore, 
that no differences in neointimal proliferation were associated with EC ETB 
deficiency in two models of vascular injury to this artery, contrary to the original 
hypotheses of this work. Whilst effects on lesion composition are interesting, they 
are perhaps of limited consequence considering that neointimal lesions are inherently 
stable. The most interesting conclusions come with comparison to the striking effects 
of pharmacological ETB blockade on wire-injury-induced neointimal lesions. In this 
context, regardless of the reasons for the ineffectiveness of EC ETB deficiency (lack 
of role in vascular function, wire-induced endothelial denudation), in this model, in 
this artery, in this species, a non-EC ETB receptor appears to offer protection against 
neointimal thickening following acute injury. Future work should address the cell 
types and mechanisms mediating this effect of non-specific ETB blockade and may 









Conclusions and future directions 
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6.1 GENERAL CONCLUSIONS 
Acute injury to the vascular wall, such as that inflicted by percutaneous coronary 
intervention, elicits formation of neointimal lesions by activation of inflammatory 
and proliferative cascades. Although often an appropriate healing response, 
excessive neointima formation can compromise vessel patency and thus represents a 
major limiting factor to the success of such procedures. It is well established that the 
endothelin (ET) system contributes to this process. In animal models, neointima 
formation is enhanced by administration of exogenous ET-1 (Trachtenberg et al., 
1993; Barolet et al., 2001) and diminished by blockade of the ETA receptor, 
consistent with the pro-mitogenic, pro-inflammatory activity of the ET-1/ETA 
interaction (Ferrer et al., 1995; Takiguchi & Sogabe, 1996; Burke et al., 1997; 
McKenna et al., 1998; Dashwood et al., 1999; Murakoshi et al., 2002; Tepe et al., 
2002; Wan et al., 2004). What is less clear is whether concurrent activation of the 
ETB receptor also contributes to lesion development. Certainly, ETB mediates many 
detrimental actions common to ETA such as induction of smooth muscle 
proliferation (Eguchi et al., 1994). ETB may, however, exert other effects that might 
limit lesion formation such as stimulating production of nitric oxide (NO; Hirata et 
al., 1993; Tsukahara et al., 1994; Mizuguchi et al., 1997), a potent inhibitor of 
neointima formation (Moroi et al., 1998; Zhang et al., 2006; Cooney et al., 2007) 
and clearance of circulating ET-1 by endothelial cells (ECs; Fukuroda et al., 1994a; 
Bagnall et al., 2006). Further, ETB receptors may promote apoptosis of vascular 
smooth muscle cells (VSMC; Cattaruzza et al., 2000; Lauth et al., 2000) and exert a 
tonic hypotensive effect by the regulation of renal sodium handling (Ge et al., 2006). 
Although much literature indirectly suggests that any role for ETB in neointima 
formation is minor, it has recently been reported that carotid artery ligation-induced 
neointima formation is accelerated in ETB-deficient mice (Murakoshi et al., 2002). 
The work presented in this thesis was, therefore, undertaken to clarify the influence 
of individual ET receptor subtypes in neointimal lesion formation following acute 





6.1.1 Induction of vascular injury 
An obvious prerequisite for any such investigation is the ability to model and 
quantify the response to vascular injury. Two models of acute injury to the mouse 
femoral artery have been previously utilised in this laboratory for similar studies. 
The first, a widely used model of intra-luminal wire injury that mimics the nature of 
injury associated with PCIs in man and is known to provide a strong stimulus for 
neointima formation (Sata et al., 2000). The second, a variation on the wire-injury 
sham operation in which ligation of the popliteal artery, just distal to its junction with 
the femoral artery is sufficient to induce neointima formation. The lesions resulting 
from this latter injury, however, are small, inconsistent and extremely focal 
(MacDonald et al, Unpublished data). In an effort to develop a more robust ligation-
induced model of neointima formation in the femoral artery, alternative ligations to 
the femoropopliteal bifurcation were investigated. It was found that ligation of the 
femoral artery immediately distal to this junction (‘partial’ ligation) also provoked 
formation of only small, focal neointimal lesions. In contrast, ligation of the femoral 
artery proximal to its bifurcation (‘complete’ ligation) elicited development of larger 
neointimal lesions over greater lengths of vessel - more reminiscent of those reported 
to occur in response to ligation of the carotid artery (Kumar & Lindner, 1997). Thus, 
both the femoral artery wire-injury and complete ligation-injury models were 
adopted for subsequent studies. These models were complementary in several ways 
and by performing both in the same animals the amount of information gleaned from 
each was increased. Perhaps the most critical difference between the two injuries is 
the denudation and re-growth of endothelial cells implicit in the wire- but not 
ligation-injury model. Any interpretation of data with regard to a hypothesised role 
of ETB in EC on neointima formation was, therefore, considered to be more 
straightforward following ligation-injury. These models also importantly differ in the 
origin of cells contributing to neointima formation. Wire-injury results in recruitment 
of bone marrow-derived progenitor cells to the neointima, whereas this does not 
appear to occur in ligation-injury models in which neointimal smooth muscle cells 




In both models, studies were undertaken to investigate vascular function in injured 
arteries with two major aims. First, to confirm the integrity of endothelium-
dependent responses after injury, and in the case of wire-injury, ensure recovery of 
endothelial function correlates with physical re-growth. Second, to determine if 
injured vessels exhibit altered functional response to ET-1 that may modify their role 
in the response to vascular injury. In wire-injured vessels, any determination of these 
parameters was prevented by the complete inability of injured femoral artery rings to 
develop any contractile force – probably reflecting the severity of injury to the 
media. Functional studies of uninjured vessels conducted in parallel, however, 
provided basic proof for the expression of ET receptors in femoral artery smooth 
muscle cells, and that the constrictor response to contractile agonists including ET-1 
was basally suppressed by the endothelium. 
 
Complete ligation-injured vessels exhibited comparatively mild functional changes. 
Although vessels dilated in response to acetylcholine, a moderate dysfunction of this 
endothelium-dependent response was present. An altered smooth muscle phenotype 
was also apparent as absolute responsiveness to a number of vasoconstrictor 
substances was impaired, although no more so for ET-1 than for other agents. 
Studies of partial ligation-injured vessels, in which no appreciable neointima 
formation is observed, indicated similar functional changes. In these too, 
endothelium-dependent vasodilatation and absolute contractility were moderately 
impaired. As such, these changes appear to occur independently of neointima 
formation and are perhaps a response to altered blood flow patterns and shear 
stresses around the site of manipulation, which are well established to regulate 
vascular structure and function (Caro et al., 1971; Cunningham & Gotlieb, 2005).  
 
6.1.2 Measurement of neointimal lesions 
Previous experience with the wire-injury model also highlighted the limitations of 
traditional histological means for the quantification of neointimal lesion burden. 
Microtomy, histological staining and lesion analysis of long lengths of injured 
femoral arteries is extremely laborious and time-consuming. Moreover, this process 
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prevents any accurate volumetric measurement of lesion burden because even careful 
serial sectioning does not truly retain z-axis information and position in 3D space.  
 
Optical projection tomography (OPT) was explored as a potential means to rapidly 
image isolated arteries in 3D for qualitative and quantitative assessment of 
morphology along the entire vessel. This proved extremely successful, with OPT 
scans bearing striking resemblance to subsequent histological staining of the same 
regions. Moreover, quantitative measurements of 2D lesion size compared well 
between the two techniques and, as such, it was possible to make volumetric 
measurements and cross-sectional profiles of luminal and lesion size. OPT scans, 
therefore, provided a valuable complement to histological analysis of neointimal 
lesion formation, providing additional power to detect the effects of interventions, 
and describing the distribution of lesion formation – data which would otherwise 
have been lost. Further, this technique may be considered particularly important 
because few alternative methods for the 3D evaluation of small arteries have been 
described, and those that have, carry severe practical limitations (McAteer et al., 
2004). 
 
6.1.3 Role of the ETA receptor 
Whilst the role of the ETA receptor in vascular remodelling following acute arterial 
injury has been previously demonstrated, it was necessary to confirm that this 
receptor plays a similar role in the femoral artery wire- and ligation-injury models. 
This was achieved by administration of a highly selective ETA receptor antagonist 
(atrasentan, 2000-fold ETA/ETB selective) to animals subject to femoral artery wire 
and ligation injury. The results of these experiments, as expected, indicated that ETA 
blockade reduced several measures of wire-injury induced lesion size and volume at 
a time point of stable lesion size and dramatically preserved the luminal cross-
section. In comparison, histological measures indicated no effect of ETA blockade 
on ligation-induced lesion formation. Analysis by OPT, however, demonstrated that 
ETA blockade reduced lesion size in the axial dimension, and, therefore, lesion 
volume; confirming both a role for ETA in this model and demonstrating one of the 
potential advantages of OPT. Whilst the mechanism of this action was not explicitly 
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investigated, no differences in lesion composition due to ETA blockade were 
apparent in either model. It must be noted, however, that lesion macrophage content 
and cell proliferation, two likely candidates for modulation by ETA, are poorly 
represented by the time-point investigated. Thus, activation of the ETA receptor by 
endogenous ETs is important in the development of neointimal hyperplasia following 
both femoral artery wire-injury and ligation-injury. This further supports the 
rationale for use of ETA antagonists in the prevention of similar remodelling 
processes in man, and provides validation of the experimental design for studies 
investigating the effects of the ETB blockade. 
 
6.1.4 Role of the ETB receptor 
The effect of ETB blockade on lesion formation was of greater uncertainty and a 
primary topic of this work. ETB blockade was achieved in a similar manner to ETA 
blockade – by administration of a selective antagonist (A192621, 1300-fold 
ETB/ETA selective) to mice subject to femoral artery wire- and ligation-injury 
procedures; either alone or in combination with ETA blockade. Neointimal lesions 
induced by wire-injury were substantially increased, both in size and in volume, by 
selective ETB antagonist treatment. An increase in neointimal lesion size with ETB 
antagonist treatment was apparent even in the presence of concurrent ETA blockade. 
Lesions in mice treated with the combination of ETA and ETB antagonists were of 
similar size to those from vehicle-treated animals and were, therefore, increased in 
size relative to those from mice subject to ETA blockade alone. These data serve to 
confirm the work of Murakoshi et al (2002) and demonstrate that the ETB receptor 
acts to moderate neointima formation following vascular injury. As such, the ETB 
receptor appears to act to limit the detrimental effects of ETA activation by 
endogenous ETs in this process. The ability of ETB blockade to increase lesion size, 
even in the presence of ETA blockade suggests that the action of ETB antagonism in 
this setting is not simply a response to elevations in blood pressure or in plasma [ET-
1], two well characterised systemic effects of this treatment. Analysis of lesion 
composition again provided little conclusive evidence with regard to mechanism of 
action, although increases in cell proliferation, and perhaps macrophage content were 
apparent in lesions from ETB antagonist treated mice. Such a pro-mitogenic, pro-
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inflammatory lesion phenotype would be consistent with inhibition of the EC ETB / 
NO pathway, as NO release inhibits inflammatory (Bath et al., 1991) and mitogenic 
processes (Garg & Hassid, 1989). Analysis of lesion composition at earlier time 
points of active lesion growth would be necessary to confirm these changes. 
 
In contrast to the positive results with ETB blockade on wire injury-induced lesion 
formation, little effect on lesion size or volume was observed with this treatment in 
the ligation-injury model. Similarly, when co-administered with an ETA antagonist, 
lesion volume was reduced in this model to a similar extent as for ETA blockade 
alone. Therefore, in the femoral artery ligation-injury model, ETB receptors have 
little role in lesion development and do not modulate the response to ETA blockade. 
This apparent difference in the actions of ETB between wire and ligation induced-
injures is surprising for several reasons. First, Murakoshi et al (2002) describe 
reduced lesion size in the carotid artery ligation model with ETB deletion or 
blockade. This may reflect differences in ETB expression or VSMC phenotype 
between carotid or femoral arteries, or perhaps the phase of lesion growth analysed - 
is growth accelerated or increased in maximum stable size? Second, if ETB blockade 
increases lesion size by an action on EC, one might predict a greater effect in the 
ligation model in which EC are not denuded, than the wire-injury model. This might 
indicate the inhibitory effect of ETB on lesion formation is not mediated by EC but 
many other differences between models may also account for this discrepancy.  For 
example, ETB may inhibit recruitment of bone marrow progenitors to wire-induced 
neointimal lesions or stretch-induced VSMC apoptosis, both processes that would 
not be expected to occur in the ligation model (Tanaka et al., 2003). Such variability 
between models at least may explain why many, but not all, publications report that 
both ETA selective and non-selective ETA/B antagonists are effective at reducing 
neointima formation.  
 
6.1.5 Role of the ETB receptor in EC 
The most compelling explanations for the observed moderating action of ETB on 
wire-induced lesion formation depend on actions of this receptor in EC such as 
stimulation of NO release (Hirata et al., 1993; Tsukahara et al., 1994; Mizuguchi et 
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al., 1997), EC mitogenesis (Goligorsky et al., 1999; Salani et al., 2000; Kuhlmann et 
al., 2005) and ET-1 clearance (Dupuis et al., 2000; Bagnall et al., 2006). 
Pharmacological tools cannot distinguish between ETB receptors expressed by 
different cell types, necessitating the use of cell-specific ETB deletion to further 
unravel the role of ETB. To understand how EC ETB might alter femoral artery 
function (and therefore neointima formation), the vasomotor responses of isolated 
femoral artery rings from EC ETB knockout animals were determined. Few 
disturbances to vascular function were apparent, importantly including endothelium-
dependent vasodilatation and vasoconstriction to ET-1. This contrasts with previous 
studies of the aorta of these mice, which were partially reproduced here, and indicate 
impaired vasodilatation to acetylcholine (Bagnall et al., 2006). Direct stimulation of 
ETB produced inconsistent responses, most reliably eliciting vasoconstriction. 
Together these data suggest that the function of EC ETB varies between vascular 
beds and is minor in the mouse femoral artery. It must be considered, however, that 
previous experience in this laboratory and inconsistency in the literature (Mizuguchi 
et al., 1997; Zhou et al., 2004) suggest that responses to ETB activation are difficult 
to reproduce in mouse vascular rings and as such may represent experimental 
limitations rather than a true physiological role. 
 
Femoral artery wire-injury was performed to determine whether deletion of ETB 
from EC alone could recapitulate the effects of pharmacological ETB blockade. 
Similarly, ligation-injuries were also studied to reveal whether deficiency of ETB 
specifically from EC alters lesion formation; for example, if a detrimental effect of 
ETB in VSMC physiologically antagonises a beneficial effect of ETB in EC. In 
neither model, however, was EC ETB deficiency found to be associated with any 
difference in measures of lesion size or volume. More subtle alterations to wire 
injury-induced lesion composition were noted, however, and possibly indicate that 
EC ETB, by some means, acts to delay lesion maturation and enhance apoptosis of 
medial VSMC. Regardless, these data suggest that in both models, any role for EC 
ETB in the regulation of neointima formation is small, which is perhaps unsurprising 
given the apparently minimal role of EC ETB in mouse femoral artery vascular 
function. Further, this contrasts with the strong effect of pharmacological ETB 
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blockade on wire-induced neointima formation (above). This suggest that ETB 
receptors expressed by other cell types offer protection against neointimal thickening 
in this model. Several possible alternative mechanisms for this response exist such as 
ETB-mediated inhibition of VSMC apoptosis (Cattaruzza et al., 2000; Lauth et al., 
2000), or stimulation of eNOS activity in neointimal VSMC (Wang et al., 2005a). 
Whilst these examples are purely speculative, this question of mechanism provides 
an intriguing avenue for further investigation. 
 
6.1.6 Relevance of findings 
Although the effects of selective ETB blockade on remodelling following vascular 
injury are mechanistically interesting, any clinical relevance is limited because no 
rationale exists for the use of the selective ETB receptor antagonists in 
cardiovascular disease patients. Selective ETA antagonists (sitaxsentan, ambrisentan) 
and non-selective ETA/B antagonists (bosentan), however, are both approved for use 
in pulmonary arterial hypertension, and are in clinical investigation for a variety of 
other conditions (e.g. systemic hypertension, chronic kidney disease; Battistini et al., 
2006). Neither antagonist strategy has been proved ultimately superior, despite much 
argument over the theoretical benefits of both treatment modalities (Bagnall & 
Webb, 2001; Battistini et al., 2006). The data presented here demonstrate that 
concurrent ETB blockade can prevent the beneficial effects of ETA blockade on 
wire-induced neointimal lesion formation. It is, therefore, tempting to suggest that 
selective ETA receptor antagonists may be superior to non-selective ETA/B agents 
in the primary prevention of diseases which feature similar remodelling processes 
such as post-interventional restenosis or vein graft disease. 
 
Beyond the primary prevention of vascular remodelling, a beneficial effect of ETA 
blockade on neointimal proliferation might indicate that selective ETA antagonists 
but not non-selective ETA/B agents have the potential to provide secondary benefits 
on other vascular proliferative/inflammatory processes, such as atherosclerosis. 
Whilst ET antagonists are never likely to be considered for primary prevention of 
atherogenesis, due to their profile of adverse effects, such an action may provide a 
secondary benefit where ET blockade is indicated for other reasons: such as the 
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treatment of resistant systemic hypertension (Battistini et al., 2006). Certainly, 
selective ET antagonists are reported to be effective at reducing lesion size in murine 
models of atherosclerosis (Barton et al., 1998; Babaei et al., 2000). Whether the 
effects of ETB blockade on femoral artery wire-injury are relevant to this process is 
more speculative and undoubtedly dependent on the mechanism through which this 
treatment increases neointimal lesion formation. Blockade of the ETB-induced NO 
release pathway, for example, might be considered to exacerbate both neointimal 
hyperplasia and atherosclerosis because NO moderates the pathogenesis of both 
conditions (Moroi et al., 1998; Kuhlencordt et al., 2001; Zhang et al., 2006). 
Conversely, inhibition of ETB-induced VSMC apoptosis might promote an unstable 
atherosclerotic plaque phenotype and, therefore, be detrimental. In this regard it is 
noteworthy that following wire-injury, combined ETA+ETB, but not selective ETA, 
blockade is associated with reduced intimal collagen and, perhaps, increased intimal 
macrophage content. In the setting of atherosclerosis both compositional changes 
might be considered to promote an unstable lesion phenotype. This question will 
ultimately be answered only with future experimentation (see below). 
 
6.2 LIMITATIONS AND FUTURE EXPERIMENTS 
The work described in this thesis has clarified the roles of ETA and ETB receptors, 
and ETB receptors expressed by EC in the response to acute vascular injury. 
Although it is apparent from these experiments that ETB receptors can exert a 
moderating effect on processes of vascular remodelling, the mechanism(s) by which 
they do so remain(s) unclear, providing an obvious avenue for future investigation. 
Further studies are also warranted both to provide additional experimental validation 
and to expand the scope of these findings. 
 
6.2.1 Further validation of EC ETB experiments 
Genetic background is an important determinant of gene expression patterns and 
cardiovascular phenotype. As such, all experiments in non genetically-modified mice 
were conducted in a single inbred strain (C57Bl/6J) known to be sensitive to wire 
injury-induced lesion formation (Roque et al., 2000; Sata et al., 2000). In studies of 
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EC ETB knockout mice, to control for variability in non-ETB gene loci, FF/tie2 (EC 
ETB-deficient) animals were directly compared with FF/-- littermates, in accordance 
with other models produced using the Cre-loxP approach (Liao et al., 2001; Ge et al., 
2006). The background on which these animals were produced, however, differs 
from that used in other experiments in this thesis, complicating direct comparisons 
between these data sets. Specifically, it is plausible that while ETB blockade 
increases wire injury-induced lesion size in the C57Bl/6 strain, it does not do so in 
the BKW/Ola/129 strain in which EC ETB knockout was created. Therefore, that 
negative results in EC ETB-deficient animals could reflect a strain difference in ETB 
function or expression. Certainly, wire-injury elicited lesions at 28 days that were 
substantially smaller in vehicle treated C57Bl6/J mice (42900 ± 3600 μm2; Chapter 
4) than in either FF/-- (73660 ± 14650 μm2) or FF/tie2 mice (70490 ± 13190 μm2; 
Chapter 5). Intima/media ratios, however, were similar between C57Bl/6J (3.1 ± 
0.3), FF/-- (3.22 ± 0.73) and FF/tie2 (3.09 ± 0.40) mice suggesting that such 
differences are a reflection of the smaller size of the C57Bl/6J strain. To address this 
question, further experiments involving the administration of A192621 to FF/-- mice 
are required. Repeated back-cross (>10 generations) of FF/-- and FF/tie2 animals on 
to the C57Bl/6J background would equally allow this question to be answered. 
Although this process is extremely time consuming, it would allow future 
experiments with FF/tie2 mice to utilize non-floxed ‘wild-type’ animals as an 
additional control and therefore enable any effect of the insertion of loxP sites in the 
ETB gene locus on outcome to be determined.  
 
An additional remaining question over the use of EC ETB knockout mice for 
vascular injury studies concerns the expression pattern of Tie2, on which specific 
deletion of ETB is dependent, by cells of the neointima. It is plausible that the EC 
that re-grow following wire-injury and denudation do not express Tie2. It is also 
possible that Tie2 may be expressed at some point during the lineage of both 
leucocytes and neointimal VSMC-like cells derived from circulating progenitors, as 
Constien et al (2001) suggest that this gene is expressed by cells of hematopoietic 
lineage. Both of these possibilities could explain the negative results from these 
studies, and could be confirmed or excluded by performing vascular injury 
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procedures in a Tie2 promoter reporter animal: for example, that produced by the 
cross of flox-STOP-flox, lacZ or GFP reporter animals and FF/tie2 mice. 
 
6.2.2 Mechanism of ETB action 
The completion of further validating experiments aside, perhaps the most interesting 
avenue for further investigation is that of the mechanism by which non-EC ETB 
receptors might act to moderate neointimal proliferation. Although basic lesion 
composition in ETB antagonist-treated mice was examined here, these studies were 
primarily designed to detect differences in morphological end points and, therefore, 
utilised a time point of lesion stabilisation at which inflammatory and proliferative 
processes are poorly represented. More conclusive observations of the effect of ETB 
blockade on inflammatory aspects of lesion formation might be drawn from 
immunohistochemistry, flow cytometry or PCR for markers of macrophages (Mac2, 
F4/80) or other leucocytes (GR-1, CD45) at more representative, earlier time points – 
macrophage content peaks ~7 days after injury (MacDonald et al, Unpublished data) 
and neutrophil accumulation within hours (Roque et al., 2000). Any effect on 
leucocyte adhesion might be determined by analysis of adhesion molecule (ICAM-1, 
VCAM-1, P-selectin) expression by the same techniques (Roque et al., 2000; Sata et 
al., 2000), or by imaging rhodamine-labeled leucocyte rolling and adhesion in vivo, 
by intra-vital microscopy (Osaka et al., 2007). Similarly, any changes in αSMA 
expression or markers of cell proliferation such as BrdU incorporation might be more 
sensitive to detection at earlier time points – neointimal proliferation peaks at ~14 
days in this model (Reis et al., 2000). VSMC apoptosis, a possible candidate for 
ETB-mediated regulation of lesion size (Cattaruzza et al., 2000; Lauth et al., 2000), 
could also be determined at this time-point (neointimal apoptosis peaks at ~14 days) 
using immunohistochemistry (terminal deoxynucleotidyl transferase dUTP nick end 
labeling) or flow cytometry (annexin V assay). The origin of neointimal VSMC-like 
cells could be determined by transplantation of GFP-labelled bone marrow and 
subsequent GFP/αSMA co-localisation in injured vessels. Alteration of extracellular 
matrix content of neointimal lesions by ETB blockade might also regulate their size 
and could be identified by biochemical assays for collagen or elastin, or by 
determining the activity of matrix degrading enzymes by zymography. 
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Whilst such observational studies might provide evidence for a mechanism of action, 
firm conclusions are prevented by the complexity of interactions between cell types 
in the developing neointima. For example, an apparent effect of ETB blockade on 
VSMC proliferation might reflect alterations in the production of mitogenic 
cytokines by macrophages rather than a direct action on VSMC. The confirmation of 
any mechanism, therefore, requires specific intervention. The further use of Cre-loxP 
cell-specific recombination approach is an obvious solution to this problem. The 
cross of transgenic SM22-Cre mice with floxed ETB mice, would allow 
determination of the effect of ETB deletion specifically from VSMC on neointimal 
lesion formation to be determined. A similar approach to reveal the role of ETB in 
macrophages on neointimal lesion formation may also be adopted, by use of a Cre-
recombinase construct driven by a macrophage specific promoter sequences such as 
that of M lysozyme (Clausen et al., 1999). A potential caveat of this approach is the 
possibility that the progenitor-derived smooth muscle-like cells, which are prevalent 
in the neointima of wire-injury induced lesions (Sata et al., 2002), may have 
abnormal expression of these markers during their lineage. Appropriate 
recombination would therefore need to be validated using Cre reporter animals. An 
alternative approach to determining the role of ETB in leucocytes on lesion 
formation would be to perform bone marrow transplantation studies between ETB 
deficient and ETB wild-type mice. In this case, however, deletion of ETB in bone 
marrow-derived neointimal VSMC-cells would be unavoidable (Sata et al., 2002). 
 
6.2.3 Other processes of vascular remodelling 
Given the apparent protection against neointimal proliferation provided by ETB 
receptor activation, and the current debate over the superiority of ETA selective or 
non-selective ETA/B antagonists, further study of the effects of ETB blockade on 
other processes of vascular remodelling might be warranted. Atherosclerosis, for 
example, bears a number of similarities to neointimal hyperplasia, but results from 
chronic rather than acute injury to the vascular wall. ETA blockade has been shown 
to inhibit atherogenesis in apoE deficient mice (Barton et al., 1998) and ETA/B 
blockade does so in LDL receptor deficient mice (Babaei et al., 2000). Neither the 
effect of selective ETB blockade nor the comparison of ETA selective and ETA/B 
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blockade, however, has been reported. Whilst tolerability issues surrounding ET 
blockade (Battistini et al., 2006) may mean ET antagonists are never likely to be 
administered solely for the prophylaxis of atherosclerosis, a beneficial anti-
atherogenic effect may provide additional rationale for use of such agents in other 
conditions where they are already indicated. Thus, experiments similar to those 
performed here in which ET antagonists are administered to an animal model of 
atherogenesis (for example, high fat-fed apoE-/- mice) and resulting lesion size and 
stability investigated, might provide clinically relevant insights into the role of ETB 
in this process. 
 
Angiogenesis is perhaps the ultimate form of vascular remodelling. It is considered 
important in the pathogenesis of several human conditions, including: cancer, 
myocardial infarction, macular degeneration and even atherosclerosis (reviewed by 
Carmeliet, 2003). ET-1 is thought to promote angiogenesis and induces an 
angiogenic phenotype in cultured endothelial cells by activation of ETB (Goligorsky 
et al., 1999; Salani et al., 2000; Kuhlmann et al., 2005). In more complex systems, 
however, the role of this EC ETB pathway in angiogenesis is less clear (Pedram et 
al., 1997; Matsuura et al., 1998; Herrmann et al., 2002), making this an ideal 
problem to address using cell-specific ETB deletion. Preliminary work in this area 
indicated that ET-1 was pro-angiogenic at low concentrations and inhibited the 
process at higher levels (Figure 6-1). Such experiments were complicated by a 
number of methodological issues, however, and as such, this strand of work was 
abandoned in favour of greater investment in vascular injury studies.  
 
6.2.4 Further development of OPT for vascular imaging 
Future development may also see the use of OPT for the examination other types of 
remodelling in small vascular structures. Atherosclerotic plaque formation, for 
example, is another widely-studied remodelling process that is also typically 
quantified by time-consuming histological analysis. Preliminary OPT scans of aortic 
arches from fat-fed apoE-/- mice clearly demonstrate atherosclerotic plaque with the 





Figure 6-1 Impact of endothelin-1 treatment on angiogenesis from aortic ring explants. 
Aortic rings were excised from male, 8-10 week old C57Bl6/J mice, cleaned of peri-adventitial material, 
embedded in matrigel basement membrane preparation and cultured in endothelial cell basal medium-2 
containing vehicle, endothelin-1 (10-12-10-7M) or corticosterone (6x10-7M). Medium and treatments were 
replaced every 2 days, and outgrowths allowed to develop for 7 days. The area of tube-like outgrowths from each 
ring was calculated from photomicrographs by morphometry. Progressive formation of tube-like structures from 
the periphery of aortic ring explants occurred from day 3, and the area of these peaked at day 7 (a). Treatment 
with endothelin-1 at the lowest dose (1pM) significantly augmented the area of outgrowth (b).  At the highest 
tested dose, endothelin-1 (100nM) significantly reduced the area of outgrowth, to a similar extent as 
corticosterone (600nM). n = 6-12. Data are mean ± SEM. ns, *, p>0.05; **, p<0.01 by two-way ANOVA with 















































    
 
 
Figure 6-2 Optical projection tomographic imaging of atherosclerotic lesions in the mouse aortic arch. 
Perfusion fixed, aortic arches from apolipoprotein E-deficient mice, fed on a western diet for 8 weeks, were subject to optical projection tomographic scanning by the methods 
developed for injured femoral arteries (section 2.5). In volume renderings of re-constructed tomograms, lesions were clearly visible in the brachiocephalic artery, the roots of the 
left common carotid and subclavian arteries and the lesser curvature of the aortic arch (a). In cross-section, these possessed atherosclerotic plaque-like morphology and could be 
distinguished from the media by their weaker fluorescent emission (b). Regions within these were devoid of fluorescence were commonly observed and may reflect sites of intra-
plaque lipid pools, which would be predicted to be removed during sample preparation. Data provided by L. Low.  
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validation of OPT for quantification of these lesions may provide advantages of 
speed and 3D analysis to studies of this process. As the traditional refractive index 
matching solution used for OPT imaging is a lipid solvent, a polar substitute, such as 
glycerol, may be necessary to preserve plaque lipid content in this setting. 
Alternatively, as has been suggested for ex vivo MRI of atherosclerotic arteries, such 
removal of lipids may provide a means to estimate the volume of extracellular lipid 
pools within plaques by measurement of the empty regions of plaque that remain 
after treatment with solvent (McAteer et al., 2004). 
 
An additional potential development of the OPT technique is the use of whole-mount 
immunofluoresence to enable the imaging of volume and distribution of particular 
cell types or other antigens (Sharpe et al., 2002; Alanentalo et al., 2007). This was, 
again, the subject of preliminary investigations. These, however, yielded little 
success due to the difficulties of antibody penetration in whole tissues and non-
specific binding of antibodies during the necessarily long reagent incubations. 
Further investigation of this possibility would require careful optimization of 
incubation and washing times, blocking reagent constitution and testing of 
alternative primary antibodies, for example, F(ab)2 antibody fragments which may 























6.3 SUMMARY OF CONCLUSIONS 
The role of ETA and ETB receptors in the remodelling that occurs following acute 
injury to the vascular wall was determined using selective pharmacological 
antagonists in two murine models of this process. These studies were extended to 
mice in which ETB receptors are selectively knocked-down in EC, thereby 
elucidating any role for ETB in EC without the confounding effects of ETB blockade 
in other cells. This work was intended to address the mechanism by which 
endogenous ETs modulate vascular remodelling and, therefore, to inform the clinical 
use of ETA selective and non-selective ETA/B antagonists in conditions in which 
similar processes may occur in man. The major findings of this project were: 
 
• Complete ligation of the femoral artery is a robust model of neointimal 
hyperplasia and results in impairments to contractile function and 
endothelium-dependent vasodilatation, independent of neointima formation. 
• OPT is a powerful technique for the rapid, non-destructive 3D evaluation of 
neointimal lesion size in small arteries 
• ETA receptors mediate exacerbation of neointima formation following acute 
arterial injury 
• ETB receptors moderate neointima formation following acute arterial injury 
through a mechanism other than blood pressure elevation, but this effect is 
dependent on the mode of vascular injury 
• Concurrent ETB blockade prevents the beneficial effect of ETA blockade on 
neointima formation 
• In the mouse femoral artery, ETB expressed by EC plays little role in 
modulating either vascular function, or neointima formation. 
 
The results of these studies, therefore, indicate that the ETB receptor acts to 
moderate the detrimental effect of endogenous ETs on the ETA receptor in this 
setting of acute vascular injury. As such, selective ETA receptor antagonists may 
offer benefits over non-selective ETA/B antagonists in similar conditions in man. 
Further experiments are required to confirm and reveal how ETB receptors on non-























Abassi, Z.A., Tate, J.E., Golomb, E., and Keiser, H.R. (1992). Role of neutral endopeptidase 
in the metabolism of endothelin. Hypertension 20, 89-95. 
Achmad, T.H., and Rao, G.S. (1992). Chemotaxis of human blood monocytes toward 
endothelin-1 and the influence of calcium channel blockers. Biochemical and biophysical 
research communications 189, 994-1000. 
Ahn, D., Ge, Y., Stricklett, P.K., Gill, P., Taylor, D., Hughes, A.K., Yanagisawa, M., Miller, 
L., Nelson, R.D., and Kohan, D.E. (2004). Collecting duct-specific knockout of endothelin-1 
causes hypertension and sodium retention. J Clin Invest 114, 504-511. 
Alanentalo, T., Asayesh, A., Morrison, H., Loren, C.E., Holmberg, D., Sharpe, J., and 
Ahlgren, U. (2007). Tomographic molecular imaging and 3D quantification within adult 
mouse organs. Nat Methods 4, 31-33. 
Ameli, S., Kaul, S., Castro, L., Arora, C., Mirea, A., and Shah, P.K. (1993). Effect of 
percutaneous transluminal coronary angioplasty on circulating endothelin levels. The 
American journal of cardiology 72, 1352-1356. 
Amiri, F., Paradis, P., Reudelhuber, T.L., and Schiffrin, E.L. (2008). Vascular inflammation 
in absence of blood pressure elevation in transgenic murine model overexpressing 
endothelin-1 in endothelial cells. Journal of hypertension 26, 1102-1109. 
Amiri, F., Virdis, A., Neves, M.F., Iglarz, M., Seidah, N.G., Touyz, R.M., Reudelhuber, 
T.L., and Schiffrin, E.L. (2004). Endothelium-restricted overexpression of human 
endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110, 2233-
2240. 
Anggard, E., Galton, S., Rae, G., Thomas, R., McLoughlin, L., de Nucci, G., and Vane, J.R. 
(1989). The fate of radioiodinated endothelin-1 and endothelin-3 in the rat. Journal of 
cardiovascular pharmacology 13 Suppl 5, S46-49; discussion S74. 
Arai, H., Hori, S., Aramori, I., Ohkubo, H., and Nakanishi, S. (1990). Cloning and 
expression of a cDNA encoding an endothelin receptor. Nature 348, 730-732. 
Arinami, T., Ishikawa, M., Inoue, A., Yanagisawa, M., Masaki, T., Yoshida, M.C., and 
Hamaguchi, H. (1991). Chromosomal assignments of the human endothelin family genes: 
the endothelin-1 gene (EDN1) to 6p23-p24, the endothelin-2 gene (EDN2) to 1p34, and the 
endothelin-3 gene (EDN3) to 20q13.2-q13.3. Am J Hum Genet 48, 990-996. 
Arthur, J.F., Yin, Z.L., Young, H.M., and Dusting, G.J. (1997). Induction of nitric oxide 
synthase in the neointima induced by a periarterial collar in rabbits. Arterioscler Thromb 
Vasc Biol 17, 737-740. 
Asahara, T., Bauters, C., Pastore, C., Kearney, M., Rossow, S., Bunting, S., Ferrara, N., 
Symes, J.F., and Isner, J.M. (1995). Local delivery of vascular endothelial growth factor 
accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat 
carotid artery. Circulation 91, 2793-2801. 
Axel, D.I., Kunert, W., Goggelmann, C., Oberhoff, M., Herdeg, C., Kuttner, A., Wild, D.H., 
Brehm, B.R., Riessen, R., Koveker, G., et al. (1997). Paclitaxel inhibits arterial smooth 
224 
 
muscle cell proliferation and migration in vitro and in vivo using local drug delivery. 
Circulation 96, 636-645. 
Azuma, H., Funayama, N., Kubota, T., and Ishikawa, M. (1990). Regeneration of endothelial 
cells after balloon denudation of the rabbit carotid artery and changes in responsiveness. 
Japanese journal of pharmacology 52, 541-552. 
Azuma, H., Hamasaki, H., Niimi, Y., Terada, T., and Matsubara, O. (1994). Role of 
endothelin-1 in neointima formation after endothelial removal in rabbit carotid arteries. Am J 
Physiol 267, H2259-2267. 
Azuma, H., Hamasaki, H., Sato, J., Isotani, E., Obayashi, S., and Matsubara, O. (1995a). 
Different localization of ETA and ETB receptors in the hyperplastic vascular wall. Journal of 
cardiovascular pharmacology 25, 802-809. 
Azuma, H., Sato, J., Hamasaki, H., Sugimoto, A., Isotani, E., and Obayashi, S. (1995b). 
Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of 
L-arginine in regenerated endothelial cells. Br J Pharmacol 115, 1001-1004. 
Azuma, H., Sato, J., Masuda, H., Goto, M., Tamaoki, S., Sugimoto, A., Hamasaki, H., and 
Yamashita, H. (1999). ATZ1993, an orally active and novel nonpeptide antagonist for 
endothelin receptors and inhibition of intimal hyperplasia after balloon denudation of the 
rabbit carotid artery. Japanese journal of pharmacology 81, 21-28. 
Babaei, S., Picard, P., Ravandi, A., Monge, J.C., Lee, T.C., Cernacek, P., and Stewart, D.J. 
(2000). Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor 
deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc Res 48, 
158-167. 
Bagnall, A., and Webb, D. (2001). Are selective endothelin A receptor antagonists better 
than mixed antagonists? Journal of cardiovascular pharmacology 38 Suppl 2, S43-46. 
Bagnall, A.J., Kelland, N.F., Gulliver-Sloan, F., Davenport, A.P., Gray, G.A., Yanagisawa, 
M., Webb, D.J., and Kotelevtsev, Y.V. (2006). Deletion of endothelial cell endothelin B 
receptors does not affect blood pressure or sensitivity to salt. Hypertension 48, 286-293. 
Banai, S., Wolf, Y., Golomb, G., Pearle, A., Waltenberger, J., Fishbein, I., Schneider, A., 
Gazit, A., Perez, L., Huber, R., et al. (1998). PDGF-receptor tyrosine kinase blocker 
AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal 
formation after balloon angioplasty in swine. Circulation 97, 1960-1969. 
Barnes, K., Brown, C., and Turner, A.J. (1998). Endothelin-converting enzyme: 
ultrastructural localization and its recycling from the cell surface. Hypertension 31, 3-9. 
Barolet, A.W., Babaei, S., Robinson, R., Picard, P., Tsui, W., Nili, N., Mohamed, F., 
Ornatsky, O., Sparkles, J.D., Stewart, D.J., et al. (2001). Administration of exogenous 
endothelin-1 following vascular balloon injury: early and late effects on intimal hyperplasia. 
Cardiovascular research 52, 468-476. 
Barton, M., Haudenschild, C.C., d'Uscio, L.V., Shaw, S., Munter, K., and Luscher, T.F. 
(1998). Endothelin ETA receptor blockade restores NO-mediated endothelial function and 
225 
 
inhibits atherosclerosis in apolipoprotein E-deficient mice. Proceedings of the National 
Academy of Sciences of the United States of America 95, 14367-14372. 
Bath, P.M., Hassall, D.G., Gladwin, A.M., Palmer, R.M., and Martin, J.F. (1991). Nitric 
oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and 
adhesion to endothelium in vitro. Arterioscler Thromb 11, 254-260. 
Battistini, B., Berthiaume, N., Kelland, N.F., Webb, D.J., and Kohan, D.E. (2006). Profile of 
past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" 
class of drug. Exp Biol Med (Maywood) 231, 653-695. 
Battistini, B., Chailler, P., D'Orleans-Juste, P., Briere, N., and Sirois, P. (1993). Growth 
regulatory properties of endothelins. Peptides 14, 385-399. 
Baynash, A.G., Hosoda, K., Giaid, A., Richardson, J.A., Emoto, N., Hammer, R.E., and 
Yanagisawa, M. (1994). Interaction of endothelin-3 with endothelin-B receptor is essential 
for development of epidermal melanocytes and enteric neurons. Cell 79, 1277-1285. 
Berne, R.M., and Levy, M.N. (2000). Principles of Physiology, Third edn (Mosby). 
Berthiaume, N., Yanagisawa, M., and D'Orleans-Juste, P. (2000a). Contribution of 
endogenous endothelin-1 and endothelin-A-receptors to the hypertensive state of endothelin-
B heterozygous (+/-) knockout mice. Journal of cardiovascular pharmacology 36, S72-74. 
Berthiaume, N., Yanagisawa, M., Labonte, J., and D'Orleans-Juste, P. (2000b). 
Heterozygous knock-Out of ET(B) receptors induces BQ-123-sensitive hypertension in the 
mouse. Hypertension 36, 1002-1007. 
Bhattacharya, I., Mundy, A.L., Widmer, C.C., Kretz, M., and Barton, M. (2008). Regional 
Heterogeneity of Functional Changes in Conduit Arteries After High-fat Diet. Obesity 
(Silver Spring) 16, 743-748. 
Birukov, K.G., Shirinsky, V.P., Stepanova, O.V., Tkachuk, V.A., Hahn, A.W., Resink, T.J., 
and Smirnov, V.N. (1995). Stretch affects phenotype and proliferation of vascular smooth 
muscle cells. Mol Cell Biochem 144, 131-139. 
Bittl, J.A., Strony, J., Brinker, J.A., Ahmed, W.H., Meckel, C.R., Chaitman, B.R., 
Maraganore, J., Deutsch, E., and Adelman, B. (1995). Treatment with bivalirudin (Hirulog) 
as compared with heparin during coronary angioplasty for unstable or postinfarction angina. 
Hirulog Angioplasty Study Investigators. The New England journal of medicine 333, 764-
769. 
Blackwell, K.A., Sorenson, J.P., Richardson, D.M., Smith, L.A., Suda, O., Nath, K., and 
Katusic, Z.S. (2004). Mechanisms of aging-induced impairment of endothelium-dependent 
relaxation: role of tetrahydrobiopterin. Am J Physiol Heart Circ Physiol 287, H2448-2453. 
Blanc-Brude, O.P., Yu, J., Simosa, H., Conte, M.S., Sessa, W.C., and Altieri, D.C. (2002). 
Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med 8, 987-994. 
226 
 
Bloch, K.D., Hong, C.C., Eddy, R.L., Shows, T.B., and Quertermous, T. (1991). cDNA 
cloning and chromosomal assignment of the endothelin 2 gene: vasoactive intestinal 
contractor peptide is rat endothelin 2. Genomics 10, 236-242. 
Bohm, F., Beltran, E., and Pernow, J. (2005). Endothelin receptor blockade improves 
endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition. 
J Intern Med 257, 263-271. 
Bohm, F., Johansson, B.L., Hedin, U., Alving, K., and Pernow, J. (2002). Enhanced 
vasoconstrictor effect of big endothelin-1 in patients with atherosclerosis: relation to 
conversion to endothelin-1. Atherosclerosis 160, 215-222. 
Bohm, F., Settergren, M., and Pernow, J. (2007). Vitamin C blocks vascular dysfunction and 
release of interleukin-6 induced by endothelin-1 in humans in vivo. Atherosclerosis 190, 
408-415. 
Bonthu, S., Heistad, D.D., Chappell, D.A., Lamping, K.G., and Faraci, F.M. (1997). 
Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation 
in genetically altered hyperlipidemic mice. Arterioscler Thromb Vasc Biol 17, 2333-2340. 
Booth, R.F., Martin, J.F., Honey, A.C., Hassall, D.G., Beesley, J.E., and Moncada, S. (1989). 
Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by 
perivascular manipulation. Atherosclerosis 76, 257-268. 
Boros, M., Massberg, S., Baranyi, L., Okada, H., and Messmer, K. (1998). Endothelin 1 
induces leukocyte adhesion in submucosal venules of the rat small intestine. 
Gastroenterology 114, 103-114. 
Boulanger, C., and Luscher, T.F. (1990). Release of endothelin from the porcine aorta. 
Inhibition by endothelium-derived nitric oxide. J Clin Invest 85, 587-590. 
Brody, J.I., Capuzzi, D.M., and Fink, G.B. (1996). In situ endothelin in coronary artery 
disease. Angiology 47, 1027-1032. 
Brown, K.D., and Littlewood, C.J. (1989). Endothelin stimulates DNA synthesis in Swiss 
3T3 cells. Synergy with polypeptide growth factors. The Biochemical journal 263, 977-980. 
Bucana, C.D., Trial, J., Papp, A.C., and Wu, K.K. (1988). Bovine aorta endothelial cell 
incubation with interleukin 2: morphological changes correlate with enhanced vascular 
permeability. Scanning Microsc 2, 1559-1566. 
Buchwald, A.B., Hammerschmidt, S., Stevens, J., Goring, J., Nebendahl, K., and Unterberg, 
C. (1996). Inhibition of neointimal proliferation after coronary angioplasty by low-
molecular-weight heparin (clivarine) and polyethyleneglycol-hirudin. Journal of 
cardiovascular pharmacology 28, 481-487. 
Buck, R.C. (1961). Intimal Thickening After Ligature of Arteries An Electron-Microscopic 
Study. Circulation research 9, 418-426. 
Buffon, A., Liuzzo, G., Biasucci, L.M., Pasqualetti, P., Ramazzotti, V., Rebuzzi, A.G., Crea, 
F., and Maseri, A. (1999). Preprocedural serum levels of C-reactive protein predict early 
227 
 
complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 34, 1512-
1521. 
Bullock, G.R., Taylor, S.G., and Weston, A.H. (1986). Influence of the vascular endothelium 
on agonist-induced contractions and relaxations in rat aorta. Br J Pharmacol 89, 819-830. 
Burke, S.E., Lubbers, N.L., Chen, Y.W., Hsieh, G.C., Mollison, K.W., Luly, J.R., and 
Wegner, C.D. (1999). Neointimal formation after balloon-induced vascular injury in Yucatan 
minipigs is reduced by oral rapamycin. Journal of cardiovascular pharmacology 33, 829-835. 
Burke, S.E., Lubbers, N.L., Gagne, G.D., Wessale, J.L., Dayton, B.D., Wegner, C.D., and 
Opgenorth, T.J. (1997). Selective antagonism of the ET(A) receptor reduces neointimal 
hyperplasia after balloon-induced vascular injury in pigs. Journal of cardiovascular 
pharmacology 30, 33-41. 
Burrell, K.M., Molenaar, P., Dawson, P.J., and Kaumann, A.J. (2000). Contractile and 
arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 
209670. The Journal of pharmacology and experimental therapeutics 292, 449-459. 
Busse, R., Edwards, G., FÈlÈtou, M., Fleming, I., Vanhoutte, P.M., and Weston, A.H. 
(2002). EDHF: bringing the concepts together. Trends in Pharmacological Sciences 23, 374-
380. 
Calne, R.Y., Collier, D.S., Lim, S., Pollard, S.G., Samaan, A., White, D.J., and Thiru, S. 
(1989). Rapamycin for immunosuppression in organ allografting. Lancet 2, 227. 
Cambrey, A.D., Harrison, N.K., Dawes, K.E., Southcott, A.M., Black, C.M., du Bois, R.M., 
Laurent, G.J., and McAnulty, R.J. (1994). Increased levels of endothelin-1 in 
bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast 
mitogenic activity in vitro. Am J Respir Cell Mol Biol 11, 439-445. 
Camenzind, E., Steg, P.G., and Wijns, W. (2007). Stent thrombosis late after implantation of 
first-generation drug-eluting stents: a cause for concern. Circulation 115, 1440-1455; 
discussion 1455. 
Cardillo, C., Kilcoyne, C.M., Cannon, R.O., 3rd, and Panza, J.A. (2000). Increased activity 
of endogenous endothelin in patients with hypercholesterolemia. J Am Coll Cardiol 36, 
1483-1488. 
Carmeliet, P. (2003). Angiogenesis in health and disease. Nat Med 9, 653-660. 
Carmeliet, P., Moons, L., Dewerchin, M., Rosenberg, S., Herbert, J.M., Lupu, F., and 
Collen, D. (1998). Receptor-independent role of urokinase-type plasminogen activator in 
pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing 
in mice. J Cell Biol 140, 233-245. 
Carmeliet, P., Moons, L., Stassen, J.M., De Mol, M., Bouche, A., van den Oord, J.J., Kockx, 
M., and Collen, D. (1997). Vascular wound healing and neointima formation induced by 
perivascular electric injury in mice. Am J Pathol 150, 761-776. 
228 
 
Caro, C.G., Fitz-Gerald, J.M., and Schroter, R.C. (1971). Atheroma and arterial wall shear. 
Observation, correlation and proposal of a shear dependent mass transfer mechanism for 
atherogenesis. Proc R Soc Lond B Biol Sci 177, 109-159. 
Cattaruzza, M., Dimigen, C., Ehrenreich, H., and Hecker, M. (2000). Stretch-induced 
endothelin B receptor-mediated apoptosis in vascular smooth muscle cells. FASEB J 14, 
991-998. 
Chamberlain, J., Evans, D., King, A., Dewberry, R., Dower, S., Crossman, D., and Francis, 
S. (2006). Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating 
cells modulates the extent of neointima formation in mice. Am J Pathol 168, 1396-1403. 
Chamley-Campbell, J., Campbell, G.R., and Ross, R. (1979). The smooth muscle cell in 
culture. Physiol Rev 59, 1-61. 
Chamley-Campbell, J.H., and Campbell, G.R. (1981). What controls smooth muscle 
phenotype? Atherosclerosis 40, 347-357. 
Chamley-Campbell, J.H., Campbell, G.R., and Ross, R. (1981). Phenotype-dependent 
response of cultured aortic smooth muscle to serum mitogens. J Cell Biol 89, 379-383. 
Chandra, S., Clark, L.V., Coatney, R.W., Phan, L., Sarkar, S.K., and Ohlstein, E.H. (1998). 
Application of serial in vivo magnetic resonance imaging to evaluate the efficacy of 
endothelin receptor antagonist SB 217242 in the rat carotid artery model of neointima 
formation. Circulation 97, 2252-2258. 
Chanez, P., Vignola, A.M., Albat, B., Springall, D.R., Polak, J.M., Godard, P., and 
Bousquet, J. (1996). Involvement of endothelin in mononuclear phagocyte inflammation in 
asthma. J Allergy Clin Immunol 98, 412-420. 
Chaux, A., Ruan, X.M., Fishbein, M.C., Ouyang, Y., Kaul, S., Pass, J.A., and Matloff, J.M. 
(1998). Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein 
grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg 115, 604-612; 
discussion 612-604. 
Chen, G., Suzuki, H., and Weston, A.H. (1988). Acetylcholine releases endothelium-derived 
hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol 95, 1165-1174. 
Cho, A., and Reidy, M.A. (2002). Matrix metalloproteinase-9 is necessary for the regulation 
of smooth muscle cell replication and migration after arterial injury. Circulation research 91, 
845-851. 
Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., and Forster, I. (1999). Conditional 
gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8, 
265-277. 
Clopath, P. (1980). The effect of acetylsalicylic acid (ASA) on the development of 
atherosclerotic lesions in miniature swine. Br J Exp Pathol 61, 440-443. 
Clouthier, D.E., Hosoda, K., Richardson, J.A., Williams, S.C., Yanagisawa, H., Kuwaki, T., 
Kumada, M., Hammer, R.E., and Yanagisawa, M. (1998). Cranial and cardiac neural crest 
229 
 
defects in endothelin-A receptor-deficient mice. Development (Cambridge, England) 125, 
813-824. 
Clowes, A.W., and Karnowsky, M.J. (1977). Suppression by heparin of smooth muscle cell 
proliferation in injured arteries. Nature 265, 625-626. 
Clowes, A.W., Reidy, M.A., and Clowes, M.M. (1983). Kinetics of cellular proliferation 
after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 49, 
327-333. 
Clowes, A.W., Ryan, G.B., Breslow, J.L., and Karnovsky, M.J. (1976). Absence of enhanced 
intimal thickening in the response of the carotid arterial wall to endothelial injury in 
hypercholesterolemic rats. Lab Invest 35, 6-17. 
Clozel, M., Breu, V., Burri, K., Cassal, J.M., Fischli, W., Gray, G.A., Hirth, G., Loffler, 
B.M., Muller, M., Neidhart, W., et al. (1993). Pathophysiological role of endothelin revealed 
by the first orally active endothelin receptor antagonist. Nature 365, 759-761. 
Clozel, M., Gray, G.A., Breu, V., Loffler, B.M., and Osterwalder, R. (1992). The endothelin 
ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochemical and 
biophysical research communications 186, 867-873. 
Clozel, M., and Salloukh, H. (2005). Role of endothelin in fibrosis and anti-fibrotic potential 
of bosentan. Ann Med 37, 2-12. 
Cole, C.W., Hagen, P.O., Lucas, J.F., Mikat, E.M., O'Malley, M.K., Radic, Z.S., Makhoul, 
R.G., and McCann, R.L. (1987). Association of polymorphonuclear leukocytes with sites of 
aortic catheter-induced injury in rabbits. Atherosclerosis 67, 229-236. 
Constien, R., Forde, A., Liliensiek, B., Grone, H.J., Nawroth, P., Hammerling, G., and 
Arnold, B. (2001). Characterization of a novel EGFP reporter mouse to monitor Cre 
recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30, 36-44. 
Cooney, R., Hynes, S.O., Sharif, F., Howard, L., and O'Brien, T. (2007). Effect of gene 
delivery of NOS isoforms on intimal hyperplasia and endothelial regeneration after balloon 
injury. Gene therapy 14, 396-404. 
Coons, A. (1941). Immunological properties of an antibody containing a fluorescent group. 
Proc Soc Exp Biol Med, 200-202. 
Cooper, D.R., Lewis, G.P., Lieberman, G.E., Webb, H., and Westwick, J. (1979). ADP 
metabolism in vascular tissue, a possible thrombo-regulatory mechanism. Thromb Res 14, 
901-914. 
Corson, M.A., James, N.L., Latta, S.E., Nerem, R.M., Berk, B.C., and Harrison, D.G. 
(1996). Phosphorylation of Endothelial Nitric Oxide Synthase in Response to Fluid Shear 
Stress. Circulation research 79, 984-991. 
Crauwels, H.M., Van Hove, C.E., Herman, A.G., and Bult, H. (2000). Heterogeneity in 




Cristiani, C., Volpi, D., Landonio, A., and Bertolero, F. (1994). Endothelin-1-selective 
binding sites are downregulated by transforming growth factor-beta and upregulated by basic 
fibroblast growth factor in a vascular smooth muscle-derived cell line. Journal of 
cardiovascular pharmacology 23, 988-994. 
Crook, M.F., Newby, A.C., and Southgate, K.M. (2000). Expression of intercellular 
adhesion molecules in human saphenous veins: effects of inflammatory cytokines and 
neointima formation in culture. Atherosclerosis 150, 33-41. 
Cui, P., Tani, K., Kitamura, H., Okumura, Y., Yano, M., Inui, D., Tamaki, T., Sone, S., and 
Kido, H. (2001). A novel bioactive 31-amino acid endothelin-1 is a potent chemotactic 
peptide for human neutrophils and monocytes. J Leukoc Biol 70, 306-312. 
Cunningham, K.S., and Gotlieb, A.I. (2005). The role of shear stress in the pathogenesis of 
atherosclerosis. Lab Invest 85, 9-23. 
Cunningham, M.E., Huribal, M., Bala, R.J., and McMillen, M.A. (1997). Endothelin-1 and 
endothelin-4 stimulate monocyte production of cytokines. Crit Care Med 25, 958-964. 
Danenberg, H.D., Fishbein, I., Epstein, H., Waltenberger, J., Moerman, E., Monkkonen, J., 
Gao, J., Gathi, I., Reichi, R., and Golomb, G. (2003). Systemic depletion of macrophages by 
liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat 
carotid artery. Journal of cardiovascular pharmacology 42, 671-679. 
Dao, H.H., Bouvet, C., Moreau, S., Beaucage, P., Lariviere, R., Servant, M., de Champlain, 
J., and Moreau, P. (2006). Endothelin is a dose-dependent trophic factor and a mitogen in 
small arteries in vivo. Cardiovasc Res. 
Daou, G.B., and Srivastava, A.K. (2004). Reactive oxygen species mediate endothelin-1-
induced activation of ERK1/2, PKB, and Pyk2 signaling, as well as protein synthesis, in 
vascular smooth muscle cells. Free Radic Biol Med 37, 208-215. 
Dashwood, M.R., Barker, S.G.E., Muddle, J.R., Yacoub, M.H., and Martin, J.F. (1993). [I-
125] Endothelin-1 Binding to Vasa Vasorum and Regions of Neovascularization in Human 
and Porcine Blood-Vessels - a Possible Role for Endothelin in Intimal Hyperplasia and 
Atherosclerosis. Journal of cardiovascular pharmacology 22, S343-S347. 
Dashwood, M.R., Mehta, D., Izzat, M.B., Timm, M., Bryan, A.J., Angelini, G.D., and 
Jeremy, J.Y. (1998). Distribution of endothelin-1 (ET) receptors (ETA and ETB) and 
immunoreactive ET-1 in porcine saphenous vein carotid artery interposition grafts. 
Atherosclerosis 137, 233-242. 
Dashwood, M.R., Noertersheuser, P., Kirchengast, M., and Munter, K. (1999). Altered 
endothelin-1 binding following balloon angioplasty of pig coronary arteries: effect of the 
ETA receptor antagonist, LU 135252. Cardiovascular research 43, 445-456. 
Davenport, A.P. (2002). International Union of Pharmacology. XXIX. Update on endothelin 
receptor nomenclature. Pharmacol Rev 54, 219-226. 
Davenport, A.P., and Kuc, R.E. (2004). Down-regulation of ETA Receptors in ETB 
Receptor-deficient Mice. Journal of cardiovascular pharmacology 44 Suppl 1, S276-278. 
231 
 
Davenport, A.P., Kuc, R.E., Maguire, J.J., and Harland, S.P. (1995a). ETA receptors 
predominate in the human vasculature and mediate constriction. Journal of cardiovascular 
pharmacology 26 Suppl 3, S265-267. 
Davenport, A.P., O'Reilly, G., and Kuc, R.E. (1995b). Endothelin ETA and ETB mRNA and 
receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-
type. Br J Pharmacol 114, 1110-1116. 
De Keulenaer, G.W., Chappell, D.C., Ishizaka, N., Nerem, R.M., Alexander, R.W., and 
Griendling, K.K. (1998). Oscillatory and steady laminar shear stress differentially affect 
human endothelial redox state: role of a superoxide-producing NADH oxidase. Circulation 
research 82, 1094-1101. 
De Meyer, G.R., Bult, H., and Herman, A.G. (1992). Selective muscarinic alterations of 
nitric oxide-mediated relaxations by neointima. Journal of cardiovascular pharmacology 20 
Suppl 12, S205-207. 
De Meyer, G.R., Bult, H., Martin, J.F., Van Hoydonck, A.E., and Herman, A.G. (1990). The 
effect of a developing neo-intima on serotonergic and adrenergic contractions. Eur J 
Pharmacol 187, 519-524. 
De Meyer, G.R., Bult, H., Ustunes, L., Kockx, M., Jordaens, F.H., Zonnekeyn, L.L., and 
Herman, A.G. (1994). Vasoconstrictor responses after neo-intima formation and endothelial 
removal in the rabbit carotid artery. Br J Pharmacol 112, 471-476. 
De Meyer, G.R., Bult, H., Van Hoydonck, A.E., Jordaens, F.H., Buyssens, N., and Herman, 
A.G. (1991). Neointima formation impairs endothelial muscarinic receptors while enhancing 
prostacyclin-mediated responses in the rabbit carotid artery. Circulation research 68, 1669-
1680. 
de Nucci, G., Thomas, R., D'Orleans-Juste, P., Antunes, E., Walder, C., Warner, T.D., and 
Vane, J.R. (1988). Pressor effects of circulating endothelin are limited by its removal in the 
pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing 
factor. Proceedings of the National Academy of Sciences of the United States of America 85, 
9797-9800. 
De Servi, S., Mazzone, A., Ricevuti, G., Fioravanti, A., Bramucci, E., Angoli, L., Stefano, 
G., and Specchia, G. (1990). Granulocyte activation after coronary angioplasty in humans. 
Circulation 82, 140-146. 
Denault, J.B., D'Orleans-Juste, P., Masaki, T., and Leduc, R. (1995). Inhibition of 
convertase-related processing of proendothelin-1. Journal of cardiovascular pharmacology 
26 Suppl 3, S47-50. 
Dhaun, N., Goddard, J., and Webb, D.J. (2006). The endothelin system and its antagonism in 
chronic kidney disease. J Am Soc Nephrol 17, 943-955. 
Di Luozzo, G., Bhargava, J., and Powell, R.J. (2000). Vascular smooth muscle cell effect on 
endothelial cell endothelin-1 production. J Vasc Surg 31, 781-789. 
232 
 
Diep, Q.N., Intengan, H.D., and Schiffrin, E.L. (2000). Endothelin-1 Attenuates {omega}3 
Fatty Acid-Induced Apoptosis by Inhibition of Caspase 3. Hypertension 35, 287-291. 
Dong, F., Zhang, X.C., Wold, L.E., Ren, Q., Zhang, Z.J., and Ren, J. (2005). Endothelin-1 
enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein 
endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. British journal of 
pharmacology 145, 323-333. 
Douglas, J.S., Jr., Holmes, D.R., Jr., Kereiakes, D.J., Grines, C.L., Block, E., Ghazzal, Z.M., 
Morris, D.C., Liberman, H., Parker, K., Jurkovitz, C., et al. (2005). Coronary stent restenosis 
in patients treated with cilostazol. Circulation 112, 2826-2832. 
Douglas, S.A., Louden, C., Vickery-Clark, L.M., Storer, B.L., Hart, T., Feuerstein, G.Z., 
Elliott, J.D., and Ohlstein, E.H. (1994). A role for endogenous endothelin-1 in neointimal 
formation after rat carotid artery balloon angioplasty. Protective effects of the novel 
nonpeptide endothelin receptor antagonist SB 209670. Circulation research 75, 190-197. 
Douglas, S.A., and Ohlstein, E.H. (1993). Endothelin-1 promotes neointima formation after 
balloon angioplasty in the rat. Journal of cardiovascular pharmacology 22 Suppl 8, S371-
373. 
Douglas, S.A., Vickery-Clark, L.M., Louden, C., Elliott, J.D., and Ohlstein, E.H. (1995a). 
Endothelin receptor subtypes in the pathogenesis of angioplasty-induced neointima 
formation in the rat: a comparison of selective ETA receptor antagonism and dual ETA/ETB 
receptor antagonism using BQ-123 and SB 209670. Journal of cardiovascular pharmacology 
26 Suppl 3, S186-189. 
Douglas, S.A., Vickery-Clark, L.M., Louden, C., and Ohlstein, E.H. (1995b). Selective ETA 
receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima 
formation in the rat. Cardiovasc Res 29, 641-646. 
Dover, A.R., Hadoke, P.W., Macdonald, L.J., Miller, E., Newby, D.E., and Walker, B.R. 
(2007). Intravascular glucocorticoid metabolism during inflammation and injury in mice. 
Endocrinology 148, 166-172. 
Duerrschmidt, N., Wippich, N., Goettsch, W., Broemme, H.J., and Morawietz, H. (2000). 
Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochemical and 
biophysical research communications 269, 713-717. 
Dupuis, J., Jasmin, J.F., Prie, S., and Cernacek, P. (2000). Importance of local production of 
endothelin-1 and of the ET(B)Receptor in the regulation of pulmonary vascular tone. Pulm 
Pharmacol Ther 13, 135-140. 
Eguchi, S., Hirata, Y., Ihara, M., Yano, M., and Marumo, F. (1992). A novel ETA antagonist 
(BQ-123) inhibits endothelin-1-induced phosphoinositide breakdown and DNA synthesis in 
rat vascular smooth muscle cells. FEBS Lett 302, 243-246. 
Eguchi, S., Hirata, Y., Imai, T., Kanno, K., and Marumo, F. (1994). Phenotypic change of 




Ehrenreich, H., Anderson, R.W., Fox, C.H., Rieckmann, P., Hoffman, G.S., Travis, W.D., 
Coligan, J.E., Kehrl, J.H., and Fauci, A.S. (1990). Endothelins, peptides with potent 
vasoactive properties, are produced by human macrophages. J Exp Med 172, 1741-1748. 
Elferink, J.G., and de Koster, B.M. (1994). Endothelin-induced activation of neutrophil 
migration. Biochem Pharmacol 48, 865-871. 
Elmarakby, A.A., Dabbs Loomis, E., Pollock, J.S., and Pollock, D.M. (2004). ETA receptor 
blockade attenuates hypertension and decreases reactive oxygen species in ETB receptor-
deficient rats. Journal of cardiovascular pharmacology 44 Suppl 1, S7-10. 
Emoto, N., and Yanagisawa, M. (1995). Endothelin-converting enzyme-2 is a membrane-
bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 
270, 15262-15268. 
Espinosa, G., Lopez Farre, A., Cernadas, M.R., Manzarbeitia, F., Tan, D., Digiuni, E., 
Mosquera, J.R., Monton, M., Millas, I., Hernando, L., et al. (1996). Role of endothelin in the 
pathophysiology of renal ischemia-reperfusion in normal rabbits. Kidney Int 50, 776-782. 
Essed, C.E., Van den Brand, M., and Becker, A.E. (1983). Transluminal coronary 
angioplasty and early restenosis. Fibrocellular occlusion after wall laceration. Br Heart J 49, 
393-396. 
Feihl, F., Liaudet, L., Levy, B.I., and Waeber, B. (2008). Hypertension and microvascular 
remodelling. Cardiovasc Res 78, 274-285. 
Feldman, L.J., Aguirre, L., Ziol, M., Bridou, J.P., Nevo, N., Michel, J.B., and Steg, P.G. 
(2000). Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in 
hypercholesterolemic rabbits. Circulation 101, 908-916. 
Feng, A.N., Chen, Y.L., Chen, Y.T., Ding, Y.Z., and Lin, S.J. (1999). Red wine inhibits 
monocyte chemotactic protein-1 expression and modestly reduces neointimal hyperplasia 
after balloon injury in cholesterol-Fed rabbits. Circulation 100, 2254-2259. 
Fernandez-Patron, C., Radomski, M.W., and Davidge, S.T. (1999). Vascular matrix 
metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circulation 
research 85, 906-911. 
Fernandez-Patron, C., Zouki, C., Whittal, R., Chan, J.S., Davidge, S.T., and Filep, J.G. 
(2001). Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through 
generation of endothelin-1[1-32]. Faseb J 15, 2230-2240. 
Ferns, G.A., Forster, L., Stewart-Lee, A., Konneh, M., Nourooz-Zadeh, J., and Anggard, 
E.E. (1992). Probucol inhibits neointimal thickening and macrophage accumulation after 
balloon injury in the cholesterol-fed rabbit. Proceedings of the National Academy of 
Sciences of the United States of America 89, 11312-11316. 
Ferrer, P., Valentine, M., Jenkins-West, T., Weber, H., Goller, N.L., Durham, S.K., Molloy, 
C.J., and Moreland, S. (1995). Orally active endothelin receptor antagonist BMS-182874 
suppresses neointimal development in balloon-injured rat carotid arteries. Journal of 
cardiovascular pharmacology 26, 908-915. 
234 
 
Fingerle, J., Au, Y.P., Clowes, A.W., and Reidy, M.A. (1990). Intimal lesion formation in rat 
carotid arteries after endothelial denudation in absence of medial injury. Arteriosclerosis 10, 
1082-1087. 
Firth, J.D., and Ratcliffe, P.J. (1992). Organ distribution of the three rat endothelin 
messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest 90, 
1023-1031. 
Fishman, J.A., Ryan, G.B., and Karnovsky, M.J. (1975). Endothelial regeneration in the rat 
carotid artery and the significance of endothelial denudation in the pathogenesis of 
myointimal thickening. Lab Invest 32, 339-351. 
Fitzgibbon, G.M., Kafka, H.P., Leach, A.J., Keon, W.J., Hooper, G.D., and Burton, J.R. 
(1996). Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 
grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll 
Cardiol 28, 616-626. 
Freiman, P.C., Mitchell, G.G., Heistad, D.D., Armstrong, M.L., and Harrison, D.G. (1986). 
Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and 
thrombin in primates. Circulation research 58, 783-789. 
Frelin, C., Ladoux, A., Marsault, R., and Vigne, P. (1991). Functional properties of high- and 
low-affinity receptor subtypes for endothelin-3. Journal of cardiovascular pharmacology 17 
Suppl 7, S131-133. 
Fryer, R.M., Rakestraw, P.A., Banfor, P.N., Cox, B.F., Opgenorth, T.J., and Reinhart, G.A. 
(2006). Blood pressure regulation by ETA and ETB receptors in conscious, telemetry-
instrumented mice and role of ETA in hypertension produced by selective ETB blockade. 
Am J Physiol Heart Circ Physiol 290, H2554-2559. 
Fukuroda, T., Fujikawa, T., Ozaki, S., Ishikawa, K., Yano, M., and Nishikibe, M. (1994a). 
Clearance of circulating endothelin-1 by ETB receptors in rats. Biochemical and biophysical 
research communications 199, 1461-1465. 
Fukuroda, T., Ozaki, S., Ihara, M., Ishikawa, K., Yano, M., and Nishikibe, M. (1994b). 
Synergistic inhibition by BQ-123 and BQ-788 of endothelin-1-induced contractions of the 
rabbit pulmonary artery. Br J Pharmacol 113, 336-338. 
Furchgott, R.F., and Zawadzki, J.V. (1980). The obligatory role of endothelial cells in the 
relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376. 
Furukawa, Y., Matsumori, A., Ohashi, N., Shioi, T., Ono, K., Harada, A., Matsushima, K., 
and Sasayama, S. (1999). Anti-monocyte chemoattractant protein-1/monocyte chemotactic 
and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. 
Circulation research 84, 306-314. 
Gallelli, L., Pelaia, G., D'Agostino, B., Cuda, G., Vatrella, A., Fratto, D., Gioffre, V., 
Galderisi, U., De Nardo, M., Mastruzzo, C., et al. (2005). Endothelin-1 induces proliferation 
of human lung fibroblasts and IL-11 secretion through an ET(A) receptor-dependent 
activation of MAP kinases. J Cell Biochem 96, 858-868. 
235 
 
Gardiner, S.M., Compton, A.M., Kemp, P.A., and Bennett, T. (1990). Regional and cardiac 
haemodynamic responses to glyceryl trinitrate, acetylcholine, bradykinin and endothelin-1 in 
conscious rats: effects of NG-nitro-L-arginine methyl ester. Br J Pharmacol 101, 632-639. 
Garg, U.C., and Hassid, A. (1989). Nitric oxide-generating vasodilators and 8-bromo-cyclic 
guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular 
smooth muscle cells. J Clin Invest 83, 1774-1777. 
Gariepy, C.E., Ohuchi, T., Williams, S.C., Richardson, J.A., and Yanagisawa, M. (2000). 
Salt-sensitive hypertension in endothelin-B receptor-deficient rats, pp. 925-933. 
Gariepy, C.E., Williams, S.C., Richardson, J.A., Hammer, R.E., and Yanagisawa, M. (1998). 
Transgenic expression of the endothelin-B receptor prevents congenital intestinal 
aganglionosis in a rat model of Hirschsprung disease. J Clin Invest 102, 1092-1101. 
Ge, Y., Bagnall, A., Stricklett, P., Strait, K., Webb, D., Kotelevtsev, Y., and Kohan, D.E. 
(2006). Collecting duct-specific knockout of the endothelin B receptor causes hypertension 
and sodium retention. Am J Physiol Renal Physiol. 
Geerts, I.S., De Meyer, G.R., and Bult, H. (2000). Collar-induced elevation of mRNA and 
functional activity of 5-HT(1B) receptor in the rabbit carotid artery. Br J Pharmacol 131, 
1723-1731. 
Gendron, M.E., Trescases-Thorin, N., Villeneuve, L., and Thorin, E. (2006). Aging 
associated with mild dyslipidemia reveals that COX-2 preserves dilation despite endothelial 
dysfunction. Am J Physiol Heart Circ Physiol. 
Gershlick, A.H., Spriggins, D., Davies, S.W., Syndercombe Court, Y.D., Timmins, J., 
Timmis, A.D., Rothman, M.T., Layton, C., and Balcon, R. (1994). Failure of epoprostenol 
(prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary 
angioplasty: results of a randomised placebo controlled trial. Br Heart J 71, 7-15. 
Gibbons, G.H., and Dzau, V.J. (1994). The Emerging Concept of Vascular Remodeling. The 
New England journal of medicine 330, 1431-1438. 
Gibson, C.M., Goel, M., Cohen, D.J., Piana, R.N., Deckelbaum, L.I., Harris, K.E., and King, 
S.B., 3rd (1998). Six-month angiographic and clinical follow-up of patients prospectively 
randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. 
Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 
32, 28-34. 
Giller, T., Breu, V., Valdenaire, O., and Clozel, M. (1997). Absence of ET(B)-mediated 
contraction in Piebald-lethal mice. Life sciences 61, 255-263. 
Glagov, S., Weisenberg, E., Zarins, C.K., Stankunavicius, R., and Kolettis, G.J. (1987). 
Compensatory enlargement of human atherosclerotic coronary arteries. The New England 
journal of medicine 316, 1371-1375. 
Godin, D., Ivan, E., Johnson, C., Magid, R., and Galis, Z.S. (2000). Remodeling of carotid 
artery is associated with increased expression of matrix metalloproteinases in mouse blood 
flow cessation model. Circulation 102, 2861-2866. 
236 
 
Goligorsky, M.S., Budzikowski, A.S., Tsukahara, H., and Noiri, E. (1999). CO-
OPERATION BETWEEN ENDOTHELIN AND NITRIC OXIDE IN PROMOTING 
ENDOTHELIAL CELL MIGRATION AND ANGIOGENESIS. Clinical and Experimental 
Pharmacology and Physiology 26, 269-271. 
Gravanis, M.B., and Roubin, G.S. (1989). Histopathologic phenomena at the site of 
percutaneous transluminal coronary angioplasty: the problem of restenosis. Hum Pathol 20, 
477-485. 
Gray, G.A., and Webb, D.J. (1996). The endothelin system and its potential as a therapeutic 
target in cardiovascular disease. Pharmacol Ther 72, 109-148. 
Gregan, B., Jurgensen, J., Papsdorf, G., Furkert, J., Schaefer, M., Beyermann, M., Rosenthal, 
W., and Oksche, A. (2004). Ligand-dependent differences in the internalization of endothelin 
A and endothelin B receptor heterodimers. J Biol Chem 279, 27679-27687. 
Grimshaw, M.J., Wilson, J.L., and Balkwill, F.R. (2002). Endothelin-2 is a macrophage 
chemoattractant: implications for macrophage distribution in tumors. Eur J Immunol 32, 
2393-2400. 
Groves, P.H., Banning, A.P., Penny, W.J., Lewis, M.J., Cheadle, H.A., and Newby, A.C. 
(1995). Kinetics of smooth muscle cell proliferation and intimal thickening in a pig carotid 
model of balloon injury. Atherosclerosis 117, 83-96. 
Gruetter, C.A., Barry, B.K., McNamara, D.B., Gruetter, D.Y., Kadowitz, P.J., and Ignarro, 
L. (1979). Relaxation of bovine coronary artery and activation of coronary arterial guanylate 
cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide 
Res 5, 211-224. 
Gruntzig, A., Hirzel, H., Goebel, N., Gattiker, R., Turina, M., Myler, R., Stertzer, S., and 
Kaltenbach, M. (1978). [Percutaneous transluminal dilatation of chronic coronary stenoses. 
First experiences]. Schweiz Med Wochenschr 108, 1721-1723. 
Guarda, E., Katwa, L.C., Myers, P.R., Tyagi, S.C., and Weber, K.T. (1993). Effects of 
endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 27, 2130-2134. 
Hadoke, P., Wainwright, C.L., Wadsworth, R.M., Butler, K., and Giddings, M.J. (1995). 
Characterization of the morphological and functional alterations in rabbit subclavian artery 
subjected to balloon angioplasty. Coronary artery disease 6, 403-415. 
Hadoke, P.W., Christy, C., Kotelevtsev, Y.V., Williams, B.C., Kenyon, C.J., Seckl, J.R., 
Mullins, J.J., and Walker, B.R. (2001). Endothelial cell dysfunction in mice after transgenic 
knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase. Circulation 104, 
2832-2837. 
Halcox, J.P., Nour, K.R., Zalos, G., and Quyyumi, A.A. (2001). Coronary vasodilation and 
improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. 
Circulation research 89, 969-976. 
237 
 
Haller, H., Schaberg, T., Lindschau, C., Lode, H., and Distler, A. (1991). Endothelin 
increases [Ca2+]i, protein phosphorylation, and O2-. production in human alveolar 
macrophages. Am J Physiol 261, L478-484. 
Han, C.I., Campbell, G.R., and Campbell, J.H. (2001). Circulating bone marrow cells can 
contribute to neointimal formation. J Vasc Res 38, 113-119. 
Han, D.K., Haudenschild, C.C., Hong, M.K., Tinkle, B.T., Leon, M.B., and Liau, G. (1995). 
Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J 
Pathol 147, 267-277. 
Harrison, D.G. (1997). Cellular and molecular mechanisms of endothelial cell dysfunction. J 
Clin Invest 100, 2153-2157. 
Haude, M., Erbel, R., Issa, H., and Meyer, J. (1993). Quantitative analysis of elastic recoil 
after balloon angioplasty and after intracoronary implantation of balloon-expandable 
Palmaz-Schatz stents. J Am Coll Cardiol 21, 26-34. 
Haudenschild, C.C., and Schwartz, S.M. (1979). Endothelial regeneration. II. Restitution of 
endothelial continuity. Lab Invest 41, 407-418. 
Haug, C., Schmid-Kotsas, A., Zorn, U., Schuett, S., Gross, H.J., Gruenert, A., and Bachem, 
M.G. (2001). Endothelin-1 synthesis and endothelin B receptor expression in human 
coronary artery smooth muscle cells and monocyte-derived macrophages is up-regulated by 
low density lipoproteins. J Mol Cell Cardiol 33, 1701-1712. 
Hayashi, K., Takahata, H., Kitagawa, N., Kitange, G., Kaminogo, M., and Shibata, S. 
(2001). N-acetylcysteine inhibited nuclear factor-kappaB expression and the intimal 
hyperplasia in rat carotid arterial injury. Neurol Res 23, 731-738. 
Hayashi, S., Watanabe, N., Nakazawa, K., Suzuki, J., Tsushima, K., Tamatani, T., 
Sakamoto, S., and Isobe, M. (2000). Roles of P-selectin in inflammation, neointimal 
formation, and vascular remodeling in balloon-injured rat carotid arteries. Circulation 102, 
1710-1717. 
Haynes, W.G., Ferro, C.J., O'Kane, K.P., Somerville, D., Lomax, C.C., and Webb, D.J. 
(1996). Systemic endothelin receptor blockade decreases peripheral vascular resistance and 
blood pressure in humans. Circulation 93, 1860-1870. 
Haynes, W.G., Strachan, F.E., and Webb, D.J. (1995). Endothelin ETA and ETB Receptors 
Cause Vasoconstriction of Human Resistance and Capacitance Vessels In Vivo. Circulation 
92, 357-363. 
Haynes, W.G., and Webb, D.J. (1992). Endothelin: a long-acting local constrictor hormone. 
Br J Hosp Med 47, 340-349. 
Haynes, W.G., and Webb, D.J. (1994). Contribution of endogenous generation of 
endothelin-1 to basal vascular tone. Lancet 344, 852-854. 
Hedman, M., Hartikainen, J., Syvanne, M., Stjernvall, J., Hedman, A., Kivela, A., Vanninen, 
E., Mussalo, H., Kauppila, E., Simula, S., et al. (2003). Safety and Feasibility of Catheter-
238 
 
Based Local Intracoronary Vascular Endothelial Growth Factor Gene Transfer in the 
Prevention of Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic 
Myocardial Ischemia: Phase II Results of the Kuopio Angiogenesis Trial (KAT). Circulation 
107, 2677-2683. 
Heijenbrok, F.J., Mathy, M.J., Pfaffendorf, M., and van Zwieten, P.A. (2000). Beta-
adrenergic responses are significantly enhanced in rat carotid artery with intimal hyperplasia. 
Naunyn-Schmiedeberg's archives of pharmacology 362, 276-283. 
Heijenbrok, F.J., van der Wal, A.C., Pfaffendorf, M., and van Zwieten, P.A. (1998). 
Morphologic and functional consequences of intimal hyperplasia in the rat carotid artery. 
Naunyn-Schmiedeberg's archives of pharmacology 357, 133-142. 
Helset, E., Lindal, S., Olsen, R., Myklebust, R., and Jorgensen, L. (1996). Endothelin-1 
causes sequential trapping of platelets and neutrophils in pulmonary microcirculation in rats. 
AJP - Lung Cellular and Molecular Physiology 271, L538-546. 
Helset, E., Sildnes, T., and Konopski, Z.S. (1994). Endothelin-1 Stimulates Monocytes in 
vitro to Release Chemotactic Activity Identified as Interleukin-8 and Monocyte Chemotactic 
Protein-1. Mediators Inflamm 3, 155-160. 
Helset, E., Sildnes, T., Seljelid, R., and Konopski, Z.S. (1993). Endothelin-1 stimulates 
human monocytes in vitro to release TNF-alpha , IL-1beta and IL-6. Mediators Inflamm 2, 
417-422. 
Heras, M., Chesebro, J.H., Penny, W.J., Bailey, K.R., Badimon, L., and Fuster, V. (1989). 
Effects of thrombin inhibition on the development of acute platelet-thrombus deposition 
during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin 
inhibitor. Circulation 79, 657-665. 
Herrmann, J., Best, P.J., Ritman, E.L., Holmes, D.R., Lerman, L.O., and Lerman, A. (2002). 
Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization 
in experimental hypercholesterolemia. J Am Coll Cardiol 39, 1555-1561. 
Hickey, K.A., Rubanyi, G., Paul, R.J., and Highsmith, R.F. (1985). Characterization of a 
coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 248, C550-
556. 
Hickey, M.J., and Kubes, P. (1997). Role of nitric oxide in regulation of leucocyte-
endothelial cell interactions. Exp Physiol 82, 339-348. 
Hiltunen, M.O., Laitinen, M., Turunen, M.P., Jeltsch, M., Hartikainen, J., Rissanen, T.T., 
Laukkanen, J., Niemi, M., Kossila, M., Hakkinen, T.P., et al. (2000). Intravascular 
adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-
denuded rabbit aorta. Circulation 102, 2262-2268. 
Hirata, Y., Emori, T., Eguchi, S., Kanno, K., Imai, T., Ohta, K., and Marumo, F. (1993). 
Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine 
endothelial cells. J Clin Invest 91, 1367-1373. 
239 
 
Hirata, Y., Takagi, Y., Fukuda, Y., and Marumo, F. (1989). Endothelin is a potent mitogen 
for rat vascular smooth muscle cells. Atherosclerosis 78, 225-228. 
Hocher, B., Schwarz, A., Slowinski, T., Bachmann, S., Pfeilschifter, J., Neumayer, H.H., and 
Bauer, C. (2004). In-vivo interaction of nitric oxide and endothelin. Journal of hypertension 
22, 111-119. 
Hocher, B., Thone-Reineke, C., Rohmeiss, P., Schmager, F., Slowinski, T., Burst, V., 
Siegmund, F., Quertermous, T., Bauer, C., Neumayer, H.H., et al. (1997). Endothelin-1 
transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not 
hypertension. J Clin Invest 99, 1380-1389. 
Hofman, F.M., Chen, P., Jeyaseelan, R., Incardona, F., Fisher, M., and Zidovetzki, R. 
(1998). Endothelin-1 induces production of the neutrophil chemotactic factor interleukin-8 
by human brain-derived endothelial cells. Blood 92, 3064-3072. 
Hojo, Y., Ikeda, U., Katsuki, T., Mizuno, O., Fukazawa, H., Fujikawa, H., and Shimada, K. 
(2001). Chemokine expression in coronary circulation after coronary angioplasty as a 
prognostic factor for restenosis. Atherosclerosis 156, 165-170. 
Hojo, Y., Ikeda, U., Katsuki, T., Mizuno, O., Fukazawa, H., Kurosaki, K., Fujikawa, H., and 
Shimada, K. (2000). Release of endothelin 1 and angiotensin II induced by percutaneous 
transluminal coronary angioplasty. Catheter Cardiovasc Interv 51, 42-49. 
Holmes, D.R., Jr., Vlietstra, R.E., Smith, H.C., Vetrovec, G.W., Kent, K.M., Cowley, M.J., 
Faxon, D.P., Gruentzig, A.R., Kelsey, S.F., Detre, K.M., et al. (1984). Restenosis after 
percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry 
of the National Heart, Lung, and Blood Institute. The American journal of cardiology 53, 
77C-81C. 
Horvath, C.J., Ferro, T.J., Jesmok, G., and Malik, A.B. (1988). Recombinant tumor necrosis 
factor increases pulmonary vascular permeability independent of neutrophils. Proceedings of 
the National Academy of Sciences of the United States of America 85, 9219-9223. 
Hosoda, C., Hiroyama, M., Sanbe, A., Birumachi, J., Kitamura, T., Cotecchia, S., Simpson, 
P.C., Tsujimoto, G., and Tanoue, A. (2007). Blockade of both alpha1A- and alpha1B-
adrenergic receptor subtype signaling is required to inhibit neointimal formation in the 
mouse femoral artery. Am J Physiol Heart Circ Physiol 293, H514-519. 
Hosoda, K., Hammer, R.E., Richardson, J.A., Baynash, A.G., Cheung, J.C., Giaid, A., and 
Yanagisawa, M. (1994). Targeted and natural (piebald-lethal) mutations of endothelin-B 
receptor gene produce megacolon associated with spotted coat color in mice. Cell 79, 1267-
1276. 
Hosoda, K., Nakao, K., Tamura, N., Arai, H., Ogawa, Y., Suga, S., Nakanishi, S., and Imura, 
H. (1992). Organization, structure, chromosomal assignment, and expression of the gene 
encoding the human endothelin-A receptor. J Biol Chem 267, 18797-18804. 
Hou, D., Narciso, H., Kamdar, K., Zhang, P., Barclay, B., and March, K.L. (2005). Stent-
based nitric oxide delivery reducing neointimal proliferation in a porcine carotid overstretch 
injury model. Cardiovasc Intervent Radiol 28, 60-65. 
240 
 
Huang, H., Yanagisawa, M., Kisanuki, Y.Y., Jelicks, L.A., Chandra, M., Factor, S.M., 
Wittner, M., Weiss, L.M., Pestell, R.G., Shtutin, V., et al. (2002). Role of cardiac myocyte-
derived endothelin-1 in chagasic cardiomyopathy: molecular genetic evidence. Clin Sci 
(Lond) 103 Suppl 48, 263S-266S. 
Huckle, W.R., Drag, M.D., Acker, W.R., Powers, M., McFall, R.C., Holder, D.J., Walsh, 
T.F., Schwartz, R.S., Greenlee, W.J., and Johnson, R.G. (2001). Effects of L-749,329, an 
ETA/ETB endothelin receptor antagonist, in a porcine coronary artery injury model of 
vascular restenosis. Circulation 103, 1899-1905. 
Huribal, M., Kumar, R., Cunningham, M.E., Sumpio, B.E., and McMillen, M.A. (1994). 
Endothelin-stimulated monocyte supernatants enhance neutrophil superoxide production. 
Shock 1, 184-187. 
Hutter, R., Carrick, F.E., Valdiviezo, C., Wolinsky, C., Rudge, J.S., Wiegand, S.J., Fuster, 
V., Badimon, J.J., and Sauter, B.V. (2004). Vascular endothelial growth factor regulates 
reendothelialization and neointima formation in a mouse model of arterial injury. Circulation 
110, 2430-2435. 
Iafrati, M.D., Karas, R.H., Aronovitz, M., Kim, S., Sullivan, T.R., Jr., Lubahn, D.B., 
O'Donnell, T.F., Jr., Korach, K.S., and Mendelsohn, M.E. (1997). Estrogen inhibits the 
vascular injury response in estrogen receptor alpha-deficient mice. Nat Med 3, 545-548. 
Ihara, M., Ishikawa, K., Fukuroda, T., Saeki, T., Funabashi, K., Fukami, T., Suda, H., and 
Yano, M. (1992). In vitro biological profile of a highly potent novel endothelin (ET) 
antagonist BQ-123 selective for the ETA receptor. Journal of cardiovascular pharmacology 
20 Suppl 12, S11-14. 
Ikeda, S., Emoto, N., Alimsardjono, H., Yokoyama, M., and Matsuo, M. (2002). Molecular 
isolation and characterization of novel four subisoforms of ECE-2. Biochemical and 
biophysical research communications 293, 421-426. 
Ingerman-Wojenski, C., Silver, M.J., Smith, J.B., and Macarak, E. (1981). Bovine 
endothelial cells in culture produce thromboxane as well as prostacyclin. J Clin Invest 67, 
1292-1296. 
Inoue, A., Yanagisawa, M., Kimura, S., Kasuya, Y., Miyauchi, T., Goto, K., and Masaki, T. 
(1989). The Human Endothelin Family: Three Structurally and Pharmacologically Distinct 
Isopeptides Predicted by Three Separate Genes. PNAS 86, 2863-2867. 
Inoue, N., Ramasamy, S., Fukai, T., Nerem, R.M., and Harrison, D.G. (1996). Shear stress 
modulates expression of Cu/Zn superoxide dismutase in human aortic endothelial cells. 
Circulation research 79, 32-37. 
Inoue, T., Uchida, T., Yaguchi, I., Sakai, Y., Takayanagi, K., and Morooka, S. (2003). Stent-
induced expression and activation of the leukocyte integrin Mac-1 is associated with 
neointimal thickening and restenosis. Circulation 107, 1757-1763. 
Irons, C.E., Flynn, M.A., Mok, L.M., and Reynolds, E.E. (1996). Endothelin and PDGF 
enhance arachidonic acid release and DNA synthesis in vascular smooth muscle cells. Am J 
Physiol Cell Physiol 270, C1642-1646. 
241 
 
Ishida, K., Takeshige, K., and Minakami, S. (1990). Endothelin-1 enhances superoxide 
generation of human neutrophils stimulated by the chemotactic peptide N-formyl-methionyl-
leucyl-phenylalanine. Biochemical and biophysical research communications 173, 496-500. 
Ishizaka, N., Kurokawa, K., Taguchi, J., Miki, K., and Ohno, M. (1995). Inhibitory effect of 
a single local probucol administration on neointimal formation in balloon-injured rat carotid 
artery. Atherosclerosis 118, 53-56. 
Janes, R.W., Peapus, D.H., and Wallace, B.A. (1994). The crystal structure of human 
endothelin. Nat Struct Biol 1, 311-319. 
Jeng, A.Y., Mulder, P., Kwan, A.L., and Battistini, B. (2002). Nonpeptidic endothelin-
converting enzyme inhibitors and their potential therapeutic applications. Can J Physiol 
Pharmacol 80, 440-449. 
Jin, Z.-G., Ueba, H., Tanimoto, T., Lungu, A.O., Frame, M.D., and Berk, B.C. (2003). 
Ligand Independent Activation of VEGF Receptor 2 by Fluid Shear Stress Regulates 
Activation of Endothelial Nitric Oxide Synthase. Circulation research, 
01.RES.0000089257.0000094002.0000089296. 
Johnstrom, P., Fryer, T.D., Richards, H.K., Harris, N.G., Barret, O., Clark, J.C., Pickard, 
J.D., and Davenport, A.P. (2005). Positron emission tomography using 18F-labelled 
endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific 
clearance by ET B receptors in vivo. Br J Pharmacol 144, 115-122. 
Jozsef, L., Khreiss, T., Fournier, A., Chan, J.S., and Filep, J.G. (2002). Extracellular signal-
regulated kinase plays an essential role in endothelin-1-induced homotypic adhesion of 
human neutrophil granulocytes. Br J Pharmacol 135, 1167-1174. 
Juergens, U.R., Racke, K., Uen, S., Haag, S., Lamyel, F., Stober, M., Gillissen, A., Novak, 
N., and Vetter, H. (2008). Inflammatory responses after endothelin B (ETB) receptor 
activation in human monocytes: new evidence for beneficial anti-inflammatory potency of 
ETB-receptor antagonism. Pulm Pharmacol Ther 21, 533-539. 
Kahaleh, M.B. (1991). Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. 
Enhanced production and profibrotic action. Arthritis Rheum 34, 978-983. 
Kanse, S.M., Wijelath, E., Kanthou, C., Newman, P., and Kakkar, V.V. (1995). The 
proliferative responsiveness of human vascular smooth muscle cells to endothelin correlates 
with endothelin receptor density. Lab Invest 72, 376-382. 
Karet, F.E., and Davenport, A.P. (1996). Localization of endothelin peptides in human 
kidney. Kidney Int 49, 382-387. 
Karne, S., Jayawickreme, C.K., and Lerner, M.R. (1993). Cloning and characterization of an 
endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J 
Biol Chem 268, 19126-19133. 
Karrillon, G.J., Morice, M.C., Benveniste, E., Bunouf, P., Aubry, P., Cattan, S., Chevalier, 
B., Commeau, P., Cribier, A., Eiferman, C., et al. (1996). Intracoronary stent implantation 
without ultrasound guidance and with replacement of conventional anticoagulation by 
242 
 
antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. Circulation 
94, 1519-1527. 
Kastrati, A., Mehilli, J., Schuhlen, H., Dirschinger, J., Dotzer, F., ten Berg, J.M., Neumann, 
F.J., Bollwein, H., Volmer, C., Gawaz, M., et al. (2004). A clinical trial of abciximab in 
elective percutaneous coronary intervention after pretreatment with clopidogrel. The New 
England journal of medicine 350, 232-238. 
Kastrati, A., Schuhlen, H., Hausleiter, J., Walter, H., Zitzmann-Roth, E., Hadamitzky, M., 
Elezi, S., Ulm, K., Dirschinger, J., Neumann, F.J., et al. (1997). Restenosis after coronary 
stent placement and randomization to a 4-week combined antiplatelet or anticoagulant 
therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic 
Regimen (ISAR) Trial. Circulation 96, 462-467. 
Kawai, N., Yamamoto, T., Yamamoto, H., McCarron, R.M., and Spatz, M. (1997). 
Functional characterization of endothelin receptors on cultured brain capillary endothelial 
cells of the rat. Neurochem Int 31, 597-605. 
Kawasaki, T., Dewerchin, M., Lijnen, H.R., Vreys, I., Vermylen, J., and Hoylaerts, M.F. 
(2001). Mouse Carotid Artery Ligation Induces Platelet-Leukocyte-Dependent Luminal 
Fibrin, Required for Neointima Development. Circulation research 88, 159-166. 
Kawashima, S., Yamashita, T., Ozaki, M., Ohashi, Y., Azumi, H., Inoue, N., Hirata, K.-i., 
Hayashi, Y., Itoh, H., and Yokoyama, M. (2001). Endothelial NO Synthase Overexpression 
Inhibits Lesion Formation in Mouse Model of Vascular Remodeling. Arterioscler Thromb 
Vasc Biol 21, 201-207. 
Kedzierski, R.M., Grayburn, P.A., Kisanuki, Y.Y., Williams, C.S., Hammer, R.E., 
Richardson, J.A., Schneider, M.D., and Yanagisawa, M. (2003). Cardiomyocyte-Specific 
Endothelin A Receptor Knockout Mice Have Normal Cardiac Function and an Unaltered 
Hypertrophic Response to Angiotensin II and Isoproterenol. Molecular and Cellular Biology 
23, 8226-8232. 
Kester, R.C. (1969). Plasminogen activator in the human prostate. J Clin Pathol 22, 442-446. 
Kimura, S., Kasuya, Y., Sawamura, T., Shinimi, O., Sugita, Y., Yanagisawa, M., Goto, K., 
and Masaki, T. (1989). Conversion of big endothelin-1 to 21-residue endothelin-1 is 
essential for expression of full vasoconstrictor activity: structure-activity relationships of big 
endothelin-1. Journal of cardiovascular pharmacology 13 Suppl 5, S5-7; discussion S18. 
Kirkby, N.S., Hadoke, P.W., Bagnall, A.J., and Webb, D.J. (2008). The endothelin system as 
a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J 
Pharmacol 153, 1105-1119. 
Kisanuki, Y.Y., Hammer, R.E., Miyazaki, J., Williams, S.C., Richardson, J.A., and 
Yanagisawa, M. (2001). Tie2-Cre transgenic mice: a new model for endothelial cell-lineage 
analysis in vivo. Dev Biol 230, 230-242. 
Kitta, Y., Nakamura, T., Kodama, Y., Takano, H., Umetani, K., Fujioka, D., Saito, Y., 
Kawabata, K., Obata, J.E., Ichigi, Y., et al. (2005). Endothelial vasomotor dysfunction in the 
243 
 
brachial artery is associated with late in-stent coronary restenosis. J Am Coll Cardiol 46, 
648-655. 
Kloog, Y., Ambar, I., Sokolovsky, M., Kochva, E., Wollberg, Z., and Bdolah, A. (1988). 
Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and 
brain. Science 242, 268-270. 
Klugherz, B.D., Meneveau, N.F., Kolansky, D.M., Herrmann, H.C., Schiele, F., Matthai, 
W.H., Jr., Groh, W.C., Untereker, W.J., Hirshfeld, J.W., Jr., Bassand, J.P., et al. (2000). 
Predictors of clinical outcome following percutaneous intervention for in-stent restenosis. 
The American journal of cardiology 85, 1427-1431. 
Kochiadakis, G.E., Marketou, M.E., Arfanakis, D.A., Sfiridaki, K., Skalidis, E.I., 
Igoumenidis, N.E., Hamilos, M.I., Kolyvaki, S., Chlouverakis, G., Kantidaki, E., et al. 
(2007). Reduced systemic inflammatory response to implantation of sirolimus-eluting stents 
in patients with stable coronary artery disease. Atherosclerosis 194, 433-438. 
Kockx, M.M., De Meyer, G.R., Andries, L.J., Bult, H., Jacob, W.A., and Herman, A.G. 
(1993). The endothelium during cuff-induced neointima formation in the rabbit carotid 
artery. Arterioscler Thromb 13, 1874-1884. 
Kockx, M.M., De Meyer, G.R., Jacob, W.A., Bult, H., and Herman, A.G. (1992). Triphasic 
sequence of neointimal formation in the cuffed carotid artery of the rabbit. Arterioscler 
Thromb 12, 1447-1457. 
Kohan, D.E. (1997). Endothelins in the normal and diseased kidney. Am J Kidney Dis 29, 2-
26. 
Komatsu, R., Ueda, M., Naruko, T., Kojima, A., and Becker, A.E. (1998). Neointimal tissue 
response at sites of coronary stenting in humans: macroscopic, histological, and 
immunohistochemical analyses. Circulation 98, 224-233. 
Komuro, I., Kurihara, H., Sugiyama, T., Yoshizumi, M., Takaku, F., and Yazaki, Y. (1988). 
Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth 
muscle cells. FEBS Lett 238, 249-252. 
Koni, P.A., Joshi, S.K., Temann, U.-A., Olson, D., Burkly, L., and Flavell, R.A. (2001). 
Conditional Vascular Cell Adhesion Molecule 1 Deletion in Mice: Impaired Lymphocyte 
Migration to Bone Marrow. J Exp Med 193, 741-754. 
Kornowski, R., Hong, M.K., Tio, F.O., Bramwell, O., Wu, H., and Leon, M.B. (1998). In-
stent restenosis: contributions of inflammatory responses and arterial injury to neointimal 
hyperplasia. J Am Coll Cardiol 31, 224-230. 
Korshunov, V.A., and Berk, B.C. (2003). Flow-Induced Vascular Remodeling in the Mouse: 
A Model for Carotid Intima-Media Thickening. Arterioscler Thromb Vasc Biol 23, 2185-
2191. 
Kubo, T., Saito, E., Hanada, M., Kambe, T., and Hagiwara, Y. (1998). Evidence that 
angiotensin II, endothelins and nitric oxide regulate mitogen-activated protein kinase activity 
in rat aorta. European Journal of Pharmacology 347, 337-346. 
244 
 
Kuc, R., and Davenport, A.P. (2004). Comparison of endothelin-A and endothelin-B 
receptor distribution visualized by radioligand binding versus immunocytochemical 
localization using subtype selective antisera. Journal of cardiovascular pharmacology 44 
Suppl 1, S224-226. 
Kuc, R.E., Maguire, J.J., and Davenport, A.P. (2006). Quantification of endothelin receptor 
subtypes in peripheral tissues reveals downregulation of ET(A) receptors in ET(B)-deficient 
mice. Exp Biol Med (Maywood) 231, 741-745. 
Kuhlencordt, P.J., Gyurko, R., Han, F., Scherrer-Crosbie, M., Aretz, T.H., Hajjar, R., Picard, 
M.H., and Huang, P.L. (2001). Accelerated atherosclerosis, aortic aneurysm formation, and 
ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout 
mice. Circulation 104, 448-454. 
Kuhlmann, C.R.W., Most, A.K., Li, F., Munz, B.M., Schaefer, C.A., Walther, S., Raedle-
Hurst, T., Waldecker, B., Piper, H.M., Tillmanns, H., et al. (2005). Endothelin-1-induced 
proliferation of human endothelial cells depends on activation of K+ channels and Ca2+ 
influx. Acta Physiol Scand 183, 161-169. 
Kumar, A., Hoover, J.L., Simmons, C.A., Lindner, V., and Shebuski, R.J. (1997). 
Remodeling and neointimal formation in the carotid artery of normal and P-selectin-deficient 
mice. Circulation 96, 4333-4342. 
Kumar, A., and Lindner, V. (1997). Remodeling with neointima formation in the mouse 
carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 17, 2238-2244. 
Kumar, C., Mwangi, V., Nuthulaganti, P., Wu, H.L., Pullen, M., Brun, K., Aiyar, H., Morris, 
R.A., Naughton, R., and Nambi, P. (1994). Cloning and characterization of a novel 
endothelin receptor from Xenopus heart. J Biol Chem 269, 13414-13420. 
Kurata, C., Callahan, R.J., Molea, N., Wilkinson, R., Fischman, A.J., and Strauss, H.W. 
(1995). Localization of [I-125] Endothelin-1 in Injured Aorta of Rabbits. Eur J Pharmacol-
Environ Toxicol Pharmacol Sect 293, 109-114. 
Kurihara, Y., Kurihara, H., Suzuki, H., Kodama, T., Maemura, K., Nagai, R., Oda, H., 
Kuwaki, T., Cao, W.H., Kamada, N., et al. (1994). Elevated blood pressure and craniofacial 
abnormalities in mice deficient in endothelin-1. Nature 368, 703-710. 
Kyriakides, Z.S., Psychari, S.N., Kolettis, T.M., Georgiadis, M., Antoniadis, A., and 
Kremastinos, D.T. (2003). Usefulness of endothelin(A) receptor antagonists for the 
prevention of in-stent restenosis in patients with stable angina pectoris or silent myocardial 
ischemia. Am J Cardiol 91, 476-+. 
Lauth, M., Berger, M.-M., Cattaruzza, M., and Hecker, M. (2000). Elevated Perfusion 
Pressure Upregulates Endothelin-1 and Endothelin B Receptor Expression in the Rabbit 
Carotid Artery. Hypertension 35, 648-654. 
Le Tourneau, T., Van Belle, E., Corseaux, D., Vallet, B., Lebuffe, G., Dupuis, B., 
Lablanche, J.M., McFadden, E., Bauters, C., and Bertrand, M.E. (1999). Role of nitric oxide 
in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: 
effects on neointimal hyperplasia and vascular remodeling. J Am Coll Cardiol 33, 876-882. 
245 
 
Leclerc, G., Isner, J.M., Kearney, M., Simons, M., Safian, R.D., Baim, D.S., and Weir, L. 
(1992). Evidence implicating nonmuscle myosin in restenosis. Use of in situ hybridization to 
analyze human vascular lesions obtained by directional atherectomy. Circulation 85, 543-
553. 
Lee, P.C., Gibbons, G.H., and Dzau, V.J. (1993). Cellular and molecular mechanisms of 
coronary artery restenosis. Coronary artery disease 4, 254-259. 
Lefkovits, J., Ivanhoe, R.J., Califf, R.M., Bergelson, B.A., Anderson, K.M., Stoner, G.L., 
Weisman, H.F., and Topol, E.J. (1996). Effects of platelet glycoprotein IIb/IIIa receptor 
blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes 
after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC 
investigators. The American journal of cardiology 77, 1045-1051. 
Leon, M.B., Teirstein, P.S., Moses, J.W., Tripuraneni, P., Lansky, A.J., Jani, S., Wong, S.C., 
Fish, D., Ellis, S., Holmes, D.R., et al. (2001). Localized intracoronary gamma-radiation 
therapy to inhibit the recurrence of restenosis after stenting. The New England journal of 
medicine 344, 250-256. 
Li, L., Chu, Y., Fink, G.D., Engelhardt, J.F., Heistad, D.D., and Chen, A.F. (2003). 
Endothelin-1 Stimulates Arterial VCAM-1 Expression Via NADPH Oxidase-Derived 
Superoxide in Mineralocorticoid Hypertension. Hypertension 42, 997-1003. 
Liao, S.J., Lin, L., Zeng, J.S., Huang, R.X., Channon, K.M., and Chen, A.F. (2007). 
Endothelium-targeted transgenic GTP-cyclohydrolase I overexpression inhibits neointima 
formation in mouse carotid artery. Clin Exp Pharmacol Physiol 34, 1260-1266. 
Liao, Y., Day, K.H., Damon, D.N., and Duling, B.R. (2001). Endothelial cell-specific 
knockout of connexin 43 causes hypotension and bradycardia in mice. Proceedings of the 
National Academy of Sciences of the United States of America 98, 9989-9994. 
Libby, P., Schwartz, D., Brogi, E., Tanaka, H., and Clinton, S.K. (1992). A cascade model 
for restenosis. A special case of atherosclerosis progression. Circulation 86, III47-52. 
Liistro, F., and Colombo, A. (2001). Late acute thrombosis after paclitaxel eluting stent 
implantation. Heart 86, 262-264. 
Lindner, V. (1995). Role of basic fibroblast growth factor and platelet-derived growth factor 
(B-chain) in neointima formation after arterial injury. Z Kardiol 84 Suppl 4, 137-144. 
Lindner, V., Fingerle, J., and Reidy, M.A. (1993). Mouse model of arterial injury. 
Circulation research 73, 792-796. 
Lindner, V., and Reidy, M.A. (1993). Expression of basic fibroblast growth factor and its 
receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study. 
Circulation research 73, 589-595. 
Lindner, V., Reidy, M.A., and Fingerle, J. (1989). Regrowth of arterial endothelium. 




Ling, G.Y., Cao, W.H., Onodera, M., Ju, K.H., Kurihara, H., Kurihara, Y., Yazaki, Y., 
Kumada, M., Fukuda, Y., and Kuwaki, T. (1998). Renal sympathetic nerve activity in mice: 
comparison between mice and rats and between normal and endothelin-1 deficient mice. 
Brain Res 808, 238-249. 
Lodge, N.J., Zhang, R., Halaka, N.N., and Moreland, S. (1995). Functional role of 
endothelin ETA and ETB receptors in venous and arterial smooth muscle. Eur J Pharmacol 
287, 279-285. 
London, S.M., and Mayberg, M.R. (1994). Kinetics of bromodeoxyuridine uptake by smooth 
muscle cells after arterial injury. J Vasc Res 31, 247-255. 
Loomis, E.D., Sullivan, J.C., Osmond, D.A., Pollock, D.M., and Pollock, J.S. (2005). 
Endothelin mediates superoxide production and vasoconstriction through activation of 
NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. The Journal of 
pharmacology and experimental therapeutics 315, 1058-1064. 
Lusis, A.J. (2000). Atherosclerosis. Nature 407, 233-241. 
Maemura, K., Kurihara, H., Morita, T., Oh-hashi, Y., and Yazaki, Y. (1992). Production of 
endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular 
injury. Gerontology 38 Suppl 1, 29-35. 
Maguire, J.J., and Davenport, A.P. (1999). Endothelin receptor expression and 
pharmacology in Human saphenous vein graft. British journal of pharmacology 126, 443-
450. 
Majno, G., Shea, S.M., and Leventhal, M. (1969). Endothelial contraction induced by 
histamine-type mediators: an electron microscopic study. J Cell Biol 42, 647-672. 
Manderson, J.A., Cocks, T.M., and Campbell, G.R. (1989). Balloon catheter injury to rabbit 
carotid artery. II. Selective increase in reactivity to some vasoconstrictor drugs. 
Arteriosclerosis 9, 299-307. 
Marano, G., Palazzesi, S., Bernucci, P., Grigioni, M., Formigari, R., and Ballerini, L. (1998). 
ET(A)/ET(B) receptor antagonist bosentan inhibits neointimal development in collared 
carotid arteries of rabbits. Life sciences 63, PL259-266. 
Marcum, J.A., Atha, D.H., Fritze, L.M., Nawroth, P., Stern, D., and Rosenberg, R.D. (1986). 
Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate 
proteoglycan. J Biol Chem 261, 7507-7517. 
Martin-McNulty, B., Zhang, L., da Cunha, V., Vincelette, J., Rutledge, J.C., Vergona, R., 
Sullivan, M.E., and Wang, Y.X. (2007). Urokinase-type plasminogen activator deficiency 
(uPA-KO) prevented carotid artery ligation-induced vascular remodeling in mice. Transl Res 
149, 70-75. 
Masood, I., Porter, K.E., London, N.J., and Pringle, J.H. (1996). Endothelin-1 expression in 
vein graft stenosis. J Vasc Surg 24, 901-902. 
247 
 
Matsuno, K., Ichimura, M., Nakajima, T., Tahara, K., Fujiwara, S., Kase, H., Ushiki, J., 
Giese, N.A., Pandey, A., Scarborough, R.M., et al. (2002). Potent and selective inhibitors of 
platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity 
relationship, and biological effects of a new class of quinazoline derivatives. Journal of 
medicinal chemistry 45, 3057-3066. 
Matsuura, A., Yamochi, W., Hirata, K., Kawashima, S., and Yokoyama, M. (1998). 
Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each 
gene expression. Hypertension 32, 89-95. 
Matthews, N. (1981). Tumour-necrosis factor from the rabbit. V. Synthesis in vitro by 
mononuclear phagocytes from various tissues of normal and BCG-injected rabbits. British 
journal of cancer 44, 418-424. 
McAteer, M.A., Schneider, J.E., Clarke, K., Neubauer, S., Channon, K.M., and Choudhury, 
R.P. (2004). Quantification and 3D reconstruction of atherosclerotic plaque components in 
apolipoprotein E knockout mice using ex vivo high-resolution MRI. Arterioscler Thromb 
Vasc Biol 24, 2384-2390. 
McCarron, R.M., Wang, L., Stanimirovic, D.B., and Spatz, M. (1993). Endothelin induction 
of adhesion molecule expression on human brain microvascular endothelial cells. Neurosci 
Lett 156, 31-34. 
McFadden, E.P., Stabile, E., Regar, E., Cheneau, E., Ong, A.T., Kinnaird, T., Suddath, 
W.O., Weissman, N.J., Torguson, R., Kent, K.M., et al. (2004). Late thrombosis in drug-
eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364, 1519-1521. 
McKenna, C.J., Burke, S.E., Opgenorth, T.J., Padley, R.J., Camrud, L.J., Camrud, A.R., 
Johnson, J., Carlson, P.J., Lerman, A., Holmes, D.R., Jr., et al. (1998). Selective ET(A) 
receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model. 
Circulation 97, 2551-2556. 
McMillen, M.A., Huribal, M., Cunningham, M.E., Kumar, R., and Sumpio, B.E. (1995). 
Endothelin-1 increases intracellular calcium in human monocytes and causes production of 
interleukin-6. Crit Care Med 23, 34-40. 
Meyer, M., Lehnart, S., Pieske, B., Schlottauer, K., Munk, S., Holubarsch, C., Just, H., and 
Hasenfuss, G. (1996). Influence of endothelin 1 on human atrial myocardium--myocardial 
function and subcellular pathways. Basic Res Cardiol 91, 86-93. 
Mickley, E.J., Gray, G.A., and Webb, D.J. (1997). Activation of endothelin ETA receptors 
masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric 
arteries. Br J Pharmacol 120, 1376-1382. 
Mihara, S., and Fujimoto, M. (1993). The endothelin ETA receptor-specific effect of 50-235, 
a nonpeptide endothelin antagonist. Eur J Pharmacol 246, 33-38. 
Miller, A.L., Plane, F., Jeremy, J.Y., McKinnon, H.J., and Jackson, C.L. (2003). Delayed 
recovery of receptor-mediated functional responses to acetylcholine in mouse isolated 
carotid arteries following endothelial denudation in vivo. J Vasc Res 40, 449-459. 
248 
 
Miller, A.M., McPhaden, A.R., Wadsworth, R.M., and Wainwright, C.L. (2001). Inhibition 
by leukocyte depletion of neointima formation after balloon angioplasty in a rabbit model of 
restenosis. Cardiovasc Res 49, 838-850. 
Millul, V., Lagente, V., Gillardeaux, O., Boichot, E., Dugas, B., Mencia-Huerta, J.M., 
Bereziat, G., Braquet, P., and Masliah, J. (1991). Activation of guinea pig alveolar 
macrophages by endothelin-1. Journal of cardiovascular pharmacology 17 Suppl 7, S233-
235. 
Minamino, T., Kurihara, H., Takahashi, M., Shimada, K., Maemura, K., Oda, H., Ishikawa, 
T., Uchiyama, T., Tanzawa, K., and Yazaki, Y. (1997). Endothelin-Converting Enzyme 
Expression in the Rat Vascular Injury Model and Human Coronary Atherosclerosis. 
Circulation 95, 221-230. 
Minor, R.L., Jr., Myers, P.R., Guerra, R., Jr., Bates, J.N., and Harrison, D.G. (1990). Diet-
induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin 
Invest 86, 2109-2116. 
Miyauchi, K., Aikawa, M., Tani, T., Nakahara, K., Kawai, S., Nagai, R., Okada, R., and 
Yamaguchi, H. (1998). Effect of probucol on smooth muscle cell proliferation and 
dedifferentiation after vascular injury in rabbits: possible role of PDGF. Cardiovasc Drugs 
Ther 12, 251-260. 
Mizuguchi, T., Nishiyama, M., Moroi, K., Tanaka, H., Saito, T., Masuda, Y., Masaki, T., 
deWit, D., Yanagisawa, M., and Kimura, S. (1997). Analysis of two pharmacologically 
predicted endothelin B receptor subtypes by using the endothelin B receptor gene knockout 
mouse. British journal of pharmacology 120, 1427-1430. 
Mnjoyan, Z.H., Doan, D., Brandon, J.L., Felix, K., Sitter, C.L., Rege, A.A., Brock, T.A., and 
Fujise, K. (2008). The critical role of the intrinsic VSMC proliferation and death programs in 
injury-induced neointimal hyperplasia. Am J Physiol Heart Circ Physiol 294, H2276-2284. 
Molenaar, P., O'Reilly, G., Sharkey, A., Kuc, R.E., Harding, D.P., Plumpton, C., Gresham, 
G.A., and Davenport, A.P. (1993). Characterization and localization of endothelin receptor 
subtypes in the human atrioventricular conducting system and myocardium. Circulation 
research 72, 526-538. 
Molet, S., Furukawa, K., Maghazechi, A., Hamid, Q., and Giaid, A. (2000). Chemokine- and 
cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in 
endothelial cells. J Allergy Clin Immunol 105, 333-338. 
Moncada, S., Gryglewski, R., Bunting, S., and Vane, J.R. (1976). An enzyme isolated from 
arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits 
platelet aggregation. Nature 263, 663-665. 
Moncada, S., Higgs, E.A., and Vane, J.R. (1977). Human arterial and venous tissues 
generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet 1, 
18-20. 
Moncada, S., Rees, D.D., Schulz, R., and Palmer, R.M. (1991). Development and 
mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular 
249 
 
nitric oxide synthesis in vivo. Proceedings of the National Academy of Sciences of the 
United States of America 88, 2166-2170. 
Monnink, S.H., van Haelst, P.L., van Boven, A.J., Stroes, E.S., Tio, R.A., Plokker, T.W., 
Smit, A.J., Veeger, N.J., Crijns, H.J., and van Gilst, W.H. (2002). Endothelial dysfunction in 
patients with coronary artery disease: a comparison of three frequently reported tests. J 
Investig Med 50, 19-24. 
Morishita, R., Gibbons, G.H., Ellison, K.E., Nakajima, M., von der Leyen, H., Zhang, L., 
Kaneda, Y., Ogihara, T., and Dzau, V.J. (1994). Intimal hyperplasia after vascular injury is 
inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest 93, 1458-1464. 
Morishita, R., Gibbons, G.H., Ellison, K.E., Nakajima, M., Zhang, L., Kaneda, Y., Ogihara, 
T., and Dzau, V.J. (1993). Single intraluminal delivery of antisense cdc2 kinase and 
proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal 
hyperplasia. Proceedings of the National Academy of Sciences of the United States of 
America 90, 8474-8478. 
Morita, S., Kitamura, K., Yamamoto, Y., Eto, T., Osada, Y., Sumiyoshi, A., Koono, M., and 
Tanaka, K. (1991). Immunoreactive endothelin in human kidney. Ann Clin Biochem 28 ( Pt 
3), 267-271. 
Moroi, M., Zhang, L., Yasuda, T., Virmani, R., Gold, H.K., Fishman, M.C., and Huang, P.L. 
(1998). Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy 
in vascular response to injury in mice. J Clin Invest 101, 1225-1232. 
Moses, J.W., Leon, M.B., Popma, J.J., Fitzgerald, P.J., Holmes, D.R., O'Shaughnessy, C., 
Caputo, R.P., Kereiakes, D.J., Williams, D.O., Teirstein, P.S., et al. (2003). Sirolimus-
eluting stents versus standard stents in patients with stenosis in a native coronary artery. The 
New England journal of medicine 349, 1315-1323. 
Motte, S., McEntee, K., and Naeije, R. (2006). Endothelin receptor antagonists. Pharmacol 
Ther 110, 386-414. 
Mulvany, M., and Halpern, W. (1977). Contractile properties of small arterial resistance 
vessels in spontaneously hypertensive and normotensive rats. Circulation research 41, 19-26. 
Murakoshi, N., Miyauchi, T., Kakinuma, Y., Ohuchi, T., Goto, K., Yanagisawa, M., and 
Yamaguchi, I. (2002). Vascular endothelin-B receptor system in vivo plays a favorable 
inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-
knockout mice. Circulation 106, 1991-1998. 
Nagao, T., and Vanhoutte, P.M. (1992). Hyperpolarization as a mechanism for endothelium-
dependent relaxations in the porcine coronary artery. J Physiol 445, 355-367. 
Nelson, R.D., Stricklett, P., Gustafson, C., Stevens, A., Ausiello, D., Brown, D., and Kohan, 
D.E. (1998). Expression of an AQP2 Cre recombinase transgene in kidney and male 
reproductive system of transgenic mice. Am J Physiol 275, C216-226. 
250 
 
Neumann, F.J., Ott, I., Gawaz, M., Puchner, G., and Schomig, A. (1996). Neutrophil and 
platelet activation at balloon-injured coronary artery plaque in patients undergoing 
angioplasty. J Am Coll Cardiol 27, 819-824. 
Nobuyoshi, M., Kimura, T., Nosaka, H., Mioka, S., Ueno, K., Yokoi, H., Hamasaki, N., 
Horiuchi, H., and Ohishi, H. (1988). Restenosis after successful percutaneous transluminal 
coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 12, 
616-623. 
Nunez, D.J., Brown, M.J., Davenport, A.P., Neylon, C.B., Schofield, J.P., and Wyse, R.K. 
(1990). Endothelin-1 mRNA is widely expressed in porcine and human tissues. J Clin Invest 
85, 1537-1541. 
Oguchi, S., Dimayuga, P., Zhu, J., Chyu, K.Y., Yano, J., Shah, P.K., Nilsson, J., and Cercek, 
B. (2000). Monoclonal antibody against vascular cell adhesion molecule-1 inhibits 
neointimal formation after periadventitial carotid artery injury in genetically 
hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 20, 1729-1736. 
Ohkita, M., Wang, Y., Nguyen, N.D., Tsai, Y.H., Williams, S.C., Wiseman, R.C., Killen, 
P.D., Li, S., Yanagisawa, M., and Gariepy, C.E. (2005). Extrarenal ETB plays a significant 
role in controlling cardiovascular responses to high dietary sodium in rats. Hypertension 45, 
940-946. 
Ohlstein, E.H., Arleth, A., Bryan, H., Elliott, J.D., and Sung, C.P. (1992). The selective 
endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. 
Eur J Pharmacol 225, 347-350. 
Ohlstein, E.H., Nambi, P., Douglas, S.A., Edwards, R.M., Gellai, M., Lago, A., Leber, J.D., 
Cousins, R.D., Gao, A., Frazee, J.S., et al. (1994). SB 209670, a rationally designed potent 
nonpeptide endothelin receptor antagonist. Proceedings of the National Academy of 
Sciences of the United States of America 91, 8052-8056. 
Ohnaka, K., Takayanagi, R., Yamauchi, T., Okazaki, H., Ohashi, M., Umeda, F., and 
Nawata, H. (1990). Identification and characterization of endothelin converting activity in 
cultured bovine endothelial cells. Biochemical and biophysical research communications 
168, 1128-1136. 
Ohuchi, T., Kuwaki, T., Ling, G.-Y., Dewit, D., Ju, K.-H., Onodera, M., Cao, W.-H., 
Yanagisawa, M., and Kumada, M. (1999). Elevation of blood pressure by genetic and 
pharmacological disruption of the ETB receptor in mice. AJP - Regulatory, Integrative and 
Comparative Physiology 276, R1071-1077. 
Opgenorth, T., Wu-Wong, J., and Shiosaki, K. (1992). Endothelin-converting enzymes. 
FASEB J 6, 2653-2659. 
Opgenorth, T.J., Adler, A.L., Calzadilla, S.V., Chiou, W.J., Dayton, B.D., Dixon, D.B., 
Gehrke, L.J., Hernandez, L., Magnuson, S.R., Marsh, K.C., et al. (1996). Pharmacological 
characterization of A-127722: an orally active and highly potent ETA-selective receptor 
antagonist. The Journal of pharmacology and experimental therapeutics 276, 473-481. 
251 
 
Opgenorth, T.J., Wessale, J.L., Dixon, D.B., Adler, A.L., Calzadilla, S.V., Padley, R.J., and 
Wu-Wong, J.R. (2000). Effects of endothelin receptor antagonists on the plasma 
immunoreactive endothelin-1 level. Journal of cardiovascular pharmacology 36, S292-296. 
Osaka, M., Hagita, S., Haraguchi, M., Kajimura, M., Suematsu, M., and Yoshida, M. (2007). 
Real-time imaging of mechanically injured femoral artery in mice reveals a biphasic pattern 
of leukocyte accumulation. Am J Physiol Heart Circ Physiol 292, H1876-1882. 
Palmer, R.M., Ferrige, A.G., and Moncada, S. (1987). Nitric oxide release accounts for the 
biological activity of endothelium-derived relaxing factor. Nature 327, 524-526. 
Patti, G., Pasceri, V., Melfi, R., Goffredo, C., Chello, M., D'Ambrosio, A., Montesanti, R., 
and Di Sciascio, G. (2005). Impaired flow-mediated dilation and risk of restenosis in patients 
undergoing coronary stent implantation. Circulation 111, 70-75. 
Peacock, A.J., Dawes, K.E., Shock, A., Gray, A.J., Reeves, J.T., and Laurent, G.J. (1992). 
Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery 
fibroblasts. Am J Respir Cell Mol Biol 7, 492-499. 
Pedram, A., Razandi, M., Hu, R.-M., and Levin, E.R. (1997). Vasoactive Peptides Modulate 
Vascular Endothelial Cell Growth Factor Production and Endothelial Cell Proliferation and 
Invasion. Journal of Biological Chemistry 272, 17097-17103. 
Pellegreffi, L., and Branzoli, U. (1987). Removal and regeneration of the endothelium of the 
left common carotid artery of rats with induced hypercholesterolemia compared with 
normocholesterolemic animals. Experimental model to quantify the endothelial layer. Artery 
14, 248-265. 
Pernow, J., Bohm, F., Johansson, B.L., Hedin, U., and Ryden, L. (2000). Enhanced 
vasoconstrictor response to endothelin-B-receptor stimulation in patients with 
atherosclerosis. Journal of cardiovascular pharmacology 36, S418-420. 
Pham, D., Jeng, A.Y., Plante, S., Escher, E., and Battistini, B. (2002). Inhibition of 
endothelin-converting enzyme for protection against neointimal proliferation following 
balloon angioplasty of the rat carotid artery. Can J Physiol Pharmacol 80, 450-457. 
Picard, P., Smith, P.J., Monge, J.C., and Stewart, D.J. (1998). Expression of endothelial 
factors after arterial injury in the rat. Journal of cardiovascular pharmacology 31 Suppl 1, 
S323-327. 
Pietersma, A., Kofflard, M., Wit, L.E.A.d., Stijnen, T., Koster, J.F., Serruys, P.W., and 
Sluiter, W. (1995). Late Lumen Loss After Coronary Angioplasty Is Associated With the 
Activation Status of Circulating Phagocytes Before Treatment. Circulation 91, 1320-1325. 
Porter, K.E., Olojugba, D.H., Masood, I., Pemberton, M., Bell, P.R.F., and London, N.J.M. 
(1998). Endothelin-B receptors mediate intimal hyperplasia in an organ culture of human 
saphenous vein. J Vasc Surg 28, 695-701. 
Properzi, G., Terenghi, G., Gu, X.H., Poccia, G., Pasqua, R., Francavilla, S., and Polak, J.M. 
(1995). Early increase precedes a depletion of endothelin-1 but not of von Willebrand factor 
252 
 
in cutaneous microvessels of diabetic patients. A quantitative immunohistochemical study. J 
Pathol 175, 243-252. 
Puchtler, H., Waldrop, F.S., and Valentine, L.S. (1973). Polarization microscopic studies of 
connective tissue stained with picro-sirius red FBA. Beitr Pathol 150, 174-187. 
Quaschning, T., Rebhan, B., Wunderlich, C., Wanner, C., Richter, C.M., Pfab, T., Bauer, C., 
Kraemer-Guth, A., Galle, J., Yanagisawa, M., et al. (2005). Endothelin B receptor-deficient 
mice develop endothelial dysfunction independently of salt loading. Journal of hypertension 
23, 979-985. 
Quaschning, T., Voss, F., Herzfeld, S., Relle, K., Kalk, P., Godes, M., Pfab, T., Kraemer-
Guth, A., Bonz, A.W., Theuring, F., et al. (2008). Lack of iNOS impairs endothelial function 
in endothelin-1 transgenic mice. Kidney Blood Press Res 31, 127-134. 
Quaschning, T., Voss, F., Relle, K., Kalk, P., Vignon-Zellweger, N., Pfab, T., Bauer, C., 
Theilig, F., Bachmann, S., Kraemer-Guth, A., et al. (2007). Lack of endothelial nitric oxide 
synthase promotes endothelin-induced hypertension: lessons from endothelin-1 
transgenic/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol 18, 730-740. 
Radomski, M.W., Palmer, R.M., and Moncada, S. (1987a). The anti-aggregating properties 
of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 
92, 639-646. 
Radomski, M.W., Palmer, R.M., and Moncada, S. (1987b). Endogenous nitric oxide inhibits 
human platelet adhesion to vascular endothelium. Lancet 2, 1057-1058. 
Reel, B., Ozkal, S., Islekel, H., Ozer, E., Oktay, G., Sozer, G.O., Tanriverdi, S., Turkseven, 
S., and Kerry, Z. (2005). The role of endothelin receptor antagonism in collar-induced 
intimal thickening and vascular reactivity changes in rabbits. J Pharm Pharmacol 57, 1599-
1608. 
Reidy, M.A., Clowes, A.W., and Schwartz, S.M. (1983). Endothelial regeneration. V. 
Inhibition of endothelial regrowth in arteries of rat and rabbit. Lab Invest 49, 569-575. 
Reidy, M.A., and Silver, M. (1985). Endothelial regeneration. VII. Lack of intimal 
proliferation after defined injury to rat aorta. Am J Pathol 118, 173-177. 
Reis, E.D., Roque, M., Cordon-Cardo, C., Drobnjak, M., Fuster, V., and Badimon, J.J. 
(2000). Apoptosis, proliferation, and p27 expression during vessel wall healing: time course 
study in a mouse model of transluminal femoral artery injury. J Vasc Surg 32, 1022-1029. 
Rensing, B.J., Hermans, W.R., Beatt, K.J., Laarman, G.J., Suryapranata, H., van den Brand, 
M., de Feyter, P.J., and Serruys, P.W. (1990). Quantitative angiographic assessment of 
elastic recoil after percutaneous transluminal coronary angioplasty. The American journal of 
cardiology 66, 1039-1044. 
Resink, T.J., Hahn, A.W., Scott-Burden, T., Powell, J., Weber, E., and Buhler, F.R. (1990). 
Inducible endothelin mRNA expression and peptide secretion in cultured human vascular 




Rizvi, M.A., Katwa, L., Spadone, D.P., and Myers, P.R. (1996). The effects of endothelin-1 
on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth 
muscle cells. J Mol Cell Cardiol 28, 243-252. 
Rodriguez-Vita, J., Ruiz-Ortega, M., Ruperez, M., Esteban, V., Sanchez-Lopez, E., Plaza, 
J.J., and Egido, J. (2005). Endothelin-1, via ETA receptor and independently of transforming 
growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle 
cells. Circulation research 97, 125-134. 
Rogerson, M.E., Cairns, H.S., Fairbanks, L.D., Westwick, J., and Neild, G.H. (1993). 
Endothelin-1 in the rabbit: interactions with cyclo-oxygenase and NO-synthase products. Br 
J Pharmacol 108, 838-843. 
Roque, M., Fallon, J.T., Badimon, J.J., Zhang, W.X., Taubman, M.B., and Reis, E.D. (2000). 
Mouse model of femoral artery denudation injury associated with the rapid accumulation of 
adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler 
Thromb Vasc Biol 20, 335-342. 
Roque, M., Kim, W.J., Gazdoin, M., Malik, A., Reis, E.D., Fallon, J.T., Badimon, J.J., 
Charo, I.F., and Taubman, M.B. (2002). CCR2 deficiency decreases intimal hyperplasia after 
arterial injury. Arterioscler Thromb Vasc Biol 22, 554-559. 
Ross, R. (1999). Atherosclerosis--an inflammatory disease. The New England journal of 
medicine 340, 115-126. 
Rubanyi, G.M., and Polokoff, M.A. (1994). Endothelins: molecular biology, biochemistry, 
pharmacology, physiology, and pathophysiology. Pharmacol Rev 46, 325-415. 
Rubinstein, I., Gurbanov, K., Hoffman, A., Better, O.S., and Winaver, J. (1995). Differential 
effect of endothelin-1 on renal regional blood flow: role of nitric oxide. Journal of 
cardiovascular pharmacology 26 Suppl 3, S208-210. 
Ruetten, H., and Thiemermann, C. (1997). Endothelin-1 stimulates the biosynthesis of 
tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by 
dexamethasone. J Physiol Pharmacol 48, 675-688. 
Russell, F.D., and Davenport, A.P. (1999). Secretory pathways in endothelin synthesis. Br J 
Pharmacol 126, 391-398. 
Ruusalepp, A., Yan, Z.Q., Carlsen, H., Czibik, G., Hansson, G.K., Moskaug, J.O., Blomhoff, 
R., and Valen, G. (2006). Gene deletion of NF-kappaB p105 enhances neointima formation 
in a mouse model of carotid artery injury. Cardiovasc Drugs Ther 20, 103-111. 
Sabate, M., Kay, I.P., van Der Giessen, W.J., Cequier, A., Ligthart, J.M., Gomez-Hospital, 
J.A., Carlier, S.G., Coen, V.L., Marijnissen, J.P., Wardeh, A.J., et al. (1999). Preserved 
endothelium-dependent vasodilation in coronary segments previously treated with balloon 
angioplasty and intracoronary irradiation. Circulation 100, 1623-1629. 
Sahara, M., Sata, M., Matsuzaki, Y., Tanaka, K., Morita, T., Hirata, Y., Okano, H., and 
Nagai, R. (2005). Comparison of various bone marrow fractions in the ability to participate 
in vascular remodeling after mechanical injury. Stem Cells 23, 874-878. 
254 
 
Saiura, A., Sata, M., Hirata, Y., Nagai, R., and Makuuchi, M. (2001). Circulating smooth 
muscle progenitor cells contribute to atherosclerosis. Nat Med 7, 382-383. 
Sakamoto, A., Yanagisawa, M., Sakurai, T., Takuwa, Y., Yanagisawa, H., and Masaki, T. 
(1991). Cloning and functional expression of human cDNA for the ETB endothelin receptor. 
Biochemical and biophysical research communications 178, 656-663. 
Sakurai-Yamashita, Y., Yamashita, K., Yoshida, A., Obana, M., Takada, K., Shibaguchi, H., 
Shigematsu, K., Niwa, M., and Taniyama, K. (1997). Rat peritoneal macrophages express 
endothelin ET(B) but not endothelin ET(A) receptors. Eur J Pharmacol 338, 199-203. 
Sakurai, T., Yanagisawa, M., Takuwa, Y., Miyazaki, H., Kimura, S., Goto, K., and Masaki, 
T. (1990). Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin 
receptor. Nature 348, 732-735. 
Salani, D., Taraboletti, G., Rosano, L., Di Castro, V., Borsotti, P., Giavazzi, R., and Bagnato, 
A. (2000). Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and 
stimulates neovascularization in vivo. Am J Pathol 157, 1703-1711. 
Sanmartin, M., Fernandez-Ortiz, A., Fantidis, P., Aragoncillo, P., Fernandez-Durango, R., 
Rollin, R., Alfonso, F., Hernandez, R., Escaned, J., and Macaya, C. (2003). Effects of 
bosentan on neointimal response following coronary angioplasty. Eur J Clin Invest 33, 762-
768. 
Sanz, M.-J., Johnston, B., Issekutz, A., and Kubes, P. (1999). Endothelin-1 causes P-
selectin-dependent leukocyte rolling and adhesion within rat mesenteric microvessels. AJP - 
Heart and Circulatory Physiology 277, H1823-1830. 
Sata, M., Maejima, Y., Adachi, F., Fukino, K., Saiura, A., Sugiura, S., Aoyagi, T., Imai, Y., 
Kurihara, H., Kimura, K., et al. (2000). A mouse model of vascular injury that induces rapid 
onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell 
Cardiol 32, 2097-2104. 
Sata, M., Saiura, A., Kunisato, A., Tojo, A., Okada, S., Tokuhisa, T., Hirai, H., Makuuchi, 
M., Hirata, Y., and Nagai, R. (2002). Hematopoietic stem cells differentiate into vascular 
cells that participate in the pathogenesis of atherosclerosis. Nat Med 8, 403-409. 
Sata, M., Tanaka, K., Ishizaka, N., Hirata, Y., and Nagai, R. (2003). Absence of p53 Leads 
to Accelerated Neointimal Hyperplasia After Vascular Injury. Arterioscler Thromb Vasc 
Biol 23, 1548-1552. 
Sato, Y., Hogg, J.C., English, D., and van Eeden, S.F. (2000). Endothelin-1 changes 
polymorphonuclear leukocytes' deformability and CD11b expression and promotes their 
retention in the lung. Am J Respir Cell Mol Biol 23, 404-410. 
Scambler, P.J., Kelly, D., Lindsay, E., Williamson, R., Goldberg, R., Shprintzen, R., Wilson, 
D.I., Goodship, J.A., Cross, I.E., and Burn, J. (1992). Velo-cardio-facial syndrome 




Schatz, R.A., Baim, D.S., Leon, M., Ellis, S.G., Goldberg, S., Hirshfeld, J.W., Cleman, 
M.W., Cabin, H.S., Walker, C., Stagg, J., et al. (1991). Clinical experience with the Palmaz-
Schatz coronary stent. Initial results of a multicenter study. Circulation 83, 148-161. 
Schatz, R.A., Palmaz, J.C., Tio, F.O., Garcia, F., Garcia, O., and Reuter, S.R. (1987). 
Balloon-expandable intracoronary stents in the adult dog. Circulation 76, 450-457. 
Schepers, A., Eefting, D., Bonta, P.I., Grimbergen, J.M., de Vries, M.R., van Weel, V., de 
Vries, C.J., Egashira, K., van Bockel, J.H., and Quax, P.H. (2006). Anti-MCP-1 gene therapy 
inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both 
in vitro and in vivo. Arterioscler Thromb Vasc Biol 26, 2063-2069. 
Schini, V.B., Hendrickson, H., Heublein, D.M., Burnett, J.C., Jr., and Vanhoutte, P.M. 
(1989). Thrombin enhances the release of endothelin from cultured porcine aortic endothelial 
cells. Eur J Pharmacol 165, 333-334. 
Schneider, J., and Gruntzig, A. (1985). Percutaneous transluminal coronary angioplasty: 
morphological findings in 3 patients. Pathol Res Pract 180, 348-352. 
Schwartz, L., Bourassa, M.G., Lesperance, J., Aldridge, H.E., Kazim, F., Salvatori, V.A., 
Henderson, M., Bonan, R., and David, P.R. (1988). Aspirin and dipyridamole in the 
prevention of restenosis after percutaneous transluminal coronary angioplasty. The New 
England journal of medicine 318, 1714-1719. 
Schwartz, R.S., Chronos, N.A., and Virmani, R. (2004). Preclinical restenosis models and 
drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 44, 1373-1385. 
Schwartz, R.S., Edwards, W.D., Bailey, K.R., Camrud, A.R., Jorgenson, M.A., and Holmes, 
D.R., Jr. (1994). Differential neointimal response to coronary artery injury in pigs and dogs. 
Implications for restenosis models. Arterioscler Thromb 14, 395-400. 
Schwartz, R.S., Holmes, D.R., Jr., and Topol, E.J. (1992a). The restenosis paradigm 
revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 20, 1284-1293. 
Schwartz, R.S., Huber, K.C., Murphy, J.G., Edwards, W.D., Camrud, A.R., Vlietstra, R.E., 
and Holmes, D.R. (1992b). Restenosis and the proportional neointimal response to coronary 
artery injury: results in a porcine model. J Am Coll Cardiol 19, 267-274. 
Schwarzacher, S.P., Lim, T.T., Wang, B., Kernoff, R.S., Niebauer, J., Cooke, J.P., and 
Yeung, A.C. (1997). Local Intramural Delivery of L-Arginine Enhances Nitric Oxide 
Generation and Inhibits Lesion Formation After Balloon Angioplasty. Circulation 95, 1863-
1869. 
Serradeil-Le Gal, C., Herbert, J.M., Garcia, C., Boutin, M., and Maffrand, J.P. (1991). 
Importance of the phenotypic state of vascular smooth muscle cells on the binding and the 
mitogenic activity of endothelin. Peptides 12, 575-579. 
Serrano, C.V., Jr., Ramires, J.A., Venturinelli, M., Arie, S., D'Amico, E., Zweier, J.L., 
Pileggi, F., and da Luz, P.L. (1997). Coronary angioplasty results in leukocyte and platelet 
activation with adhesion molecule expression. Evidence of inflammatory responses in 
coronary angioplasty. J Am Coll Cardiol 29, 1276-1283. 
256 
 
Serruys, P.W., de Jaegere, P., Kiemeneij, F., Macaya, C., Rutsch, W., Heyndrickx, G., 
Emanuelsson, H., Marco, J., Legrand, V., Materne, P., et al. (1994). A comparison of 
balloon-expandable-stent implantation with balloon angioplasty in patients with coronary 
artery disease. Benestent Study Group. The New England journal of medicine 331, 489-495. 
Serruys, P.W., Emanuelsson, H., van der Giessen, W., Lunn, A.C., Kiemeney, F., Macaya, 
C., Rutsch, W., Heyndrickx, G., Suryapranata, H., Legrand, V., et al. (1996). Heparin-coated 
Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot 
Study. Circulation 93, 412-422. 
Serruys, P.W., Herrman, J.P., Simon, R., Rutsch, W., Bode, C., Laarman, G.J., van Dijk, R., 
van den Bos, A.A., Umans, V.A., Fox, K.A., et al. (1995). A comparison of hirudin with 
heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. 
The New England journal of medicine 333, 757-763. 
Serruys, P.W., Luijten, H.E., Beatt, K.J., Geuskens, R., de Feyter, P.J., van den Brand, M., 
Reiber, J.H., ten Katen, H.J., van Es, G.A., and Hugenholtz, P.G. (1988). Incidence of 
restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative 
angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 77, 361-
371. 
Sethi, A.S., Lees, D.M., Douthwaite, J.A., and Corder, R. (2005). Factor VIIa stimulates 
endothelin-1 synthesis in TNF-primed endothelial cells by activation of protease-activated 
receptor 2. Clin Sci (Lond) 108, 255-263. 
Setsuda, M., Inden, M., Hiraoka, N., Okamoto, S., Tanaka, H., Okinaka, T., Nishimura, Y., 
Okano, H., Kouji, T., Konishi, T., et al. (1993). Probucol therapy in the prevention of 
restenosis after successful percutaneous transluminal coronary angioplasty. Clin Ther 15, 
374-382. 
Shahar, I., Fireman, E., Topilsky, M., Grief, J., Schwarz, Y., Kivity, S., Ben-Efraim, S., and 
Spirer, Z. (1999). Effect of endothelin-1 on alpha-smooth muscle actin expression and on 
alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol 21, 
759-775. 
Sharifi, A.M., and Schiffrin, E.L. (1997). Apoptosis in aorta of deoxycorticosterone acetate-
salt hypertensive rats: effect of endothelin receptor antagonism. Journal of hypertension 15, 
1441-1448. 
Sharpe, J., Ahlgren, U., Perry, P., Hill, B., Ross, A., Hecksher-Sorensen, J., Baldock, R., and 
Davidson, D. (2002). Optical projection tomography as a tool for 3D microscopy and gene 
expression studies. Science 296, 541-545. 
Shi-Wen, X., Chen, Y., Denton, C.P., Eastwood, M., Renzoni, E.A., Bou-Gharios, G., 
Pearson, J.D., Dashwood, M., du Bois, R.M., Black, C.M., et al. (2004). Endothelin-1 
Promotes Myofibroblast Induction through the ETA Receptor via a rac/Phosphoinositide 3-
Kinase/Akt-dependent Pathway and Is Essential for the Enhanced Contractile Phenotype of 
Fibrotic Fibroblasts. Mol Biol Cell 15, 2707-2719. 
Shi-Wen, X., Denton, C.P., Dashwood, M.R., Holmes, A.M., Bou-Gharios, G., Pearson, 
J.D., Black, C.M., and Abraham, D.J. (2001). Fibroblast matrix gene expression and 
connective tissue remodeling: role of endothelin-1. J Invest Dermatol 116, 417-425. 
257 
 
Shi-Wen, X., Renzoni, E.A., Kennedy, L., Howat, S., Chen, Y., Pearson, J.D., Bou-Gharios, 
G., Dashwood, M.R., du Bois, R.M., Black, C.M., et al. (2007). Endogenous endothelin-1 
signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. 
Matrix Biol 26, 625-632. 
Shi, S.J., Rakugi, H., Higashimori, K., Jiang, B.B., Higaki, J., Mikami, H., and Ogihara, T. 
(1994). Augmentation by converting enzyme inhibition of accelerated endothelin release 
from rat mesenteric arteries following nephrectomy. Biochemical and biophysical research 
communications 202, 246-251. 
Shichiri, M., Kato, H., Marumo, F., and Hirata, Y. (1997). Endothelin-1 as an 
autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension 30, 1198-
1203. 
Shichiri, M., Yokokura, M., Marumo, F., and Hirata, Y. (2000). Endothelin-1 Inhibits 
Apoptosis of Vascular Smooth Muscle Cells Induced by Nitric Oxide and Serum 
Deprivation via MAP Kinase Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology 
20, 989-997. 
Shimada, K., Yonetani, Y., Kita, T., Suzumura, A., Takayanagi, T., and Nakashima, T. 
(1998). Cyclooxygenase 2 expression by endothelin-1-stimulated mouse resident peritoneal 
macrophages in vitro. Eur J Pharmacol 356, 73-80. 
Shimokado, K., Raines, E.W., Madtes, D.K., Barrett, T.B., Benditt, E.P., and Ross, R. 
(1985). A significant part of macrophage-derived growth factor consists of at least two forms 
of PDGF. Cell 43, 277-286. 
Shimokawa, H., Aarhus, L.L., and Vanhoutte, P.M. (1987). Porcine coronary arteries with 
regenerated endothelium have a reduced endothelium-dependent responsiveness to 
aggregating platelets and serotonin. Circulation research 61, 256-270. 
Shimokawa, H., Flavahan, N.A., and Vanhoutte, P.M. (1989). Natural course of the 
impairment of endothelium-dependent relaxations after balloon endothelium removal in 
porcine coronary arteries. Possible dysfunction of a pertussis toxin-sensitive G protein. 
Circulation research 65, 740-753. 
Shindo, T., Kurihara, H., Maemura, K., Kurihara, Y., Ueda, O., Suzuki, H., Kuwaki, T., Ju, 
K.H., Wang, Y., Ebihara, A., et al. (2002). Renal damage and salt-dependent hypertension in 
aged transgenic mice overexpressing endothelin-1. J Mol Med 80, 105-116. 
Shirai, N., Naruko, T., Ohsawa, M., Ikura, Y., Sugama, Y., Hirayama, M., Kitabayashi, C., 
Ehara, S., Inoue, T., Itoh, A., et al. (2006). Expression of endothelin-converting enzyme, 
endothelin-1 and endothelin receptors at the site of percutaneous coronary intervention in 
humans. Journal of hypertension 24, 711-721. 
Shohet, R.V., Kisanuki, Y.Y., Zhao, X.S., Siddiquee, Z., Franco, F., and Yanagisawa, M. 
(2004). Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to 
hyperthyroid cardiac hypertrophy. Proceedings of the National Academy of Sciences of the 
United States of America 101, 2088-2093. 
258 
 
Shoji, M., Sata, M., Fukuda, D., Tanaka, K., Sato, T., Iso, Y., Shibata, M., Suzuki, H., Koba, 
S., Geshi, E., et al. (2004). Temporal and spatial characterization of cellular constituents 
during neointimal hyperplasia after vascular injury: Potential contribution of bone-marrow-
derived progenitors to arterial remodeling. Cardiovasc Pathol 13, 306-312. 
Sigwart, U., Puel, J., Mirkovitch, V., Joffre, F., and Kappenberger, L. (1987). Intravascular 
stents to prevent occlusion and restenosis after transluminal angioplasty. The New England 
journal of medicine 316, 701-706. 
Singh, M., Gersh, B.J., McClelland, R.L., Ho, K.K., Willerson, J.T., Penny, W.F., and 
Holmes, D.R., Jr. (2005). Predictive factors for ischemic target vessel revascularization in 
the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll 
Cardiol 45, 198-203. 
Sinzinger, H., Zidek, T., Fitscha, P., O'Grady, J., Wagner, O., and Kaliman, J. (1987). 
Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivo. 
Prostaglandins 33, 915-918. 
Sogabe, K., Nirei, H., Shoubo, M., Nomoto, A., Ao, S., Notsu, Y., and Ono, T. (1993). 
Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. 
The Journal of pharmacology and experimental therapeutics 264, 1040-1046. 
Spaet, T.H., Stemerman, M.B., Veith, F.J., and Lejnieks, I. (1975). Intimal injury and 
regrowth in the rabbit aorta; medial smooth muscle cells as a source of neointima. 
Circulation research 36, 58-70. 
Spatz, M., Kawai, N., Merkel, N., Bembry, J., and McCarron, R.M. (1997). Functional 
properties of cultured endothelial cells derived from large microvessels of human brain. Am 
J Physiol 272, C231-239. 
Speciale, L., Roda, K., Saresella, M., Taramelli, D., and Ferrante, P. (1998). Different 
endothelins stimulate cytokine production by peritoneal macrophages and microglial cell 
line. Immunology 93, 109-114. 
Squadrito, F., Deodato, B., Bova, A., Marini, H., Saporito, F., Calo, M., Giacca, M., 
Minutoli, L., Venuti, F.S., Caputi, A.P., et al. (2003). Crucial role of nuclear factor-kappaB 
in neointimal hyperplasia of the mouse carotid artery after interruption of blood flow. 
Atherosclerosis 166, 233-242. 
Steele, P.M., Chesebro, J.H., Stanson, A.W., Holmes, D.R., Jr., Dewanjee, M.K., Badimon, 
L., and Fuster, V. (1985). Balloon angioplasty. Natural history of the pathophysiological 
response to injury in a pig model. Circulation research 57, 105-112. 
Steg, P.G., Pasquier, C., Huu, T.P., Chollet-Martin, S., Juliard, J.M., Himbert, D., Pocidalo, 
M.A., Gourgon, R., and Hakim, J. (1993). Evidence for priming and activation of neutrophils 
early after coronary angioplasty. Eur J Med 2, 6-10. 
Stemerman, M.B., Spaet, T.H., Pitlick, F., Cintron, J., Lejnieks, I., and Tiell, M.L. (1977). 




Stone, G.W., Ellis, S.G., Cox, D.A., Hermiller, J., O'Shaughnessy, C., Mann, J.T., Turco, 
M., Caputo, R., Bergin, P., Greenberg, J., et al. (2004). A polymer-based, paclitaxel-eluting 
stent in patients with coronary artery disease. The New England journal of medicine 350, 
221-231. 
Strachan, F.E., Spratt, J.C., Wilkinson, I.B., Johnston, N.R., Gray, G.A., and Webb, D.J. 
(1999). Systemic blockade of the endothelin-B receptor increases peripheral vascular 
resistance in healthy men. Hypertension 33, 581-585. 
Sullivan, C.J., and Hoying, J.B. (2002). Flow-Dependent Remodeling in the Carotid Artery 
of Fibroblast Growth Factor-2 Knockout Mice. Arterioscler Thromb Vasc Biol 22, 1100-
1105. 
Sullivan, T.R., Jr., Karas, R.H., Aronovitz, M., Faller, G.T., Ziar, J.P., Smith, J.J., O'Donnell, 
T.F., Jr., and Mendelsohn, M.E. (1995). Estrogen inhibits the response-to-injury in a mouse 
carotid artery model. J Clin Invest 96, 2482-2488. 
Suri, C., Jones, P.F., Patan, S., Bartunkova, S., Maisonpierre, P.C., Davis, S., Sato, T.N., and 
Yancopoulos, G.D. (1996). Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, 
during embryonic angiogenesis. Cell 87, 1171-1180. 
Tabuchi, Y., Nakamaru, M., Rakugi, H., Nagano, M., and Ogihara, T. (1989). Endothelin 
enhances adrenergic vasoconstriction in perfused rat mesenteric arteries. Biochemical and 
biophysical research communications 159, 1304-1308. 
Takahashi, S., Oida, K., Fujiwara, R., Maeda, H., Hayashi, S., Takai, H., Tamai, T., Nakai, 
T., and Miyabo, S. (1992). Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on 
the proliferation of rat aortic smooth muscle cells in culture. Journal of cardiovascular 
pharmacology 20, 900-906. 
Takase, H., Sugiyama, M., Nakazawa, A., Toriyama, T., Hayashi, K., Goto, T., Sato, K., 
Ikeda, K., Ueda, R., and Dohi, Y. (2003). Increased endogenous endothelin-1 in coronary 
circulation is associated with restenosis after coronary angioplasty. Can J Cardiol 19, 902-
906. 
Takayanagi, R., Kitazumi, K., Takasaki, C., Ohnaka, K., Aimoto, S., Tasaka, K., Ohashi, M., 
and Nawata, H. (1991). Presence of non-selective type of endothelin receptor on vascular 
endothelium and its linkage to vasodilation. FEBS Lett 282, 103-106. 
Takiguchi, Y., and Sogabe, K. (1996). The selective endothelin ETA receptor antagonist 
FR139317 inhibits neointimal thickening in the rat. Eur J Pharmacol 309, 59-62. 
Takuwa, N., Takuwa, Y., Yanagisawa, M., Yamashita, K., and Masaki, T. (1989). A novel 
vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover in Swiss 
3T3 fibroblasts. J Biol Chem 264, 7856-7861. 
Tanaka, H., Sukhova, G., Schwartz, D., and Libby, P. (1996). Proliferating arterial smooth 
muscle cells after balloon injury express TNF-alpha but not interleukin-1 or basic fibroblast 
growth factor. Arterioscler Thromb Vasc Biol 16, 12-18. 
260 
 
Tanaka, H., Sukhova, G.K., Swanson, S.J., Clinton, S.K., Ganz, P., Cybulsky, M.I., and 
Libby, P. (1993). Sustained activation of vascular cells and leukocytes in the rabbit aorta 
after balloon injury. Circulation 88, 1788-1803. 
Tanaka, K., Sata, M., Hirata, Y., and Nagai, R. (2003). Diverse contribution of bone marrow 
cells to neointimal hyperplasia after mechanical vascular injuries. Circulation research 93, 
783-790. 
Tanaka, K., Sata, M., Natori, T., Kim-Kaneyama, J.R., Nose, K., Shibanuma, M., Hirata, Y., 
and Nagai, R. (2008). Circulating progenitor cells contribute to neointimal formation in 
nonirradiated chimeric mice. FASEB J 22, 428-436. 
Tanja Rauma-Pinola, P.P.k.M.I.R.S.H.R.O.V.H.R.T.H. (2006). Adrenomedullin gene 
transfer induces neointimal apoptosis and inhibits neointimal hyperplasia in injured rat 
artery. The Journal of Gene Medicine 8, 452-458. 
Tardif, J.C., Cote, G., Lesperance, J., Bourassa, M., Lambert, J., Doucet, S., Bilodeau, L., 
Nattel, S., and de Guise, P. (1997). Probucol and multivitamins in the prevention of 
restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. The New 
England journal of medicine 337, 365-372. 
Taylor, T.A., Gariepy, C.E., Pollock, D.M., and Pollock, J.S. (2003). Unique endothelin 
receptor binding in kidneys of ETB receptor deficient rats. American journal of physiology 
284, R674-681. 
Teirstein, P.S., Massullo, V., Jani, S., Popma, J.J., Mintz, G.S., Russo, R.J., Schatz, R.A., 
Guarneri, E.M., Steuterman, S., Morris, N.B., et al. (1997). Catheter-based radiotherapy to 
inhibit restenosis after coronary stenting. The New England journal of medicine 336, 1697-
1703. 
Telemaque-Potts, S., Kuc, R.E., Maguire, J.J., Ohlstein, E., Yanagisawa, M., and Davenport, 
A.P. (2002). Elevated systemic levels of endothelin-1 and blood pressure correlate with 
blunted constrictor responses and downregulation of endothelin(A), but not endothelin(B), 
receptors in an animal model of hypertension. Clin Sci (Lond) 103 Suppl 48, 357S-362S. 
Telemaque-Potts, S., Kuc, R.E., Yanagisawa, M., and Davenport, A.P. (2000). Tissue-
specific modulation of endothelin receptors in a rat model of hypertension. Journal of 
cardiovascular pharmacology 36, S122-123. 
Tepe, G., Brehme, U., Seeger, H., Raschack, M., Claussen, C.D., and Duda, S.H. (2002). 
Endothelin A receptor antagonist LU 135252 inhibits hypercholesterolemia-induced, but not 
deendothelialization-induced, atherosclerosis in rabbit arteries. Invest Radiol 37, 349-355. 
Thyberg, J. (1998). Phenotypic modulation of smooth muscle cells during formation of 
neointimal thickenings following vascular injury. Histol Histopathol 13, 871-891. 
Todaka, T., Yokoyama, C., Yanamoto, H., Hashimoto, N., Nagata, I., Tsukahara, T., Hara, 
S., Hatae, T., Morishita, R., Aoki, M., et al. (1999). Gene transfer of human prostacyclin 




Touchard, A.G., and Schwartz, R.S. (2006). Preclinical restenosis models: challenges and 
successes. Toxicol Pathol 34, 11-18. 
Trachtenberg, J.D., Sun, S., Choi, E.T., Callow, A.D., and Ryan, U.S. (1993). Effect of 
endothelin-1 infusion on the development of intimal hyperplasia after balloon catheter 
injury. Journal of cardiovascular pharmacology 22 Suppl 8, S355-359. 
Tschudi, M.R., and Luscher, T.F. (1994). Characterization of contractile endothelin and 
angiotensin receptors in human resistance arteries: evidence for two endothelin and one 
angiotensin receptor. Biochemical and biophysical research communications 204, 685-690. 
Tsujino, M., Hirata, Y., Eguchi, S., Watanabe, T., Chatani, F., and Marumo, F. (1995). 
Nonselective ETA/ETB receptor antagonist blocks proliferation of rat vascular smooth 
muscle cells after balloon angioplasty. Life sciences 56, PL449-454. 
Tsukahara, H., Ende, H., Magazine, H.I., Bahou, W.F., and Goligorsky, M.S. (1994). 
Molecular and functional characterization of the non-isopeptide-selective ETB receptor in 
endothelial cells. Receptor coupling to nitric oxide synthase. J Biol Chem 269, 21778-21785. 
Ueda, M., Becker, A.E., Tsukada, T., Numano, F., and Fujimoto, T. (1991). Fibrocellular 
tissue response after percutaneous transluminal coronary angioplasty. An 
immunocytochemical analysis of the cellular composition. Circulation 83, 1327-1332. 
Valdenaire, O., Rohrbacher, E., and Mattei, M.G. (1995). Organization of the gene encoding 
the human endothelin-converting enzyme (ECE-1). J Biol Chem 270, 29794-29798. 
Verma, S., Li, S.H., Badiwala, M.V., Weisel, R.D., Fedak, P.W., Li, R.K., Dhillon, B., and 
Mickle, D.A. (2002). Endothelin antagonism and interleukin-6 inhibition attenuate the 
proatherogenic effects of C-reactive protein. Circulation 105, 1890-1896. 
Viswanathan, M., De Oliveira, A.M., Johren, O., and Saavedra, J.M. (1997). Increased 
endothelin ET(A) receptor expression in rat carotid arteries after balloon injury. Peptides 18, 
247-255. 
von Geldern, T.W., Tasker, A.S., Sorensen, B.K., Winn, M., Szczepankiewicz, B.G., Dixon, 
D.B., Chiou, W.J., Wang, L., Wessale, J.L., Adler, A., et al. (1999). Pyrrolidine-3-carboxylic 
acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) 
selectivity. Journal of medicinal chemistry 42, 3668-3678. 
Waldron, G.J., Ding, H., Lovren, F., Kubes, P., and Triggle, C.R. (1999). Acetylcholine-
induced relaxation of peripheral arteries isolated from mice lacking endothelial nitric oxide 
synthase. Br J Pharmacol 128, 653-658. 
Walls, J.R., Sled, J.G., Sharpe, J., and Henkelman, R.M. (2007). Resolution improvement in 
emission optical projection tomography. Phys Med Biol 52, 2775-2790. 
Wan, S., Yim, A.P.C., Johnson, J.L., Shukla, N., Angelini, G.D., Smith, F.C.T., Dashwood, 
M.R., and Jeremy, J.Y. (2004). The endothelin 1(A) receptor antagonist BSF 302146 is a 
potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery 
interposition grafts. J Thorac Cardiovasc Surg 127, 1317-1322. 
262 
 
Wang, C.-H., Cherng, W.-J., Yang, N.-I., Kuo, L.-T., Hsu, C.-M., Yeh, H.-I., Lan, Y.-J., 
Yeh, C.-H., and Stanford, W.L. (2008). Late-Outgrowth Endothelial Cells Attenuate Intimal 
Hyperplasia Contributed by Mesenchymal Stem Cells After Vascular Injury. Arterioscler 
Thromb Vasc Biol 28, 54-60. 
Wang, C.H., Anderson, N., Li, S.H., Szmitko, P.E., Cherng, W.J., Fedak, P.W., Fazel, S., Li, 
R.K., Yau, T.M., Weisel, R.D., et al. (2006). Stem cell factor deficiency is 
vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate. Circulation 
research 99, 617-625. 
Wang, C.H., Li, S.H., Weisel, R.D., Fedak, P.W., Hung, A., Li, R.K., Rao, V., Hyland, K., 
Cherng, W.J., Errett, L., et al. (2005a). Tetrahydrobiopterin deficiency exaggerates intimal 
hyperplasia after vascular injury. American journal of physiology 289, R299-304. 
Wang, K., Zhou, X., Zhou, Z., Mal, N., Fan, L., Zhang, M., Lincoff, A.M., Plow, E.F., 
Topol, E.J., and Penn, M.S. (2005b). Platelet, not endothelial, P-selectin is required for 
neointimal formation after vascular injury. Arterioscler Thromb Vasc Biol 25, 1584-1589. 
Wang, X., Douglas, S.A., Louden, C., Vickery-Clark, L.M., Feuerstein, G.Z., and Ohlstein, 
E.H. (1996). Expression of Endothelin-1, Endothelin-3, Endothelin-Converting Enzyme-1, 
and Endothelin-A and Endothelin-B Receptor mRNA After Angioplasty-Induced Neointimal 
Formation in the Rat. Circulation research 78, 322-328. 
Wedgwood, S., Dettman, R.W., and Black, S.M. (2001). ET-1 stimulates pulmonary arterial 
smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol 
Lung Cell Mol Physiol 281, L1058-1067. 
Weidinger, F.F., McLenachan, J.M., Cybulsky, M.I., Gordon, J.B., Rennke, H.G., 
Hollenberg, N.K., Fallon, J.T., Ganz, P., and Cooke, J.P. (1990). Persistent dysfunction of 
regenerated endothelium after balloon angioplasty of rabbit iliac artery. Circulation 81, 
1667-1679. 
Weissberg, P.L. (2000). Atherogenesis: current understanding of the causes of atheroma. 
Indian heart journal 52, 467-472. 
Weissberg, P.L., Witchell, C., Davenport, A.P., Hesketh, T.R., and Metcalfe, J.C. (1990). 
The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with 
platelet-derived growth factor for vascular smooth muscle cells. Atherosclerosis 85, 257-
262. 
Weksler, B.B., Marcus, A.J., and Jaffe, E.A. (1977). Synthesis of prostaglandin I2 
(prostacyclin) by cultured human and bovine endothelial cells. Proceedings of the National 
Academy of Sciences of the United States of America 74, 3922-3926. 
Werner, N., Priller, J., Laufs, U., Endres, M., Bohm, M., Dirnagl, U., and Nickenig, G. 
(2002). Bone marrow-derived progenitor cells modulate vascular reendothelialization and 
neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. 
Arterioscler Thromb Vasc Biol 22, 1567-1572. 
Wessale, J.L., Adler, A.L., Novosad, E.I., Calzadilla, S.V., Dayton, B.D., Marsh, K.C., 
Winn, M., Jae, H.S., von Geldern, T.W., Opgenorth, T.J., et al. (2002). Pharmacology of 
263 
 
endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and 
in vivo studies. Clin Sci (Lond) 103 Suppl 48, 112S-117S. 
Whittle, B.J., Lopez-Belmonte, J., and Rees, D.D. (1989). Modulation of the vasodepressor 
actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific 
inhibitor of nitric oxide formation. Br J Pharmacol 98, 646-652. 
Whittle, B.J., Moncada, S., and Vane, J.R. (1978). Comparison of the effects of prostacyclin 
(PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins 
16, 373-388. 
Widder, J.D., Chen, W., Li, L., Dikalov, S., Thony, B., Hatakeyama, K., and Harrison, D.G. 
(2007). Regulation of Tetrahydrobiopterin Biosynthesis by Shear Stress. Circulation research 
101, 830-838. 
Widmer, C.C., Mundy, A.L., Kretz, M., and Barton, M. (2006). Marked heterogeneity of 
endothelin-mediated contractility and contraction dynamics in mouse renal and femoral 
arteries. Exp Biol Med (Maywood) 231, 777-781. 
Wilcox, J.N., Subramanian, R.R., Sundell, C.L., Tracey, W.R., Pollock, J.S., Harrison, D.G., 
and Marsden, P.A. (1997). Expression of multiple isoforms of nitric oxide synthase in 
normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 17, 2479-2488. 
Wilson, S.H., Simari, R.D., and Lerman, A. (2001). The effect of endothelin-1 on nuclear 
factor kappa B in macrophages. Biochemical and biophysical research communications 286, 
968-972. 
Wolf, G.L., LeVeen, R.F., and Ring, E.J. (1984). Potential mechanisms of angioplasty. 
Cardiovasc Intervent Radiol 7, 11-17. 
Wolff, R.A., Tomas, J.J., Hullett, D.A., Stark, V.E., van Rooijen, N., and Hoch, J.R. (2004). 
Macrophage depletion reduces monocyte chemotactic protein-1 and transforming growth 
factor-beta1 in healing rat vein grafts. J Vasc Surg 39, 878-888. 
Wong, A.L., Haroon, Z.A., Werner, S., Dewhirst, M.W., Greenberg, C.S., and Peters, K.G. 
(1997). Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. 
Circulation research 81, 567-574. 
Woods, M., Mitchell, J.A., Wood, E.G., Barker, S., Walcot, N.R., Rees, G.M., and Warner, 
T.D. (1999). Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: 
evidence for intracellular endothelin-converting enzyme. Molecular pharmacology 55, 902-
909. 
Wu-Wong, J.R., Chiou, W.J., and Wang, J. (2000). Extracellular Signal-Regulated Kinases 
Are Involved in the Antiapoptotic Effect of Endothelin-1. Journal of Pharmacology And 
Experimental Therapeutics 293, 514-521. 
Wypij, D.M., Nichols, J.S., Novak, P.J., Stacy, D.L., Berman, J., and Wiseman, J.S. (1992). 
Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 
in the perfused rat lung. Biochem Pharmacol 43, 845-853. 
264 
 
Xu, D., Emoto, N., Giaid, A., Slaughter, C., Kaw, S., deWit, D., and Yanagisawa, M. (1994). 
ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big 
endothelin-1. Cell 78, 473-485. 
Xu, Q. (2004). Mouse models of arteriosclerosis: from arterial injuries to vascular grafts. Am 
J Pathol 165, 1-10. 
Xu, S., Denton, C.P., Holmes, A., Dashwood, M.R., Abraham, D.J., and Black, C.M. (1998). 
Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma 
fibroblasts. Journal of cardiovascular pharmacology 31 Suppl 1, S360-363. 
Xu, S.W., Howat, S.L., Renzoni, E.A., Holmes, A., Pearson, J.D., Dashwood, M.R., Bou-
Gharios, G., Denton, C.P., du Bois, R.M., Black, C.M., et al. (2004). Endothelin-1 induces 
expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem 
279, 23098-23103. 
Yanagisawa, H., Hammer, R.E., Richardson, J.A., Emoto, N., Williams, S.C., Takeda, S., 
Clouthier, D.E., and Yanagisawa, M. (2000). Disruption of ECE-1 and ECE-2 reveals a role 
for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 105, 1373-
1382. 
Yanagisawa, H., Yanagisawa, M., Kapur, R.P., Richardson, J.A., Williams, S.C., Clouthier, 
D.E., de Wit, D., Emoto, N., and Hammer, R.E. (1998). Dual genetic pathways of 
endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin 
converting enzyme-1 gene. Development (Cambridge, England) 125, 825-836. 
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, 
Y., Goto, K., and Masaki, T. (1988). A novel potent vasoconstrictor peptide produced by 
vascular endothelial cells. Nature 332, 411-415. 
Yang, L.L., Gros, R., Kabir, M.G., Sadi, A., Gotlieb, A.I., Husain, M., and Stewart, D.J. 
(2004). Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated 
cardiomyopathy in mice. Circulation 109, 255-261. 
Yang, Z.H., Krasnici, N., and Luscher, T.F. (1999). Endothelin-1 potentiates human smooth 
muscle cell growth to PDGF - Effects of ETA and ETB receptor blockade. Circulation 100, 
5-8. 
Yang, Z.H., Richard, V., von Segesser, L., Bauer, E., Stulz, P., Turina, M., and Luscher, T.F. 
(1990). Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine 
and serotonin in human arteries. A new mechanism of vasospasm? Circulation 82, 188-195. 
Yeh, Y.C., Burns, E.R., Yeh, J., and Yeh, H.W. (1991). Synergistic effects of endothelin-1 
(ET-1) and transforming growth factor alpha (TGF-alpha) or epidermal growth factor (EGF) 
on DNA replication and G1 to S phase transition. Biosci Rep 11, 171-180. 
Yokoi, H., Daida, H., Kuwabara, Y., Nishikawa, H., Takatsu, F., Tomihara, H., Nakata, Y., 
Kutsumi, Y., Ohshima, S., Nishiyama, S., et al. (1997). Effectiveness of an antioxidant in 
preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol 
Angioplasty Restenosis Trial. J Am Coll Cardiol 30, 855-862. 
265 
 
Yokoyama, T., Miyauchi, K., Kurata, T., Sato, H., and Daida, H. (2004). Effect of probucol 
on neointimal thickening in a stent porcine restenosis model. Jpn Heart J 45, 305-313. 
Yoshida, T., Kiuchi, K., Nejima, J., Kudo, M., Asano, G., and Takano, T. (2000). Expression 
of endothelin-1 after endothelial denudation of thoracic aortas in experimental 
hypercholesterolemic rats. J Nippon Med Sch 67, 342-351. 
Yoshizumi, M., Kim, S., Kagami, S., Hamaguchi, A., Tsuchiya, K., Houchi, H., Iwao, H., 
Kido, H., and Tamaki, T. (1998). Effect of endothelin-1 (1-31) on extracellular signal-
regulated kinase and proliferation of human coronary artery smooth muscle cells. British 
journal of pharmacology 125, 1019-1027. 
Yoshizumi, M., Kurihara, H., Morita, T., Yamashita, T., Oh-hashi, Y., Sugiyama, T., 
Takaku, F., Yanagisawa, M., Masaki, T., and Yazaki, Y. (1990). Interleukin 1 increases the 
production of endothelin-1 by cultured endothelial cells. Biochemical and biophysical 
research communications 166, 324-329. 
Zhang, L.N., Wilson, D.W., da Cunha, V., Sullivan, M.E., Vergona, R., Rutledge, J.C., and 
Wang, Y.X. (2006). Endothelial NO synthase deficiency promotes smooth muscle progenitor 
cells in association with upregulation of stromal cell-derived factor-1alpha in a mouse model 
of carotid artery ligation. Arterioscler Thromb Vasc Biol 26, 765-772. 
Zhao, Y.Y., Gao, X.P., Zhao, Y.D., Mirza, M.K., Frey, R.S., Kalinichenko, V.V., Wang, 
I.C., Costa, R.H., and Malik, A.B. (2006). Endothelial cell-restricted disruption of FoxM1 
impairs endothelial repair following LPS-induced vascular injury. J Clin Invest 116, 2333-
2343. 
Zhou, Y.B., Dirksen, W.P., Zweier, J.L., and Periasamy, M. (2004). Endothelin-1-induced 
responses in isolated mouse vessels: the expression and function of receptor types. Am J 
Physiol-Heart Circul Physiol 287, H573-H578. 
Ziegler, T., Bouzourene, K., Harrison, V.J., Brunner, H.R., and Hayoz, D. (1998). Influence 
of oscillatory and unidirectional flow environments on the expression of endothelin and 
nitric oxide synthase in cultured endothelial cells. Arterioscler Thromb Vasc Biol 18, 686-
692. 
Zimmerman, M.A., Selzman, C.H., Reznikov, L.L., Miller, S.A., Raeburn, C.D., Emmick, J., 
Meng, X., and Harken, A.H. (2002). Lack of TNF-alpha attenuates intimal hyperplasia after 
mouse carotid artery injury. American journal of physiology 283, R505-512. 
Zou, Y., Hu, Y., Mayr, M., Dietrich, H., Wick, G., and Xu, Q. (2000). Reduced neointima 
hyperplasia of vein bypass grafts in intercellular adhesion molecule-1-deficient mice. 
Circulation research 86, 434-440. 
Zwolak, R.M., Adams, M.C., and Clowes, A.W. (1987). Kinetics of vein graft hyperplasia: 














From: Nicholas Kirkby 
Date: 14th July 2009 
 
Dear Sir/ Madam, 
 
I am an author on a review article published in the British Journal of Pharmacology in 
March 2008: 
 
"The endothelin system as a therapeutic target in cardiovascular disease: great expectations 
or bleak house?" Volume 153(6). Pages 1105-1119. 
 
I would like to include a copy of this article in my PhD thesis, and would be grateful if you 







From: Wade, Katie - Oxford On Behalf Of Permission Requests - UK 
Date: 15th July 2009 
 
Dear Nicholas Kirkby 
 
Thank you for your email request. Permission is granted for you to use the material below 
for your thesis/dissertation subject to the usual acknowledgements and on the understanding 





Katie B Wade 
Permissions Assistant  
Wiley-Blackwell 
 
